AU2009200024A1 - Azaindoles - Google Patents

Description

AUSTRALIA

Patents Act COMPLETE SPECIFICATION

(ORIGINAL)

Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Aventis Pharma Limited Actual Inventor(s): Paul Joseph Cox, Tahir Nadeem Majid, Justine Yeun Quai Lai, Andrew Morley, Shelley Amendola, Stephanie Daniele Deprets, Chris Edlin, Charles J Gardner, Dorothea Kominos, Brian Leslie Pedgrift, Frank Halley, Timothy Alan Gillespy, Michael Edwards, Francois Frederic Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard and Chantal Carrez Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title:

AZAINDOLES

Our Ref 846099 POF Code: 460434/460435 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): -1eooeq

AZAINDOLES

The present application is a divisional application from Australian patent application number 2002302849, the entire disclosure of which is incorporated herein by reference.

This invention is directed to substituted azaindoles, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases.

Protein kinases participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into several groups; those which preferentially phosphorylate serine and/or threonin residues and those which preferentially phosphorylate tyrosine residues K. Hanks and T.

Hunter, FASEB. 1995,9, pages 576-596]. The serine/threonine kinases include for example, protein kinase C isoforms C. Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdc2 Pines, Trends in Biochemical Sciences, 1995,18, pages 195- 197]. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor Iwashita and M. Kobayashi, Cellular Signalling, 1992,4, pages 123-132], and cytosolic non-receptor kinases such as p56tck, p59fYn, ZAP-70 and csk kinases Chan et. al., Ann. Rev. Immunol., 1994,12, pages 555-592].

Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, over-expression or inappropriate activation of the enzyme; or by over-or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.

Spleen tyrosine kinase (Syk) is a 72-kDa cytoplasmic protein tyrosine kinase that is expressed in a variety of hematopoietic cells and is an essential element in several cascades that couple antigen receptors to cellular responses. Thus, Syk plays a pivotal role in signalling of the high affinity IgE receptor, FcsRI, in mast cells and in receptor antigen signalling in T and B lymphocytes. The signal transduction pathways present in mast, T and B cells have common features. The ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity. However, they interact with transducing subunits that contain immunoreceptor tyrosine based activation motifs (ITAMs) Reth, Nature, 1989,338, pages 383-384]. These motifs are present in both the and y subunits of the FcsRI, in the subunit the of T cell receptor (TCR) and in the IgGa and IgG subunits of the B cell receptor (BCR). [N.

S. van Oers and A. Weiss, Seminars in Immunology, 1995,7, pages 227-236] Upon binding of antigen and multimerization, the ITAM residues are phosphorylated by protein tyrosine kinases of WO 03/000688 PCT/GB02/02799 S-2the Src family. Syk belongs to a unique class oftyrosine kinases that have two tandem Src homology 2 S(SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to c- ITAMs and this SH2 -mediated association of Syk with an activated receptor stimulates Syk kinase activity and localises Syk to the plasma membrane.

In Syk deficient mice, mast cell degranulation is inhibited, suggesting that this is an important target Sfor the development of mast cell stabilising agents [P.S.Costello, Oncogene, 1996, 13, pages 2595- 2605]. Similar studies have demonstrated a critical role for Syk in BCR and TCR signalling [A.M.Cheng, Nature, 1995, 378, pages 303-306, (1995) and D.H.Chu et al., Immunological Reviews, 1998, 165, pages 167-180]. Syk also appears to be involved in eosinophil survival in response to and GM-CSF [S.Yousefi et al., J. Exp. Med., 1996, 183, pages 1407-1414]. Despite the key role of Syk in mast cell, BCR and T cell signalling, little is known about the mechanism by which Syk transmits downstream effectors. Two adaptor proteins, BLNK (B cell Linker protein, SLP-65) and SLP-76 have been shown to be substrates of Syk in B cells and mast cells respectively and have been postulated to interface Syk with downstream effectors [M.lshiai et al., Immunity, 1999, 10, pages 117- 125 and L.R.Hendricks-Taylor et al., J.Biol. Chem, 1997, 272, pages 1363-1367]. In addition Syk appears to play an important role in the CD40 signalling pathway, which plays an important role in B cell proliferation [M.Faris et al., J.Exp. Med., 1994, 179, pages 1923-1931].

Syk is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F.Yanaga et al., Biochem. 1995, 311, (Pt. 2) pages 471- 478].

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in integrin-mediated signal transduction pathways. FAK colocalizes with integrins in focal contact sites and FAK activation and its tyrosine phosphorylation have been shown in many cell types to be dependent on integrins binding to their extracellular ligands. Results from several studies support the hypothesis that FAK inhibitors could be useful in cancer treatment. For example, FAK-deficient cells migrate poorly in response to chemotactic signals and overexpression of C-terminal domain of FAK blocks cell spreading as well as chemotactic migration (Sieg et al, J. Cell Science, 1999, 112, 2677-2691; Richardson A. and Parsons Cell, 1997, 97, 221-231) in addition, tumor cells treated with FAK antisense oligonucleotides lost their attachment and underwent apoptosis (Xu et al, Cell Growth Differ. 1996, 4, 413-418). FAK has been reported to be overexpressed in prostate, breast, thyroid, colon and lung cancers. The level of expression of FAK is directly correlated with tumors demonstrating the most aggressive phenotype.

WO 03/000688 PCT/GB02/02799 -3- Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Abnormal enhanced neovascularization is observed in rheumatoid arthritis, diabetic retinopathy and during tumor development (Folkman, Nat. Med., 1995, 1,27-31.). Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. Extensive studies in the field of tumor angiogenesis in the past two decades have identified a number of therapeutic targets including kinases, proteases and integrins resulting in the discovery of many new antiangiogenic agents, including kinase insert domain-containing receptor (KDR, also known as VEGFR-2, vascular endothelial growth factor receptor-2) inhibitors some of which are currently under clinical evaluation (Jekunen, et al Cancer Treatment Rev. 1997 23, 263-286.). Angiogenesis inhibitors may be used in frontline, adjuvant and even preventive settings for the emergence or regrowth of malignancies.

-Several proteins involved in chromosome segregation and spindle assembly have been identified in yeast and drosophila. Disruption of these proteins results in chromosome missegregation and monopolar or disrupted spindles. Among these kinases are the Ipll and aurora kinases from S.cerevisiae and drosophila respectively, which are required for centrosome separation and chromosome segregation. One human homologue of yeast Ipll was recently cloned and characterized by different laboratories. This kinase termed Aurora2, STKI 5 or BTAK belongs to the serine/threonine kinase family. Bischoffet al showed that Aurora2 is oncogenic and is amplified in human colorectal cancers (EMBO J, 1998, 17, 3052-3065). It has also been exemplified in cancers involving epithelial tumors such as breast cancer.

The type 1 insulin-like growth factor receptor (IGFIR) is a transmembrane receptor tyrosine kinase that binds primarily to IGFI but also to IGF2 and insulin with lower affinity. Binding ofIGFl to its receptor results in receptor oligomerization, activation of tyrosine kinase, intermolecular receptor autophosphorylation and phosphorylation of cellular substrates (its two major substrates are IRSI and She). The ligand-activated IGFIR induces mitogenic activity in normal cells. Several clinical reports underline the important role of the IGF-I pathway in human tumor development: IGF-I-R overexpression is frequently found in various tumors (for example breast, colon, lung, skin, sarcoma) and is often associated with an aggressive phenotype; (ii) high circulating IGFI concentrations are strongly correlated with prostate, lung and breast cancer risk; (iii) epidemiological studies implicate the IGFI axis as a predisposing factor in the pathogenesis of breast and prostate cancer [Baserga R. The IGF-I receptor in cancer research, Exp Cell Res. (1999) 253:1-6; Baserga R. The contradictions of the IGFI-Receptor, Oncogene (2000) 19: 5574-81; Khandwala HM. et al. The effects of IGFs on tumorigenesis and neoplastic growth, Endocrine Reviews (2000) 21: 215-44; Adams TE et al.

Structure and function of the IGFIR, CMLS (2000) 57: 1050-93.] WO 03/000688 PCT/GB02/02799 -4-

O

0 International Application Number PCT/US/00/15181, filed June 2, 2000, dicloses a series of 2substituted benzimidazoles, indoles, benzoxazoles, and benzothiazoles which are reported to be useful for inhibiting cell death.

We have now found a novel group of substituted azaindoles, which have valuable pharmaceutical properties, in particular, the ability to inhibit protein kinases, more particularly, the ability to inhibit SSyk kinase, Aurora2, KDR, FAK and IGFI R.

0 01 lO

L

WO 03/000688 PCT/GB02/02799 Thus, in one aspect, the present invention is directed to pharmaceutical compositions comprising compounds of general formula xl R 3 CR1

N

N

H

wherein:- Rlrepresents aryJ or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R 4 Iy 2 -Ny y 2

-N(R

6 7

-N(R

6 3

Y

4

-N(R

6 7

-N(R

6 )-S0 2

-R

7

-N(R

6 )-S0 2

-NY

3

Y

4 _S0 2 -NY I y 2 and R2represents hydrogen, acyl, cyano, halo, lower alkenyl, _Z 2

R

4

_SO

2

NY

3 y 4

-NY

1 y 2 or lower alkyl optionally substituted by a substituent selected from aryl, cyano, heteroaryl, beterocycloalkyl, hydroxy,

-Z

2

R

4 Iy 2 -C0 2

R

8 -Ny 3 y 4

-N(R

6

-N(R

6 2

-N(R

6 7

-N(R

6 )-S0 2

-R

7

-N(R

6 )-S0 2 -Ny 3 y 4

-SO

2 NY Iy 2 and one or more halogen atoms;

R

3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2

R

4 -C(=O)-0RS or -C(=O)-Ny 3 y 4

R

4 represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloal kyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CH-O or a 6- or 7-membered cyclic acetal derivative thereof), -C&=O)-Ny 1 y 2 -C(=O)-0R 5 -NYy 2

-N(R

6 7

-N(R

6 3 y 4

N(R

6 )-S0 2

-R

7

-N(R

6 )-S0 2 -Ny 3 y 4

_Z

3

R

7 and one or more groups selected from hydroxy, alkoxy and carboxy;

R

5 represents hydrogen, alkyl, alkenyl, aryl, arylalky), heteroaryl or heteroarylalkyl;- R6epresents hydrogen or lower alkyl; WO 03/000688 PCT/GB02102799 -6-

R

7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R

8 represents hydrogen or lower alkyl; R represents aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO or a 6- or 7-membered cyclic acetal derivative thereof), I y 2 -C(=O)-0R 5 -NY I y 2

-N(R

6 7

-N(R

6 3 y 4

-N(R

6 )-S0 2

-R

7

-N(R

6 y-S0 2

-NY

3 y 4

-Z

3

R

7 and one or more groups selected from hydroxy, alkoxy and carboxy; XIrepresents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN,

C-R

4 C-NY 1

Y

2 C-OH, CZ 2 R, C-C(=O)-0R 5 C-C(=O)-NTyIy 2

C-N(R

8

C-N(R

6 7

C-N(R

6 3 y 4

C-N(R

6 )-S0 2 -Ny 3 y 4

C-N(R

6 )-S0 2

-R,

C-S0 2 -Ny 3 y 4

C-NO

2 or C-alkenyl or C-alkynyl optionally substituted by aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, I y 2 -C(=O)-0R 5

-NY

1 I y 2

-N(R

6

-N(R

6 3 y 4

-N(R

6 7

-N(R

6 )-S0 2

-R

7

-N(R

6 )-S0 2

-NY

3 y 4 -S0 2 -NYly 2 and -Z 2

R

4 Y I and y 2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(=O)-Ny 3

Y

4 -C(=O)-0R 5 -Ny 3 y 4

-N(R

6 7

-N(R

6 3 y 4

-N(R

6 )-S0 2

-R

7

-N(R

6 )-S0 2

-NY

3 y 4 and -OR 7 or the group -NY Iy 2 may form a cyclic amine; y 3 and y 4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -Ny 3 y 4 may form a cyclic amine; ZIrepresents 0 or S; Z2represents 0 or S(O)n;

Z

3 represents 0, S(O0n NR 6 n is zero or an integer I or 2; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and their prodrugs, and their acid bioisosteres; together with one or more pharmaceutically acceptable carriers or excipients.

In another aspect, the invention concerns the compounds of formula as defined above, but excluding the compounds 2-phenyl- I H-pyrrolo[2,3-b]pyridine, 2-(4-bromo-phenyl)-3-methyl- I H-pyrrolof2,3- WO 03/000688 WO 03/00688PCT/GB02/02799 b]pyridine, 4-(3-methyl- 1 H-pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid methyl ester, 2-(4-ch loro-phenyl)- I H-pyrrolo[2,3-b]pyridine, 2-(4-methoxy-plienyl)- I H-pyrrolo[2,3-b~pyridine, 5-methyl-2-phenyl- I Hpyrrolo [2',3-b]pyridime, 4-methiyl-2-phenyl- IH-pyrrolo [2,3 -b]pyridine, 2-pyridin-3-yl- IH-pyrrolo[2,3b]pyridine, 4-(3-methyl- I H--pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid, 2-(4-methoxy-phenyl)-3 -methyl- 1 H-pyrrolo[2,3 -b]pyridine, 2-(4-methyl-phenyl)-3-methyl- I H-pyrrolo[2,3-b~pyridine, 4-(3-methyl- I Hpyrrolo[2,3-b]pyridin-2-yl)-benzoic acid isopropyl ester, 2-pheny]-3-methyl- II--pyrrolo[2,3-b]pyridine, 5-bromo-2-phenyl-3 -methyl-I H-pyrro lo[2,3 -b~pyridime, 6-ch loro-2-phenyl- IH-pyrrolo[2,3-b]pyridime, 6-chloro-4-methyl-2-phienyl- I H-pyrrolo[2,3-b~pyridime, 4-methyl-2-phenyl- I H-pyrrolo[2,3-b]pyridin-3yl-carboxaldehyde, 2-phienyl- 1I--pyrrolo[2,3-b]pyridin-3-yl-acetonitri le, 2-phenyl-3 -prop- I -enyl- I Hpyrrolo[2,3-b)pyridine, 4-niethyl-2-phenyl-11H-pyrrolo[2,3-b]pyrid in-3-yl-carboxaldehyde, d imethyl-(2phenyl- IH-pyrrolo[2,3-b]pyridini-3-ylmethyl)-amine, 2,2'-diphenyl- IH,] 'H-[3,3']bi[pyrrolo[2,3b~pyridinyl], 2-(2-phenyl- I H-pyrrolo[2,3-b]pyridin-3-yl)-acetamide, 3-allyl-2-phenyl-] H--pyrrolo[2,3b]pyridine, (2-phenyl- I H-pyrrolo[2,3 -b]pyridin-3-yI)-acetonitrile, 2-phenyl- I I-pyrrolo[2,3-b]pyridine- 3-carbaldehyde, 3-morphiolin-4-ylmethyl-2-phenyl- I H-pyrrolo[2,3-b]pyridime, N-[2-(2-phenyl- I Hpyrrolo[2,3-b~pyrid in-3-yl)-ethyl]-acetamide, 6-phenyl-5 H-pyrrolo[2,3-blpyrazine, 6-(4-methoxy- H-pyrrolo[2,3-b]pyrazine, 6-(4-chloro-phenyl)-SH-pyrrolo[2,3-b~pyrazine, 6-(2-chlorophenyl)-5H--pyrrolo[2,3-b]pyrazine, 3-methyl-6-phenyl-5H-pyrrolo[2,3-b)pyrazine, 2-methyl-6-phenyl- 5H-pyrrolo[2,3-b]pyrazine and 7-methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine.

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:- "Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, I986,2 l,p 2 83 "Bicisosterism In Drug Design"; Yun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995, pages 34-38 WO 03/000688 PCT/GB02/02799 -8-

O

"Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH 2 0H, -C(=O)-CH 2 SH, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-l,2,4-oxadiazolidinyl or Sheterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-l -methylpyrazolyl.

O

"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.

0 I "Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms 2 to 4 carbon atoms) in the chain. "Branched," as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain, which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

"Alkenyloxy" is an alkenyl-O- group wherein alkenyl is as defined above. Exemplary alkenyloxy I groups include allyloxy.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein.

Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched WO 03/000688 PCT/GB02/02799 -9chain having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.

Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl.

"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

"Alkylenedioxy" mean's an -O-alkylene-O- group in which alkylene is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

"Alkylsulfinyl" means an alkyl-SO- group in which the alkyl group is as previously described.

Preferred alkylsulfinyl groups are those in which the alkyl group is Cl_ 4 alky).

"Alkylsulfonyl" means an alkyl-S0 2 group in which the alkyl group is as previously described.

Preferred alkylsulfonyl groups are those in which the alkyl group is Cl4alkyl.

"Alkylsulfonylcarbamoyl" means an alkyl-S0 2 group in which the alkyl group is as previously described. Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is

C

1 4 alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.

"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain.

Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

WO 03/000688 PCT/GB02/02799 "Aryl" as a group or part of a group denotes: an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Except where otherwise defined, aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, ary]thio, carboxy (or an acid bioisostere), cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY 3

Y

4

-CONY

3 4

-SO

2

NY

3 4

-NY

3 -C(=O)alkyl, -NY 3

SO

2 alkyl or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or -NY 3

Y

4 "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a Cl-4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl group is as previously described.

Exemplary arylalkyloxy groups include benzyloxy and I- or 2-naphthalenemethoxy.

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which arylalkyl is as previously described.

An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described.

An exemplary arylalkylthio group is benzylthio.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.

"Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described.

Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Arylsulfinyl" means an aryl-SO- group in which the aryl group is as previously described.

"Arylsulfonyl" means an aryl-S02- group in which the aryl group is as previously described.

WO 03/000688 PCT/GB02/02799 -11- "Arylsulfonylcarbamoyl" means an aryl-S0 2 group in which the aryl group is as previously described.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.

"Azaheteroaryl" means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are selected from carbon, oxygen, sulfur, and nitrogen. Examples of azaheteroaryl groups include benzimidazolyl, imidazolyl, indazolinyl, indolyl, isoquinolinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, quinazolinyl and tetrahydroindolizinyl.

"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which may also contain a further heteroatom-containing group selected from O, S, SO 2 or NY 7 (where Y 7 is hydrogen, alkyl, aryl, arylalkyl, 7 -C(=0)-OR 7 or -S0 2

R

7 and (ii) may be fused to additional aryl phenyl), heteroaryl (e.g.

pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.

"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C 3 -8cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro and chloro.

WO 03/000688 PCT/GB02/02799 -12- "Heteroaroyl" means a heteroaryl-C(=0)- group in which the heteroaryl group is as described herein.

Exemplary heteroaryl groups include pyridylcarbonyl.

"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaryl moiety is as previously described.

"Heteroaryl" as a group or part of a group denotes: an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above except where otherwise defined); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure (examples of such groups include pyrindanyl groups, optionally substituted by one or more "aryl group substituents" as defined above, except where otherwise defined). Optional substituents include one or more "aryl group substituents" as defined above, except where otherwise defined.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C l 4 alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means a heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

"Heteroaryloxy" means a heteroaryl-O- group in which the heteroaryl group is as previously described.

Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

"Heteroarylsulfonylcarbamoyl" means a heteroaryl-S0 2 group in which the heteroaryl group is as previously described.

"Heterocycloalkenyl" means a cycloalkenyl group which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY 7 WO 03/000688 PCT/GB02/02799 -13- "Heterocycloalkyl" means: a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY 7 and may be optionally substituted by oxo; (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more "aryl group substituents," and a heterocycloalkyl group are fused together to form a cyclic structure. (Examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).

"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

"Prodrug" means a compound which is convertible in vivo by metabolic means by hydrolysis) to a compound of formula including N-oxides thereof. For example an ester of a compound of formula containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule.

Alternatively, an ester of a compound of formula containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

Suitable esters of compounds of formula containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-P-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

Suitable esters of compounds of formula containing a carboxy group are, for example, those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.

Suitable esters of compounds of formula containing both a carboxy group and a hydroxy group within the moiety -L -Y include lactones formed by loss of water between said carboxy and hydroxy groups. Examples of such lactones include caprolactones and butyrolactones.

An especially useful class of esters of compounds of formula containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-l-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

WO 03/000688 PCT/GB02/02799 -14- Where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

WO 03/000688 PCT/GB02/02799 As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

With reference to formula above, the following are particular and preferred groupings: RI may particularly represent optionally substituted heteroaryl, especially optionally substituted azaheteroaryl. Exemplary optionally substituted azaheteroaryls include indolyl, pyridyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, imidazolyl, indazolyl, indolizinyl, tetrahydroindolizinyl and indazolinyl. Optional substituents include one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, R 4 -C(=0)-OR 5 ly 2

-NY

1 2 and -OR. R 1 more preferably represents optionally substituted indolyl, optionally substituted indolizinyl or optionally substituted pyrrolyl. R 1 still more preferably represents optionally substituted indol-3-yl, indolizin-l-yl, optionally substituted pyrrol-3-yl, optionally substituted indol-2-yl or optionally substituted pyrrol-2-yl.

RI may also particularly represent optionally substituted aryl, especially optionally substituted phenyl.

Optional substituents include one or more groups selected from alkylenedioxy, halo, heteroaryl, hydroxy, R 4 -NY IY 2 and -OR. RI still more preferably represents 4-substituted phenyl, more especially 4-tertiarybutylphenyl.

R

2 may particularly represent hydrogen.

R

2 may also particularly represent acyl.

R

2 may also particularly represent halo.

R

2 may also particularly represent lower alkyl optionally substituted by cyano, halo, hydroxy, heteroaryl,-C(=O)-NY 1 Y 2 tetrazolyl, -CO 2

R

8

-NY

3 y 4

-N(R

6

-N(R

6

Y

2

-N(R

6 )-S0 2

-R

7 or -N(R 6

)-SO

2 -Ny 3

Y

4 R2 may also particularly represent lower alkenyl.

WO 03/000688 PCT/GB02/02799 -16-

R

3 may particularly represent hydrogen.

R

3 may also particularly represent optionally substituted aryl, especially optionally substituted phenyl.

R

3 may also particularly represent -C(=0)-OR 5

R

3 may also particularly represent lower alkyl methyl).

X may particularly represent N.

X

1 may also particularly represent CH.

X1 may also particularly represent C-halo, especially C-C1.

X

1 may also particularly represent C-CN.

X1 may also particularly represent C-OH.

XI may also particularly represent C-aryl C-phenyl).

XI may also particularly represent C-heteroaryl, especially C-azaheteroaryl C-pyridyl,

CH

3

N

C

CH

3 X1 may also particularly represent C-Z 2 R, especially C-lower alkoxy, more especially C-OCH 3

X

1 may also particularly represent C-C(=O)-OR 5 especially C-C(=0)-OH or C-C(=O)-OtBu.

WO 03/000688 PCT/GB02/02799 -17- XImay also particularly represent C-C(=O)-NY Iy 2 especially C-C(=O)-NI{ 2 C-C(0)-NBl-CH 3

C-C(=O)-NH-CH

2

-CH

2

-CH

2

-CH

3 C-C(=O)-NWK-j I C-C(=-O)-NH1

C-C(=O)-NH-CH

2

-CH

2 OH, C-CQ=O)-NH-CH-,-CH(CH 3 )OH, C-C(=O)-NH-CH 2

-C(CH

3 2

-OH,

0

C-C(=O)-N'H-C(CI-

3 2 -CH2)OH. C-C(=O)-NH-CH 2

CH-

2 0CH 3 C- C(=O)-NH-C-I 2 C-C(=O)-NH-CHT C-C(=O)-N(CH 3 2 0,

HO

CH 3 OOH or C-C(0)-N more especially

C-C(=O)-NH-C(CH

3 2

-CH

2

OI-I.

CH 3 CH 3 0 X I may also particularly represent C-Ny I y 2 C-N-i b C-NH b)/ CH 3 0 2 C CH 3 OCH 3 CNH CN 1\/d ~CN ~CNH CH 3 C-Nil -0 OCH 3 C-NII-CH--<, C-N-CHi-\ C-N]H-CH 2 a C-NH-CH 2 /OCH 3

CH

3 0

C-NH-CM

2 NH-CO /or C-N O--\0)especially C-NH- WO 03/000688 PCT/GB02/02799 -18- Xl may also particularly represent C-heterocycloalkenyl C H or C- N-CO t Bu).

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular embodiment of the invention is a compound of formula (I)

R

2

R

3 R I

N

N

H

(1) wherein:- RI represents aryl or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, hydroxy, heteroaryl, heterocycloalkyl, I Y 2

-N(R

6 7

-N(R

6 3

Y

4

-N(R

6 7

-N(R

6 )-S0 2

-R

7

-N(R

6

)-SO

2

-NY

3

Y

4 and -S-0-NI y 2 or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate.

A particular preferred group of compounds of the invention are compounds of formula WO 03/000688 PCT/GB02/02799 -19-

S

2 4

S

R (R )p 6

R(

2 N N 9 C- H R (la) Sin which R 2

R

3 and X 1 are as hereinbefore defined; R 9 is hydrogen, alkenyl or R 4

R

10 is alkenyloxy, 4 5 carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, R 4 -C(=O)-NYI Y 2

-OR

4

-N(R

6 7

-N(R

6 )-S0 2

-R

7 or -NY y 2 p is zero, or an integer 1 or 2; and the residue

R

2 R 1 is attached to position 2 or 3 of the indole ring; and their corresponding N N

H

N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and their prodrugs.

Compounds of formula (la) in which R 2 represents hydrogen are preferred.

Compounds of formula (la) in which R 3 represents hydrogen are preferred.

Compounds of formula (la) in which X 1 represents:

N;

(ii) CH; (iii) C-aryl C-phenyl);

CH

3 (iv) C-heteroaryl, especially C-azaheteroaryl C-pyridyl or C I 0

CH

3 C-halo C-CI); (vi) C-CN; WO 03/000688 PCT/GB02/02799 (vii) C- Z 2 R, particularly C-lower alkoxy (e.g.C-OCH 3 (viii) C-C(=O)-0R 5 particularly C-C(=O)-OtBu; (ix) -Ny' Iy 2

C-C(=O)-NH-CH

3

C-C(=O)-NB--CH

2

-CH

2

OH,

C-C(=O)-NH-CH

2

-CH(CH

3 )OH, C-C(=O)-NH-CH 2

-C(CH

3 2

-OH,

C-C(0)-NH-C(CH3) 2

-CH

2 OH, or C-C(=O)-NII-CH 2

CH

2

OCH

3 more especially

C-C(=O)-NH-C(CH

3 2

-CH

2 OH; or CH 3

CH

3 O0 CH 302C Wx C-NYly 2 C-NH b C-NH b C-NH b CH 3 OCH 3 C-NH- C-NH -d CH, C-NIH OCR 3 C-NH-CH C-NH-CR 2

T

C-NH-CR

1 2 F, C-Nil-CR 2

OCH

3 C-NH-CH /NH-CO or C-N 0) especially

CH

3 0

C-NH\/

CH 3 are preferred. Compounds of formula (1a) in which XI represents N, C-H, C-CN, C- 0 CH 3 or C-C(=0)-NH-C(CH 3 2

-CH-

2 0H are especially preferred.

WA flIflfh~i~PCT/GB02/02799 -21- Compounds of formula in which R 9 represents: hydrogen; (i i) CI-4alkyl -cH 3 or -CH 2 CH 3 (iii) C j 4 alkyl substituted by hydroxy -CH 2 OH, -CH 2

CH

2 OHor -CH 2 CH 2 CH 2

OH]

(iv) C 1 4 alkyl substituted by -N(R 6 7 Le.g. -CH 2 CH 2 CH 2 NHC CH 3); Cj..

4 alkyl substituted by -C(=O)-Ny 1 y 2 -CH~j-C -N 0Oor -CH\C/NNJ or CH 3 H21C-CH 2 (vi) cycloalkylalkyl substituted by hydroxy -C-CH 2 CHn 2

OH

are preferred. Compounds of formula (1a) in which R 9 represents 'hydrogen, -CH 3 or -CH 2 CH 3 are especially preferred.

Compounds of formula (1a) in which R 10 represents: carboxy or an acid bioisostere I

-N

(ii) hydroxy; (iii) alkyl substituted by carboxy -CH 2 CH 2 CO 2

H];

S

(iv) alkyl substituted by -N(R 6 )-S0 2

-R

7 -CH-~NHSO\ Ii; alkyl substituted by -N(R 6 )-CO-Ny 3 y 4

-CH-.IH-CO-NH-

WO 03/000688 PCT/GB02/02799 -22- N CH 3 CH...N C 3 (vi) heteroaryl 1 r pyridyl]; N N- (vii) -OR 4 in which R 4 is alkyl -0CH 3 (viii) -OR 4 in which R 4 is alkyl or cycloalkylalkyl substituted by one or more hydroxy groups -OCH 2 CH 2 OH, -OCH 2 CH 2 CH 2 OH, -OCH (CHM 3 CH 2

OH,

H 2C-CH 2 21 1 -OCH 2 CH (OH) CH 3 1 -0-C-CM 2 Or -OCH 2 CH (OH) CH 2

OH;

CH

2

O

(ix) -OR 4 in which R.

4 is alkyl substituted by one or more alkoxy groups (e.g.

-OCH (CH 3

CH

2 OCH 3 1;

-OR

4 in which R 4 is alkyl or cycloalkyl substituted by one or more carboxy groups [e.g.

Co 2H H 2C-CH2 121 12 -0CM 2 Co 2 H, -OCH (CH 3

CO

2 H, -0-ti -CH, or -O-C-CH 2 2 CoM2 H C-CM 2 e 21C CH2O (xi) -OR 4 in which R 4 is cycloalkyl substituted by Iy 2 [eg. -0C- M or CONH 2 H C-CM 2 2 1 1I -0-C-CM 2 CONHC

C

3 (xii) in which R is alkyl -c -CM 3 1; (xiii) -C(0)-NY 1 y 2 -C'ONH 2 -CNHCH 3 -CONHCH (CH 2 OH 2 -CONHCH 2 C 2 -CONBC (CH 3 2

CH

2 OM -C(=O)-NH-CH- 2

-C(CH

3 2

-OH-,

-C(=O)-NH-CH

2 -CHi 2

-CO

2 H, -CONCH 2 CH 2 OCH 3 1 -CONHCH 2 C 2 CONH 2 or -CONM or N -NH WO 03/000688 PCT/GB02/02799 -23- (xiv) -N(R 6 7 -NHC CH 3 are preferred. Compounds of formula (1a) in which RIO represents carboxy, pyridyl, S 0 -CH-1NU-S 2 -CHi-NH-CO-NH H 2C-CH 2CO2 H H 2C-CH 2 N 1 j2 j2 2) 1 2 N CH OH CO 2 h CONH 2 -CONHC (CR 3 2

CH

2 oH, -C(0)-NH-CH 2

-C(CH

3 2 -OH or -CONHCH 2 CH 2 ocH 3 are especially preferred.

When p is 1, RIO is preferably attached to position 5, or position 6, of the indolyl ring.

When p is 2, the R 1 0 groups are preferably attached to positions 5 and 6 of the. indolyl ring.

A preferred group of compounds of the invention are compounds of formula in which:- R 2 is hydrogen; R 3 is hydrogen; X I is CH, C-aryl C-phenyl], C-heteroaryl, C-pyridyl Or CH 3 C I C-halo C-Cl], C-CN, C-lower alkoxy q-OCH 3 I, C-C(=O)-0R 5 [e.g.

CH~

C-C(=O)-0tBu), C-C(=0)-Ny 1 y 2 [especially C-C(0)-N1-CH 3

C-C(=O)-NH-CH-

2

-CH

2

OH,

C-C(=O)-NH-CH

2

-CH-(CH

3 )OH, C-C(=Oy-NH-CH 2

-C(CH

3 2 -OH, C-C(=O)-NH-C(CH 3 2

-CH

2

OH

or C-C(=O)-NH-CH 2

CH-

2 0CH 3 more especially C-C(=0)-NH-C(CH3) 2

-CH

2 O0fj, or C-NY 1 y 2 CII 0 [especially C-NH ,3;R 9 is hydrogen, (ii) C].~alkyl e.g. -CH 3 or -CH 2 CH..j (iii) C 1 4 alkyl substituted by hydroxy -CH 2 OH, -CH 2 CH 2 OH or -CH 2 CH 2

CH

2 OH1, (iv)

C

1 4 alkyl substituted by -N(R 6 7 -cH 2 CH 2 CH 2 NHC CH, CI- 4 alkyl WO 03/000688 WO 03/00688PCT/GB02/02799 -24substituted by IY 2 -CH 2 C -N 0 or -CH 2-CO-NH 7 1 or (vi) cycloalkylalkyl substituted by hydroxy RI 0 is carboxy or an acid bioisostere [e.g.

I (ii) hydroxy, (iii) alkyl substituted by carboxy C 2 alkyl

-N

S

substituted by -N(R 6 )-S0 2

-R

7 -CHTNH- so 2 alkyl substituted by -N(R 6

)-CO-

Ny 3 y 4 -C1i-v%~-CO-NH 0 (vi) heteroaryl CH3

NN

I or pyridyl], (vii) -OR 4 in which R 4 .is alkyl -OCH 3 (viii) -OR 4 in which

N

R

4 is alk-yl or cycloalkylalkyl substituted by one or more hydroxy groups -OC:H 2 CH 2

OH,

H C-CE 2 -OC 2 CH 2 CH 2 OH-, -OCH (CHE 3 CH 2 OH, -OCH 2 CH (OH) CHE 3 -0-C-CH 2 or CH 2

OH

-OCH 2 CH (OH) CH 2 OH 1, (ix) -OR 4 in which R 4 is alkyl substituted by one or more alkoxy groups -OCH (CH 3 CH 2 OCH 3

-OR

4 in which R 4 is alkyl or cycloalkyl substituted by one or more H C-CE 2 carboxy groups -OCE 2 CO H, -OCH (CEH C 2 or 21-C 1C 2

OR

4 in which R 4 CO 2

H

H C-CH H2C-CH 2 1 1 2 21 1 2 is cycioalkyl substituted by Iy 2 -0-c-CH 2 or -0-C-CE 2 (xii) CONE 2 CONHCH 3 -C(0O)-R in which R is alkyl -C -CE 3 (xi ii) Iy 2

-CONE

2 WO 03/000688 PCT/CB02/02799 -CONHCH 3 CONHCH (CH 2 OH) 2' -CONHCH 2

CH

2 OH, -CONHC (CHO) 2

CH

2

OH,

-C(=O)-NH-CH

2

-C(CH

3 2 -OH, -C(=O)-NH--CH 2

-CH-

2 -CO2H, -CONCH 2

CH

2

OCH

3

N

-NEC CE 3 the R 1 0 group is attached to position 5, or position 6, of the indolyl ring when p is 1 and the R 1 0 groups are attached to position 5 and 6 of the indolyl ring when p is 2; and the.

corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g.

hydrates) of such compounds and their N-oxides and prodrugs.

A further preferred group of compounds of the invention are compounds of formula (la) in which:- R 2 is hydrogen; R 3 is hydrogen; X I i s N; R 9 is hydrogen, (ii) C 1 4 alkyI e.g. -CH 3 or -CH 2 CH 3 0iii) C 1- 4 alkyl substituted by hydroxy -CH 2 0H, -CE 2

H

2 O or

-CH

2

CH

2

CH

2 (iv) C I 4 alky) substituted by -N(R 6 7 [e.g.

_C

2 CH 2 CH 2 NC CH 3 M (v G 14 alkyl substituted by -C(0)-Ny Iy 2 [e.g.

-CH -C -N 0* or -CH-CO-'NH N or (vi) cycloalkylalkyl substituted by 22 2 hydroxy -C-CHj R 10 is carboxy or an acid bioisostere /1 O hydroxy, (iii) alkyl substituted by carboxy -CH 2 CH 2 CO 2 H (iv) alkyl substituted by

S

-N(

6 )-0 2

R

7 e~g J 2 1\1S 2 I alkyl substituted by -N(R 6 )-CO-YY [eg N CHE 3 N_ H3 ]C-k-Ohj (vi) heteroaryl 'I or pyridyl], (vii) -OR 4 in which R 4 is alkyl OCH 3 (viii) -OR 4 in which R 4 is alkyl or WO 03/000688 WO 03/00688PCT/G B02/02 799 -26cycloalkylalkyl substituted by one or more hydroxy groups -oCH 2 CH 2 O -OCH 2 CH 2 CH 2 H C-CH 2 -OCH (CH 3 CH 2 OH, -OCH 2 CH (OH) CH 3 -O--C-CH 2 or -OCH 2 CH (OH) CH 2 OH (ix)

-OR

4 in which R 4 is alkyl substituted by one or more alkoxy groups 0CC (CH 3 CH 2 OCH 3

-OR

4 in wvhich R 4 is alkyl or cycloalkyl substituted by one or more carboxy groups (e.g.

H C-CC 2 -OCH CO H, -OCH (CH) COH or ICR (xi) -OR 4 in which R 4 is cycloalkyl Co2H H C-CCH C-CH 12 eCg 2 2 21 12 subtittedby C(O)-YY o-cC1 or -O-C-CH 2 (xii) in which R CONH 2 CONHCH 3 is alkyl -C -CH 3 (xi ii) Iy 2 CONH 2 -CONHCH 3 -CONHCH (CH 2 OH 2 -CONHCH 2 CH 2 OH, -CONHC (CH 3 )2 CH 2

OH,

-C(=O)-NI-I-CI-

2

-C(CH

3 2 -OH, -C(=-O)-NH-CH 2

-CH

2

-CO

2 H, -CONHCH 2 CH 2 OCH 3

N

-NHC e 3 the RIO group is attached to position 5, or position 6, of the indolyl ring when p is I and the R 10 groups are attached to position 5 and 6 of the indolyl ring when p is 2; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g.

hydrates) of such compounds and their N-oxides and prodrugs.

Another particular group of compounds of the invention are compounds of formula WO 03/000688 WO 03/00688PCT/GB02/02799 -27-

R

3

R

4

CNN

in which R 2

R

3

R

9 RIO0, X I and p are as hereinbefore defined, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of compounds of formula (Ib) and their N-oxides and prodrugs.

Compounds of formula (Ib) in which R 2 represents hydrogen are preferred.

Compounds of formnula (Ib) in which R 3 is hydrogen are preferred.

Compounds of formula (1b) in which XI represents:

N;

(ii) CH; W 15 (iii) C-aryl C-phenyl); CH 3 (iv) C-heteroaryl, especially C-azaheteroaryl 0-pyridyl or C

CH

3 *C-halo C-Cl); (vi) C-CN; (Vii) C- Z 2 R, particularly C-lower alkoxy (e-g.C-OC- 3 (viii) C-C(=0)-0R 5 particularly C-CQ=O)-OtBu; (ix) Iy 2 C-CQ=0)-NH-CH- 3 C-C(-0)-NH-CH 2

-CH-

2

OH,

C-C(=O)-NH-CH-

2

-CH(CH-

3 )OH, C-C(=O)-NB--CH- 2

-C(CH

3 2

-OH,

WO 03/000688 PCT/GB02/02799 -28- C-C(0)-NIH-C(CH 3 2

-CH

2 OH, or C-C(=O)-NH-CH 2

CH

2

OCH

3 more especially C-C(=O)-M-l-C(CH 3 2

-CH

2 )OH; or CH 3

CH

3 0 CH 3 0 2

C

C-Ny 1 y 2 C-NH C-NH b C-NH b CH 3 OCH 3 C-NHI- C-NH ,CNH -0 CH 3 C-NH -0 OCH 3 C-NH-CH -K C-NH--CH 2

C-NH-CH

2 FC-H-R OH 3

C-NH-CH

1 /NH-CO _0 or C-N 0 especially

CH-

3 0 C-NH\ CH 3 are preferred. Compounds of formula (1b) in which X I represents N, C-H, C-CN, C_ 0 CH 3

CH

3 O0 C-NH b or C-C(=O)-NH-C(CH 3 2

-CH

2 OH are especially preferred.

Compounds of formula (lb) in which R 9 represents hydrogen are preferred.

Compounds of formula (Tb) in which R 9 represents Cl~alkyl are also preferred.

WO 03/000688 PCT/GB02/02799 0 -29-

O

r Compounds of formula (lb) in which p is zero are preferred.

SA preferred group of compounds of the invention are compounds of formula (Ib) in which:- R 2 is hydrogen; R 3 is hydrogen; X 1 is CH, C-aryl C-phenyl], C-heteroaryl, C-pyridyl or

CH

C-halo C-CI], C-CN, C-lower alkoxy C-OCH 3

C-C(=O)-OR

5 [e.g.

CH3 S C-C(=O)-O t Bu], C-C(=O)-NY 1

Y

2 [especially C-C(=O)-NH-CH 3

C-C(=O)-NH-CH

2

-CH

2 0H, C-C(=0)-NH-CH 2

-CH(CH

3 )OH, C-C(=O)-NH-CH 2

-C(CH

3 2 -OH, C-C(=O)-NH-C(CH 3 2

-CH

2 0H or C-C(=O)-NH-CH 2

CH

2 0CH 3 more especially C-C(=O)-NH-C(CH 3 2 -CH20H] or C-NY 1

Y

2 CH O [especially C--NH R 9 is hydrogen or Cl_4alkyl -CH 3 p is zero; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g.

hydrates) of such compounds and their N-oxides and prodrugs.

A further preferred group of compounds of the invention are compounds of formula (Ib) in which:- R 2 is hydrogen; R 3 is hydrogen; X 1 is N; R 9 is hydrogen or Cl-4alkyl -CH 3 p is zero; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g.

hydrates) of such compounds and their N-oxides and prodrugs.

Another particular group of compounds of the invention are compounds of formula

R

2 9 H R WO 03/000688 PCT/GB02/02799 in which R 2

R

3

R

9 RIO, XI and p are as hereinbefore defined, and the residueR

N

is preferably attached to position 2 or 3 of the pyrrole ring and the group -(RIOp is preferably attached C1 to position 4 or 5 of the pyrrole ring, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of compounds of formula (1c) and their N-oxides and prodrugs.

C1 Compounds of formula (1c) in which R 2 represents hydrogen are preferred.

Compounds of formula (1c) in which R 3 is hydrogen are preferred.

Compounds of formula (1c) in which X I represents: N (ii) CH; (iii) C-aryl C-phenyl);

CH

-N

(iv) C-heteroaryl, especially C-azaheteroaryl C-pyridyl or C I 1).

0 CH 3 C-halo C-Cl); (vi) C-CN; (vii) C- Z 2 R, particularly C-lower alkoxy (e.g.C-OC- 3 (viii) C-C(0O)-0R 5 particularly C-C(0)-OtBu; or Iy 2 C-C(=0)-NE--CH 3 C-Ce=O)-N--CH 2

-CH-

2 0H,

C-C&O)-NH-CH

2

-CH(CH

3 )OH, C-C(=0)-NH-CH 2

-C(CH

3 2

-OH,

C-C(=O)-NH-C(CJ-

3 2 OH, or C-C(=O)-NH-CH 2

CH

2

OCH

3 more especially

C-C(=O)-NH-C(CH

3 2

-CH

2 OH; or WO 03/000688 WO 03/00688PC TICB02/02 799 -31- *C-NY Iy 2 (e.g.

C-NH GH 3 C-NH /OCH 3 ,5

C-NH-CH

2

/F

C-NI--CH C-NH-CH C-NH-GHl 2

/OCH

3 ,3 C-NH-GCl, NH-CO- 1 o 0) especially CH 3

-N

are preferred. Compounds of formula (1c) in which X I represents N, C-H, C-CN, C I, CH 3

CH

3 O0 C-NH b or C-C(=O)-NH-C(CH 3 2

-CH

2 OH are especially preferred.

Compounds of formula (Ic) in which R 9 represents C 1 4 alkyl -CH 3 are preferred.

A particular embodiment of of the invention is given by compounds of formula (1c) in which R 9 represents optionally substituted C 1 4. alkyl.

Compounds of formula (1c) in which p is I are preferred.

WO 03/000688 PCT/GB02/02799 -32- Compounds of formula (Ic) in which R 10 represents aryl phenyl] are preferred.

A particular embodiment of of the invention is given by compounds of formula (Ic) in which R' i represents optionally substituted aryl or optionally substituted heteroaryl.

A preferred group of compounds of the invention are compounds of formula (Ic) in which:- R 2 is hydrogen; R 3 is hydrogen; X 1 is CH, C-aryl C-phenyl], C-heteroaryl, C-pyridyl or

CH

3

-N

C I C-halo C-CI], C-CN, C-lower alkoxy C-OCH 3

C-C(=O)-OR

5 [e.g.

CH

3 C-C(=O)-OtBu], C-C(=O)-NY 1y 2 [especially C-C(=O)-NH-CH 3

C-C(=O)-NH-CH

2

-CH

2

OH,

C-C(=O)-NH-CH

2

-CH(CH

3 )OH, C-C(=O)-NH-CH 2

-C(CH

3 2 -OH, C-C(=O)-NH-C(CH 3 2

-CH

2

OH

or C-C(=O)-NH-CH 2 CH20CH 3 more especially C-C(=O)-NH-C(CH 3 2 -CH2OH or C-NY y 2 CH O [especially C-NH- R 9 is C 1 -4alkyl -CH, p is 1; R 1 0 is aryl phenyl]; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

A further preferred group of compounds of the invention are compounds of formula (Ic) in which:- R 2 is hydrogen; R 3 is hydrogen; X 1 isN; R 9 is Cl_ 4 alkyl -CH p is 1; R 1 0 is aryl phenyl]; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

A particular embodiment of the invention are compounds of formula (Ic) wherein R 9 is C-4 alkyl substituted by alkoxy or C.

4 alkyl substituted by -NY'Y 2 and R' 1 is optionally substituted heteroaryl or optionally substituted aryl.

Another particular group of compounds of the invention are compounds of formula WO 03/000688 PCT/GB02/02799 6 -33- NN2 3 c~Kl H (1d) in which R 2

R

3 RIO, X I and p are as hereinbefore defined, and the corresponding N-oxides, and their prodrugs; and pharmaceutical ly acceptable salts and solvates hydrates) of compounds of formula (1d) and their N-oxides and prodrugs.

Compounds of formula (Id) in which R 2 represents: hydrogen; (ii) lower alkyl methyl); (iii) lower alkyl substituted by -CONY 1 y 2

CH

2

CH

2 CON1i 2 or -CH 2

CH

2 CON HCH 3 (iv) lower alkyl substituted by carboxy -CH 2

CH

2

CO

2 lower alkyl substituted by tetrazolyl -CHF-CHK 4/ W 15 (vi) lower alkyl substituted by hydroxy -CH 2

CH-

2

CH

2 OH or -CH 2

CH

2

C(CH

3 2 0H); (vii) lower alkyl substituted by -N(R 6 )-S0 2

-R

7

-CH

2

CH

2

CH

2

NHSO

2

CH

3 (viii) lower alkyl substituted by -N(R 6

-CH

2

CH

2

CH

2

NHC&=O)CH

3 or (ix) lower alkyl substituted by -C(0O)-R -CH 2

CH

2 C(0O)CH 3 are preferred.

Compounds of formula (1d) in which R 3 is hydrogen are preferred.

Compounds of formula (1d) in which X I is N are preferred.

Compounds of formula (1d) in which p is I are preferred.

WO 03/000688 PCT/GB02/02799 -34- Compounds of formula (Id) in which R 10 represents alkyl tertiarybutyl] are preferred.

RIO is preferably attached at position 4.

A preferred group of compounds of the invention are compounds of formula (Id) in which:- R 2 is (i) hydrogen, (ii) lower alkyl methyl), (iii) lower alkyl substituted by -CONYIy 2 (e.g.

-CH

2

CH

2

CONH

2 or -CH 2

CH

2

CONHCH

3 (iv) lower alkyl substituted by carboxy (e.g.

N-NH

-CH

2

CH

2

CO

2 lower alkyl substituted by tetrazolyl -CH HCH I (vi) lower NyN alkyl substituted by hydroxy -CH 2

CH

2

CH

2 0H or -CH 2

CH

2

C(CH

3 2 0H]; (vii) lower alkyl substituted by -N(R 6 )-S0 2

-R

7

-CH

2

CH

2

CH

2

NHSO

2

CH

3 (viii) lower alkyl substituted by

-N(R

6

-CH

2

CH

2

CH

2

NHC(=O)CH

3 or (ix) lower alkyl substituted by (e.g.

-CH

2

CH

2

C(=O)CH

3

);R

3 is hydrogen; XI is N; p is 1; R 10 is alkyl tertiary-butyl] and R 10 is attached at position 4; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Particular compounds of the invention of formula are selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table 1 to the carbon atom in the heteroaromatic ring of one of the fragments (B103 to BI 16) shown in Table 2.

Particular compounds of the invention of formula (la) are selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table 1 to the carbon atom in the five membered ring of one of the fragments (B to B39 or B1 17 to B123) shown in Table 2, and joining the carbon atom of the phenyl ring in one of the fragments (BI to B39 or B 17 to B123) shown in Table 2 to the oxygen atom of one of the fragments (Cl to C19 or C79 to C96) depicted in Table 3.

Particular compounds of the invention of formula (la) are also selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table I to the carbon atom in the five membered ring of one of the fragments (BI to B39 or B 17 to B123) shown in Table 2, and joining the carbon atom of the phenyl ring in one of the fragments (B1 to B39 or B 117 to B 123) shown in Table 2 to the carbon atom of one of the fragments (C20 to C44, C47 to C61, C65 to C78 or C97) depicted in Table 3.

WO 03/000688 PCT/GB02/02799 Particular compounds of the invention of formula (la) are also selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table 1 to the carbon atom in the five membered ring of one of the fragments (Bi to B39) shown in Table 2, and joining the carbon atom of the phenyl ring in one of the fragments (BI to B39) shown in Table 2 to one of the nitrogen atom of the fragments (C45, C62 or C63), or to a hydrogen atom fragment (C46) or to a fluorine atom fragment C64) depicted in Table 3.

Particular compounds of the invention of formula (Ib) are selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table I to the carbon atom in the five membered ring of one of the indolizine fragments (B40 or B41) shown in Table 2, and joining the carbon atom in the six membered ring of one of the indolizine fragments or B41) shown in Table 2 to the oxygen atom of one of the fragments (Cl to C19 or C79 to C96), (ii) the carbon atom of one of the fragments (C20 to C44, C47 to C61, C65 to C78 or C97), (iii) the nitrogen atom of one of the fragments (C45, C62 or C63), (iv) a hydrogen atom fragment (C46)) or a fluorine atom fragment C64) depicted in Table 3.

Particular compounds of the invention of formula (Ib) are also selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table 1 to the carbon atom in the indolizine fragment (B42) shown in Table 2.

Particular compounds of the invention of formula (Ic) are selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al to A87) shown in Table 1 to the carbon atom in one of the pyrrole fragments (B43 to B54) shown in Table 2.

Particular compounds of the invention of formula (Id) are selected from the compounds formed by joining the carbon atom of one of the azaindoles fragments (Al or A29, A61 or A64 to A66) shown in Table 1 to the carbon atom in one of the fragments (B55 to B100) shown in Table 2.

TABLE 1 WO 03/000688 WO 03/00688PCT/GB02/02799 -36- A3 N A4 CF 3

III

N

N

HH

0 CH 3 A6 0 11CF 3 N N H H A7 A8A 0 N N N 0

H

H

A9 0 NHCH 3 AIO 0 NH 2

N

H H All A12 O0 N N NN NN N C

H

H

WO 03/000688 PCT/GB02102 799 WO 03/000688 PCT/GB02/02799 WO 03/000688 WO 03/00688PCT/GB02/02799 'c-I -39- WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/GB02/02799 WO 03/000688 WO 03/00688PCT/GB02/02799 A63 F zA64 N N N NN NN H H A66 N

NN

C*

C H

NN

H

A67 0 0 N A68 H OH N.0 N~l

N~

H

WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/GB02/02799 (Ni WO 03/000688 WO 03/00688PCT/GB02/02799 -47- TABLE 2 BI C B2 C KN K CH 3

H

B3 C*B4 C K

K

CH 2 CH 3 CH 2

OH

C*B6 C CH2 CH2 OHCH2CH 2CH2OH B7 r-*B8 C K

K

CH 2 CH 2 CH 2 NHCOCH 3 CH2 B9 C*BIO C

*C*C-

CH CH 2 NH 2

N

COH

OH

WO 03/000688 PCT/G B02102 799 WO 03/000688 PCT/GB02/02799 -49- WO 03/000688 PCTGB02O2 799 i4C~] WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/GB02/02799 WO 03/000688 PTGO/29 PCT/GB02/02799 4

C~]

B69 B70

OH

*601- O\ H*

J

B71 ,0B72 Br B73 OH B74 0 S N N

OH

B76 B77 \~B78

O

B79 \B80

H

*0 NH 2 *CO N B81 B82/ C\3N\ *0

-NO

B83 \B84 *C N N-H *CN

N

(N

B860 N N-S0 ~0 -0 WO 03/000688 PCT/GB02/02799 WO 03/000688 PCT/CB02/02799 4

C~]

B 107 B108C 0 N B 109 BlIO/ /C cN

K/S\

[jN Bill BI 12 C No

N-

BI153 *C BI164

N-D

H

O OH B117 C* B118 C OCH OCH 3 *C*C

KNN

ZZCH 2CH 2 OH

C)

0 WO 03/000688 PCT/GB02/02 799 4

C~]

WO 03/000688 WO 03/00688PCT/GB02/02799 TABLE 3 Cl C2 *O-CH =0

HO

C3 OH C4 OH *0 C6 *0 so HO C7 C8 *0 *0 0

H-N

HO

OH

C9 HCIO *0-H *0 OH CiI C12 COOH

H

C13 C 14 *0 *0 MeO0 CI 0 CONH 2 CONHCH 3 *0 0 cis *0H WO 03/000688 WO 03/00688PCT/GB02/02799 -58- C19 OH C20 0 0 C -CH 3

HO

C21 C22 *CH-CH 2-CO2 H 2 CH2-C 2 C23 0 C24 0 *C-NH-CH *C-NH-CH 2-CH 2-CONH2 0 C26 0 11 11 *C-NH-CH -CK -OCH3 *C-NH-CH 2-CE 2-CON CH 3 C27 C28 0

*C-OH

*C-NH

C29 0 C0 *C-NH 2*C-NH C31 0 C32 0 *C-NH *C-NH OH HO OH C33 0 C34 0 C-NH *C-NH-CH 2-CH -OH HO-- OH N C36 H *C NN

N-N\\I

N-N

C37 C38C38 WO 03/000688 PCT/G B02/0 2799 WO 03/000688 WO 03/00688PCT/GB02/02799 059 0C6 I I

N-OH

3 1 C60 1 0 11

*C-NH

0=

S

-N 0

H

C6] 0 062 /CH3 *C-NH-CH -CONH *NH-S 2 2 0 0 063 *NH2 064 065 *CN C66 H

ICO

H

067 C68 *C

N

N-N CH 3 C69 C70 *CH-NH-CO-CH H s *CHE2 0 0 C71*C -NH C72 H

N

*CH/ N-7 073 C74 H 0 0 H N N llN-< *H 2CH 0 2 H WO 03/000688 WO 03/00688PCT/GB02/02799 -61- C76 H 2 H NHe~ C s *CH N N 0 O77 C78 0 2 0 C79 *0 C80 *0 OH OH OH C81 NH 2 C82 C83 0\ C84 0 OJ N 0 -N

OH

OH

0 C86 -OH OH0* *0H*0 C87 0 C88 OH

ORH

0 C89 OMe C90 0 00 N0 0 N 0 WO 03/000688 PCT/GB02/02799 C91 -C92 O NH

OH

C93 -C94 CH

*O-CH

CH

3 O NH L^OMe C96 *O-CF2H *0-

CF

2 H0 C97 O

II

*C-NH

OH

Particular compounds of the invention of formula may be denoted as the product of all combinations of each of groups Al to A87 in Table 1 and each of groups BI to B 123 in Table 2 and each of groups C to C97 in Table 3. Further particular compounds of the invention of formula may be denoted also as the product of all combinations of each of groups Al to A87 in Table I and each of groups Bi to B123 in Table 2.

Thus, for example, the combination which may be denoted as A -Bl-C1 is the product of the combination of group A in Table I and B1 in Table 2 and CI in Table 3, namely

/CH

3

CH,

Example I hereinafter described.

WO 03/000688 WO 03100688PCT/GB02I02799 -63rl Particular compounds contemplated by the present invention, then, include all of the compounds made up of each of the combinations Al to A87 -BI to B123 CI to C97, and each of the combinations Al to A87 -BlItoBl123.

Particular compounds of the invention are:- -methyl-I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; I-methyl-I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; 6-(3 -bromophenyl)-5 H-pyrrolot2,3 -blpyrazine; 7-iso-propyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine; 6-(4-bromopheny l)-5H-pyrrolo[2,3-b]pyrazine; 2-(4-bromophenyl)- I H-pyrrolo[2,3-b]pyrazine; 6-(4-[1I,3]dioxan-2-yl-phenyl)-5H-pyrrolol2,3-b]pyrazine; ,3]dioxan-2-yl-phenyl)-5H-pyrrolo[2,3-b]pyrazine; 2-(5H-pyr-rolo[2,3-b]pyrazin-6-yl)-quinoline; 3-(SH-pyrrolo[2,3-b]pyrazini-6-yI)-isoquinoline; I-methyl-I H-inidol-5-yl]-5H--pyrrolot2,3-b)pyrazine; 6-(5-methoxy-1 -methyl- I H-indol-3-yI)-2-methyl-5H-pyrrolo[2,3-b]pyrazine; 3-methyl-6-( 1-methyl- I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; I -benzyl-5-methoxy- I H-indol-3-yl)-5 H-pyrrolo(2,3-b]pyrazine; ZO 6-(l I-methyl-I H-pyrrol-3-yl)-5 H-pyrrolo[2,3-b]pyrazine; I-methyl-i H-pyrrol-2-yl)-5H-pyrrolo[2,3-b]pyrazine; 6-indol izin- I -yl-5H-pyrrololl2,3-b]pyrazine; 6-(3-methyl-indol izin- I -yl)-5H-pyrrolo[2,3-b]pyrazine; -methyl-2-phenyl-I H-pyrrol-4-yI)-5H-pyrrolof2,3-b]pyrazine; 6-(5,6,7,8-tetrahydro-inidol izin-I -yI)-5H-pyrrolo[2,3-b]pyrazine; 6-fu ran -3 -yl-S H-pyrro lo[2,3 pyrazine; dimethyl-[4-(5H-pyrrolo[2,3-b)pyrazin-6-yl)-plienyl]-am ine; I-methyl- I H- indol-3 -yl)-7-mnethyl-5H-pyrrolo[2,3 -b]pyrazine; 6-(4-terrt-butylphenyl)-5J--pyrrolo[2,3-b]pyrazine; 6-(4-ter-t-butylphenyl)-7-methiyl-5H-pyrrolol2,3-blpyrazine; 6-(3 ,4-d i methoxyphenyl)-5H-pyrrolo[2,3 -b]pyrazine; 6-(4-aminophenyl)-7-methyl-51-I-pyrrolo[2,3-b]pyrazine; -methiyl)ethoxyphenyl]-5H-pyrrolo(2,3-b]pyrazine; 6- (1 H-I -methyl-2-(methylthio)imidazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine; I-methyl-I H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; I-methyl-4-phenyl- IH-pyrrol-3-yl)-5 H-pyrrolo[2,3-b]pyrazine; WO 03/000688 WO 03/00688PCT1GB02/02799 -64- 6-(4-fluorophenyl)-5H--pyrrolo[2,3-b~pyrazine; 6-(4-methoxypheiy 1)-5 H-pyrrolo[2,3 pyrazine; 6-[4-(tert-butyl)phenyl]-7-(prop- I -enyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-methylth iophenyl)-SH-pyrro lo [2,3-b]pyrazine; 6-(3-metlhoxylphenyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(l -methyl-I H-pyrazol-4-yI)-5H-pyrrolo[2,3-b~pyrazine; 6-(l -methyl-5-phenyl- I H-pyrazol-3-yI)-5H-pyrrolo[2,3 -bipyrazine; 6-(pyrid in-2-yl)-5H-pyrrolIo [2,3 pyrazi ne; 6-(pyrid in-4-yi)-5 H-pyrrolo[2,3 pyrazine; 6-(3,4-dimethylphenyl)-5H--pyrrolo[2,3-b]pyrazine; 6-(4-hydroxyphenyl)-5H-pyrrolol2,3 -b]pyrazine; 6-(4-trifluoromethoxyphlenyl)-5 H-pyrrolo[2,3-b]pyrazine; 6-(4-am inophenyl)-5H-pyrrolo[2,3-b]pyrazine; I-methyl-2-phenyl- IH-pyrrol-3-yI)-5 H-pyrrolo[2,3-b]pyrazine; 1,5-dimethyl- I 1-pyrrol-3-yI)-SH-pyrrol o[2,3-b~pyrazine; 6-(1I,4-dinmethyl- IH-pyrrol-3-yI)-5H-pyrrolo[2,3 -b]pyrazine; I-methyl-4-phenyl- IH-pyrrol-3-yI)- IH-pyrrolo[2,3-b]pyridine; 3-[3-(5H-pyrrolo[2,3-b]pyrazin-6-yI)-indol-1I-yI]-propan- I-ol; 3-[5-methoxy-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I-yI]-propan- I-ol; 2-[3-(5H-pyrrolo[2,3-blpyrazini-6-yI)-indo- I -yIl-ethanoI; H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; 2-[5-r-nethoxy-3-(5H-pyrrolo[2,3 -b]pyrazin-6-yI)-indol-1I-yI]-ethanol; 3-[3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I -yl]-propylamine; 3-[S-methoxy-3-(SH-pyrrolo[2,3-blpyrazi n-6-yl)-indol- I -yi]-propylamime; N- {3-[3-(SH-pyrrolo[2,3-b] pyrazin-6-yl)-indol- I -yl]-propyl }-acetamide; N-[4-(5H-pyrrolo[2,3-b)pyazi n-6-yl)-phenylj-acetam ide; I-(3-niorpholin-4-yI-propyl)- I H-indol-3-yI]-5H-pyrrolo[2,3-bjpyrazine; 6-[]I-(3-piperidin- I -yI-propylI)-1 H--indol-3-yI-5H-pyrrolo[2,3-bjpyrazine; 6-f {I-[3-(pyridin-3-yloxy)-propyl)- IH-indol-3-yi)}-5H-pyrrolo[2,3-b]pyrazine; 1 -mnethyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I 6-(2-cliloro-5-rnethoxy- 1-methyl-I H-indol-3-yi)-5H-pyrrolo[2,3-b]pyrazine; 3-(5H--pyrrolo[2,3 -b]pyrazini-6-yl)-benzaldehyde; 4-(5H-pyrrolo(2,3-b]pyrazini-6-yI)-benzaldehyde; [3-(5H-pyrrolo[2,3-b]pyrazini-6-yI)-indol- I -yI]-methanol; [3 H-pyrrolo (2,3 pyrazi n-6-y I)-pheny1] -methanol; [4-(5H-pyrrolo[2,3-b]pyrazi n-6-yl)-phenyl]-methanol; WO 03/000688 PCT/GB02/02799 I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazinie; 2-[5-methoxy-3-(5 H-pyrrolo[2,3-bjpyrazini-6-yI)-indol- I -yI]-1I -morphol in-4-yl-ethanone; (Ki 2-[5-inethoxy- I-(2-morphol in-4-yI-2-oxo-ethyl)- IH-indol-3-yI] IH-pyrrolo[2,3-b]pyridine-4carbonitrile; [5-methoxy-3-(]IH- pyrro lo[2,3 pyrid in-2-yl)-indolI- I -yl] -acetic acid; 4-methoxy-2-(5-methoxy- I-methyl-I H-i ndol-3-yI)- IH-pyrrolo[2,3-b]pyridine; 4-methoxy-2-(5-methoxy- I H-indol-3-yl)- 1 H-pyrrolo[2,3-b]pyridine; ~~K1 4-ch Ioro-2-(4-iert-butyl phenyl)- I H--pyrrolo[2,3-b]pyridine; I-methyl- I I--indol-3-yI)-S-phenyl- I H-pyrrolo[2,3 -b]pyridine; 1 -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-I H-indol-5-yloxy]-propan-2-oI; r5,6-dimethoxvy-3-( IH-pvyrrolor2.3-blpyridin-2-vI)-indol-I -yil-acetic acid, 2-[5-methoxy-3-( I H-pyrrolo[2.37b~pyridin-2-yI)-indol- l-yl]- I -morpholin-4-yi-ethanone; I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)- IH-indol-5-yloxy]-cyclobutanecarboxylic acid amide; I -methyl-3-( IH-pyrrolo[2,3 -blpyridin-2-yl)-I H-indol-5-yloxy]-cyclobutanecarboxylic acid methylamide; I -methyl-3-( IH-pyrrolo[2,3-b] pyrid in-2-yl)- IH-indole-5-carboxylic acid methylamide; I -methyl-3-( IH-pyrrolo[2,3-b] pyrid in-2-yI)- IH-indole-5-carboxyl ic acid (2-hydroxy-ethyl)-amide; I -methyl-3-( IH-pyrrolo[2,3 pyridin-2-yl)- IH-indole-5-carboxylic acid (2-morpholin-4-yl-ethyl)amide; 1 -methyl-3-( 1 H-pyrrolo[2,3 -bjpyridin-2-yl)- I H-indole-5-carboxylic acid (2-carbamoyl-ethyl)-amide; I -methyl-3-( IH-pyrrolo[2,3-b] pyrid in-2-yl)- IH-indole-5-carboxylic acid bis-(2-hydroxy-ethyl)-am ide; I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indole-5-carboxylic acid amide; I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- 1H-indole-5-carboxylic acid (2-hydroxy- 1,1-bishydroxymethyl-ethyl)-am ide; I -methyl-3-( IH-pyrrolo[2,3-b] pyrid in-2-yI)- 1H-indole-5-carboxylic acid (2-hydroxy-l1-hydroxymethyl- I -methyl-ethyl)-amide; I -methyl-3-( IH-pyrrolo[2,3-b] pyridin-2-yl)- IH-indole-5-carboxyl ic acid (2,3-dihydroxy-propyl)am ide; 1 -methyl-3-( IH-pyrrolo[2,3 -bjpyrid in-2-yl)- IH-indole-S-carboxylic acid (2-hydroxy- 1,1-dimethylethyl)-amide; I -methyl-3-( IH-pyrrolo[2,3 -b~pyridi n-2-yl)- IH-i ndole-5-carboxylic acid (2-hydroxy-l1-hydroxymethiylethyl)-amide; I -niethyt-3-( I H-pyrrolo[2,3 pyrid in-2-yl)- I H-indole-6-carboxyl ic acid (2-carbarnoyl-ethyl)-am ide; I -methyl-3 H-pyrrolo [2,3 -b]pyridin-2-yl)- I H-indole-6-carboxylit acid (2-hydroxy-ethyl)-am ide; 1 -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indole-6-carboxylic acid (I H-[JI,2,4]triazol-3-yl)aniide; WO 03/000688 WO 03/00688PCTIGB02/02 799 -66r~~l -methyl-3-( IH-pyrrolo[2,3 -b]pyrid in-2*-yl)- I H-indole-6-carboxylic acid (2-hydroxy-1I-hydroxymethylethyl)-amide; c-i -methyl-3-(SH-pyrrolo[2,3-b]pyrazin-6-yl)- IH-indole-5-carboxyl ic acid (2-hydroxy- 1,1-d imethylethyl)-amide; 3-[6-(4-tirt-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yI]-N-methylpropionamide; c=I 3-[6-(4-teri-butylphenyl)-5H-pyrrolo[2,3-b] pyrazin-7-yI)-N,N-dimethylpropionamide; I -methyl-3-(5H-pyrrolo pyrazin-6-yI)- IH-indole-5-carboxyl ic acid 2-methoxyethylamide; I -methyl-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yl)- 1H-indole-5-carboxyl ic acid 2-th ien-2-ylethylamide; I -methyl-3 -(5H-pyrrolo[2,3-b] pyrazin-6-yl)- IH-indole-5-carboxylic acid 2-fluoroethylamide;, 1 -rnethyl-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yl)- IH-indole-5-carboxyl ic acid 2-carboethoxyethylarnide; I -methyl-3-(5H-pyrrolo[2,3 -b]pyrazin-6-yI)-I H-indole-5-carboxylic acid (hydroxymethyl)carbomethoxy-methy lam ide; I -methyl-3-{5H-pyrrolo[2,3-b]pyrazin-6-yl)- I H-indole-5-carboxylic acid 2-hydroxyethylamide; I -iethyl-3 -(5H-pyrrolo[2,3 -b~pyrazin-6-yl)- IH-indole-5-carboxylic acid methylamide; I -methyl-3 H-pyrrolo[2,3-b]pyrazin-6-yI)- 1H-indole-5-carboxylic acid dimnethylarmide; [I -methyl-3-(5H-pyrrolo[2,3-blpyrazin-6-yl)- IH-indol-5-yI morpholin-4-yI ketone; 4-hydroxy-[ 141 -methyl-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yl)- 341) -methyl-3-(5H-pyrro lo[2,3 pyrazi n-6-yl)- I H- indol1-5 -yI]carbonylamnin oprop ion ic acid methylamide; -methyl-3-(5 H-pyrrolo[2,3-bjpyrazin-6-yi)- I1--indole-5-carboxyl ic acid 3 -hydroxypropy lam ide; 3- I-methyl)ethoxyphenyl]-5H-pyrrolo(2,3-b]pyrazin-7-y }propionic acid methylamide; 3-[6-(4-methoxypheniyl)-5H--pyrrolo[2,3-b]pyrazin-7-yI]propionic acid methylamide; 3- I-methyl)etlioxyphenyl]-5H-pyrrolo[2,3-blpyrazin-7-yI) propionamide; 3- {6-(4-hyd roxyphenyl)-5 H-pyrrolo[2,3-b~pyrazin-7-yI} propionam ide; 3-[6-(4-fl uorophenyl)-5H-pyrrolo[2,3-blpyrazin-7-yl~propionic acid methylamnide; 3-[4-(3,5-dimethyl-isoxazolyl-4-yI)- IH-pyrrolo[2,3-b]pyridin-2-yI]- 1-methyl-I acid (2-mnethoxy-ethyl)-amnide; 3-[4-(3,5-dimethyl-isoxazolyl-4-yl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indole-5-carboxylic acid (2methoxy-ethyl)-am ide; 3 -(4-cyano- IH-pyrrolo[2,3-b]pyrid in-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy- 1,1dimethyl-ethyl)-amide; 3-(4-cyano- IH-pyrro lo[2,3-b]pyrid in-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy-2-methylpropyl)-amide; 2-f5.6-dimethoxy-3-( IH-12yrrolor2.3-blnyridin-2-yfl-indol- I-vil- 1-morrphol ir-4-yl-ethanone; [I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-acetic acid; I-methyl-3-( I H-pyrrolo[2,3-b~pyridin-2-yl)- I H-indol-5-yloxy)-propionic acid; WO 03/000688 WO 03/00688PCT/GB02/02799 -67- I -nethyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-cyclobutanecarboxylic acid; I -methyl-3-( I H-pyrrolo[2,3-b~pyridin-2-yl)- I H-indole-5-carboxyl ic acid; I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- -(cyclobutanecarboxyl ic acid)-3- I H-pyrroio[2,3-h]pyridin-2-yl]- I H-indol-5-yloxy} cyclobutaiiecarboxylic acid; I -methyl-3-( 1H-pyrrolo[2,3-b~pyridin-2-yl)- IH-indole-6-c~arboxylic acid; 341 -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-y)-1 H-indol-5-yi]-propionic acid; I -methyl-3-(SH-pyrrolo[2,3-b]pyrazin-6-yl)- 1H-indole-5-carboxylic acid; lo [2,3-b]pyrazin-6-yl)-phenoxy]acetic acid; 3-[2-dimedhylamino-5-(51--pyrrolo[2,3-b]pyrazin-6-yI)-phenyl] propionic acid; 34-I-nethyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I H-indol-5-yI]carbonylaminopropionic acid; ,5-diniethyl-isoxazole-4-yi)- IH-pyrrolo[2,3-bjpyridine-2-yI]- I-methyl-I H-indole-5-carboxyl ic acid; ,5-imethyl-isoxazole-4-yl)- 1H-pyrrolo[2,3-bjpyridine-2-yl]- 1H-indole-5-carboxyl ic acid; 4-(3,5-d imethyl1-i soxazolIe-4-y)-2-(5-methoxy- 1 -methyl- I H- indol1-3 1 H-pyrrolo[2,3 pyrid i fe; 4-(3 ,5-dimethyl-isoxazole-4-yI)-2-(5-methoxy- I H-indol-3-yl)- IH-pyrrolo[2,3-b]pyridine;' 3-(4-methoxy- IH-pyrrolo[2,3-bjpyridine-2-yl)- 1-methyl-I H-indole-5-carboxyl ic acid; 3-(4-cyaino- IH-pyrrolo[2,3-b~pyridine-2-yl)-I -methyl-I H-indole-5-carboxylic acid; I H-pyrrolo[2,3-b~pyridine-2-yl)-I H-indole-5-carboxylic acid; 2-(5-m-ethoxyl-]IH-indol-3-yl)- IH-pyrrolo[2,3-b]pyridine -4-carboxylic acid; potassium 2-(5-methoxy4- 1H-indo l-3-yI)-I H-pyrrolo[2,3-b]pyridine-4-carboxylate; I-methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)-I 241 -metlhyl-3-( IH-pyrrolo[2,3-bjpyrid in-2-yI)- I I-indol-5-yloxy]-propan- I-ol; (I1-[1I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy]-cyclobutyl} -methanol; 2-(6-phenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-ethanol; I -methyl-3-(5H-pyrrolo[2,3-b]pyraziin-6-yl)- I H-indol-5-yl]carbonylaminopropionic acid; 2-[2-methoxy-5-(5H-pyrrolo[2,3 -b]pyrazin-6-yl)-phenoxy]-ethanol; 3-[2-dirnethylamino-5-(5H-pyrrolo[2,3-blpyrazin-6-yl)-phenyfl-propan- I-ol; 3- I-methyl)ethoxyphenyl]-5H-pyrrolo[2,3-b]pyrazin-7-y propanal; 2-(5-methoxy- 1-methyl-I H-indol-3-yl)- IH-pyrrolo[2,3-b]pyridiine; 3-fl -methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yI)- I I-indol-5-yloxy]-propane-1I,2-diol; I-methlyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- 3-fl -metlhyl-3-( 1I-pyrrolo[2,3-b]pyridin-2-yl)-1 H-indol-5-yloxy]-propan-2-ol; 241 -niethyl-5-(2H-tetrazol-5-yI)- II--indol-3-yl]- IH-pyrrolo[2,3-b]pyridine; 2-fl -methyl-5-(2-methyl-2H-tetrazol-5-yI)- IH-indol-3-yI]-1 H-pyrrolo[2,3-b]pyridine; 1-methyl-I 1--tetrazol-5-yl)-l H-indol-3-yl)]1--pyrrolo[2,3-b~pyridine; WO 03/000688 WO 03/00688PCT/GB02/02799 -68- I -niethyl-3 H-pyrrolo[2,3-b~pyrid in-2-yI)- I 2-(5,6-dimethoxy- I -methyl- I H-indol-3-yI)- I H-pyrrolo[2,3-b]pyridine; I -methyl-3-( I H-pyrrolo [2,3-b]pyridin-2-yl)- 1H-indol-5-yloxy]-propane- I ,2-diol; I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy]-propane-1 ,2-diol; 2-[5-(2-methoxy- I -methy -ethoxy)- I -m-ethyl- I H-indol-3-yl]- I H-pyrrolo[2,3-b]pyridime; 2-[1 -methy 1-5-(5-m ethyl-[ I ,2,4]oxadiazol-3-yl)- I H-indol-3-yI]- I H-pyrrolc[2,3-bjpyridine; (R)-3-[6-methoxy- I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy]-propane-1 ,2-diol; 6-methoxy-] -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I I -methyl-I H-indol-3-yI)-4-pheiiyl- I H-pyrrolo[2,3-b]pyridine; 2-[5-(pyridin-4-yl)- 1-methyl-I H-indol-3-yl]- I H-pyrrolo[2,3-bjpyridine; I -methyl-I l--indol-3-yl)- I H-pyrrolo[2,3-b]pyridine-4-carbonitrile; 4-cliloro-2-(5-methoxy- I -methyl-i H-indol-3-yl)- I1--pyrrolo[2,3-b]pyridime; I -methyl-I H-indol-3-yl)-4-(pyridin-3-yI)-I H-pyrrolo[2,3-b]pyridine; 1-methyl-I H-indol-2-yl)- I H-pyrrol o[2,3 pyri dine; 2-(5-irnethoxy- 1 -methyl-I H-indol-3-yl)-3-methyl- I I--pyrrolo[2,3-b]pyridine; 2-(1 H-pyrrol-2-yl)- I H-pyrrolo[2,3-b]p-yridine; 2-(I -methyl- I H-pyrrol-2-yl)-I l--pyrrolo[2,3-b~pyridine; 4-chloro-2-(5-methoxy- I H-indol-3-yI)- I I--pyrrolo [2,3-b]pyri dine; I -methy I H-pyrrolo[2,3-b)pyrid in-2-yl)- I H-indol-6-ol; 2-(6-isopropoxy-S-methoxy- 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridine; 2-[5,6-d imethoxy- I -(2-morphol in-4-yl-ethyl)- I H-indol-3-yl]- I H-pyrrolo[2,3-b]pyridine; I -methyl-3-( I H-pyrrolo[2,3-b]pyrid in-2-yl)- 1 I -methyl-3-(I H-pyrrolo[2,3-b]pyridin-2-yI)- I I -methyl-3-( I H-pyrrolo[2,3-b] pyrid in-2-yl)- I H-indol-5-yl]-acetam ide; N- -methyl-3-( I H-pyrrolo[2,3-b~pyridin-2-yI)- I H-indol-5-yI]methyl }thien-2-yi-sulfonamide; I I -hydroxymethyl-cyclobutoxy)-3-( 1 H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -ylJ-cyclobutyl methanol; f I I -methyl-3-(S1--pyrrolo[2,3-b]pyrazin-6-yl)- I H-indol-5-yloxy]-cyclobutyl) -methanol; 5-[6-(4-teri-butylphenyl)-5H-pyrrolo[2,3 -b]pyrazin-7-ylethyl-21--tetrazole; 3-[6-(4-tert-butylphenyl)-5H-pyrrolo[2,3 -b]pyrazin-7-yl)-propionitri le; 3-[6-(4-terrt-butylphenyl-5 H-pyr-rolo[2,3 -b]pyrazin-7-yI]-propionam ide; 3-[6-(4-ter-t-butylphenyl)-SH-pyrrolo[2,3-b]pyrazin-7-yl]-propionic acid; 1-m ethyl)ethoxyphenyl)-5H-pyrrol o[2,3 -b]pyrazin-7-yI) prop ionic acid; 3-[6-(4-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl~propionic acid; 3-16-4-methoxyphenyl)-5H-pyrrolof2,3-b]pyrazin-7-yI]propion ic acid; 3-[6-(4-ter-t-butyl-plieny I)-5H-pyrro Io[2,3 -b~pyrazin-7-yI]-propan- 1-ol; WO 03/000688 PCT/GB02/02799 -69- CK1 [2-methoxy-5-(5H-pyrrol o[2,3-b]pyrazin-6-yl)-phenoxy)acetic acid ethyl ester; 2-nmethoxy-5-(5H-pyrro lo[2,3-b] pyrazin-6-yl)phenol; 3 -fluoro-2-(5-methioxy- I1-methyl-I H--indol-3 I H-pyrrolo[2,3-blpyridine; 3-{6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-blpyrazin-7-yI) propion ic acid; ethyl 3- {6-(4-hydroxyphenyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl }propionate; 2-(S-methoxy- 1 I--indol-3-yl)- I H-pyrrolo[2,3 -b]pyrid ine-4-carbonitrile; 6-(4-methylsu Ifinylphenyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-methylsu lfonylphenyl)-5 H-pyrrolo[2,3 -b]pyrazine; 3 -(6-(4-tert-butylpheny)-51--pyrro lo[2,3-b] pyrazi n-7-yI)propy lam ine; N- {3-(6-(4-tert-butylpheilyl)-5H-pyrrolIo[2,3-b~pyrazin-7-yl)propyl acetamide; 4 N- {3-(6-(4-:ert-butylphenyl)-5H-pyrro Io[2,3-blpyrazin-7-yl)propyl }cyclopropylcarboxyl ic acid am ide; N- {3-(6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-b)pyrazin-7-yl)propyl~butyramide; N- {3-(6-(4-iert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl)propyl} methoxyacetamide; N- {3-(6-(4-tert-butylphenyl)-5H--pyrrolo[2,3-b~pyrazin-7-yl)propyl) thien-2ylcarboxylic acid am ide; N- {3-(6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-bjpyrazin-7-yl)propyl)}-N '-propyI urea; N- {3-(6-(4-irt-butylpheny))-5 H-pyrrolo[2,3 pyrazin-7-yI)propyl} -N '-carboethioxymethyl urea; N- {I -methlI-3-( IH-pyrro lo[2,3-b]pyrid in-2-yl)- IH-indol-5-yljmethyl) -N'-tetrahydropyran-2-ylurea; N- {3 -(6-(4-tert-butyl ph enyl)-5 H-pyrrolo[2,3 -b~pyrazi n-7-yi)propyl} iethyl urea; N- {3-(6-(4-tert-butylphenyl)-S H-pyrrolo[2,3-b]pyrazin-7-yl)propyl }methanesulfonamide; N- {3-(6-(4-tert-butylphenlyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl)propyl }thien-2-ylsulfonamide N- {3-(6-(4-iert-butylphenyl)-5 H-pyrrolof 2,3-b]pyrazin-7-yl)propyl d imethylisoxazol-4.-ylsulfonam ide; N- {3-(6-(4-zert-butylphenyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl)propyl) I -methylimidazol-4-ylsulfonamide; 4w ~2-(5-methoxy- 1-methyl-i H-iridol-3 -yI)-l1H-pyrrolo[2,3 -blpyridi ne-4 carboxyl ic acid (2-hydroxy- 1,1 dimethyl-ethyi)-amide; 3-(4-ch loro- 1H-pyrrolo[2,3 pyridin-2-yI)- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy- 1,1dimethyl-ethyl)-am ide; 1-methyl-I H-indol-3 IH-pyrrolo[2,3-b]pyridin-4-yl)-morphol in-4-yl-methanone; 3-[6-(4-hydroxyph enyl1)-5 H-pyrrolIo[2,3 pyrazi n-7-yl]-N-methyl prop ionam ide; I-ethyl-5-miethoxy- I 1-indol-3-yl)-I H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy- 1,1 dimethyl-ethyl)-amide; I1-mnethyl- I H-indol-3-yI)- 1H-pyrrolo[2,3,-b]pyrid ine-4-carboxylic acid (2-methoxy-ethyl) amnide; I-methyl-I H-indol-3-yl)- I H-pyrrolo[2,3 ,-b]pyrid ine-4-carboxyl ic acid (2-hydroxy-2methyl-propyl) amide; 2-(5-methoxy- I-methyl- I H-indol-3-yI)- I1--pyrrolo[2,3 ,-b]pyridinie-4-carboxylic acid (2-hydroxypropyl) amnide; WO 03/000688 WO 03/00688PCT/GB02/02799 C1 2-(5-methoxy- I1-methyl- I H-indol-3 -yl)-l H-pyrroio[2,3 pyridine-4-carboxylic acid (2-hydroxy-ethyl) amide; -1 H-inidoi-3 -yl)-I H-pyrrolo pyridine-4-carboxyl ic acid (2-methoxy-ethyl) am ide; -methyl-I H-indol-3-yl)- 1H-pyrrolo[2,3-bjpyridine-4 carboxylic acid; 3 -(4-ch loro- IH-pyrrolo[2,3-b]pyrid i-methyl-I H-indole-5-carboxyl ic acid; 2-(lI -ethyl-5-methoxy- I H-indo 1-3 yl)-lI H-pyrrolo(2,3 ,-blpyridine-4-carboxylic acid; 2-(S-i-nethoxy-1 H-indol-3-yl)- IH-pyrrolo[2,3-b~pyridine-4 carboxamide; 3-[6-(4-morpholin4-yl ph enyl)-5 H-pyrro Io [2,3 pyrazin-7-yl]-N-niethyl prop ionamide; 6-(4-pyrrolidin- I-yl phenyl)-5 H-pyrrolo[2,3-b]pyrazine; C) 10 6-(4-(furan-2-yl)phenyl)-5H-pyrrolo[2,3-b] pyrazine; 4 (Ni ,5-dimethiyl isoxazol-4-yl)phenyl)-5H-pyrrolo[2,3-b]pyrazine; 2-[4-(5H-pyrrolo[2,3 ,-b]pyrazin-6-yl)phenyl]-propan-2-ol; I -[4-(5H-pyrrolo[2,3-b]pyrazin-6-yI)phenyl] ethanone; {2-morphol in-4-ylethiyl -p iperazin-1I-yI)phenyl]-5H-pyrrolo[2,3-b]pyrazine; 6-(4-piperazin- I -ylpheniyl)-5 H-pyrrolo[2,3-b~pyrazine; 2-methyl-4-[6-(4-tert-butyl-plhenyl)-5H-pyrrolo[2,3-b]pyrazin-7-y]-butan-2-ol; IH-pyrrolo[2,3-b]pyridini-2-yl)- 1-methyl-I 2- {[5-methoxy-3-( 1H-pyrrolo[2,3-b~pyrid in-2-yI)-indol- 1-yl]-I -methylpiperazin)-4y1 }-ethanorie; N-cyclobutyl-2-[5-methoxy-3-( IH-pyrroio[2,3-b]pyridin-2-yi)-indol-1I-yl]-acetam ide; !O N-(3-im idazol- 1-yl-propy l)-2-(5-methoxy-3-( I 1--pyrrolo[2,3-b]pyridin-2-yl)-indol- 1-yI]-acetamide; I ihydro-pyrrol- 1-yl)-2-[5-methoxy-3-( I J-pyrrolo[2,3-b]pyridin-2-yI)-indol-1I-yl]-ethanone; N-cyclohexyl-2-[S-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- I-yI]-acetamide; 4w N-cyclopentyl-2-[5-inethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-1I-yI]-acetamide; N-(3-dimethyl-amino-propyl)-2-[5-methoxy-3-( 1 H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1I-yI)-acetamide; 6-{2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- I -yI]-acetylamino}-hexanoic acid methyl ester;.

1-ri ,4']bipiperidinyl- 1'-yl-2-[5-niethoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol-1I-yl]-ethanone; N-(3,3-dimethyl-butyl)-2-[S-methoxy-3-( IH-pyrrolo[2,3-b]pyridir-2-yl)-indol-I -yl]-acetamide; N-(3-ethoxy-propyl)-2-[5-miethoxy-3-( I H-pyrrolo[2,3 -blpyridin-2-yI)-indol-lI-yl]-acetamide; 1 -(3,3-dirnethyl-piperidin- I -yl)-2-[S-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- 1-yi]-ethanone; 2-[5-methoxy-3-( I11-pyrrolo[2,3-blpyridin-2-yI)-indoi-1I-yl)-N-(3-oxo-isoxazolid in-4-yI)-acetamide; I -[4-(4-chloro-phenyl)-piperazin-1I-yl]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol-I -yl]ethanone; I -(4-hiydroxy-piperidin- I-yl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b~pyridin-2-yl)-indol- 1-yl]-ethanone; 2-[5-mnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yi)-iindol- -thiazolidin-3-yl-ethanone;, WO 03/000688 PCT/GB02/02799 -71- C1 2-[5-methoxy-3-(] I pyrrolo[2,3-b]pyridin-2-yl)-indol-1 I -[4-(3-phenyl-aIlyi)-piperazin- I -yI]ethanone; N-furan-2-ylmethyl-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-acetamide;, 2-[5-methoxy-3-( I H-pyrrolo[2,3-b] pyridin-2-yi)-indol- I -yl]-N-(2-pyridin-4-yl-ethyl)-acetamide; N-cyclopropylmethyl-2-[5-methoxy-3 -(I1 H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yl]-N-propyl-acetamide; I -cyclohexyl-ethyl)-2-[5-methoxy-3-( I 1--pyrrolo[2,3-b~pyridin-2-yI)-indol- I -yi]-acetam ide; 2-[5-rnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yI]-N-methyl-N-pyridin-3-ylmethyl-acetamide; 2-[5-methoxy-3-( 1 H-pyrrolo[2,3-blpyridin-2-yI)-indol-I -yI]-l -(4-m-tolyl-piperazin- I -yi)-ethanone; 2-[5-methoxy-3-(I H-pyrrololl2,3-b] pyridin-2-yI)-indol-1 -yfl-N-(2-phenylsu Ifanyl-ethyl)-acetamide; C) 10 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridini-2-yl)-indol-I -yl]-N-(4-morpholin-4-yI-phenyl)-acetamide; N-cyclopropyl-2-[5-miethioxy-3-( IH-pyrrolo[2,3-b]pyrid in-2-yI)-indol- I -yI]-acetamide; 2-tS-methioxy-3-( 1 H-pyrrolo(2,3-b]pyridin-2-yI)-indol- l-yfl-l -(3-methyl-piperazin-1I-yi)-ethanone; N-(4-cyclohexyl-phenyl)-2-[5-inethoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yI)-indolI -yi]-acetamide; 2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyrid in-2-yI)-indol- I -yI]-N-(2-methyl-cyclohexyl)-acetam ide; N -cyc lohexyl rn ethyl [5 -rnethoxy-3 I H-pyrrolo[2,3-b~pyridin-2-yI)-indoi- I -yi]-acetamide; 2-[S-methoxy-3-(l H pyrrolo[2,3-b~pyrid in-2-yI)-indol- I myI]- I -pyrrol id in- I -yi-ethanoiie; 4- {2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyrid in-2-yI)-indol- I -yi]-acetyl -piperazin-2-one; 4- {2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-acetyl} -3,3-dimethyl-piperazin-2-one; 4- 12-[5-methoxy-3 H-pyrrolo[2,3-b]pyridin-2-yI)-indol- 1-yl]-acetyl)}-1 -methyl-piperazin-2-one; !0 2-[5-methoxy-3-( 1H-pyrrolo[2,3 -b]pyrid in-2-yl)-indol-J -thiomorpholin-4-yi-ethanone; N-(2-hydroxy-2-phenyl-ethyl)-2-[5-methoxy-3 H-pyrrolo[2,3-b]pyrid in-2-yI)-indol- 1 -yi]-acetamide; I imethyl-morphol i n4-yI)-2-[5-methoxy-3-( IH-pyrrolo[2,3-blpyrid in-2-yi)-indol- I -yI]-ethanone; N-(4-diethylam iiomethyl-plhenyl)-2-[5-methoxy-3-( I H--pyrrolo[2,3 -b]pyrid in-2-yl)-indol-I -yl]acetamide; N-[2-(4-hydroxy-pheniyl)-ethyl]-2-[5-rnethoxy-3-( I H-pyrrolo[2,3-blpyridin-2-yl)-indol-1I-yl]-acetam ide; 2-[5-methox3y-3-(] IHpyrrolo[2,3-b]pyrid in-2-yI)-indol-1I-yI]-N-(tetrahydro-furan-2-ylmethyl)acetarnide; 2-[5-methoxy-3-( II--pyrrolo[2,3-b]pyrid in-2-yI)-indol-1I-yI]-N-pyrid in-2-ylmethyl-acetamide; N-(1I,2-dimethyl-propyl)-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yI]-acetam ide; N-(3 -benzyloxy-pyrid in-2-yI)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b] pyrid i -2-yI)-indol-I -yI]-acetam ide; 2-[5-methoxy-3-(] I pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yIjJ-N-quinol in-3-yI-acetamide;, 2-(5-rnethoxy-3-( I H-pyrrolo(2,3-b~pyridini-2-yl)-indol- I -yi]-N-quinol in-8-yi-acetamide; N-isoquinolin-5-yI-2-[5-methoxy-3-(1 H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-acetam ide; 2-[5-methoxy-3-( I -I-pyrrolo[2,3-b~pyridin-2-yi)-indol-I -methyl-butyl)-acetarniide; N-isoquinolin- I -yI-2-[5-niethoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yI)-indol- I -yI]-acetarnide; 2-[5-inethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yI]-N-quinolin-2-yI-acetamide; WO 03/000688 PCT/GB02/02799 -72- ~I 1 ,6-dihydro-2H-pyrid in- I -yl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b~pyridin-2-yi)-indoI- I -yl]-ethanone; 2-[5-methoxy.3 H-pyrrolo[2,3 -bipyrid in-2-yI)-indol-1I-yl]-N-[3-(4-methyl-piperazin-1I-yI)-propyI]acetamide; N-(2-cyclohex- I-enyl-ethiyl)-2-[5-inethoxy-3-( I H-pyrrolo[2,3-b]pyridini-2-yI)-indo I-I-yI]-acetamide; I H-iiidol-3-yl)-ethyl]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yl]-acetamide; 2-[5-methoxy-3-( 1 H-pyrro lo[2,3 -b]pyrid in-2-yI)-indol- l-yl]-l -[4-(tetrahydro-furan-2-carbonyl)piperazin-l -yI]-ethanone; N-adarnainan- 1-yI-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol- I-yI]-acetamide; N-(2-d iniethy lam ino-ethyl)-2-[5-rnethoxy-3-( 1 H-pyrrolo[2,3-b]pyrid in-2-yi)-indol- 1 -yI]-N-methyl- 0 acetarnide; I -(4-benizo[ I,3]d ioxoi-5-ylmethyl-piperazin-1I-yI)-2-[5-methoxy-3-( I 1-pyrrolo[2,3 -bipyrid in-2-yl)indol- I -yi]-ethanone; I Ioro-benzyl)-piperazi n- I -yI]-2-[5-methoxy-3 H-pyrrolo[2,3 -b]pyridini-2-yI)-indol- I -yI]ethanone; 2-[5-methoxy-3-(1 H--pyrrolo[2,3-b]pyridin-2-yi)-indol- I I -phenyi-ethyl)-piperazin- I -yl]ethanone; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yI)-indol-I -yIJ-1 -[4-(2-morphol in-4-yl-ethyl)-piperazin- I1yI]-ethanone; I -[4-(4-methoxy-phenyl)-piperazin- I -yi]-2-[5-methoxy-3-( I 1-pyrrolo[2,3-b]pyrid in-2-yI)-indol- I -yI]ethanone; 2-[5-methoxy-3-( 1 H-pyrrolo[2,3-.b]pyridin-2-yI)-indol-1I-yI]-N-f3-(2-oxo-pyrrolidin-1I-yi)-propyi]acetamide; 2-[5-nmethoxy-3-(I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-1 -yI]-I -piperidin-I -yl-ethanone; 2-[5-methoxy-3-( 1H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yl]-N-(2-piperidin-I -yi-ethyl)-acetamide; 2-[5-methoxy-3 H--pyrro Io[2,3-b]pyrid in-2-yl)-indol- I -yI]-N-(2-pyrrolidin- 1 -yi-ethyl)-acetamide; 1 -[4-(2-methoxy-etliyl)-piperazin- I -yl]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol I -yl]ethanone; 1 -[4-(2-dimethylamino-ethiyl)-piperazin- I -yI]-2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yl)-indol- Iyi]-ethanone; N-isobutyl-2-[5-rnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yI]-acetamide; 1 -[4-(4-tert-butyl-benzyl)-piperaziin- I -yI]-2-[5-methioxy-3-(I H-pyrroio[2,3-b~pyridin-2-yi)-inidol- I -yI]ethanone; 2-[5-methoxy-3-(I H-pyrrolo[2,3 -b]pyridin-2-yI)-indol- I I -rnethyl-3-phenyl-propyl)-acetam ide; N-(4-d jethylamino- I -methyl-butyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]acetamide; N-benzyl-N-(2-hydroxy-ethyl)-2-[5-methoxy-3-( 1 H-pyrrolo[2,3-b)pyridin-2-yi)-indol- I -yl)-acetamide; WO 03/000688 PCT/GB02/02799 -73-.

1- {4-[2-(2-hydroxy-etlioxy)-ethyl]-p iperazi n- I -yl }-2-[5-methoxy-3 H-pyrrolo[2,3-bjpyrid in-2-yl)indol- I -yl]-ethanone; I -hydroxymethyl-2-niethiyl-butyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yI)-indol- Il-yI]acetam ide; N-benzyl-2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yI)-indol- I -yI]-N-methyl-acetamide; N-(2-methoxy- I -methyl-ethyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yl)-indol- I -yI]-acetamide; N-(3-hiydroxy-propyl)-2-[5-mnethioxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- I -yI]-acetamide; N-(3-methoxy-phenyl)-2-[5-methoxy-3-( I H--pyrrolo[2,3 -b]pyridin-2-y!)-indol- I -yfl-acetamide; benzhydryi-piperazin- I -yl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yl)-indol- I -yi)-ethanone; 1 -{4-benzyl-p iperazin- I -yI)-2-[S-rnethoxy-3-( I H-pyrrolo[2,3-b] pyridin-2-yl)-indol- I -yi]-ethanone; 2-[5-methoxy-3 H-pyrrolo[2,3-b] pyrid in-2-yi)-indol- I -pyrrol idin- I -yI-propyl)-acetamide; -ben zyl-p iperi d in-4-y [5-m ethoxy-3-(l I pyrrolo[2,3-b]pyridin-2-yi)-indol- I -yl)-acetamide; I -[4-(4-chloro-phenyl)-4-hiydroxy-piperidin- I -yI]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yt)indol- I -yII-ethanone; 2- f{2-[5-methoxy-3-( I H-pyrrolo[2,3-bjpyridin-2-yi)-indol-I -yI]-acetylamino}-3-methyl-pentanoic acid methyl ester; 2-[5-methoxy-3-(I !--pyrrolo[2 ,3 -b~pyrid in-2-yI)-indol-1I-yl]-N-(2-methyl-qu inolin-4-yi)-acetamide; N-(2-benzylsu Ifanyl- I -ydroxymethyl-ethyl)-2-[S-methoxy-3 1--pyrrolo[2,3-b]pyrid in-2-yI)-indol- IyI]-acetamide; IH-pyrrolof 2,3-b]pyridin-2-yi)-pyrrol-1I-yI)-acetic acid; 2- IH-pyrrolo[2,3-b] pyridin-2-yl)-pyrrol- l-yl]-I -cyclopropylamino} -ethanone; N-(3-ethoxy-propyl)-2-[2-( IH-pyrrolo[2,3-b]pyrid in-2-yI)-pyrrol- I-yl]-acetamide; I -pyrrol id in- I-yl-2-[2-(I H-pyrrolo[2,3-b] pyridin-2-yi)-pyrrol-l -yI]-ethanone; I -(3,6-dihydro-2H-pyridin- H-pyrrolo[2,3-b]pyridin-2-yi)-pyrrol-lI-yI]-ethanone; I -methyl-4- IH-pyrrolo[2,3 -blpyridin-2-yi)-pyrroi- yI]-acetyl }-piperazin-2-one; IH-pyrrolo[2,3-b] pyrid in-2-yl)-pyrrol- I-yI]-N-(tetrahydro-furan-2-ylmethyl)-acetamide; I irethyl-morphol IH-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I-yl]-ethanone; H-pyrrolo[2,3-b]pyrid in-2-yi)-pyrrol- I-yI]-I -thiomorphol in-4-yI-ethanone; I -(4-hydroxy-p iper id i n- I -yI)-2 H-pyrro Io[2,3 -b]pyrid in-2-yi)-pyrrol- I -yfl-ethanone; 1 -(3,3-dimethyl-piperid in- H-pyrrolo[2,3-b~pyridiin-2-yI)-pyrrol-1 -yi)-ethanone; 4- IH-pyrrolo[2,3-b] pyridin-2-yl)-pyrrol-1I-yi]-acetyl) -piperazi n-2-one; I-methyl-butyl)-2-[2-( IH-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I-yI]-acetam ide; N-bicyclo[2.2. I)hept-2-yI-2-[2-( II--pyrrolo[2,3-b]pyrid in-2-yi)-pyrrol-1I-yI]-acetam ide; N-[3-(4-r-nethyl-piperazin-1I-yI)-propyl]-2-[2-( IH-pyrrolo[2,3-b)pyridin-2-yI)-pyrrol-I -yl]-acetanlide; 1 imethylamino-propy )-piperazin- H-pyrrolo[2,3-blpyridin-2-yi)-pyrrol- I-yl]ethanone; WO 03/000688 WO 03/00688PCT/GB02/02799 -74- I -(4-methyl-piperazin- I H-pyrrolo[2,3 -b]pyrid in-2-yl)-pyrro-1 -yl]-ethanone; I loro-phenyl)-4-hydroxy-piperidin- I J--pyrrolo[2,3-b)pyridin-2-yI)-pyrrol- I -yl]ethanone; I -hydroxy-phenyl)-piperazin- Il-yl]-2-[2-(I H-pyrrolo[2,3-b]pyridin-2-yl)-pyrrol- I -yl]-ethanone; 3-[5-methoxy-2-( 1 H-pyrrolo[2,3-b]pyridin-2-yI)-indol-1 -yl]-propionic acid; 3-[S-methoxy-2-(l H-pyrrolo[2,3-b]pyrid in-2-yl)-indol- I1-y]]-l -morphol in-4-yl-propan- 1 -one; 3-[5-methoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- 1 -yi]-N-phenyl-propionamide; 3-[5-methoxy-2-( 1 H-pyrrolo[2,3-b]pyridin-2-yl)-indot- Il-yl]-lI -thiomorpholin-4-yl-propan- 1 -one; 3-(5-miethoxy-2-( I H-pyrrolo[2,3-b] pyridin-2-yI)-indol- I -yI]-lI -(4-methyl-piperazin- I -yl)-propan- I -one; 3 .{5-methoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- 1-yl]-N-(tetrahydro-furan-2-ylmethyl)propionamide; N-(2-hydroxy-2-pheniyl-ethyl)-3-[5-nietlhoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- I -yl]propionamide; N-(2-hydroxy-ethyl)-3-[5-methoxy-2-( I H-pyrrolof2.3-blpyridin-2-fl)-indol- 1 -yll-propionamide:, 1 loro-phenyl)-4-hydroxy-piperidin- I -yl]-2-[5-methoxy-2-( I H-pyrrolo[2,3-b~pyridin-2-yl)indol- I -yl]-ethanone; 1 -methyl- I H-indoi-3-yI)-4-morphol in-4-yl- I H-pyrrolo[2,3 -b]pyridine; 1 -methyl- I H-indol-3-yl)-4-piperidin- Il-yl-lI H-pyrrolo[2,3-b]py'ridine; 1 -methyl- I H-indol-3 I H-pyrrolo[2,3 -b]pyridin-4-yl]-(2-methoxy-phenyl)-amine; [2-(5-methoxy- 1-methyl- I H-indol-3-yl)- I H-pyrrolo[2,3 -b]pyridin-4-yI]-o-to lyl-amine; 1 -methyl- I H-indol-3-yI)- I H-pyrrolo[2,3-b]pyridin-4-yl]-(3-methoxy-phenyl)-amine; 1 -methyl- I H-indol-3-yI)- I H-pyrrolo[2,3 -b]pyridin-4-yl]-m-tolyl-amine; (4-fluoro-phenyl)-[2-(5-metlioxy- 1 -methyl- I H-indol-3 1 H-pyrrolo[2,3-b]pyridin-4-yl]-amine; 1-methyl- I H-indoi-3-yl)- I H-pyrrolo[2,3-b]pyrid in-4-yl]-(4-methoxy-phenyl)-aminie; [2-(5-rnethoxy- I -methyl- I I--indol-3-yl)- I H--pyrrolo[2,3-bjpyrid in-4-yl]-p-tolyl-amine; I -methyl- I H-indol-3-yI)-1 H-pyrrolo[2,3-bjpyridin-4-yl]-amine; (4-fluoro-benzyl)-[2-(5-methoxy- 1 -methyl- I H-indol-3-yI)- I H--pyrrolo[2,3 -b~pyridin-4-yli-amime; (4-methoxy-benzyl)-[2-(5-methoxy- 1 -methyl- I H-indol-3-yl)- 1 H-pyrrolo[2,3 -b)pyridin-4-yI]-amine; (2-methoxy-ethyl)-[2-(5-methoxy- 1 -methyl- I H--indol-3 I H-pyrrolo[2,3-b]pyridin-4-yl]-amine; 3-[2-(5-methoxy- 1-methyl-I H-indol-3-yl)- I I-pyrrolo[2,3-b)pyridin-4-ylamino]-benzoic acid methyl ester; I1-methyl- I H-indol-3-yl1)- I H-pyrrolo[2,3-b]pyrid in-4-yl]-amine; I -methyl- I H-indol-3-yl)-I H-pyrrolo[2,3-b]pyridin-4-yI]-phenyl-aniine; 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridin-4-yI] -amine; 2-(5-methoxy- IH-indol-3-yl)-I H-pyrrolo[2,3,-b]pyridinie-4-carboxylic acid methylamide; IH-indol-3 IH-pyrrolo[2,3 ,-b]pyrid ine-4-carboxylic acid, tert-butyl ester, WO 03/000688 PCT/GB02/02799 cK1 and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable saits and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula of the invention for the inhibition of SYK are:- 6-(5-methoxy- I-methyl-I 1--indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as AlI-B 1-Cl), Example 1(a); I-methyl-I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as Al-B] -C46), Example 1 3-[3 H-pyrrolo[2,3-b] pyrazin-6-yi)-indol-1I-yl)-propan-l1-ol, (compound denoted as Al -B6-C46), Example 2(a); 4 r~l 3-[5-methoxy-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I-yl]-propain- I-ol, (compound denoted as A]- B6-C Example 2(b); 2-[5-rnethoxy-3 -(SH-pyrrolo[2,3-b] pyrazin-6-yl)-indol- I-yl]-ethanol, (compound denoted as Al ClI), Example 2(d); 6-(IH-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as A I-132-C46), Example 2(e); N- {3-[3-(5H-pyrrolo[2,3 -bjpyrazin-6-yl)-indol-1I-yl]-propyl)}-acetamide, (compound denoted as Al -B7- C4*6), Example 4(a); I -methyl-3 -(5H-pyrrolo[2,3 -b]pyrazin-6-yl)- I H-indol-5-ol, (compound denoted as Al -B 1 -C Example 7; [3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol-l-yl]-methanol, (compound denoted as A2-B4-C46), Example 9(c); I H4-indol-3-yi)-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as AlI -B2-C Example 2-[5-methoxy-3-(5H-pyrrolo[2,3 -b]pyrazin-6-yl)-indol- I-yl]-l -morpholin-4-yI-ethanone, (compound denoted as A I-B 8-C I Exam ple 12(a); 2 -meth oxy- 1 -morph oIi n -4-y I-2-oxo-ethy 1 H- in do 1-3 -ylI]- I H- pyrro Io [2,3 -b]lpyri din e-4 carbonitri le, (compound denoted as A3-B8-C Example 12(b) 4-metlioxy-2-(5-methoxy- I-methyl-I I--indol-3-yl)- I 1-pyrrolo[2,3-blpyridine, (compound denoted as A5-Bl1-Cl), Example 13(b); 4-methoxy-2-(5-methoxy- IH-inidol-3-yl)- IH-pyrrolo[2,3-b~pyridine, (compound denoted as A5-B32-Cl), Example 13(c); 1 -metliyl-3-(l1H-pyr rol o[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-propan-2-ol, compound demoted as A2-B I Example 13(f); 1 -methyl-3-(1JIH-pyrrolo[2,3-b]pyridiii-2-yl)- IH-indol-5-yloxy]-cyclobutanecarboxylic acid amide, (compound denoted as A2-13I -C 15), Example 14(b); WO 031000688 WO 03/00688PCT/G B02/02799 -76- I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy]-cyclobutanecarboxylic acid methylamide, (compound denoted as A21I-B I-C 16), Example 14(c); I -methyl-3-( 1H-pyrrolo [2,3-b]pyrid in-2-yl)- 1H-indole-5-carboxyl ic acid (2-hydroxy-ethyl)-amide, (compound denoted as A2-B]I-C34), Example 14(e); I -methyl-3-( 1H-pyrrolo[2,3 -b~pyridin-2-yl)- 1H-indole-S-carboxylic acid (2-carbamoyl-ethyl)-arnide, ci (compound denoted'as A2-B I-C24), Example 14(g); I -rethyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)- IH-indole-5-carboxyl ic acid amide, (compound denoted as A2-1I-C29), Example 14(i);.

I -methyl-3-( IH-pyrrolo[2,3 -blpyridin-2-yl)- 1H-indole-5-carboxylic acid (2-hydroxy- 1,1-dimethylethyl)-amide, (compound denoted as A2-13I -C3 Example 14(m); 4 1I -methyl-3-( 1 H-pyrrolo[2,3-blpyridin-2-yl)- I H-indole-5-carboxylic acid (2-hydroxy- I -hydroxymethylethyl)-amide, (compound denoted as A2-135-033), Example 14(n);- 1 -methyl-3-( 1 H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indole-6-carboxylic acid (2-carbamoyl-ethyl)-amide, (compound denoted as A2-B I 8-C24), Example 14(o); I -methiyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)-1 H-indole-6-carboxylic acid (1 H-fl ,2,4)triazol-3-yl)aniide, (compound denoted as A2-13I -C51), Example 14(q); 1 -methyl-3-(5H-pyrrolo[2,3-b~pyrazin-6-yl)- IH-indole-5-carboxyl ic acid 2-methoxyethylamide, (compound denoted as Al1-B3 1 -C25), Example 14(v); I -methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- IH-indole-5-carboxyl ic acid 2-hydroxyethylamide, ZO (compound denoted as AlI-B I -C34), Example 14{aa); I -methyl-3-(5H-pyrrolo[2,3-b] pyrazin-6-yl)- 1H-indole-5-carboxyl ic acid methylamide, (compound denoted as Al-B 1-C23), Example 14(ab); ,5-dimnethyl-isoxazolyl-4-yl)-1 H-pyrrolo[2,3-b]pyridin-2-yl]- 1-methyl-i acid (2-methoxy-ethyl)-amide, compound denoted as A83-B Il-C25), Example 14(amn); ,5-dimethyl-isoxazolyl-4-yl)- II--pyrrolo[2,3-b]pyridin-2-yl]- IH-indole-5-carboxylic acid (2methoxy-ethyl)-amide, (compound denoted as A83-B2-C25), Example I 4(an); 3-(4-cyano- IH-pyrrolo[2,3-bjpyridin-2-yl]- 1-methyl-I H-indole-S-carboxylic acid (2-hiydroxy- 1,1 dimethyl-ethyl)-amide, (compound denoted as A3-BI-C3 Example 14(ao); 3 -(4-cyano- 1H-pyrrolo[2,3-b]pyrid in-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy-2-methylpropyl)-amide, (compound denoted as A3-B I-C97), Example 14(ap); [I -riiethyl-3-( I pyrrolo[2,3-b]pyrid in-2-yl)- 1H-indol-5-yloxy]-acetic acid, (compound denoted as A2- BI-C6), Example I -methyl-3 1--pyrro lo[2,3 pyrid in-2-yl)- I H-indol1-5-yloxy]-prop ionic acid, (compound denoted as AlI -B I Example 1 1 -[1I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy)-cyclobutane- I -carboxylic acid, (compound denoted as A2-B3I -C 11), Example WO 03/000688 PCT/GB02/02799 -77- 1 -methyl-3-( IH-pyrrolo(2,3 -b~pyridin-2-yl)- 1H-indol-5-ol, (compound denoted as A2-B 1-Cl 0), Example 1 -methiyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indole-6-carboxylic acid, (compound denoted as A2- B1I8-C28), Example 3 -m nethyl1-3 H-pyrrolIo[2,3 -b]pyrid in-2-yl)- I H-indol-5-yl]-prop ion ic acid, (compound denoted as A2-13I -C2 Example I -methyl-3 -(5H-pyrrolo(2,3 -b]pyrazin-6-yI)- IH-indole-5-carboxylic acid, (compound denoted as Alt- BI-C28), Example ,5-d iinethyl-isoxazole-4-yI)- IH-pyrrolo[2,3-b~pyridine-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid, (compound denoted as A83-B1I-C28), Example ,5-imethyl-isoxazole-4-yJ)- IH-pyrrolo[2,3-b]pyridine-2-yI]- i I-indole-5-carboxylic acid, (compound denoted as A83-B32-C28), Example 4-(3,5-dimethyl-isoxazole-4-yI)-2-(5-methoxy- 1-methyl-I H-indo1-3-yl)- IH-pyrrolo(2,3-b]pyridine, (compound denoted as A83-BI1-CI), Example 4-(3,5-dimethyl-isoxazole-4-yl)-2-(S-methoxy- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridine, (compound denoted as A69-B32-C Example 3-(4-methoxy- IH-pyrrolo(2,3-b]pyridine-2-yJ)- I-methyl-I I--indole-5-carboxyl ic acid, (compound denoted as A5-B3 I -C2 Example IH-pyrrolo[2,3-b~pyridine-2-yl)- IH-indole-5-carboxylic acid, (compound denoted as A2-B32-C28), Example -methyl-3-( IH-pyrrolo[2,3-bjpyridin-2-yl)- 1H- indol-5-yloxy]-ethanol, (compound denoted as A2-' 13I-0), Example 16(a); I-methyl-3-( 1H-pyrrolo[2,3-b~pyridin-2-y1)- 1H-indol-5-yloxy]-propan- I-ol, (compound denoted as A2-13 I-C Example 16(b); I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)- I H-indol-S-yioxy]-cyclobutyl) -methanol, (compound denoted as A2-B3 I -C 12), Example 16(c); I -methyl- I H-indol-3-yl)- I 1--pyrrolo[2,3 -b]pyridine, (compound denoted as A2-B3 I-Cl1), Example 1 7(a); I -nethyl-3 IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-propane- 1,2-dial, (compound denoted as A2-1I-C9), Example 17(b); 3 I-methyl-3-( IH-pyrrolo[2,3-bjpyridin-2-yl)- IH-indol-5-yloxy]-propan- I-ol, (compound denoted as A2-B I-C4), Example 1 7(c); I-methyl-3 -(]IH-pyrrolo[2,3-b] pyridin-2-yI)- IH-indol-5-yloxy]-propan-2-ol, (compound denoted as' A2-B3 I-C5), Example 17(d); I -methyl-5-(2H-tetrazol-5-yl)- I H-indol-3-yl]- 1 H-pyrrolo[2,3-b]pyridine, (compound denoted as A2- B I-C36), Example 17(e); WO 03/000688 WO 03/00688PCT/GB02/02799 -78- I-methyl-5-(2-methyl-2H-tetrazol-5-yl)- 1H-indol-3-yll]IH-pyrrolo[2,3-b]pyridine, (compound denoted as A2-13I -C3 Example 17(f); 1 -methiyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yl]-ethanone, (compound denoted as A2-B 1- Example 17(h); 2-(5 ,6-d imethoxy- I-methyl-I H-indol-3-yl)- 1H-pyrrolo[2,3-bJ pyridine, (compound denoted as A2-B 17- CI), Example 17(i); -[I1 -methyl-3 I H-pyrrol o[2,3 pyri din-2-yi)- I H-i ndol-5-yloxy] -propane- I1,2-d iol, (compound denoted as A2-B3 I -C80), Example 17(j); I-methyl-3-(l H-pyrrolo[2,3-b]pyridin-2-yl)-I H-indol-5-yloxy] -propane- I1,2-d io 1, (compound denoted as A2-B I-C89), Examiple 17(k); 2-[5-(2-methoxy- I-methyl-ethoxy)- 1-methyl-I H-indol-3-yl]- IH-pyrrolo[2,3-b]pyridine, (compound denoted as A2-B I -Cl Example 17(l); I-methy l-5-(5-methyl-[1I,2,4]oxad iazol-3-yl)- IH-indol-3-yl]- IH-pyrrolo[2,3-b]pyridine, (compound denoted as A2-B I-C68), Example 17(m); -[6-niethoxy- I -methyl1-3-(1I H-pyrrolo [2,3 pyrid in-2-yl)- I H- indol1-5 -yloxy]-pro pane- 1,2-d iol, (compound denoted as A2-B I 7-C80), Example 17(n); 6-methoxy- I-methyl-3-(I H-pyrrolo[2,3-b]pyridin-2-yI)- IH-indol-5-ol, (compound denoted as A2-B 17- Gb1), Example 17(o); 1-methyl-I H-indol-3-yl)-4-phenyl- I I-pyrrolo[2,3-b]pyridine, (compound denoted as A13-B1-CI), Example 17(p); 1-methyl-I H-indol-3 -yI)-I H-pyrrolo[2,3-b]pyridine-4-carbon itrile, (compound denoted as A3 -B I-CI1), Example 17(r); 4-ch loro-2-(S-mnethoxy- I-methyl-I H-indol-3-yl)- 1H-pyrrolo[2,3-b] pyridine, (compound denoted as A28-BI-CI), Example 17(s); 2-(5-methoxy-I -methyl-I H-inidol-3-yl)-4-(pyridin-3-y)-1 H-pyrrolo[2,3-b]pyridine, (compound denoted as A 15-B3 1-Cl1), Example 17(t); 4-ch loro-2-(5-methoxy- 1H-indol-3-yl)- IH-pyrrolo[2,3-b] pyridine, (compound denoted as A28-B32-C I), Example 17(y); 1-methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)-I H-indol-5-yl]-acetamide, (compound denoted as A2- B1-C45), Example 19(b); f I I-hydroxymethyl-cyclobutoxy)-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol-1I-yI]-cyclobutyl} methanol, (compound denoted as A2-133-C 12), Example (I1 -[1I -methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I H-indol-5-yloxy]-cyclobutyl}-methanol, (compound denoted as A I-B I-C 13), Example 2-(5-methoxy- IH-indol-3-yI)- IH-pyrrolo[2,3-b]pyridine-4-carbonitrile, (compound denoted as A3-B2- ClI), Example 32; WO 03/000688 PCT/CB02/02799 I-methyl-I H-inidol-3-yl)- IH-pyrrolo[2,3-b]pyridine-4 carboxylic acid (2-hydroxy- 1,1dimethyl-etllyl)-amide, (compound denoted as A68-B I1-Cl), Example 3 -(4-chloro- I H-pyrrolo[2,3-b]pyrid in-2-yl)- I -methyl-I H-indole-5-carboxyl ic acid (2-hydroxy-1,1I dimethyl-ethyl)-amide, (compound denoted as A28-B I-C3 Example I-ethyl-5-methoxy- IJ--indol-3-yl)- IH-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy- 1,1dimethyl-ethyl)-amide, (compound denoted as A68-B33-C Example 1-methyl-I H-indol-3-yl)- IH-pyrrolo[2,3 ,-b~pyridine-4-carboxyl ic acid (2-hydroxy-2methyl-propyl) amnide, (compound denoted as A70-B I1-C Example 2-(S-methioxy- I-methiyl-I H-indol-3-yl)- IH-pyrrolo[2,3,-b]pyridine-4-carboxyl ic acid (2-hydroxypropyl) amide, (compound denpoted as A85-B I-Cl), Example I -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy-ethyl) amide, (compound enoted as A86-B I-C Example -1 H-indol-3 -yl)-1 H-pyrrolo[2,3 ,-b]pyrid ine-4-carboxylic acid (2-methoxy-ethyl) amnide, (compound denoted as A69-B2-C Example 2-(5-methoxy- IH-indol-3 -yl)-l H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid methylamide, (compound denoted as A9-B2-C Example I H-indol-3-yl)- I H--pyrrolo[2,3,-bjpyridine-4-carboxylic acid, tert-butyl ester, Example 61; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (I a) of the invention for the inhibition of SYK are:-- I-methyl-I H--indol-3-yl)-SH4-pyrrolo[2,3-b]pyrazine (compound denoted as AlI-B I -Cl1), Example 1 -methyl-3-( 1H-pyrrolo[2,3-bjpyridini-2-yl)- I I--indol-5-yloxy]-cyclobutanecarboxylic acid amide, (compound denoted as A2-B I -C 15), Example 14(b); ,S-dimethyl-isoxazolyl-4-yi)- I H-pyrrolo[2,3-b~pyridin-2-yl]- I1-methyl-i I H-indole-5-carboxyl ic acid (2-methoxy-ethyl)-amide, (compound denoted as A83-B I-C25), Example 14(am); 3 -(4-cyano- IH-pyrirolo[2,3-b]pyridin-2-yl]- 1-methyl-I H-iindole-5-carboxyl ic acid (2-hydroxy-2-methylpropyl)-amide, (compound demoted as A3-B 1-97), Example 14(ap); ,5 -dimiethlyl-isoxazo le-4-yl)- I H--pyrrolo[2,3-blpyridine-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid, (compound denoted as A83-B I-C28), Example ,5-irnethyl-isoxazole-4-yI)- IH-pyrrolo[2,3-b]pyridine-2-yl]-I H-indole-5-carboxyl ic acid, (compound denoted as A83-B2-C28), Example 4-(3,5-dim-ethyl-isoxazole-4-yI)-2-(5-niethoxy- 1-methyl-I H-indol-3-yl)- IH-pyrrolo[2,3-b]pyridime, (compound denoted as A83-B I1-Cl1), Example WO 03/000688 PCT/GB02/02799 CK1 I -methyl-5-(2H-tetrazol-5-yl)- IH-indol-3 -yl]-i H-pyrrolo[2,3-b] pyridine, (compound denoted as A2- B I-C36), Example 17(e); I1-methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridine-4-carbonitrile, (compound denoted as A3-B I-C Example 17(r); l I -nethyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I 1--indol-5-yloxy]-cyclobutyl} -methanol, (compound denoted as A I-B I-C 13), Example 2-(S-methioxy- 1-methyl- 1H-indol-3-yl)- II--pyrrolo[2,3-b]pyridine-4 carboxylic acid (2-hydroxy- 1,1 dimethyl-ethyl)-amide, (compound denoted as A68-B I-C Example I-ethyl-5-methoxy- IH-indo[-3-yl)- IH-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy- 1,1dimethyl-ethyl)-amide, (compound denoted as A68-B3-C Example 4 and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ib) of the invention for the inhibition of SYK are:- 6-indolizin- I-yl-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as Ali-B40-C46), Example I1(p); 6-(3-methyl-indoizin- I-yl)-5H--pyrrolo[2,3-b~pyrazine, (compound denoted as A I-B41I-C46), Example I and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (1c) of the invention for the inhibition of SYK are:- 1 -methyl-4-phenyl- I H--pyrrol-3-y)-5H-pyrrolo[2,3-b]pyrazine, (compound denoted as AlI -B43), Example I (ad); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (1d) of the invention for the inhibition of SYK are:- 6-(4-teri-butylphenyl)-SH-pyrrolo[2,3-b]pyrazine, (compound denoted as Al -B5 Example 1(w); 6-(4-tert-butylphenyl)-7-metliyl-5 H-pyrroio[2,3 -b]pyrazine, (compound denoted as A29-B55), Example 1 3-[6-(4-tert-butylphenyl-5 H-pyrro lo[2,3-blpyrazin-7-yl]-N-methylpropionamide, (compound denoted as A33-1333), Example 14(t); 5-[6-(4-fer-t-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]ethyl-2H-tetrazole, (compound denoted as A35-B55), Example 22; 3 -[6-(4-lert-butyl phenyl-5 H-pyrro lo[2,3 pyrazi n-7-yl] -prop ionam ide, (compound denoted as A32- Example 24; WO 03/000688 PCT/GB02/02799 -81- 3-[6-(4-i'eri-butylphenyl-SH-pyrrolo[2,3-b]pyrazin-7-yl]-propionic acid, (compound denoted as A3 I1- Example 25(a); 3 -[6-(4-ter-t-butyl-phenyl)-SH-pyrrolo[2,3-b]pyrazin-7-yl]-propan- I-ol, (compound denoted as A3 0- Example 26; 3-(6-(4-tert-butylphienyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl)propyl} acetam ide, (compound denoted as A39-1355), Example 3 6(a); N-(3 -(6-(4-tert-butylphenyl)-5 H-pyrrolo[2,3-blpyrazin-7-yl)propyl} methanesulfonarnide, A3 8-1355), Example 39(a); 2-methyl-4-[6-(4-tert-butyl-phenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-butan2-ol, (compound denoted as A59-1355), Example 4 ri 4-[6-(4-zert-butyl-pheniyl)-SH-pyrrolo[2,3-h]pyrazin-7-y]-butan-2-one, (compound denoted as A58-B55), Example 51; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (la) of the invention for the inhibition of Aurora.2 are: I -methyl-3-( IH-pyrrolo[2,3-b] pyrid in-2-yJ)- IH-indole-6-carboxyl ic acid, (compound denoted as A2- B I8-C28), Example 2-[1I -methyl-5-(pyridin-4-yl)- I l--indol-3-yl3-4- I H-pyrrolo[2,3-b~pyridine, (compound denoted as A2- BI-C37), Example 17(q); N- (I -methyl-3-( IH-pyrrolo[2,3-b)pyridin-2-yl)- 1H-indol-5-yl]methyl }thien-2-yl-sulfonamide, (compound denoted as A2-13 I -C69), Example 19(c); I-methyl-3-( IH-pyrrolo[2,3-b~pyridin.2-yl)- IH-indol-5-yl~methyl 4-N' -tetrahydropyran-2-ylurea, (compound denoted as A2-13I -C74), Example 37(c); 2-[5-methoxy-3-( 1H-pyrrolo[2,3 -b]pyridin-2-yI)-indol-1I-yI]-N-(2-methyl-quinolin-4-yl)-acetamide, (compound denoted as A2-B 123 -Cl1), Example 53(cf); I-methyl-I H-indol-3-yl)- IH-pyrrolo(2,3-blpyrid in-4-yl]-(2-methoxy-phenyl)-amine, (compound denoted as A87-B I -ClI), Example 59(b); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of form-ul]a (1c) of the invention for the inhibition of Aurora2 are:- 1-methiyl-I H-pyrrol-2-yl)-5 H-pyrrolo[2,3-b)pyrazine, (compound denoted as Al -B53), Example 1(o); 1and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

WO 03/000688 PCT/GB02/02799 -82-

R

2 Compounds of formula (la) in which the R' residue is attached to the 2 position of

N:

H

R

2 the indole ring and compounds of formula (Ic) in which the R residue is attached

H

to the 2 position of the pyrrole ring show selectivity for inhibition of Aurora2.

R

2 Compounds of formula (la) in which the R residue (wherein R 2 is hydrogen and

H

X is CH) is attached to the 3 position of the indole ring and compounds of formula (Ic) in which the

R

2 R I residue (wherein R 2 is hydrogen and X 1 is CH orN, especially N) is attached to

H

the 3 position of the pyrrole ring are preferred for the inhibition of IGFIR.

Preferred compounds of formula (Ia) of the invention for the inhibition of IGFIR are:- 2-[5,6-dimethoxy-3-( H-pyrrolo[2,3-b]pyridin-2-yl)-indol-l-yl]-l-morpholin-4-yl-ethanone, A2-B 118- Cl, Example 14(aq); 2-[5,6-dimethoxy- -(2-morpholin-4-yl-ethyl)-l H-indol-3-yl]-l H-pyrrolo[2,3-b]pyridine, A2-B 122-Cl, Example 17(ab); 2-(5,6-dimethoxy-l-methyl-I H-indol-3-yl)- H-pyrrolo[2,3-b]pyridine methanesulfonate, Example 21(g); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, WO 03/000688 PCT/GB02/02799 -83- "1 compounds of the invention and compositions containing compounds of the invention for use in therapy.

SCompounds within the scope of the present invention block kinase catalytic activity according to tests described in the literature and in vitro procedures described hereinafter, and which tests results are S believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further Sembodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of protein kinase inhibitors Syk, 0 10 Aurora2, KDR, FAK and IGFI For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example asthma: inflammatory dermatoses psoriasis, dematitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease); allergic rhinitis and allergic conjunctivitis; joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. The compounds are also useful in the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute synovitis, autoimmune diabetes, autoirmnune encephalomyelitis, collitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, graft v host disease and other transplant associated rejection events, cancers and tumours (such as colorectal, prostate, breast, thyroid, colon and lung cancers) and inflammatory bowel disease.

Additionally, the compounds are useful as tumor anti-angiogenic agents.

S A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of psoriasis.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

Another special embodiment of the therapeutic methods of the present invention is the treating of cancers and tumours.

WO 03/000688 PCT/GB02/02799 -84r1 According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of a protein kinase inhibitor Syk, Aurora2, KDR, FAK and IGFIR) for example O conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention.

"Effective amount" is meant to describe an amount of compound of the present invention effective in Sinhibiting the catalytic activity a protein kinase, such as Syk, Aurora2, KDR, FAK and IGFIR, and Sthus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as 4 treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.

Compounds of the invention may be administered by any suitable means. In practice compounds of the present invention may generally be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, L diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets.

To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols.

When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

WO 03/000688 PCT/GB02/02799 For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.

Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

WO 03/000688 PCT/GB02/02799 -86- C1 The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and c¢ may find much weaker maintenance doses adequate. For other patients, it may be necessary to have Slong-term treatments at the rate of I to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or 0 two doses per day.

0 Compounds of the invention may be prepared by the application or adaptation of known methods, by 0 10 which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 1989.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

Compounds of formula wherein R 1

R

2 and R 3 are as hereinbefore defined, and X 1 is N or CH may be prepared by application or adaptation of the procedures described by Davis et al Tetrahedron, 1992, 48, page 939-952, for example: reaction of compounds of formula (III):- 2

R

3

N

wherein R 2 and R 3 are as hereinbefore defined and X 1 is N or CH, with a suitable base, such as lithium diisopropylamide (or butyllithium), in an inert solvent, such as tetrahydrofuran, and at a temperature from about -26 0

C;

(ii) treatment of the resulting anion with nitriles of formula

R

I

-CN (IV) WO 03/000688 PCT/GB02/02799 -87wherein R 1 is as defined hereinbefore at a temperature at about -15 0 C to about room temperature.

This procedure is particularly suitable for the preparation of compounds of formula where R I is optionally substituted N-methylindol-3-yl, R 2 and R 3 are hydrogen and XI is N or CH.

Compounds of formula wherein R

I

R

2

R

3 and X 1 are as hereinbefore defined may also be prepared by application or adaptation of the procedure described by Chang and Bag, J.Org.Chem., 1995, 21, pages 7030-7032, for example reaction of compounds of formula wherein R 1

R

2

R

3 and X 1 are as hereinbefore defined, and X 2 is a halogen, preferably iodine, atom or a.triflate group, with a boronic acid of formula

RI-B(OH)

2

(VI)

wherein R 1 is as defined hereinbefore. The coupling reaction may conveniently be carried out for example in the presence of a complex metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and sodium bicarbonate, in aqueous dimethylformamide at a temperature up to reflux temperature.

Compounds of formula wherein R 2

R

3 and X 1 are as hereinbefore defined and R 1 is aryl or heteroaryl substituted by -NY 1 y 2 may be prepared by reaction of the corresponding compounds in which R 1 is aryl or heteroaryl substituted by -OSO 2

CF

3 with amines of formula HNY 1 y 2 The reaction may conveniently be carried out at a temperature at about 200 0 C in a microwave oven.

Compounds of formula wherein R 2

R

3 and X i are as hereinbefore defined and RI is aryl or heteroaryl substituted by heteroaryl may be prepared by reaction of the corresponding compounds in WO 03/000688 PCT/GB02/02799 -88-

O

N which RI is aryl or heteroaryl substituted by -OSO 2

CF

3 with an heteroaryl boronic acid. The reaction c may conveniently be carried out in the presence of sodium carbonate solution and tetrakis(triphenylphosphine)palladium[0], in an inert solvent, such as dioxane, and at a temperature at about 180°C in a microwave oven.

C1 Compounds of the invention may also be prepared by interconversion of other compounds of the

O

S invention.

O

Thus, for example, compounds of formula containing a carboxy group may be prepared by hydrolysis of the corresponding esters. The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50 0 C to about 80 0

C.

As another example compounds of formula containing a carboxy group may be prepared by acid catalysed removal of the tert-butyl group of the corresponding tert-butyl esters using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.

As another example compounds of formula containing a carboxy group may be prepared by Shydrogenation of the corresponding benzyl esters. The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

As another example of the interconversion process, compounds of formula containing a I Y 2 group may be prepared by coupling compounds of formula containing a carboxy group with an amine of formula HNY y 2 to give an amide bond using standard peptide coupling procedures, for example coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide) at room temperature. The coupling may also be brought about by reaction of compounds of formula containing a carboxy group with N-{(dimethylamino)(l H- WO 03/000688 PCT/GB02/02799 -89- 1,2,3-triazaolo[4,5-b]pyridin- 1 -yl)methylene}-N-methylmethanaminium hexafluorophosphate N-oxide in the presence of a suitable base, such as diisopropylethylamine, in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature, followed by reaction with an amine-of formula HNY 1 y 2 (ammonium chloride can be used for the preparation of compounds of formula containing a -C(=O)-NH 2 group). The coupling may also be brought about by reaction of compounds of formula containing a carboxy group with 2-(1H-benzotriazole-l-yl)1,1,3,3tetramethyluronium hexafluorophosphate, in dry dimethylformamide, followed by reaction with an amine of formula HNY i y 2 in the presence of diisopropylethylamine.

As another example of the interconversion process, compounds of formula containing a -CH 2

OH

group may be prepared by the reduction of corresponding compounds of formula containing a -CHO or -CO 2

R

7 (in which R 7 is lower alkyl) group. For example, the reduction may conveniently be carried out by means of reaction with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about room temperature to about reflux temperature.

As another example of the interconversion process, compounds of formula in which R 1 is aryl or heteroaryl substituted by -CO 2 Me may be prepared by: treating compounds of formula in which RI is aryl or heteroaryl substituted by hydroxy, with N-phenyltrifluoromethanesulfonimide in the presence of a suitable base, such as triethylamine, in an inert solvent, such as dichloromethane, and at a temperature at about -78 0

C;

(ii) reaction of the resulting triflate with carbon monoxide in the presence of a suitable catalyst palladium acetate), 1,3-bis(diphenylphosphino)propane, triethylamine and methanol, in an inert solvent, such as dimethylformamide at a pressure of about 1 atmosphere, and at a temperature at about room temperature.

This procedure is particularly suitable for the preparation of compounds of formula in which R I is 5-carboxymethyl-N-methylindol-3-yl.

As another example of the interconversion process, compounds of formula in which R 1 is aryl or heteroaryl substituted by -SONYI y 2 may be prepared by: treating compounds of formula in which R 1 is aryl or heteroaryl substituted by hydroxy, with N-phenyltrifluoromethanesulfonimide as described hereinabove; (ii) treating the resulting triflate with tertiary-butylmercaptan in the presence of sodium tertiary-butoxide, palladium acetate, lithium chloride and WO 03/000688 PCT/GB02/02799

O

Sbis(diphenylphosphino)-1,l'-binaphthyl in an inert solvent, such as toluene, and at a C temperature at about 110-120 0

C;

C (iii) reaction of the resulting compounds of formula in which R 1 is aryl or heteroaryl

O

substituted by -StBu, with trifluoroacetic acid and mercuric acetate, in an inert solvent, such as toluene, and at a temperature at about room temperature, followed by treatment Swith hydrogen sulfide; O (iv) reaction of the resulting compounds of formula in which RI is aryl or heteroaryl Ssubstituted by -SH, with chlorine in aqueous acetic acid at a temperature at about room temperature; C 10 reaction of the resulting compounds of formula in which R 1 is aryl or heteroaryl substituted by -SO 2 CI, with an amine of formula HNY l y 2 As another example of the interconversion process, compounds of formula in which RI is aryl or heteroaryl substituted by aryl (or heteroaryl) may be prepared by treating compounds of formula in which R 1 is aryl or heteroaryl substituted by hydroxy with N-phenyltrifluoro-methanesulfonimide as described hereinabove followed by reaction of the resulting triflate with an aryl (or heteroaryl) boronic acid ester in the presence of a suitable catalyst palladium tetrakis(triphenylphosphine) and aqueous sodium bicarbonate, in an inert solvent, such as dimethylformamide, and at a temperature at about 120-150C.

As another example of the interconversion process, compounds of formula in which R 1 is aryl or heteroaryl substituted -C(=O)CH 3 may be prepared by treating compounds of formula in which R 1 is aryl or heteroaryl substituted by hydroxy with N-phenyltrifluoro-methanesulfonimide as described hereinabove followed by reaction of the resulting triflate with n-butyl vinyl ether in the presence of a suitable catalyst palladium acetate), 1,3-bis(diphenylphosphino)butane and triethylamine, in an inert solvent, such as dimethylformamide, and at a temperature at about 80 0

C.

As another example of the interconversion process, compounds of formula containing a

-C(OH)CH

3

R

12 (where R 12 is alkyl) group may be prepared by treating compounds of formula (I) containing a -C(=O)CH 3 group with a Grignard reagent, such as methyl magnesium iodide when R 1 2 is methyl, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

another example of the interconversion process, compounds of formula in which R 1 is aryl or roaryl substituted by hydroxy may be prepared by reaction of the corresponding compounds of WO 03/000688 PCT/GB02/02799 0 -91-

O

1 formula in which R 1 is aryl or heteroaryl substituted by methoxy with a Lewis acid, such as boron tribromide, in an inert solvent, such as dichloromethane and at a temperature from about 0°C to about room temperature. Alternatively compounds of formula in which R 1 is aryl or heteroaryl substituted by hydroxy may be prepared by reaction of the corresponding compounds of formula in which R 1 is aryl or heteroaryl substituted by benzyloxy with iodotrimethylsilane, in an inert solvent, such as acetonitrile and at a temperature at about 50 0

C.

O

O

C

As another example of the interconversion process, compounds of formula in which R I is aryl or O heteroaryl substituted by -OR (in which R is optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, C 10 heterocycloalkyl or heterocycloalkylalkyl) may be prepared by alkylation the corresponding compounds of formula in which R I is aryl or heteroaryl substituted by hydroxy, with compounds of formula (VII):-

R-X

3

(VII)

wherein R is as just hereinbefore defined and X 3 is a halogen, preferably bromo, atom, or a tosyl group, using standard alkylation conditions. The alkylation may for example be carried out in the presence of a base, such as an alkali metal carbonate potassium carbonate or cesium carbonate), an alkali metal alkoxide potassium tertiary butoxide) or alkali metal hydride sodium hydride), in dimethylformamide, or dimethyl sulfoxide, at a temperature from about 0°C to about 100IC.

Alternatively compounds of formula in which R I is aryl or heteroaryl substituted by -OR (in which R is optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl) may be prepared by reaction of the corresponding compounds of formula in which RI is aryl or heteroaryl substituted by hydroxy with the appropriate alcohol of formula (Vll):- R-OH (VII) wherein R is as just hereinbefore defined in the presence of a triarylphosphine, such a triphenylphosphine, and a dialkyl acetylenedicarboxylate, such as diisopropylacetylenedicarboxylate or dimethylacetylenedicarboxylate, in an inert solvent, such as toluene, and at a temperature at about room temperature. This procedure is particularly suitable for the preparation of compounds of formula in which R 1 is heteroaryl substituted by -OR (in which R is optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl).

WO 03/000688 PCT/GB02/02799 S-92- As another example of the interconversion process, compounds of formula in which R 1 is aryl or Sheteroaryl substituted by -OR (where R is propyl substituted by hydroxy), may be prepared by reaction of the corresponding compounds of formula in which RI is aryl or heteroaryl substituted by -OR (where R is propenyl) with borane followed by reaction with hydrogen peroxide in the presence of CK, sodium hydroxide. This procedure is particularly suitable for the preparation of compounds of formula 0 in which R I is indolyl substituted by -OCH 2

CH(CH

3 )OH and -OCH 2

CH

2

CH

2

OH.

As another example of the interconversion process, compounds of formula in which RI is aryl or N 10 heteroaryl substituted by-OR (where R is a 1,3-dihydroxyalkylene group) may be prepared by reaction of the corresponding compounds where R is alkenyl with osmium tetroxide in the presence of 4methyl-morpholine N-oxide. The reaction may conveniently be carried out in an inert solvent, such as acetone, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (la) in which R 9 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, or alkyl substituted by -C(=O)NY Y 2

-OR

7 -C(=0)-OR 7 -NY ly 2 may be prepared by alkylation of the corresponding compounds of formula (la) in which R 9 is hydrogen, with the appropriate halide of formula R9-X 4

(IX)

C wherein R 9 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, or alkyl substituted by -C(=O)NY y 2

-OR

7 -C(=0)-OR 7 -NY 1 2 and X 4 is a halogen, preferably bromine, atom, using standard alkylation conditions for example those described hereinbefore.

As another example of the interconversion process, compounds of formula containing a

-N(R

6 3 y 4 group in which R 6 and Y 3 are both hydrogen and Y 4 is as hereinbefore defined may be prepared by reaction of the corresponding compounds of formula containing an amino group with an isocyanate of formula O=C=NY 4 in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula containing sulfoxide linkages may be prepared by the oxidation of corresponding compounds containing linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g.

WO 03/000688 PCT/GB02/02799 -93- 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulfate in a medium S such as aqueous methanol, buffered to about pH5, at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.

As another example of the interconversion process, compounds of formula containing sulfone 0 linkages may be prepared by the oxidation of corresponding compounds containing or sulfoxide O linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

As another example of the interconversion process, compounds of formula containing a cyano group may be prepared by reaction of the corresponding compounds of formula containing a -C(=O)-NH 2 group with phosphorus pentachloride in the presence oftriethylamine. The reaction may conveniently be carried out in an inert solvent, such as tetrahydrofuran, and at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula containing a

NH

2 group may be prepared by reaction of the corresponding compounds of formula containing a 0 cyano group with hydrogen peroxide in the presence of sodium hydroxide. The reaction may conveniently be carried out in methanol at a temperature at about room temperature.

W As another example of the interconversion process, compounds of formula containing a tetrazolyl group may be prepared by reaction of the corresponding compounds of formula containing a cyano group with azidotributyltin. The reaction may conveniently be carried out in an inert solvent, such as toluene, and at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula in which R 2 is a fluoro may be prepared by reaction of the corresponding compounds of formula in which R 2 is hydrogen with methyl magnesium bromide (in an inert solvent, such as tetrahydrofuran, and at a temperature at about o0C) followed by reaction with l-chloromethyl-4-fluoro-l,4-'diazoniabicyclo[2,2,2]octane bis(tetrafluoroborate) at a temperature from about 0°C to about reflux temperature.

As another example of the interconversion process, compounds of formula in which X 1 is C-NY Y 2 (wherein yl and Y 2 are as hereinbefore defined and only one ofY 1 and Y 2 represents WO 03/000688 PCT/GB02/02799 6 -94- 0 r, hydrogen), may be prepared by reaction of the corresponding compounds of formula in which X 1 is halo (e.g.chloro) with an amine of formula HNY 1

Y

2 (wherein Y 1 and Y 2 are as immediately hereinbefore defined) in the presence of cesium carbonate and tris-(dibenzylideneacetone)dipalladium(0), in an inert solvent, such as 1,2-dimethoxyethane, and at a temperature at about 80 0

C.

As another example of the interconversion process, compounds of formula in which X 1 is C-CN Smay be prepared by reaction of compounds of formula in which XI is C-halo, preferably C-CI, with zinc cyanide in the presence of zinc powder, [l'l-bis(diphenylphosphino)ferrocene] Sdichloropalladium(II) complex and dichloromethane (catalytic amount) and N,N-dimethylacetamide at SC', 10 a temperature at about 150°C.

As another example of the interconversion process, compounds of formula containing a -C(=0)-OR 5 group (in which R 5 is as hereinbefore defined) may be prepared by reaction of the corresponding compounds of formula containing a group with alcohols of formula

R

5 -OH. For example when R 5 is tert-butyl the reaction may conveniently be carried out in the presence of I'-carbonyldiimidazole and 1,8-diazabicyclo[5.4.0]undec-7-ene at a temperature at about room temperature.

It will be appreciated that compounds of the present invention may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism.

It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

WO 03/000688 PCT/GB02/02799 The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For.example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with.the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Compounds of formula (IV) wherein R I is as defined hereinbefore may be prepared by reaction of the corresponding compounds of formula

R

I

-CHO (1) wherein R I is as hereinbefore defined, with hydroxylamine hydrochloride in an inert solvent, such as dimethylformamide, and at a temperature at about 150 0

C.

Compounds of formula (IV) wherein RI is represented by the formula WO 03/000688 PCT/GB02/02799 -96- 4 5 (R (I)6 2

N

R

in which R 10 and p are as hereinbefore defined and R 9 is alkyl, alkenyl, cycloalkyl or alkyl substituted by -C(=O)NY 1

Y

2

-OR

7 -C(=0)-OR 7

-NY

1 y 2 may be prepared by alkylation of the corresponding IH-indoles of formula (IV) wherein RI is represented by the formula in which R 10 and p are as hereinbefore defined and R 9 is hydrogen, with the appropriate (optionally substituted)alkyl-, alkenyl- or cycloalkyl-halide using standard alkylation conditions. The alkylation may for example be carried out in the presence of a base, such as an alkali metal carbonate, e.g.

potassium carbonate, or alkali metal hydride, e.g. sodium hydride, in an inert solvent, such as dimethylformamide or dimethyl sulfoxide, at a temperature from about room temperature to about 100 0

C.

Compounds of formula (IV) wherein R is 5,6,7,8-tetrahydroindolizin-l-yl may be prepared by:reaction of piperidine-2-carboxylic acid with formic acid and acetic anhydride at a temperature at about room temperature; (ii) treatment of the resulting sodium-l-formyl-piperidine-2-carboxylate with 4-toluenesulfonyl chloride in an inert solvent, such as dichloromethane, and at a temperature at about room temperature; (iii) reaction with acrylonitrile in the presence oftriethylamine at a temperature at about room temperature.

Compounds of formula wherein R 1 is as defined hereinbefore may be prepared by formylation of compounds of formula RI-H (2) wherein RI is as defined hereinbefore using standard reaction conditions, for example using a Vilsmeier-Haack formylation reaction with phosphorus oxychloride in dimethylformamide. This WO 03/000688 PCT/GB02/02799 -97-

O

C procedure is particularly suitable for the preparation of compounds of formula where R 1 is optionally substituted N-methylindol-3-yl.

Compounds of formula wherein R 2

R

3 and X 1 are as hereinbefore defined and X 2 is qn iodine atom, may be prepared by iodination of compounds of formula

OR

2 N

N

(3)

H

wherein R 2

R

3 and X' are as hereinbefore defined. The iodination reaction may conveniently be carried out by the application or adaptation of the procedure described by Saulnier and Gribble, J.Org.Chem., 1982, 47, 1982, for example by treatment of compounds of formula with lithium diisopropylamide in an inert solvent, such as tetrahydrofuran, and at a temperature at about -78 0

C,

followed by reaction of the resulting anion with iodine. This reaction is conveniently carried out with the indole NH protected with for example a tosyl group.

Compounds of formula wherein R 2

R

3 and X I are as hereinbefore defined may be prepared by t cyclisation of compounds of formula 3 CHR (4) N N

H

wherein R 2

R

3 and X are as hereinbefore defined. The cyclisation reaction may conveniently be carried out in the presence of an alkali metal alkoxide, such as sodium ethoxide, in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature.

WO 03/000688 PCT/GB02/02799 -98-

O

C1 Compounds of formula wherein R 3 and X 1 are as hereinbefore defined and R 2 is hydrogen may be S prepared by cyclisation of compounds of formula X CH 3

R

3 gCH O N N OEt cN wherein R 3 and XI are as hereinbefore defined. The cyclisation reaction may conveniently be carried out in the presence of sodamide, in N-methylaniline and at a temperature from about 120 0 C to about 200 0

C.

Compounds of formula wherein R 3 and X I are as hereinbefore defined and R 2 is methyl (or C]_ 4 alkyl optionally substituted by -Z 1

R

4 in which Z 1 and R 4 as hereinbefore defined) may be prepared by cyclisation of compounds of formula X X R3 (6) N N R 1

H

wherein R 3 and X 1 are as hereinbefore defined, R 1 1 is hydrogen (or C 1 -3alkyl optionally substituted by -Z 1

R

4 in which ZI and R 4 as hereinbefore defined) and X 5 represents a halogen, preferably a bromine, atom, or a triflate group. The cyclisation may conveniently be carried out in the presence of a complex metal catalyst such as tetrakis(triphenylphosphine)palladium(0), a tertiary amine, such as triethylamine, and a triarylphosphine, such as triphenylphosphine, in an inert solvent, such as dimethylformamide and at a temperature at about 60 0 C to about 120°C. This procedure is particularly suitable for the preparation of compounds of formula wherein R 3 and X 1 are as hereinbefore defined, X 1 is N and R 2 is C-CH 3 Compounds of formula wherein R 3 R2 and XI are as hereinbefore defined may be prepared by: reaction of compounds of formula WO 03/000688 PCT/GB02/02799 o -99ct X 6 N

NH

2 Swherein

R

3 and X I are as hereinbefore defined and X 6 is a halogen, preferably iodine, atom with acetylenes of formula

R

2 -C=C-SiMe 3 (8) wherein R 2 is as hereinbefore defined, in the presence of a complex metal catalyst such as [1,1 '-bis(diphenylphosphino)-ferrocene]palladium (II) chloride, lithium chloride and sodium carbonate, in an inert solvent, such as dimethylformamide, and at a temperature up to about 100 0

C.

(ii) desilylation.

Compounds of formula wherein R 2

R

3 and X 1 are as hereinbefore defined may be prepared by reaction of compounds of formula 01 X CH 2

R

2

R

N NH wherein R 2

R

3 and X 1 are as hereinbefore defined with a mixture of formic acid and acetic anhydride.

Compounds of formula wherein R 3 and XI are as hereinbefore defined may be prepared by reaction of the corresponding compounds of formula wherein R 3 and X 1 are as hereinbefore defined and R 2 is hydrogen with triethylorthoformate, in the presence of an acid catalyst, such as hydrogen chloride, in ethanol and at a temperature from about room temperature to about reflux temperature.

WO 03/000688 PCT/GB02/02799 -100- 0 Compounds of formula wherein R 3

R

1 I and X 1 are as hereinbefore defined and X 5 is a halogen Satom may be prepared by alkylation of compounds of formula wherein R 3

X

1 and X 6 are as hereinbefore defined with the appropriate alkenyl halide of formula

CR

1

CH=CH-CH

2

-X

7 Swherein R 1 is as hereinbefore defined and X 7 is a halogen, preferably bromine, atom. The alkylation Smay conveniently be carried out in the presence of an alkali metal hydride, such as sodium hydride, in 10 an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Compounds of formula wherein R 3 and X 1 are as hereinbefore defined and X 6 is a bromine atom, may be prepared by bromination of compounds of formula

X

1 N NH 2 (1 1) wherein R 3 and X 1 are as hereinbefore defined, in dimethylsulfoxide.

Compounds of formula wherein R 3 and X 1 are as hereinbefore defined and X 5 is an iodine atom, may be prepared by iodination of compounds of formula (11) wherein R 3 and X 1 are as hereinbefore defined. The iodination may be carried out by the application or adaptation of the method of W-W.Sy, Synth.Comm., 1992, 22, pages 3215-3219.

Compounds of formula wherein R 1

R

2

R

3 and X 1 are as hereinbefore defined and X 5 is a triflate group may be prepared by reaction of compounds of formula WO 03/000688 PCT/GB02/02799 0 -101- 0 CM R 2 c R 3 N N C H (12) wherein R 2

R

3 and X 1 are as hereinbefore defined, with triflic anhydride in the presence of Hunigs base, in an inert solvent,.such as dichloromethane, and at a temperature at about 0°C. This reaction is 4 5 conveniently carried out with the indole NH protected with for example a tosyl group.

Compounds of formula (12) wherein R 2

R

3 and X 1 are as hereinbefore defined may be prepared by reaction of compounds of formula R CHO N

N

(13) wherein R 3 and X I are as hereinbefore defined with meta-chloroperbenzoic acid, in an inert solvent, such as dichloromethane, and at a temperature at about 5°C. This reaction is conveniently carried out with the indole NH protected with for example a tosyl group.

Compounds of formula (13) wherein R 3 and X 1 are as hereinbefore defined may be prepared by reaction of compounds of formula

X

N

N

(14) WO 03/000688 PCT/GB02/02799 -102-

O

wherein R 3 and XI are as hereinbefore defined with lithium diisopropylamide, in an inert solvent, such as tetrahydrofuran, followed by reaction with dimethylformamide and at a temperature at about -78 0

C.

S This reaction is conveniently carried out with the indole NH protected with for example a tosyl group.

Compounds of formula (14) wherein R 3 and X 1 are as hereinbefore defined may be prepared by reaction of compounds of formula wherein R 3 and X 1 are as hereinbefore defined and X 6 is iodo, with trimethylsilylacetylene in the presence of a complex metal catalyst such as Sbis(diphenylphosphino)-ferrocene]palladium (II) chloride, followed by desilylation.

Compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-Z 2 R (in which Z 2 is O and R is alkyl) may be prepared by reaction of compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-halo, preferably C-CI, with an alcohol of formula R-OH in the.

presence of an alkali metal hydroxide, such as sodium hydroxide. The reaction is conveniently carried out under pressure and at a temperature at about 170°C.

Compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-OH may be prepared by reaction of compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-halo, preferably C-CI, with an aqueous alkali metal hydroxide solution, such as sodium hydroxide solution.

The reaction is conveniently carried out under pressure and at a temperature at about 180 0

C.

Compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-CI may be prepared by oxidation of compounds of formula (14) wherein R 3 is as hereinbefore defined and Xl is C-H with 3-chloroperbenzoic acid, in an inert solvent, such as dichloromethane, and at a temperature at about 0°C followed by reaction of the resulting pyrrolo[2,3-b]pyridine N-oxide with phosphorus oxychloride at reflux.

Compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-C(=O)-OR 5 group (in which R 5 is as hereinbefore defined) may be prepared by reaction of the corresponding compounds of formula containing a group with alcohols of formula R 5 -OH. For example when R 5 is tert-butyl the reaction may conveniently be carried out in the presence of 1-l'-carbonyldiimidazole and 1,8-diazabicyclo[5.4.0]undec-7-ene at a temperature at about room temperature.

WO 03/000688 PCT/GB02/02799 -103- Compounds of formula (14) wherein R 3 is as hereinbefore defined and X 1 is C-heteroaryl (for example

CH

3

N

C- I may be prepared by reaction of compounds of formula

CH

3 (16) in which R 3 is as hereinbefore defined with the appropriate heteroaryl boronic acid (for example dimethylisoxazole-4-boronic acid) in the presence of tetrakis(triphenylphosphine)palladium(0) and aqueous sodium bicarbonate. The reaction may conveniently be carried out in dimethylformamide at a temperature at about 110 0

C.

Compounds of formula (VI) wherein R 1 is as defined hereinbefore may be prepared by:reaction of compounds of formula

R

1

-X

8 C wherein R 1 is as defined hereinbefore and X 8 is a halogen, preferably bromine, atom, in the presence oftributylborate, with a suitable base, such as butyllithium, in an inert solvent, such as tetrahydrofuran, and at a temperature at about 00 0

C.

Compounds of formula (VI) wherein R 1 is as defined hereinbefore may also be prepared by treatment of compounds of formula wherein R 1 is as defined hereinbefore and X 8 is a -HgOAc group, with borane, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Compounds of formula (15) wherein R 1 is optionally substituted indol-3-yl and X 8 is a bromine atom may be prepared by reaction of optionally substituted indoles with bromine in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature.

WO 03/000688 PCT/GB02/02799 -104- Compounds of formula (13) wherein R 1 is optionally substituted indol-3-yl and X 8 is a -HgOAc group may be prepared by reaction of optionally substituted indolines with mercuric acetate in glacial acetic acid at a temperature at about room temperature.

The present invention is further exemplified but not limited by the following illustrative Examples and Reference Examples.

400M Hz 1H nuclear magnetic resonance spectra (NMR) were recorded on a Varian Unity INOVA machine. In the nuclear magnetic resonance spectra (NMR) the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: s singlet; d= doublet; t triplet; m multiplet; q quartet; dd doublet of doublets; ddd doublet of double doublets.

High Pressure Liquid Chromatography Mass Spectrometry (LC-MS) conditions for determination of retention times (RT) were as follows:- METHOD A: YMC ODS-A-HPLC column (50mm x 4mm) operated under gradient elution conditions with mixtures of water and acetonitrile, 95:5 and 5:95, containing 0.1% formic acid as the mobile phase gradient (0.00 minutes, 95%A:5%B; linear gradient to 100% B at 2 minutes; then hold until 3.4 minutes); flow rate 2ml/minute with approximately 200p.l/minute split to the Mass Spectrometer; injection volume 10-40gl; in line Diode Array (220-450nm), in line Evaporative light scattering (ELS) detection ELS temperature 50 0 C, Gain 8 1.8ml/minute; Source temperature 150 0

C;

METHOD B: 3 micron Luna C18 HPLC column (30mm x 4.6mm) operated under gradient elution conditions with mixtures of(A) water containing 0.1% trifluoroacetic acid and acetonitrile containing 0.1% trifluoroacetic acid as the mobile phase gradient 0.00 minutes, 95%A:5%B; 0.50 minutes, 95%A:5%B; 4.50 minutes, 5%A:95%B; 5.00 minutes, 5%A:95%B; 5.50 minutes, 95%A:5%B; flow rate 2ml/minute with approximately 200pl/minute split to the Mass Spectrometer; injection volume 10-40 1; in line Diode Array (220-450nm), in line Evaporative light scattering (ELS) detection ELS temperature 50 0 C, Gain 8 1.8ml/minute; Source temperature 150 0

C.

METHOD C: LC-MS analyses were conducted on a Micromass instrument model LCT linked to an HP 1100 model instrument. Compound abundance were detected using an HP model G1315A photodiode array detector in the 200-600 nm wavelength range and a Sedex model 65 evaporative light scattering detector. Mass spectra were acquired in the 180 to 800 range. Data were analysed using the Micromass MassLynx software. Separation were carried out on a Hypersil BDS Cl 8, 3 pm particle size column x 4.6 mm) eluted by a linear gradient of 5 to 90% acetonitrile containing 0.05% (v/v) WO 03/000688 PCT/GB02/02799 -105trifluoroacetic acid in water containing 0.05% trifluoroacetic acid in 3.5 minutes at a flow rate of 1 ml/minute. The total runtime including column reequilibration was 7 minutes.

METHOD D: Hypersil BDS C- 8 column (4.6 mm x 50 mm) reverse phase operated under gradient elution conditions with mixtures of(A) water containing 0.05% trifluoroacetic acid and acetonitrile containing 0.05% trifluoroacetic acid as the mobile phase gradient: (0.00 minutes 100%A:0%B; linear gradient to 100% B at 2 minutes; then hold until 3.5 minutes); flow rate ImL/minute with approximately 0.25mL/minute split to the Mass Spectrometer; injection volume 10 4L; Hewlett Packard Model HP 1100 Series UV detector wavelength 200nm; Evaporative light scattering (ELS) detection -temperature 46 0 C, nitrogen pressure 4bar.

High Pressure Liquid Chromatography Mass Spectrometry (LC-MS) triggered purification conditions were as follows:- Compounds were purified by LC/MS using a Waters FractionLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager makeup pump, a Waters model 2700 autoinjector, two Rheodyne model LabPro switches, a Waters model 996 photodiode 1/1000 of the flow was mixed with methanol (0.5 ml/minute flow rate) and sent to the detectors, this flow was split again 3 of the flow was sent to the photodiode array detector and V1 to the mass spectrometer; the rest of the output of the column (999/1000) was sent to the fraction collector were flow was directed normally to waste unless expected mass signal was detected by the FractionLynx software. The FractionLynx software was supplied with molecular formulas of expected compounds and triggered the collection of compounds when mass signal corresponding to [M+H] and are detected. In certain cases (depending on analytical LC-MS result, when [M+2H] was detected as an intense ion) the FractionLynx software was additionally supplied with calculated half molecular weight in these conditions collection was also triggered when mass signal corresponding to [M+2H] and [M+Na+H] are detected. Compounds were collected in tarred glass tubes. After collection, solvent was evaporated in a Jouan model RC 10.10 centrifuge evaporator or a Genevac model HT8 centrifuge evaporator and the amount of compound was determined by weighing of the tubes after solvent evaporation. Array detector, a Waters model ZMD mass spectrometer and a Gilson model 204 fraction collector. The Waters FractionLynx software controlled the instrument.

Separation were conducted alternatively on two Waters Symmetry columns (C 8 5LM, 19 x 50 mm, catalogue number 186000210), one column was under regeneration by a 95/5 water/acetonitrile mixture containing 0.07% trifluoroacetic acid while the other one is separating. Columns were eluted by a linear gradient of acetonitrile containing 0.07% trifluoroacetic acid in water containing 0.07% trifluoroacetic acid, from 5 to 95% in 8 minutes at a flow rate of ml/minute. At the output of the separating column the flow was split to the 1/1000 ratio using a LC Packing AccuRate splitter.

WO 03/000688 PCT/GB02/02799 -106- The high pressure liquid chromatography retention times (HPLC: RT values) were determined by:- (i) Method A, C18 Phenomenex (150 x 4.6mm) column using gradient elution with a mixture of acetonitrile and water with 0.1% trifluoroacetic acid as the mobile phase (0-1 minute 5% acetonitrile; 1-12 minutes ramp up to 95% acetonitrile; 12-14.95 minutes 95% acetonitrile; 14.95-15 minutes 0% acetonitrile); or Method B, YMC ODS-AQ (2 X 50mm) column using gradient elution with a mixtures of acetonitrile and water with 0.1% formic acid as the mobile phase [95/5/0.1% to 5/95/0.1% and a flow rate of 0.4 mL/minute); or Method C, 3 micron BDS C18 Hypersil (50 x 4.6 mm) using gradient elution with a mixture of acetonitrile and water with 0.1% formic acid as the mobile phase (95 5 water acetonitrile formic acid for 0.1 minute linear gradient to 5 95 water/ acetonitrile formic acid at 2 minutes and hold until 3.5 minutes).

The thin layer chromatography (TLC) RF values were determined using Merck silica plates.

EXAMPLE 1 6-(5-Methoxv-l-methyl-lH-indol-3-vl)-5H-pyrrolor2,3-blpyrazine, Al-BI-CI, the'pirduct of the combination of group Al in Table 1 and BI in Table 2 and Cl in Table 3:- OMe N N N HMe A stirred solution of diisopropylamine (59.9 mL) in tetrahydrofuran (1400 mL), at -15 0 C and under nitrogen, was treated with a solution of n-butyllithium in hexanes (131 mL, 1.6M) over 25 minutes, whilst maintaining the temperature below -10 0 C. After stirring for 30 minutes the mixture was treated with methylpyrazine (26.8g) over 15 minutes, then stirred for 1 hour and then treated with a solution of H-indole-3-carbonitrile [53g, Reference Example in tetrahydrofuran (600 mL) over 1 hour, keeping the temperature below -10°C. The reaction mixture was allowed to warm to room temperature over 2 hours, then stood overnight and then treated with water (100 mL). The tetrahydrofuran was removed in vacuo and the resultant mixture was partitioned between ethyl acetate (500 mL) and water (200 mL). The two layers were separated, and the aqueous layer was extracted with ethyl acetate (200 mL). The combined organics were washed with water (500 mL) then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (19:1, v/v) to give the title compound (19.4g) as a grey solid, m.p. 270- 272 0 C. MS: 279(MH+).

WO 03/000688 PCT/GB02/02799 -107- 1-methyl- I H-indol-3-yl)-5H-pyrrolo[2.3 -bloyrazine, AlI-B I -C46, thle product of the combination of group AlI in Table I and B I in Table 2 and C46 in Table 3:-

NN

(7MN N N, H me By proceed ing in a manner similar to Example I1(a) above but using l-methyl-i ndol e-3 -carbon itrile [Reference Example there was prepared 64( 1-methyl- I H--indol-3-yl)-5H-pyrrolor2,3-blpyrazine as a yellow solid, m.p. 264-266"C. [Elemental analysis:- C, 72.34; H, 4.68; N, 22.28%. Calculated for

C

15

H

12

N

4 C, 72.56; H, 4.87; N, 22.57%].

6-(3-bromophenyl)-5H-pyrrolo[2,3-bl nyrazine, AlI -B9 1, the product of the combination of group AlI in Table I and B91 in Table 2:- Br

N

H

By proceeding in a manner similar to Example I1(a) above but using 3-bromobenzonitrile, there was prepared 6-(3-bromophenyl)-5H-pyrrolof2,3-blvyrazine as a colourless solid, m. p. 247-249*C. MS: 276(M1-i+).

7-iso-propyl-6-phenyl-5H-pyrrolor2,3-blpyrazine A61-BIOO, the product of the combination of group AlI in Table I and BIOO in Table 2:-

N'

H

By proceeding in a manner similar to Example 1 above but using 2-isobutylpyrazine and benzonitri le, there was prepared 7-iso-propyl-6-phenyl-5H-pvrrolor2,3-bl nyrazine as a colourless solid, mn.p. 216-218'C. MS: 238(MH+).

6-(4-bromophenyl)-5H-pyrrolor2,3-blpyrazine, AlI -B90, the product of the combination of group AlI in Table 1 and B90 in Table 2:- WO 03/000688 PCT/GB02/02799 -108-

H

By proceeding in a manner similar to Example 1(a) above but using 4-bromobenzonitrile, there was prepared 6 -(4-bromoohenyl)-5H-pyrrolo[2,3-blpyrazine as a colourless solid, m.p. 326-329'C. MS: 276(MH4+).

6-(4-fi .31dioxan-2-yl-phenfl)-5H-1nvrrolo[2.3-blpvra-zine Al -B87, the product of the combination of group AlI in Table I and B87 in Table 2:- By proceeding in a manner similar to Example above but using 2 -(4-cyanophenyl)-1,3-dioxane (prepared according to the procedure described in US patent application No.- 5750723 for example 3a), there was-prepared 6 444F1, 3 1dioxan-2-yl-phenyl)-5H-pyrrolor2,3-blpyrazinii-as a yellow solid, m.p.

288-289'C. TLC: RF 0.34 (ethyl acetate/pentane:/) 6-(3-F I 31dioxan-2-yl-Rhenyl)-5H-pyrrolof2.3-blpyrazine, Al -B88, the product of the combination of group AlI in Table I and B88 in Table 2:- 0

(N

By proceeding in a manner similar to Example I1(a) above but using 2 -(3-cyanophenyl)-l,3-dioxane (prepared according to the procedure described in US patent application No. 5750723 for example 3a), there was prepared 6 3 3 1dioxan-2-yl-phenyl' 5H-pyrrolor2,3-bloyrazine as a yellow solid, m.p.

205-206*C. [Elemental analysis:- C, 68.28; H, 5.46; N, 15.02%. Calculated for C I 6 H I 5

N

3 0 2

C,

68.3 1; H, 5.37; N, 14.94%].

2-(5H-nvrolof2,3-blpyrazin-6-yl)-cuinoine Al -B 103, the product of the combination of group AlI in Table I and B 103 in Table 2:- WO 03/000688 PCT/GB02/02799 -109-

NN

H

By proceeding in a manner similar to Example I1(a) above but using 2-quinolinecarbonitrile, there was prepared 2-A5H-pyrrolof2.3-bpyrazin-6-yl)-guinoline as a pale yellow solid, m.p. 293-295*C. MS: 247(MH+). [Elemental analysis:- C, 72.76; H4, 3.82; N,22.56%. Calculated for C I 6 H I 5

N

3 0 2

C,

73.16; H, 4.09; N, 22.56%].

3 -(5H-pyrrolo[2,3-blpyrazin-6-vl)-isociuinoline, AlI-B 104, the product of the combination of group AlI in Table I and B 104 in Table 2:-

CN

H

By proceeding in a manner similar to Example 1 above but using 3-isoquinolinecarbonitrile, there was prepared 3-5-yrl[,-l~rai-:y)iounln as a green solid, m.p. 281-285'C. MS: 247(M]4+).

6-rl-methyl-lH-indol-5-yll-5H-py'rrolor2.3-blpyraine. A]-B65, the product of the combination of group AlI in Table I and B65 in Table 2:-

(NN

N N Me

H

By proceeding in a manner similar to Example 1(a) above but using [Reference Example there was prepared 6-F I-methyl-I H-indol-5-yll-5 H-pyrrolor2.3-blpyrazine as a yellow solid, m.p. 260-265'C. MS: 249(MH+).

6-(5-methoxy- I -methyl- I H-indol-3-.yl')-2-methvl-5H-tpyrrolor2,3-b]Ryrazine A64-B I -Cl1, the product of the combination of group A64 in Table I and B I in Table 2 and C I in Table 3:- WO 03/000688 WO 03/00688PCT/G B02/02 799 -110- By proceeding in a manner similar to Example I1(a) above but using 2,6-dimethylpyrazine, there was prepared 6-(5-methoxy- 1-methyl-I H-indol-3-vl)-2-methvl-5H-pyrrolo[2,3-blpyrazine as a ye!llow solid, MS: 293(MH+). 1 INMR [(CD 3 2 S0]: 8 12.2-12.3 (IH, broad 8.54, 8.56 (each IH, 7.50 (IH, d, J=8.9 Hz); 7.47 (1 H, d, J=2.4 Hz); 6.96 (1 H, dd, J=8.9 and 2.4 Hz); 6.91 (1IH, 3.91, 3.87 and 2.57(each 3H, s).

3-methyl-6-(l-methyl-I H-indol-3-yI)-5H-Dyrrolo[2,3-blpyrazine, A66-BI-C], the product of the combination of group A66 in Table I and B]I in Table 2 and ClI in Table 3:- By proceeding in a manner similar to Example 1 above but using 2,5-dimethylpyrazine and l-methyl-lH-indole-3-carbonitrile [Reference Example there was prepared 3-methyl-6-(Imethyl-lH-indol-3-vl)-5H-pvrrolo[2.3-blpvrazine as a yellow solid, m.p. 170-175'C. MS: 263(MH 4 (in) I-benZyl-5-methoxy- IH-indol-3-yl)-5H-pyrrolo r2,3-blpvrazine Al -B24-C I, the product of the combination of group AlI in Table 1 and B24 in Table 2 and C I in Table 3:- By proceeding in a manner similar to Example I1(a) above but using Il-benzyl-5-methoxy-1IH-indole-3carbonitri le [Reference Example there was prepared 64( -bengyl-5-methoxv- I H-indol-3-0l-5 Hpyrrolor2.3-blpyrazine as a yellow solid, m.p. 240-244'C. TLC- RF 0.5 (dichloromethane/methanol: WO 03/000688 PCT/GB02/02799 -111- 1-methyl- I H-pyrrol-3-yl)-5H-pyrrolo[2.3-blpyrazine, AlI -B54, the product of the combination of group AlI in Table 1 and 354 in Table 2:-

H

By proceeding in a manner similar to Example 1(a) above but using I -methyl- IH-pyrrole-3 -carbon itri le (Reference Example there was prepared I-methyl-I H-pyrrol-3-yi)-5 H-Ryrrolof2.3-blpyrazine as ayellow solid, m.p. 211-213'C. MS: l99(MH+).

6 -(l-methvl-I H-prrol-2-vYS5H-pyrrolor2,3-blpyrazine, A]l-B53, the product of the combination of group Al in Table I and B53 in Table 2:-

H

By proceeding in a manner similar to Example 1(a) above but using l-methyl-lH-pyrrole-2-carbonitrile [Reference Example there was prepared I-methyl-I H-pyrrol-2-yfl)-H-pyrrolor2,3-bl Dyrazine as a yellow solid, m.p. 208-209'C. MS: I 99(MI-i).

6-inidol izin- I-vl-5H-pyrrolor2,3-blpyrazinie. Al -B40-C46, the product of the combination of group AlI in Table 1 and B40 in Table 2 and C46 in Table 3:-

H

By proceeding in a manner similar to Example above but using indolizine-l-carbonitrile (Reference Example there was prepared 6-indolizin-l-vl-5H-nyrrolor2,3-blpyrazine as a yellow solid, m.p. 224-225'C (with decomposition). MS: 235(MH+).

6 3 -methyl-indolizin-1-yl)-5H-pyrrolof2.3-blpyrazine, A]-B4]-C46, the product of the combination of group AlI in Table I and B41 in Table 2 and C46 in Table 3:- WO 03/000688 PCT/GB02/02799 -112-

H

By proceeding in a manner similar to Example 1 above but using 3-methyl-indolizine-1 -carbon itrile [Reference Example there was prepared 6-(3-methyl-indolizin-1-vl)-5H-pyrroloR23-bvrazine as a yellow solid, m.p. 233-235 0 C (with decomposition). MS: 249(MH4+).

I-methyl-2-phenyl- IH-pyrrol-4-yl)-5H-pvrrolof 2,3-bloyrazine. Al-B52, the product of the combination of group AlI in Table I and B52 in Table 2:-

(N

H

By proceeding in a manner similar to Example l(a) abovu but using l-methyl-5-phenyl-IH-pyrrole-3carbonitrile [Reference Example there was prepared 6-(1 -methyl-2-phenyi-I pvrrolor2,3-blpyrazine as a yellow solid, m.p. 221-222*C (with decomposition). MS: 275(MH+).

6-(5,6,7,8-tetrahydro-indolizin-1-yl)-SH-pyrrolof2,3-blpyrazine Al-Bill, the product of the combination of group AlI in Table I and B Ill in Table 2:-

(N/

H

By proceeding in a manner similar to Example 1(a) above but using 5,6,7,8-tetrahydro-indolizine-1 carbonitri le [Reference Example there was prepared 6-(5,6,7,8-tetrahydro-indol pyrrolor2.3-blpvrazine as a yellow solid, m.p. 236-238 0 C (with decomposition). MS: 239(MH+).

6-furan-3-vl1-5H-ovrrolor2,3-blpyrazine A I-B 107, the product of the combination of group AlI in Table I and B 107 in Table WO 03/000688 PCT/GB02/02799 -113- CN :N c-i

H

By proceeding in a manner similar to Example I above but using 3-furonitrile there wvas prepared 6-furan-3-yl-5H-pyrrolof2,3-blpyrazine as an orange solid. MS: l86.79(MH+). TLC: RF =0.45 c-K1 (dichloromethane/methanol 19/1).

S dimethvl-r4-(5H-pyrrolor2.3-blcpvrazin-6-yl)-rnhenvll.amine, Al -B6 I, the product of the combination of group AlI in Table I and B61 in Table 2:- K N N N By proceeding in a manner similar to Example 1(a) above but using 4 -N,N-dimethylarniinobenzonitrjle, there was prepared dimethvl-r4-(5H-pyrrolof2,3-blpyrazin-6-yl):ohenyll-amine as a yellow solid, m.p.

297-298'C. MS: 239(Mf-I).

6-(5-methox-1 1-methyl-I H-indol-3-yl)-7-methyl-5H-pyrrolof2.3-bl oyrazine. A29-B I -ClI, the product of the combination of group A29 in Table I and B I in Table 2 and ClI in Table 3:-

H

By proceeding in a similar manner to Example 1 but using ethylpyrazine there was prepared I-methyl-I H-indol-3 -yi)-7-methvl-5H-pyrrolo[2.3-blpvrazine as a yellow solid, m.p.

243-244 0 C. HPLC (METHOD RT =6.73 minutes.

6-(4-ter:-butylp~henyl)-SH-oyrrolor2.3-blpyrazine, AlI -B55, the product of the combination of group Al in Table I and B55 in Table 2:-

CN

N

N

H

By proceeding in a manner similar to Example 1 above but using 4-tert-butylbenzonitrile, there was prepared 6-(4-tert-butvlnhenyl)-5H-pvrrolo[2,3-blpyrazine as a yellow solid. LC-MS: Method B: RT -3.29 minutes, 2S2(MH-l).

WO 03/000688 PCT/GB02/02799 -114- 64(4-Iert-butylphenyl)-7-methyl-5 H-pvrrolo[2,3-bNpyrazine. A29-B55, the product of the combination of group A29 in Table I and B55 in Table 2:- N N

H

By proceeding in a manner similar to Example I above but using 2-ethylpyrazine and 4-tertbutylbenzonitri le, there was prepared 6 4 -ter-t-butvlohenvl)-7-methyl-5H-pvrrolor2,3-blpyrazine as a yellow solid, m.p. 213-214'C. MS: 266(MI-1).

6-(3,4-dimethoxyphenvl)-5H-pyrrolof2,3 -blrpvrazine, Al -B7 I, the product of the combination of group AlI in Table I and B71 in Table 2:- 0- N I'll 0 N N

H

By proceeding in a manner similar to Example I above but using 3,4-dimethoxy-benzonitrile, there was prepared 6 -(3,4-dimethoxyohenyl)-5H-pyrrolof23-blpvrazine as a yellow/orange solid, m.p. 212- 214'C. MS: 256(MH+).

6-(4-aminophenyl)-7-methyl-5H-pyrroof2.3-blpyrazine, A29-B79, the product of the combination of group A29 in Table I and B79 in Table 2:- SNH 2 N N

H

By proceeding in a manner similar to Example I above but using 2-ethylpyrazine and 4-aminobenzon itri le, there was prepared 6-(4-aminophenl)-7-methl-5H-prrolo2,3-b iwrazine as a brown solid, mn.p. 330-332'C. MS: 225(MH+).

(aa) 6-r4-( I -methyl)ethoxyphenyll-5H-pvrrolof2,3-blpyrazine, AlI -B63, the product of the combination of group Al in Table I and B63 in Table 2:- WO 03/000688 PCT/GB02/02799 -115-

H

By proceeding in a manner similar to Example I1(a) above but using 4-(1-methyl)-ethoxybenzonitrile [Reference Example 51], there was prepared I-methyl)ethoxyRhenyll-5H--pyrrolo r2,3-binyrazine as a yellow solid. MS -254(MH-f). H-PLC (METHOD RT 1.64 minutes.

(ab) 6- 0I H- I -methyl-2-(methylthio)imidazol-5-yl)-5H-prrolor2.3-blpyrazine~ AlI-B 1 10, the product of the combination of group AlI in Table I and B I 10 in Table 2:-

N-

N

N N

H

By proceed ing in a manner simnilar to Example 1 above but using I H-5-cyano- I-methyl-2- (rnethylthio)imidazole [Reference Example 52], there was prepared 6- 0 H- I-methyl-2- (methylthio~imidazol-5-yi)-5H-pyrrolo[2,3-blpvrazine as a yellow solid, m.p. 230*C. MS 246(MH4-).

(ac) 6-0 I-methyl-I H-indazol-3-yl)-5H--pyrrolor2.3-blpvrazine AlI -B2 1, the product of the combination of group AlI in Table I and B21 in Table 2:- N: N N

H

By proceed ing in a manner si m ilar to Examp le I1(a) above but us ing 3-cyano- I-methyl- IH-indazole [Reference Example there was prepared I-methyl-I H-indazol-3-yl)-5H-pyrrolo[2,3bipyrazine as a yellow solid. MS: 250(MH+), 248(MH-). IH NMR [(CD3) 2 S0]: 5 12.5-12.6 (1IH, broad 8.38 (1 H, d, 1=2.4 Hz); 8.24 I H, J=7.9 Hz); 8.21 I H, J=2.4 Hz); 7.76 I H, J=8.1I Hz); 7.48 I 7.32 IH); 7.29 I 4.18 3H).

(ad) 6-(0 -methyl-4-phenyl- IH-pvrrol-3-yl)-SH-pyrrolo[2,3-blpyrazine Al -B43, the product of the combination of group AlI in Table 1 and B43 in Table 2:- WO 03/000688 PCT/GB02/02799 -116-

H

By proceeding in a manner similar to Example I1(a) above but using 3-cyano-l-methyl-4-phenyl-lHpyrrole [Reference Example there was prepared 6-(l-methyl-4-phenyl-1IH-pyrrol-3-yl)-5HpyrroloF2.3-blovrazine as a solid, mn.p. 195'C (with decomposition). MS: 275(MH4-).

(ae) 6-(4-fluoroohenyl)-5H-pyrrolof2,3-blpyrazine A1-B89, the product of the combination of group AlI in Table I and B89 in Table 2:-

H

By proceeding in a manner similar-to Example I1(a) above but using 4-fluorobenzonitrile, there %Vag prepared 6-(4-fluorophenyl')-5H-Ryrrolof2,3-blpvrazine as an off-white solid. IH NMR [(CD 3 2 S0]: 8 12.3 I H) 8.4 I 8.2 I 8.05 2H), 7.4 21-4), 7.2 I NIS: 213(MH+).

(af) 6-(4-mnethoxvnhenyl'l-5H-pyrrolo'2.3-blpyrazine, A I-B77, the product of the combination of group AlI in Table I and B77 in Table 2:-

OCH

3

H

By proceeding in a manner similar to Example I above but using 4-methoxy-benzonitrile, there was prepared 6-(4-methoxyvnhenyl)-5H-pyrrolor2.3-blpyrazine as an off-white solid, m.p. 244-246'C. MS: 225(MH+).

(ag) 6-44-(ter-t-butvl~hhenyll-7-(nrop-I -enyl)- 5H-prrolo[2,3-b~pyrazine, A43-B55, the product of the combination of group A43 in Table I and B55 in Table 2:- WO 03/000688 PCT/GB02/02799 By proceeding in a manner similar to Example I above but using 4-(teriiary-butyl)benzonitrile and 4-(pyrazinyl)-l -butene [Reference Example 59) there was prepared 6-f4-(tert-butvl)ohenyll-7-(proo-I enyl)- 5H-Ryrrolo[2 3-blpyrazine as a yellow solid, m.p. 207-208*C. MS: 292(M1{+).

(ah) 6-(4-methylth iophenyl)-5H-nvrrolo2,3-blpyrazine, AlI -B92, the product of the combination of group AlI in Table I and B92 in Table 2:-

H

By proceeding in a manner similar to Example 1 above but using 4-(methylthio)benzonitrile there was prepared 6-(4-methvlthiopheivfl)-5H-pvrrolor2,3-blpyrazine as a yellow solid. MS: 242(MH+).

I H NMR [(CD 3 2 S0): 5 12.48 (1lH, 8.3 7 (1lH, 8.18 (11-H, 7.98 (2H, d, J=7.9 Hz); .7.19 (2H-, d, J=7.9 Hz); 7.11 (1IH, 2.52 (3 H, s).

(ai) 6-(3-methoxylphenyl)-5H-pyrrolo[2,3-blrpyrazine AlI -B62, the product of the combination of group AlI in Table I and B62 in Table 2:- 0-

H

By proceeding in a manner similar to Example I above but using 3-methoxybenzonitrile there was prepared 6-(3-methoxylphenyl)-5H-pyrrolo[2,3-b]pyrazine as an orange solid, m.p. 194-1 96'C. MS: 226(MH-1).

(aj) 6-(I-methvl-1 H-ovrazol-4-yl)-5H-pyrrolor2,3-blpyrazine' A I-B 108, the product of the combination of group AlI in Table I and B 108 in Table 2:-

N

H

By proceeding in a manner similar to Example 1 above but using I -methlyi-4-cyanopyrazole (prepared according to the procedure described by Yoshida in JJ-Iet.Chem., 1995, 32, page 701) there was prepared 6-(1-methyl-lH-pyrazol-4-vl')-5H-ovrrolo[2,3-blpyrazine as an orange solid, m.p. 232- 234 0 C. MS: 200(MH+).

WO 03/000688 PCT/GB02/02799 (ak) I-methyl-5-phenvl- IH-Ryrazol-3 -yl)-5H-pyrroloF2,3-blpyrzine Al -B 109, the product of the combination of group AlI in Table I and B 109 in Table 2:- By proceeding in a manner similar to Example I1(a) above but using phenylpyrazole [Reference Example I1(k)] there was 6:(Q -methyl-5-phenyl. I pvrrolof2,3-bjovrazine as an orange solid, m.p. 222-223'C. HPLC RT 7.36 minutes.

(al) 6-(pyridin-2-yl')-5H-pyrrolor2,3-blpvrazine, Al-BI 01, the product of the combination of group Al in Table 1 and BIOlI in Table 2:- IIIN N

H

By proceeding in a manner similar to Example I above but using 2-cyano-pyridine there was prepared 6-(pvridin-2-vl)-5H-pyrrolo[2,3-blpyrazine as a yellow solid, m.p. 234-235*C. IH NMR [(CD3) 2 S0]: 6 8.71 (1IH, d, J=4.1 Hz); 8.3 8 (1 H, 8.24 (1 H, 8.17 (1IH, d, J=8.2 Hz); 7.93 (1lH, t, J=8.2 Hz); 7.41 (11-H, in); 7.3 6 (1lH, s).

(am) 6-(pyridin-4-yl)-5H-pvyrrolor2,3-bmpyrazine, A I-B 102, the product of the combination of group AlI in Table I and B 102 in Table 2:-

N

By proceeding in a manner similar to Example I above but using 4-cyano-pyridine there was prepared 6-(pyridin-4-yl)-5H-pyrrolor2,3-blpvrazine as a yellow solid, m.p. 324-326 0 C. I H- NMR

[(CD

3 2 S0J: 5 8.69 (2H, d, J=7.1 Hz); 8.45 (11H, 8.33 (1IH, 8.00 (2H1, d, J=7.1 Hz); 7.47 (11H, s).

(an) 6-(3,4-dimethylphenyl)-5H-pyrrolor2.3-blnvrazine, A I-B75, the product of the combination of group AlI in Table I and B75 in Table 2:- WO 03/000688 PCT/GB02/02799 -119- Ca 3 14 CH3 IN N

H

By proceeding in a manner similar to Example I above but using 3,4-dimethylbenzonitrile there was prepared 6-(3.4-dimethylphenyl)-5H-p~yrrolof2,3-blrnvrazine as a yellow solid. MS: 224 (MHj,.

HPLC: RT =2.4 minutes.

(ao) 6-(4-hydroxvohenvfl-5H-pyrrolof2,3-blpvrazine, A I-B78, the product of the combination of group AlI in Table I and B78 in Table 2:-

H

By proceeding in a manner similar to Example I above but using 4-hydroxybenzonitrile there was prepared 6-(4-hydroxvophenyl)-5H-pyrrolof2,3-blpvrazine as a pale yellow solid. MS: 212 (ap) 6-(4-trifl uoromethoxyphenll-5H-nvyrrolof 2.3-bi nyrazine, Al -B76, the product of the combination of group AlI in Table I and B76 in Table 2:-

H

By proceeding in a mnanner similar to Example I above but using 4-trifluoromethoxybenzonitrile there was prepared 6 -(4-trifluoromethoxyphenyl)-5H-pvrrolof2,3-blpyrazine as a pale orange solid.

MS: 280 RT =2.64 minutes.

(aq) 6-(4-aminophenvl)-5H-pvrrolo(2.3-blpyrazine, A I-B79, the product of the combination of group AlI in Table I and B79 in Table 2:- NH2, N N

H

By proceeding in a manner similar to Example I above but using 4 -aminobenzonitrile, and subjecting the reaction product to chromatography on silica eluting initially with a mixture of ethyl WO 03/000688 PCT/GB02/02799 -120acetate and pentane and then with ethyl acetate, there was prepared 6-(4-aminophenyl)-5H-pyrrolo[2,3bipyrazine as a yellow solid. MS: 21 RT=2.12 minutes.

(ar) I-methyl-2-phenyl- IH-pvrrol-3-yl)-5H-pvrrolo[2.3 -blnvrazine. Al-B 112, the product of the combination of group AlI in table I and B1 112 in Table 2:

NZ-

N

N

H

By proceeding in a manner similar to Example 1(a) above but using 1-methyl-2-phenyl-I H-pyrrole-3carbonitrile [Reference Example there was prepared 6-(1-methyl-2-phenyl-1 pyrrolo[2,3-b]pyrazine as a yellow solid, m.p. 210'C (with decomposition). MS: El (70eV); mn/z 274 (100%).

(as) 6-(1.2-dimethyl-IH-prrol-4-yl)-5H-pvrrolof2,3-blovrazine AI-BI 13, the product of the combination of group AlI in table I and BI 113 in table 2: N N

H

By proceeding in a manner similar to Example 1(a) above but using I ,5-dimethyl- IH-pyrrole-3carbonitrile [Reference Example there was prepared 6-(l 2-dimethyl-] pyrrolor2.3-blpyrazine as a yellow solid, m.p. 253'C. [Elemental analysis:- C, 67.60; H, 5.68; N, 26.22%. Calculated for C 12 H I 2

N

4 C, 67.9 1; H, 5.70; N, 26.40%].

(at) 64l1,4-dimethv-H-pvrrol-3-l)-5H-nvyrrolo23-blpvrazine, AI-BI 14, the product of the combination of group AlI in table I and BI 114 in table 2:

N

H

By proceeding in a manner similar to Example 1(a) but using 1,4-d irethyl- IH-pyrrole-3 -carbon itri Ie [Reference Example there was prepared I 4-d imethvl- IH-pyrrol-3-yl)-5-pynrrolof2,3bipyrazine as a yellow solid, m.p. 21 0'C. MS: El (70eV); m/z= 212 (100%).

WO 03/000688 PCT/GB02/02799 (au) I -rethyl-4-phenyl- IH-pvrrol-3-yl)- IH-pyrrolof2,3-blpyridine, A2-B43, the product of the combination of group A2 in table I and B43 in table 2:

\N

NN

H

By proceeding in a manner similar to Example 1(a) but using 3-methylpyridine and 3-cyano-l -methyl- 4-phenyl-I H-pyrrole [Reference Example there was prepared 2 4(I-methyl-4-phenyl-lH-pyrrol- 3-yl)- IH-pyrrolo[2,3-blpvridine as a brown solid, m.p. 140'C (with decomposition). MS: El mlz =273 (100%).

EXAMPLE 2 3 -f3-(5H-Pyrrolo[2.3-blpyrazin-6-yl).indol-1l-propanlol, AI-B6-C46, the product of the combination of group AlI in Table 1 and B6 in Table 2 and C46 in Table 3: N A solution of 6- I-[3-(tert-butyl-dimethyl-silanyloxy)-propyi]- IH-indol-3 -yl}-5H-pyrrolo[2,3bipyrazine [29g, Reference Example in tetrahydrofuran (500 mL) under nitrogen was treated with a solution of tetrabutylammonium fluoride in tetrahydrofuran (144 mL, I OM). After stirring at ambient temperature for 4 hours the reaction mixture was concentrated in vacuo. The residue was treated with water to give a solid which was filtered then washed with water and then dried to give the title compound (I17.5g) as a yellow-brown solid, m.p. 220-221 0 C. MS: 293(MH+).

3 -rS-methoxy-34(5H-pyrrolor23-blpyrazin6vi)indol. I -ylj-propan- I -ol, AlI -B6-C 1, the product of the combination of group AlI in Table 1 and B6 in Table 2 and ClI in Table 3:- WO 03/000688 PCT/GB02/02799 -122- By proceeding in a manner similar to Example 2(a) above but using I-[3-(tert-butyl-dimethyl- 1H-indol-3-yl }-5H-pyrrolo[2,3-b]pyrazine [Reference Example there was prepared 3-f5-methoxy-3 -(5--Dyrrolor2.3 -blpyrazin-6-yI)-indo)l-y -vpropan-l-ol as a yellow solid, m.p. 225-228 0 C. MS: 323(MH-I).

TLC: RF 16 (dichloromethane/methanol :19/1, vlv).

24[3-45 H-pvrrolo[23 -blprazi n-6-yl)-i ndo I- I -vl -ethanol, AlI -B 5-C46, the product of the combination of group AlI in Table 1 and 135 in Table 2 and C46 in Table 3:- N N N

OR

H

By proceeding in a manner similar to Example 2(a) above but using 6-{l-[2-Qert-butyl-dimethylsilanyloxy)-ethyl]- I H-indol-3-yl }-SH-pyrrolo[2,3-b~pyrazine [Reference Example there was prepared 2-f3-(5H-pyrrolor2,3-blnvrazin-6-yl)-indol-l1-vll-ethanoI as a yellow solid, m.p. 272-273*C.

2-rS-methoxv-3-(5H-pyrrolor2,3-blpyrazin-6-vflindo[ -vyl-ethanol. Al-B35-C 1, the product of the combination of group A]I in Table I and B5 in Table 2 and C I in Table 3:- 0 N

\N

H

OR

By proceeding in a manner similar to Example 2(a) above but using I-[2-(tert-butyl-dimethyl- I H-indol-3-yl} -5I--pyrrolo[2,3-b]pyrazine (Reference Example there was prepared 2-T5-methoxy-3-(5H-pyrrolor2,3-blpvrazin-6-yl)-indol I -vll-ethanoI as a grey solid, rnmp. 270-273'C. MS: 309.43 WO 03/000688 PCT/GB02/02799 -123- 6-1 H--Indol- 3 -yl)-5H-ovrrolor2.3-blpyrazine, AJI-B2-C46, the product of the combination of group AlI in Table I and B32 in Table 2 and C46 in Table 3:k

H

By proceeding in a manner similar to Example 2 above but using 6 -[l-(2-trimethylsilanylethoxymethyl)-1 H-indol-3-yl]-5 H-pyrrolo[2,3-b] pyrazine [Reference Example there was prepared 6-1 H-indol-3-vyl)-5H-Ryrrolof2,3-blpyrazine as an orange solid. I H NMR [(CD 3 2 S0]: 8 12.54 (1IH, br 8.32 (11-H, d, J 2.8 Hz); 8.27 (1IH, 8.19 (1IH, d, J 2.8 Hz); 8.12 (1IH, in); 7.71 (I H, in); 7.30 (2H, in); 7.03 (1 H, d, J 2.0 Hz).

EXAMPLE 3 3 3 -(5H--Pyrrolo[2.3-blpvrazin-6-vfl-indol-l-l-oropvlamine, A]-B23-C46, the product of the combination of group Al in Table I and B23 in Table 2 and C46 in Table 3:-

H-N,

A solution of 3-[3 -(5H-pyrrolo[2,3 -b]pyrazin-6-yl)-indol-1I-yl]-propan-I -ol [1 2g, Example and carbon tetrabromide (19.l1g) in dichloromethane (300 m.L) at ambient temperature was treated with a solution of triphenylphosphine (12.9g) in dichioromethane (100 mL) over 5 minutes. After stirring at ambient temperature for 3 hour the reaction mixture was filtered'and the solid was washed with sparing amounts of dichioromethane. The filtrate and washings were evaporated to yield a brown gum, which was mixed with liquid ammonia (ca 80 mL) in a sealed pressure vessel and allowed to stir at ambient temperature for 18 hours. The vessel was then cooled to-78 0 C and then cautiously vented. The ammonia was allowed to evaporate and the residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane, methanol and concentrated ammonia (900:100:7, v/v/v) to give the title compound as a yellow solid m.p. 170-C. I H NMR [(CD 3 2 S0]: 8 8.28 d, 1=2.7 Hz); 8.18 (1 H, 8. 10, 7.64 (each I1-H, d, J=7.7 Hz); 8.09 (11-H, d, J=2.7 Hz); 7.29, 7.23 (each WO 03/000688 PCT/GB02/02799 -124- 1 H, td, J=7.1I and 1.0 Hz); 6.97 (1 H, 4.32 (2H, t, J=7.0 Hz); 2.57 (2H, t, J=6.5 Hz); 1.89 (2H, quintet, J=6.4 Hz).

3 -[5-metboxcy-3 -(5H-pyrrolo[2,3-blpyrazin-6-yl)-indol-1 -vil-Dropviamine, Al -B23-C 1, the product of the combination of group Al in Table I and B23 in Table 2 and CI in Table 3:-

,NH

N,

N N N k-

H

By proceeding in a manner similar to Example 3(a) above but using 3-[5-methoxy-3-(5H-pyrrolo[2,3b]pyrazin-6-yl)-indol-1I-yl]-propan- I -ol [Example there was prepared 3-[5-methoxvy-3-(5pvrrolor2,3-blpvrazin-6-vl)-indol- I -yll-propylamnine as a yellow solid, m.p. 95-1 00 0 C and 150-1 60"C. MS: 322(MH-I). TLC: RF 0.2 (dichloromethane/methanol/concentrated ammonia 900/100/7, v/vlv).

EXAMPLE 4 N- (3-f3-(5H-Prrolof2,3-blpyrazin-6-vI)-indol-l1 -ll-oropyl 1-acetamide, Al-B7-C46, the product of the combination of group AlI in Table 1 and B7 in Table 2 and C46 in Table 3:- I N

NN

Acetyl chloride (3 1 p1) was added dropwise to a solution of 3-[3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- 1-yl]-propylamine [100mg, Example and triethylamine 52 2 1il) and dichloromethane (20 mL) at ambient temperature under a nitrogen atmosphere. After stirring for 24 hours at ambient temperature the reaction mixture was evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol 1, v/v) to give the title compound (82mg) as a yellow solid, m.p. 260'C. MS: 334(MH+).

N-[4-(5H-Pvrrolor2,3-bl ovazin-6-yl)-phenyll-acetamide, AlI -B80, the product of the combination of group AlI in Table I and B80 in Table 2:- H HC WO 03/000688 PCT/GB02/02799 -125- By proceeding in a manner similar to Example 4(a) above but using 6-(4-aminophenyl)-5Hpyfrolo[2,3-b]pyrazine [Example l(aq) not Reference Example I(aq)] there was prepared pyrrolor2.3-blpvazin-6-vl')-phenyll-acetamide as a yellow solid. MS: 253. l(MH*4). RT=2.3 minutes.

EXAMPLE 6-rl -(3-Mor:phol in-4-Yl-p-ropy)- 1 H-indol-3-yl]-5H-pyrrolo 2.3 -blpyrazine, Al -B27-C46, the product of the combination of group AlI in Table 1, B27 in Table 2 and C46 in Table 3:- NN N 0 A mixture of 3-[3-(SK-pyrrolo[2,3-b~pyrazin-6-yl)-indol-1I-yl)-propylbromide [250mg, Reference Example morpholine (0.5 mL), potassium carbonate (100mg) and potassium iodide (2 crystals) in ethyl methyl ketone was heated at reflux for 2 hours. The mixture was then allowed to cool to ambient temperature over 16 hours then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol 1, v/v) to give a yellow glass which was triturated with ethyl acetate and pentane to give the title compound (40mg) as a yellow solid, m.p.

180-185*C. MS: 362(MH+).

64f -(3-piperid in-I -yl-propl. I H-indol-3-vll-5H-pvrrolo[2,3-blpyrazine Al -B26, the product of the combination of group AlI in Table I and B26 in Table 2:- N N

H

C>

By proceeding in a manner similar to Example 5(a) above but using piperidine, there was prepared 6-fL -(3-piperidin- I -vI-propyl)-] H-indol-3-vll-5H-pyrrolof2.3-blpyrazine as a yellow solid, m.p. 240'C.

MS: 360(MH--).

WO 03/000688 PCT/GB02/02799 -126- EXAMPLE 6 6-flI -r3-(Pvridin-3-yloxy)-propyll1 I -indol-3-vI I-5H-pyrrolor2.3-bloyrazine, AlI -1322-C46, the product of the combination of group AlI in Table 1 and B22 in Table 2 and C46 in Table 3:-

N

H

A solution of diisopropylazodicarboxylate (269iiM) in tetrahydrofuran (0.5 mL) was added dropwise, o,er 2 minutes, to a solution of triphenylphosphine (359mg) in tetrahydrofuran (2.5 mL) at 0 0 C under an atmosphere of nitrogen. After stirring at that temperature for 20 minutes the mixture was treated with a solution of 3-hydroxypyridine (65mg) in tetrahydrofuran (I mL) over I minute then with a suspension of 3-[3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol-l-yl]-propan-I -ol [200mg, Example in tetrahydrofuran (2 mL). The mixture was allowed to warm to ambient temperature over 1 8 hours then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and methanol v/v) to give the title compound (I 10mg) as a yellow solid, m.p. 208- 209'C. MS: 370(MH+).

EXAMPLE 7 1 -Methyl-3-(5H4-pyrrolor2,3-bl pvrazin-6-yl)- I H-indol-5-ol, AlI-B I -Cl 10, the product of the combination of group AlI in Table I and B I in Table 2 and CI10 in Table 3:-

HO

N

N

H

A mixture of 6-(5-methoxy- 1 -methyl-I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine [200mg, Example I1(a)] hydrobromic acid 5O0pil) and glacial acetic acid (3 mL) was heated under reflux for 14 hours.

After cooling the mixture was neutralised by addition of saturated sodium bicarbonate solution. The resulting dark solid was filtered and then dried to give the title compound (1 80mg) as a black solid, 289-290'C. MS: 264(MH-l).

WO 03/000688 PCT/GB02/02799 -127- EXAMPLE 8 6-(2-Chloro-5-methoxy- I-methyl-I H-indol-3-yl)-5H-pyrrolo[2.3-blpyrazine. Al-B 15-Cl, the product of the combination of group Al in Table I and BISin Table 2and Cl in Table 3:- 0 KNN N,, H CI A solution of 6-(5-methoxy- 1-methyl-I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine [100mg, Example I1(a)] in dimethoxy ethanol (25 mL), cooled to -78'C, was treated with a solution of n-butyllithiumn in hexanes (I 721id, 2.5M). After stirring for 30 minutes the mixture was treated with 4-toluenesulfonyl chloride (82mg) then allowed to warm slowly to ambient temperature and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (19: 1, vlv) to give the title compound (45mg) as a black solid. MS: 3l3(MH+). I H NMR

[(CD

3 2 S0]: 6 12.20 (1 H, 8.39 (IH, d, J=3 Hz); 8.2J (1IH, d, J=r3 Hz); 7.54 (11-1, d, J=9 Hz); 7.30 (I H, d, J=2 Hz); 6.96 QIH, dd, J=9 and 2 Hz); 6.84 (1 H, d, J=2 Hz); 3.82 (3H, 3.81 (3H, s).

EXAMPLE 9 3-(5H-Pyrrolof2,3-blpvrazin-6-yl)-benzaldgh de. AI-B96, the product of the combination of group AlI in Table 1 and B96 in Table 2:-

CHO

A solution of 6 -(3-[l,3]dioxan-2-y-phenyl)-5H-pyrrolo[2,3-b]pyrazine [1.

6 g, Example in dichloromethane (50 mL) was treated with trifluoroacetic acid (5 mL). The resultant mixture was heated at reflux for 6 hours, then allowed to cool overnight and then evaporated. The residue was triturated with diethyl ether to give a yellow solid, which was recrystallised from ethyl acetate to give the title compound (0.6g).as a yellow crystalline solid, m.p. 268-270'C. [Elemental analysis:- C, 69.96; H, 3.92; N, 18.69%. Calculated for C 13

H

9

N

3 C, 69.95; H, 4.06; N, 18.82%].

4-(5H-pvrrolor2,3-blpvrazin-6-yl)-benzaldehyde hydrate. Al -B95, the product of the combination of group AlI in Table I and B95 in Table 2:- WO 03/000688 PCT/GB02/02799 -128-

N

H

By proceeding in a manner similar to Example 9(a) above but using 6-(4-Ii1,3]dioxan-2-yl-phenyl)-5Hpyrrolo[2,3-b]pyrazine [Example 1 there was prepared 4-(5H-pvyrrolo[2.3-bl pyrazin-6-yl)benzaldehyde hydrate as a yellow solid, m.p. >295'C. [Elemental analysis:- C, 67.57; H, 4.33;) S 5 N,1 8.04%. Calculated for C 13

H

9

N

3 0mH 2 C, 67.23; 4.34; N, 18.09%].

f3-(5H-pyrrolof2,3-blovrazin-6vl)-indol- I -yll-methanol. AlI -B4-C46, the product of the combination of groupAlI in Table I and B4 in Table 2 and C46 in Table 3:-

NN

H CH 2

OH

By proceeding in a manner similar to Example 9 above but using 6-[l-(2-trimethylsilanylethoxymethyl)-l H-indol-3-y]-5H--pyrrolo[2,3-b~pyrazine [Reference Example there was prepared r3-(5H4-pyrrolor2,3-blpyrain-6-l)-indol-1-ll-methanoI as a brown solid, m.p. >320'C.

I H NMR [(CD 3 2 S0]: 5 8.13(lIH, 7.90 (2H, 7.75 (1 H, 7.50 (1IH, 7.15-7.25 (2H, in), 6.85 (I H, 5.60 s).

EXAMPLE r3-(5H-PyrroloF2,3-bl ovrazin-6-yl)-Dhenyll-methanol. Al -B98, the product of the combination of groupAlI in Table I and B98 in Table 2:- CE OH

NZ

H

A suspension of 3-(5H-pyrrolo[2,3-bjpyrazin-6-yl)-benzaldehyde [0.4g, Example in ethanol mL) was treated with sodium borohydride (200mg). The mixture was allowed to stir at ambient temperature for I hour then treated with water (10 mL) and then evaporated. The residual solid was triturated with water (50 inL) to give a pale yellow solid which was washed with water and then recrystallised from methanol to yield the title. comrpound (0.35g) as a yellow crystalline solid, m.p. 225- 226*C. [Elemental analysis:- C, 68.72; H, 4.73, N,18.44%. Calculated for C 13 HI 1

N

3 C, 69.32; H, 4.92; N, 18.65%].

WO 03/000688 PCT/GB02/02799 -129r4-(5H-ovrrolor2,3 -blpvrazin-6-yvlVphenyll-methanol, Al -B97, the product of the combination of group Al in Table 1 and B97 in Table 2:- CH 2OH N' 7

H

By proceeding in a manner similar to Example I10(a) above but using 4-(5H-pyrrolo[2,3-bjpyrazin-6yl)-benzaldehyde [Example there was prepared f4-(5H-pyrrolo[2.3-blpyrazin-6-yl)-nhenvllmethanol as a yellow solid, mn.p. 284-285'C. [Elemental analysis:- C, 68.61; H, 4.65; N, 18.28.

Calculated for C 13 HI 1

N

3 C, 69.32; H, 4.92; N, 18.65%].

EXAMPLE I1I I H-indol-3-yl)-5H-pyrrolor2,3 -blpvrazine, Al -B2-C 1, the product of the combination of group AlI in Table I and B 1 in Table 2 and ClI in Table 3:- 0

H

A cooled solution of 1-benzyl-5-methoxy- I H-indol-3-yl)-5H-pyrrolo[2,3 -b]pyrazine Example I1(m)] in tetrahydrofuran (20 mL) was treated with liquid ammonia (20 mL) then with sodium (100mg). After stirring at -78'C for 30 minutes the reaction mixture was allowed to warm slowly to ambient temperature, then treated with water (50 mL) and then extracted three times with ethyl acetate mL). The combined extracts were dried over sodium sulfate and then evaporated. The residue was triturated with diethyl ether to give the title compound (14mg) as a brown solid, m.p. 268-27]'C. MS: 265 .24(MH+).

EXAMPLE 12 2-f5-Methoxy-3 -(5H--pyrrolor2.3-b] pyrazin-6-y l)-indol- 1 -vii- -morpholin-4-vl-ethanone, AI-B8-C], the product of the combination of group Al in Tablel1and B8in Table 2and CI in Table 3:- WO 03/000688 PCT/GB02/02799 -130- 0 A stirred solution of 6-(5-methoxy-IH-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine [70mg, Example 11] in dry dimethylforrnamide (10 niL) was treated with sodium hydride (21.6mg, 60% dispersion in mineral oil). After stirring for 30 minutes this mixture was treated with a solution of 4-(2chloroacetyl)morpholine (44.1 mg) in dimethylformamide (1 mL) and stirring was continue d for a further 3 hours. The reaction mixture was poured into water (20 mL) and then extracted three times with ethyl acetate (30 mL). The combined extracts were dried over sodium sulfate and then evaporated.

The residue Was triturated with diethyl ether to give the title compound (55mg) as a yellow solid, m.p.

263-267'C. MS: 392.2](MH-,).

2-r5-methoxv- I -(2-morphol in-4-yl-2-oxo-ethyl)- 1H-indol-3-vll- 1H-pvrroloF2,3-b1lpvridine-4carbonitrile. A3-B8-C I, the product of the combination of group A3 in Table I and B8 in Table 2andClI in Table 3:ome

CNN

N

N

By proceeding in a manner similar to Example 12 above but using 2-(5-methoxy-1H-indol-3-yl)- I H-pyrrolo[2,3 ,-b]pyridine-4-carbonitrile [Example 32], there was prepared 2-r5-methoxy- 1-(2morpholin-4-vl-2-oxo-ethyl)-I H-iindol-3-yll-1 H-pyrrolor2.3-blpyridine-4-carbonitrile as a yellow solid.

LC-MS: METHOD D: RT =3.55 minutes, 416(MH+).

EXAMPLE 13 r5-Methoxy-3-(lH-pyrrolor2,3-blpyridin-2yl)-indol-1-ll-acetic acid, A2-B25-C 1, the product of the combination of group A2 in Table I and B25 in Table 2 and C I in Table 3:- WO 03/000688 PCT/GB02/02799 0

NN

N 0 H I

H

A mixture of {S-methoxy-3- I -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-bjpyridin-2-yl]-indol-l -yil acetic acid ethyl ester [4.67g, Reference Example methanol (250 rnL) and aqueous potassium hydroxide (SM, 25 mL) were heated under reflux for 7 hours. The methanol was removed under reduced pressure and the residue was treated with water (20 mL) and the pH of this solution was adjusted to 7 by addition of concentrated hydrochloric acid. The resulting yellow solid was filtered and subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and methanol v/v) to give the title compound (1 .69g) as a white solid. MS: 32O(M-H+U). HPLC (METHOD A): RT =6.67 minutes.

4-methoxy-2-(5-methoxy- I-methyl-I H-indol-3-yl)- I H-pyrro Io[2.3-blpvridine, AS-B 1-Cl, the product of the combination of group AS in Table I and BI in Table 2 and C I in Table 3:- 0 N N

H

By proceeding in a similar manner to Example 13(a) but using 4-methoxy-2-(5-methoxy-l-methyl-IHindol-3-yl)- I-(toluene-4-su Ifonyl)- 1H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 4-methoxv-2-(5-methoxv- I-methyl-1I14-indol-3-yi)- 1H-pyrrolo[2,3-blovridine as a tan solid, m.p. 288-289 0 C. MS: 307(MI-f).

4-methoxv-2-(5-methoxy-I H-indol-3-yl)-1 H-pvrrolor2,3-blpvridine, A5-B32-C 1, the product of the combination of group A5 in Table I and B2 in Table 2 and C I in Table 3:- WO 03/000688 PCT/GB02/02799 -132- By proceeding in a similar manner to Example 13(a) but using 4-methoxy-2-(5-methoxy-IH-indol-3yI)-l -(to luene-4-su Ifoinyl)- IH-pyrrolo[2,3-b]pyridine (Reference Example 39) there was prepared 4-methoxy-2-(5-methoxy-IH-indol-3-yJ)-IH-Ryrrolo[2,3-blpvridine as a tan solid, m.p. 294-295*C.

MS: 294(MWf).

4-chloro-2-(4-iert-butylphenyl)- IH-nvrrolor2,3-blpyridine, A28-B5 5, the product of the combination of group A28 in Table I and B55 in Table 2:- By proceeding in a similar manner to Example 13(a) but using 4-chloro-2-(4-tert-butylphenyl)-I-' (toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridime (Reference Example 120j)] there was prepared 4-chloro-2-(4-ter:-butvlphenyl)- 1H-pyrrolo[2.3 -bi pyridine as a cream coloured solid. TLC: RF 0.71 (ethyl acetate/ heptane 1: 1 HNMR [(CD 3 2 S0): 8 12.52 (1 H, 8.16 (1IH, d, J=6.1 Hz); 7.93 (2H4, d, J=8.1 Hz); 7.50 (2H, d, J=8. 1 Hz); 7.21 (1 H, d, J=6. 1 Hz); 6.96 (111, 1.30 (9H, s).

2-(5-methoxy- 1-methyl-I H-indol-3-yl)- 5-phenyl-1 H-pyrrolo[2,3-blop'ridine, A65-B i-Cl, the product of the combination of group A65 in Table 1 and B I in Table 2 and C I in Table 3:-

L

N

H

By proceeding in a-similar manner to Example 13(a) but using 2-(5-methoxy-1-metllyl-IH-indol-3-yl)- I -(toluene-4-sulfonyl) I H-pyrrolo(2,3-b]pyri dirne (Reference Example 130j)] there was prepared 2-(5-methoxy- I-methyl- IH-indol-3-yl)- 5-phenyl- IH-pyrrolo[2,3-blcpyridine as a cream coloured solid, m.p. 240-242"C. MS: 354(MH-L).

WO 03/000688 PCT/GB02/02799 -133- 1-f] -methyl-3-( 1H-nvrrolo[2.3-bl ovrid in-2-vlV 1 H-indol-5-yloxy1-propan-2-ol, A2-B 1-CS, the product of the combination of group A2 in Table I and B I in Table 2 and C5 in Table 3:- By proceeding in a manner similar to Example 13 above but using -methyl-3-[1I-toluene-4sulfonyl)- IH-pyrrolo[2,3-b]pyrid in-2-yl]- 1H-indol-5-yloxy} -propan-2-oI [Reference Example 79], there was prepared i-rl -methyl-3-( IH-pyrrolor2.3-blpvrid in-2-yl)- IH-indol-5-yloxyl-prooan-2-oI as a cream solid. m.p. 198-199'C. l-PLC (Method RT 6.69 minutes.

r5,6-Dimethoxy-3-( I H-pyrrolor2,3-blpyridin-2-yl)-indol- I -yll-acetic acid, A2-B 121 -Cl1, the I0 product of the combination of group A2 in Table I and B 121 in Table 2 and C I in Table 3:- By proceeding in a manner similar to Example 13(a) but using {S,6-dimethoxy-3-[1-(toluene-4sulfonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl]-indol- Il-yl -acetic acid tert-butyl ester [Reference Example 13(q)] there was prepared f5.6-d imetboxy-3-( IH-pyrrolo[2.3-blpvridin-2-yl)-indol- I -Yll-acctic acid as a khaki solid. [Elemental analysis:- C, 60.28; H, 5.16; N, 10.85%. Calculated for

C

1 9 H] 7

N

3 0 4 .1 .5H 2 C, 60.3 1; H, 5.33; N, 11. MS: El (70eV); m/z =351 (100%).

EXAMPLE 14 2-f r5-Methoxy-3-( IH-pyrrolof 2,3-blpvridin-2-yl')-indol-1I-vll-lI-morphol in-4-yl I-ethanone, A2-B8-C 1, the product of the combination of group A2 in Table I and B8 in Table 2 and C I in Table 3:- WO 03/000688 PCT/GB02/02799 -134- N N N A suspension of [5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol-1I-yI]-acetic acid [60mg, Example 13(a)] in dry dimethylformamide (7 mL) was treated with N-{(dimethylamino)(IH-l, 2, 3, -triazolo [4, in-i -yI)methylene} -N-methylmethanaminium hexafluorophosphate N-oxide (71mg) and 5 diisopropylethylamine (45p1). After stirring at room temperature for 30 minutes morpholine (I 8pi) was added and the mixture stirred at ambient temperature for a further 12 hours. The solvent was removed in vacuo and the residue was suspended in saturated sodium bicarbonate solution. The precipitated solid was filtered then dried to give the title compound (10mg) as a violet coloured solid, m.p. 243-247*G. MS: 39 I1-fl -methyl-3-0 H-12yrrolo[2,3-blpyridin-2-vl)- I H-indol-5-yloxyl-cyclobutaner-arboxyl ic acid amide, A2-B I-CI15, the product of the combination of group A2 in Table I and B I in Table 2 and CI15 in Table 3:-

NN

H

By proceeding in a manner similar to Example 14(a) above but using I-[1-methyl-3-(I H-pyrrolo[2,3b]pyridin-2-yl)- I 1-indol-5-yloxy]-cyclobutanecarboxylic acid [Example 15(c)] and ammon ium chloride, there was prepared 141 -methyl-3-( IH-ovrrolof 2,3-bi pyridin-2-yl)- cyclobutanecarboxylic, acid amide as a pale lilac solid, m.p. 267-268*C. MS: 36](MH 4 I 1-rI -methyl-3-( I H-pyrrolor23-bjpyridin-2-Yl)- I H-indol-5-vloxyl-cyclobutanecarboxvlic acid methylamide. A2-B1I-C 16, the product of the combination of group A2 in Table I and B81 in Table 2 and C 16 in Table 3:- WO 03/000688 PCT/GB02/02799 -135c-I- N NH Nc-K1 By proceeding in a manner similar to Example 14(a) above but using l-[J-methyl-3-(IH-pyrrolo[2,3b] pyridin-2-yl)- I H-indol-5-yloxy]-cyclobutanecarboxyl ic acid [Example 1 and methylamine, there was prepared i-ri -methyl-3-( IH-pyrrolo[2.3-blrgvrid in-2-yl i-I H-indol-5-yloxyl-cyclobutanecarboxyl ic 5 acid methylamide as a pale lilac solid, m.p. 249-250 0 C. MS: 375(MH+).

I -methvl-3-( IH-pyrrolof2,3-bl pvridin-2-vl)-l H-indole-5-carboxylic acid methylamide, A2-B I-C23, the product of the combination of group A2 in Table I and B I in Table 2 and C23 in Table 3:- 0

HN

N N

N.

H

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(I H-pyrrolo[2,3b~pyridin-2-yl)- 1 H-indole-5-carboxylic acid [Example 15(d)) and methylamine, there was prepared I methyl-34( H-pyrrolor2,3-b1rpvridin-2-l)- I H--indole-5-carboxylic acid methylami de as a pale orange solid, m.p. 186'C. MS: 304(MH+).

I -methyl-3-( IH-pyrrolof 2,3-blpyridin-2-ylI- IH-indole-5-carboxyl ic acid (2-hydroxy-ethyl)- A~njk A2-B I-C34, the product of the combination of group A2 in Table 1 and BI in Table 2 and C34 in Table 3:- By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(I H-pyrrolo[2,3b~pyridin-2-yl)- IH-indole-5-carboxyl ic acid [Example 15(d)] and ethanolamime, there was prepared WO 03/000688 PCT/GB02/02799 -136- I -methyl-3-( 1H-pyrrolor2,3 -blpyrid in-2-yl)- 1H-indole-5-carbox~ylic acid (2-hydroxy-ethyb-am ide as a yellow solid, m.p. 256-257*C. MS: 335(MH+).

(f I-methyl-3 -U H-pyrrolo[2.3 -blpyridin-2-yl)- IH-indole-5-carboxyl ic acid (2-morghol in4-yIethyl)-amide A2-B1I-C47, the product of the combination of group A2 in Table I and B!I in Table 2 and C47 in Table 3:- By proceeding in a manner similar to Example 14(a) above but using I -methyl-3-(] H-pyrrolo[2,3b]pyridin-2-yl)- I H-indole-5-carboxyl ic acid [Example 15(d)] and 2-aminoethyl morpholine, there was 0 prepared 1 -methyl-3-( IH-pyrrolo[2,3-blovridin-2-vl)- IH-indole-5-carboxyl ic acid (2-morphol in-4-yiethvl)-amide as a colourless solid, m.p. 268-270'C. MS: 404(M1-I).

I -methyl-3-( IH-pyrrolo[2.3-blpyridin-2-yl)- IH-indole-5-carboxvlic acid (2-carbamoyl-ethyl)amd A2-BI-C24, the product of the combination of group A2 in Table l and BI in Table 2 and C24 in Table 3:- By proceeding in a manner similar to Example 14(a) above but using I -methyl-3-(I H-pyrrolo[2,3b]pyrid in-2-yl)- 1 H-indole-5-carboxyl ic acid [Example 15(d)] and 1-alan ine-amide, there was prepared I -methyl-3-( I H-pyffolol 2,3-blpyrid in-2-yl)- I H4-indole-5-carboxvylic acid (2-carbamoyi-ethyl)-amide as a colourless solid, m.p. 286-288 0 C. MS: 362(MH-).

I -methyl-3 -(IH-pyrrolor2,3-blpyridin-2-yl)- I f-indole-5-carboxylic acid bis-(2-hydroxy-ethyl)amd~ A2-BJI-C48, the product of the combination of group A2 in Table l and BI in Table 2 and C48 in Table 3:- WO 03/000688 PCT/GB02/02799 -137- C1 HO 0

-OH

ciN N

H

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(] H-pyrrolo[2,3b]pyridin-2-yl)- IH-indole-5-carboxyl ic acid [Example 15(d)] and d jethanolamine, there was prepared I -methyl-3-( I H-pyrroloF2,3-blpyridin-2-yl)- 1 H-indole-5-carboxyl ic acid bis-(2-hydroxy-ethyl)-amide c1 5 as a yellow solid, m.p. 230-232'C. MS: 379(MH+).

I -methyl-3 H-12yrrolo[2,3-blpvrid in-2-vyl)- IH-indole-5-carboxyl ic acid am ide, A2-B I-C29, the product of the combination of group A2 in Table I and B I in Table 2 and C29 in Table 3:-

H

2 N 0 N N

N.

H

By proceeding in a manner similar to Example 14(a) above but using I-methyl-3-(1H-pyrrolo[2,3b]pyridin-2-yl)-1 H-indole-5-carboxylic acid [Example 1 and ammonium chloride, there was prepared I -methvl-3-( IH-pvrrolof2.3-bl pyridini-2-yl)-1 H-indole-5-carboxyl ic acid amide as a yellow solid, m.p. 330-332 0 C. MS: 29l(MH+).

(j I-methyl-3-( IH-pyrroloF2.3-blpyridin-2-vl)-1 H-indole-5-carboxyl ic acid (2-hydroxy-]1.1-bishydroxymethyl-ethyl)-arniide, A2-B I-C49, the product of the combination of group A2 in Table I and B I in Table 2 and C49 in Table 3:- WO 03/000688 PCT/(;B02/02799 -138- By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(IH-pyrrolo[2,3b]pyridin-2-yl)- I H-indole-5-carboxyl ic acid [Example 15(d)] Ind tris(hydroxymethyl) aminomethane, there was prepared I-ehl3(IHoroo23bordn2v) -noe5crov cai 2 hvdroxy-l. 1-bis-hydroxymethyl-ethl)-amfide as a yellow solid, m.p. 205-206'C. MS: 395(MH+).

I -methyl-3-(11 -pyorrolo[2,3-blpyridin-2-vlV-I H-indole-5-carboxvlic acid (2-hydroxcy-lIhydroxymethyl-l-methl-ethvl)-amide, A2-BI-C30, the product of the combination of group A2 in Table I and B I in Table 2 and C30 in Table 3:-

HO

H

0

N

OH

NN

N

H

D By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(lf-I-pyrrolo[2,3b]pyridin-2-yl)-lI H-indole-S-carboxylic acid [Example 15(d)] and 2-amino-2-methyl-1, 3-propanediol, there was prepared I -methyl-3-( IH-ovrrolo[2,3-bl pyridin-2-yvlI 1 R-indole-5-carboxyl ic acid (2hydroxy- I-hydroxvmethyl- l-methyl-ethl)-amide as a yellow solid, m.p. 180-182*C. MS: 379(MH+).

1 -methyl-3-0 H-pyrrolor2.3-bpyridin-2-vl' -IH-indole-5-carboxylic acid (2.3-dihydroxypropvl)-amide, A2-13 I -C50, the product of the combination of group A2 in Table I and B I in Table 2 and C50 in Table 3:- 0)-

H

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(lH-pyrrolo[2,3b~pyridin-2-yl)-IH-indole-5-carboxylic acid [Example 15(d)] and 3-amnino-I, 2-propanediol, there was prepared I -methyl-3-( IH-pyrrolo[2.3 -blpyridin-2-yfl)-1H-indole-5-carboxyl ic acid (2,3-dihydroxvpropyl')-amide as a yellow solid, m.p. 171-172'C. MS: 365(M1-1).

(in) I -methyl-3-( I H-pyrrolor2,3-blpyridin-2-yfl- IH-indole-5-carboxvi ic acid (2-hydroxy-I J.dimethyl-ethyl)-amide, A2-B I-C3 1, the product of the combination of group A2 in Table I and B 15 in Table 2 and C31I in Table 3:- WO 03/000688 PCT/GB02/02799 -139-

H

N

OH

NN

H

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(]H-pyrrolo[2,3- .b]pyridin-2-yl)-1 H-indole-5-carboxylic acid (Example 15(d)] and 2-amino2-methyl- I -propanol, there was prepared I -methyl-3-( 1H-pyrrolor2,3-blpyridin-2-vl)- IH-indole-5-carboxyl ic acid (2-hydroxy- 1.1dimethyl-ethyl)-amide as a yellow solid, m.p. 161-162 0 C. MS: 365(MH+).

I -methyl-3-( H-pyrrolo[2,3-blovridin-27,yi)- IH-indole-5-carboxylic acid (2-hydroxy- 1hvdroxymethvl-ethyl)-amide, A2-B I-C33, the product of the combination of group A2 in Table I and B] in Table 2 and C33 in Table 3:-

H

0 N C oH

OH

N N N

H

By proceeding in a manner similar to Example 14(a) above but using I -methyl-3-(1 H-pyrrolo[2,3b]pyridin-2-yl)- I H-indole-5-carboxylic acid [Example 15(d)] and serinol, there was prepared 1-methyl- H-pyrrolor2.3-bloyridin-2-vl)- I H-indole-5-carboxyl ic acid (2-hydroxy- I -hydroxymethyl-ethyl)amide as a yellow solid, m.p. 178-179-C. MS: 365.41(MH+).

1 -methyl-3-( H-pyrrolof2,3-bjovridin-2-yl)- I H-indole-6-carboxylic acid (2-carbamoyi-ethyl)amd A2-B I 8-C24, the product of the combination of group A2 in Table]I and BI 1Sin Table 2 and C24 in Table 3:- 0

HN

0 N N

N

H

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(IH-pyrrolo[2,3b]pyridin-2-yl)-IH-indole-6-carboxylic acid [Example 15(g)] and 3-amino-propionamide WO 03/000688 PCT/GB02/02799 -140hydrochloride, there was prepared I -methvl-3-( IH-pyrrolo[2,3-blpyridin-2-l-I H-indole-6-carboxyl ic acid (2-carbamoyl-ethyl)-amide as a pale yellow solid, m.p. 277-280'C. MS: 362(MH+).

1 -methyl-3 H-pyrrolor2,3-blpyridin-2-vl)- IH-i ndole-6-carboxylic acid (2-hydroN3v-ethvl)amide, A2-B I18-C34, the product of the combination of group A2 in Table l and B] 8 in Table 2 and C34 in Table 3:-

OH

HN

0

H

By proceeding in a manner similar to Example 14(a) above but using l-methyl-3-(I H-pyrrolo[2,3b]pyridin-2-yI)-1IH-indoie-6-carboxylic acid [Example 15(g)] and ethanolamine, there was prepared 1 -methyl-3-(l H-pyrrolo[2,3-blpyridin-2-yl)- 1H-indole-6-carboxyl ic acid (2-hydroxy-ethyl)-amide as a brown solid, m.p. 264-267*C. MS: 335(MH+).

1 -methyl-3-( IH-pyrrolor2.3-bl pyridin-2-yl)- IH-indole-6-carboxylic acid (1 r 2,41triazol-3yl)-amide, A2-B1I8-C5 1, the product of the combination of group A2 in Table I and B 18 in Table 2 and C51 in Table 3:- N N

HN

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(IH-pyrrolo(2,3bjpyrid in-2-yl)- IH-indole-6-carboxylic acid [Ex ample 15(g)] and lH-[1,2,4]triazol-3-ylamine, there was prepared I -methyl-3-( 1 H-pyrrolor23 -b1pyridin-2-yfl- 1 H-indole-6-carboyl ic acid 0I H- [1.2,41triazol-3-yi)-amide as a yellow solid, m.p. 343-345'C. MS: 358(MH+).

I -methyl-3-( 1 H-pyrrolor2.3-b1 pyridin-2-yl)- I H-indole-6-carboxylic acid (2-hvdroxy- I hydroxyrnethyl-ethyl)-amide, A2-B]I8-C33, the product of the combination of group A2 in Table I and B 18 in Table 2 and C33 in Table 3:- WO 03/000688 PCT/CB02/02799 -141- Hg

N

HO

By proceeding in a manner similar to Example 14(a) above but using 1-methyl-3-(1I--p yrrolo[2,3b]pyridin-2-yI)-l H-indole-6-carboxylic acid (Example 15(g)] and serinol, there was prepared 1-methyl- 3 H-pyrrolor2.3-blpyrid in-2-yl)- IH-indole-6-carboxylic acid (2-hydroxy- I-hydroxymethyl-ethyl)amnide as a light brown solid, rn.p. 247-249*C. MS: 365(MH+).

I -methyl-3-(5H-pyrrolor2,3 -blpyrazin-6-yl)-Il-indole-5-carboxylic acid (2-hydroxy- 1.1dimethyl-ethyl)-amide, AI-BI-C31, the product of the combination of group A] in Table 1 and B I in Table 2 and C31 in Table 3:-

H

NN

H

By proceeding in a similar manner to Example 14(a) but using 1-methyl-3-(5H-pyrrolo[2,3-b]pyrazin- 6-yl)- IH-indole-5-carboxylic acid [Example 15(i)] and 2-amino-2-methyl- I-propanol there was prepared I -methvl,-3-(5H-pyrrolor2.3-blvvrazin-6-yl)- 1H-indole-5-carboxyl ic acid (2-hydroxy-j 1.dimethyl-ethyll-amide as a yellow solid, m.p. 210-214'C. MS: 364(I').

(W 3-[6-(4-tert-butvlphenvl-5H-cowrolor2.3-blpvrazin-7-yll-N-methylpropionamide, A33-B5 5, the product of the combination of group A33 in Table I and B55 in Table 2:- 0/

N*

H

N

N

H

By proceeding in a manner similar to Example 14(a) above but using 3-[6-(4-tert-butylphcnyl-SHpyrrolo[2*3-b]pyrazin-7-yl]-propionic acid [Example 25(a)] and methylamine, there was prepared 3 -[6-(4-tert-butvlphenvl-5H-pvrrolor2,3-blpyrazin-7-yll-N-methvlpropionamide as an off-white solid, m.p. 222-228*C. MS: 337(M1T-i+).

WO 03/000688 PCT/GB02/02799 -142- 3-[6-(4-ter-t-butylphenyl-5H-pyrrolor2,3-blpvrazin-7-yll-NN-dimethylpropionamide, A34-B55, the product of the combination of group A33 in Table I and B55 in Table 2:- By proceeding in a manner similar to Example 14(a) above but using 3-[6-(4-tert-butylphenyl-5pyrrolo[2,3-b]pyrazin-7-yl]-prop ionic acid [Example 25(a)] and dimethylamime, there was prepared 3-[6-(4-tert-butvlphenvi-5H-prrolor23-blnvrazin-7-y11-N.N-dimethylpropionamide as an off-white solid, m.p. 203-204 0 C. MS: 19 I -methyl-3 -(5H-pyrrolo[2,3 -blpyrazin-6-yD-1 H-indole-5-carboxyl ic acid 2-methoxyethylamide, AlI-B I -C25, the product of the combination of group AlI in Table I and B I in Table 2 and C25 in Table 3:- H 7 By proceeding in a manner similar to Example 14 above but using I -methyl-3-(SH-pyrrolo[2,3bjpyrazin-6-yl)-l H-indole-5-carboxylic acid [Example 15(i)] and 2-methoxyethylamine, there was prepared I -methyl-3-(5H--pyrrolo[2,3-blpyvrazin-6-yi)- I H--indole-5-carboxylic acid 2methoxyethylamide as an orange solid. MS: 35O(MH+). H-PLC (Method RT =1.27 minutes.

1 -methyl-3-(5H-nvrrolo(2.3-blpvrazin-6-yl- I H-indole-5-carboxcylic acid 2-thien-2ylethylamide, AlI-B I -C27, the product of the combination of group AlI in Table 1 and B I in Table 2 and C27 in Table 3:- WO 03/000688 PCT/GB02/02799 -143-

H

N

By proceeding in a manner similar to Example 14 above but using l-methyl-3-(5H-pyrrolo[2,3blpyrazin-6-yl)- IH-indole-5-carboxylic acid [Example 15(i)] and 2-thien-2-ylethylamine, there was prepared I -methyl-3-(5H-pyrrolo[2,3-bl pyrazin-6-yl)-1 H-indole-5-carboxylic acid 2-th ien-2ylethylamide as a yellow solid. MS: 4O2(MH4-). 1-PLC (Method RT= 1.45 minutes.

Wx I -methyl-3-(5H-ovrrolo[2,3-bl pvrazin-6-yfl- I H-indole-5-carboxyl ic acid 2-fluoroethylamide, Al -B I-C53, the product of the combination of group Al in Table I and B I in Table 2 and C53 in Table 3:-

H

0

F

NN

H

By proceeding in a manner similar to Example 14 above but using I-methyl-31(5H-pyrrolo[2,3' b]pyrazin-6-yl)-l H-indole-5-carboxylic acid [1 and 2-fluoroethylamine, there was prepared I -methyl-3 -(SH-pyrrolor2,3-blpyrazin-6-vl)- 1H-indole-5-carboyl ic acid 2-fluoroethylamide as an orange solid. MS 338(Ml-f). H-PLC (Method RT-1.3O minutes.

I -methyl-3-(5 H-pvrrolo[2.3-blpyrazin-6-yl)- IH-indole-5-carboxyl ic acid 2carboethoxyethylamide, AI-BI-C54, the product of the combination of group A2 in Table 1 and B I in Table 2 and C54 in Table 3:- Ho-' 00 N NN By proceeding in a manner similar to Example 14 above but using 1-methyl-3-(5H--pyrrolo[2,3b]pyrazin-6-yl)- IH-indole-5-carboxyl ic acid [Example 15(i)] and f3-alanine ethyl ester hydrochloride, WO 03/000688 PCT/GB02/02799 -144there was prepared I -methyl-3 -(SH--nrrolo[2,3-bl oyrazin-6-yl)- 1 H-indole-S-carboxyl ic acid 2-carboethoxvethylamide as an orange solid. MS :392(MH+). HPLC (Method RTI1.38 minutes.

(z 1 -methyI-3-(5H-pyrrolor2,3-blpyrazin-6-y)-1 H-indole-5-carboxylic acid (hydroxymethyl)carbomethoxy-methylamide, AlI-B Il-CS2, the product. of the combination of group AlI in Table I and BI in Table 2 and C52 in Table 3:- By proceeding in a manner similar to Example 14 above but using l-methyl-3-{5H-pyrrolo[2,3b]pyrazin-6-yl)- 1H-indole-5-carboxylic acid [Example 1 and serine methyl ester hydro'chloride, there was prepared I -methyl-3-(5H-pyrrolor2.3-blpvrazin-6-yl')- I H-indole-5-carboxylic acid (hvdroxvmethvl)-carbomethoxy-methylamide as an orange solid. MS 394(MW). HPLC (Method C): RTrl.24 minutes.

(aa) I -methyl-3-(5H-pyrrolo[2.3-bl ovrazin-6-yl)-]IH-indole-5-carboxyl ic acid 2-hvdroxyethylamide, AI-BI-C34, the product of the combination of group Al in Table I and BI in Table 2 and C34 in Table 3:- By proceeding in a manner similar to Example 14 above but using l-methyl-3-(5H-pyrrolo[2,3b]pyrazin-6-yl)- IH-indole-5-carboxylic acid [Example 15(i)] and ethanolamine, there was prepared 1 -methyl-3-(5H-rpyrrolor2,3-bl pyrazin-6-yl)- I H-indole-5-carboxylic acid 2-hydroxyethylamide as a yellow solid, m.p. 171-173'C (with decomposition). MS 336(MH+).

WO 03/000688 PCT/GB02/02799 WO 0/00088 CT/G02/0799-145- (ab) I -methyl-3 -(5H-pvyrrolof2,3-blpyrazin-6-yl)- I H-indole-5-carboxylic acid methylam ide.

AlI-B I-C23, the product of the combination of group AlI in Table I and B I in Table 2 and C23 in Table 3:-

H

0 N N N

H

S 5 By proceeding in a manner similar to Example 14 above but using I -methyl-3-(5H-pyrrolo[2,3r~l bjpyrazin-6-yl)-I H-indole-5-carboxylic acid [Example 15(i)] and methylamine, there was prepared I -methyl-3-(5H-1pyrrolor2,3-blpyrazin-6-yi)- IH-indole-5-carboxylic acid methylamide as a beige solid, MS :304(N{Wr). 'H-NMR [(CD 3 2 S0]: 858.64 (1 H, broad 8.59 I1H, J=1.0 Hz); 8.27(d, I H, J=2.4 Hz); 8.17 I 8.15 I1H, J=2.4 Hz); 7.82(dd, I H, J=1.0 Hz, 7.9 Hz); 7.62 I H, J=7.9 Hz); 7.21 1H); 3.96 3H); 2.82 3H).

(ac) I -methyl-3-(5H-pyrrolo(2,3-bloyrazin-6-yl)- 1H-indole-5-carboxylic acid dimethylamide.

A1-B1-C55, the product of the combination of group Al in Table I and BI in Table 2 and in Table 3:- By proceeding in a manner similar to Example 14 above but 1-methyl-3-(5H-pyrrolo[2,3-b]pyrazin- 6-yl)-]1H-indole-5-carboxyl ic acid [Example 15(i)] and dimethylamine, there was prepared I -methyl-3- (5H-pyrrolor2,3-blpvrazin-6-yl)- IH-indole-5-carboxvl ic acid dimethylamide as a yellow solid. MS: 32O(MH+). I HNMR [(CD 3 2 S0]: 858.26 I H, J=2.1 Hz); 8.18 I 8.15 I H,J=2.l H-z); 7.62(d, Il-, J=8.1 H4z); 7.372 (dd, IH, J= 1 .0 Hz, 8.1 H4z); 6.98 IH4); 3.94 314; 3.05 6H).

(ad) F 1-methyl-3-(5 H-pyrrolo[2,3-b] oyrazin-6-yO)- IH-indol-5-ylI morohol in-4-yi ketone.

AI-BI-C56, the product of the combination of group Al in Table]I and BI in Table 2 and C56 in Table 3:- WO 03/000688 PCT/CB02/02799 -146- 0

N,

N

N

H

By proceeding in a manner similar to Example 14 above but using I1-methyl-3-(5H-pyrrolo[2,3 b]pyrazin-6-yl)-1J--indole-5-carboxylic acid [Example 15(i)] and morpholine, there was prepared f 1 -methyl-3 -(5H-pyrrolor23-bl ovrazin-6-yl)l H-indol-5-yllmorpholin-4-yl ketone as a yellow solid, MS: 362(MH+).

(ae) 4-hydroxy-F i-ri -methvyl-3-(5 H-1nvrrolo[2.3-blpvyrazin-6-vi)- IH-indol-5 -yilcarbonyi-piperidine A I-B I-C57, the product of the combination of group AlI in Table I and B I in Table 2 and C57 in Table 3:-

OH

N

0

H

By proceeding in a manner similar to Example 14 above but using l-methyl-3-(5H-pyrrolo[2,3b)pyrazin-6-yl)- I H-indole-5-carboxyl ic acid [Example 15(i)] and 4-hydroxypiperidine, there was prepared 4-hydroxv-f -Fl -methyl-3-(5H--pyrrolof2,3-blpvyrazin-6-yl)- 1H-indol-5-yllcarbonylpi peridine as a yellow solid, MS: 376(M14+), 398(MNaTJ.

(af) 3-Fl -methyl-3-(5H-pvrrolor2.3-blpyrazin-6-vl)- I H--indol-5-yllcarbonylaminopropionic acid methylamide, A I-B I-C26, the product of the combination of group AlI in Table I and B]I in Table 2 and C26 in Table 3:- WO 03/000688 PCT/GB02/02799 -147- By proceeding in a manner similar to Example 14 above but using 3-[1-methyl-3-(5H-pyrrolo[2,3b]pyrazin-6-yl)- I H-indol-5-yl]carbonylaminopropionic acid [Example I15(l)] and methylamine, there was prepared 3-ri -methvl-3 -(5H-pyrrolor2.3-blpyrazin-6-vl)- IH-indol-5-yll carbonylaminopropion ic acid methylamide as a yellow solid. MS :377(MH+). HPLC (Method RT =1.20 minutes.

(ag) I -methyl-3 -(5H-pvrrolof2,3-bl ovrazin-6-yI)- I H-indole-5-carboxcylic acid 3-hydroxypropylamide, AI-BI-C34, the product of the combination of group Al in Table I andBlI in Table 2and C34 in Table 3:- H

OH

N

H

By proceeding in a manner similar to Example 14 above but using 1-methyl-3-(5H--pyrrolo[2,3b]pyrazin-6-yl)-I H-indole-5-carboxylic acid [Example 1 and 3-hydroxypropylamine, there was prepared I -methyl-3-(5H-pyrrolor2,3-blnvrazin-6-yl) IH-indole-5-carboxyl ic acid 3hydroxyproovlamide as a yellow solid. MS 350(MIl-I). HPLC (Method RT 1.22 minutes.

(ah) 3- I-methvflethoxvnhenyll-5H-pyrrolor2,3-blpyrazin-7-yl 1-N-methyl propionamide, A33-B63, the product of the combination of group A33 in Table I and B63 in Table 2:- 0 H

N

H

By proceeding in a manner similar to Example 14(a) above but using -methyl)ethoxyphenyl]- SH-pyrrolo[2,3-b]pyrazin-7-yl }propionic acid [Example 25(b)] and methylamine, there was prepared 3-f 6-r4-( 1-methyl~ethoxyphenyll-5H-pyrrolo[2,3-b1 pyrazin-7-yl 1-N-methyl propionam ide as a yellow solid, MS: 339(MH+). HPLC (Method RT 1.49 minutes.

(ai) 3-[6-(4-methoxyphenvl)-5H-pvrrolo[2,3-blpyrazin-7-vll- N-methyl propionamide, A3 3-B77, the product of the combination of group A33 in Table I and B77 in Table 2:- WO 03/000688 WO 03/00688PCT/GB02/02799 -148- By proceeding in a manner similar to Example 14(a) above but using 3 -[6-(4-methoxyphenyl)-5Hpyrrolo[2,3-bjpyrazin-7-yI]propionic acid [Example 25(d)] and methylamine, there was prepared 3-r6-(4-methoxyphenyl)-5 H-pyrrolo[2.3-bl ovrazin-7-yllpropionic acid methylamide as an off-white solid. I HNMR [(CD3) 2 S0]: 8 12.0 I1-H) 8.3 IH), 8.2 7.7 2H), 7.1 2H), 3.8(s, 3H), 3.05 2H), 2.6 2H) 2.5 3H). MS: 3 (aj) 3 -f 6-r[4-(1I -methvl)ethoxyphenyl -5 H-pyrrolo[2.3-blpvrazin-7vp Ipro ionam ide. A32-B63, the product of the combination of group A32 in Table I and B63 in Table 2:- By proceeding in a manner similar to Example 14(a) above but using -methyl)ethoxyphenyl]- 5H-pyrrolo[2,3 -b]pyrazin-7-yI propionic acid [Example 25(b)]and ammonium chloride, there was prepared 3-f 6-r4-( I-methyl)ethoxvyphenyll-5H-nvrrolor2.3-blnrazin7vyl Irooionamide as a white solid. MS: 325(M1-1). I-PLC (Method RT=l.44 minutes.

(ak) 3- 6-(4-hydroxyphenyl)-5 H-ovrro lof 2.3 -bi ,pvrazin-7-vi I prop ionam ide. A32-B78, the product of the combination of group A32 in Table I and B78 in Table 2:- By proceeding in a manner similar to Example 14(a) above but using 3-{6-(4-hydroxyphenyl)-5Hpyrrolo[2,3-b]pyrazin-7-yl~propionic acid [Example 30] and ammoniumn chloride, there was prepared WO 031000688 PCT/GB02/02799 -149- 3i16-(4-hdrovyphenfl-5H-prrolor23-blpyrazin-7-yl1propionamide as a white solid. MS: 283(MJH+). I-PLC (Method RT= 2.18 minutes.

(al) 3-[6-(4-fluorophenyl)-5H-pyrrolor2,3-blpvrazin-7-yll-N-methyI propionamide, A33-B89, the product of the combination of group A33 in Table 1 and B89 in Table 2:- By proceeding in a manner similar to Example 14(a) above but using 3-[6-(4-fluorophenyl)-5Hpyrrolo[2,3-b]pyrazin-7-yi]propionic acid [Example 25(c)] and methylamine, there was prepared 3-[64(4-fluorophenl)-SH-nvrrolor23 -blpyrazin-7-yll-N-methyI propionamide as an off-white sol id.

I H NMR [(CD 3 2 S01: 8 12.5 I1-H) 8.4 I 8.2 7.8 2H), 7.4 2H), 3.1 2H), 2.6 2.5 3H). MS: 298(MH+).

(am) 3 .5-d imethyl-isoxazolyl-4-:yl)- IH-pyffolo[2.3-blpyridin-2-yll- I-methyl-I carboxylic acid (2-methoxy-ethl)-amide A83-BJI-C25, the product of the combination of group A83 in Table 1 and B I in Table 2 and C25 in Table 3:- By proceeding in a manner similar to Example 14 above but using 3-[4-(3,5-dimethyl-isoxazole-4yl)- IH-pyrrolo[2,3-b]pyridine-2-yl]- I-methyl-i H-indole-5-carboxylic acid [Example 15(m)] and 2-methoxyethylamine, there was prepared 3-r4-(3.5-dimethvl-isoxazolyl-4-yl)- IH-pyrrolo[2,3blpyridin-2-yll-l -methyl-I H-indole-5-carboxylic acid (2-methoxy-ethyl)-amide as a solid, m.p. 249- 250 0 C. MS: 443(M+).

WO 03/000688 PCT/GB02/02799 -150- (an) .5-dimethyl-isoxazolyl-4-vl')- 1 H-pyrrolo[2,3-bjpyridin-2-yll- I acid (2-methoxv-ethyl)-amide A83-B2-C25, the product of the combination of group A83 in Table I and B2 in Table 2 and C25 in Table 3:-

H

N-0 0 H

H

By proceeding in a manner similar to Example 14 above but using 3-[4-(3,5-dimethyl-isoxazole-4yl)-I H-pyrrolo[2,3-blpyridine-2-yl]- IH-indole-5-carboxyl ic acid [Example 15(n)] and 2-metboxyethylamine, there was prepared 3-[4-(3,5-dimethyl-isoxazolyl-4-ylU- 1H-ovrrolof 2.3acid (2-methoxy-ethvl)-amide as a white solid, m.p. 274-275 0

C.

MS: 430(MH+).

(ao) 3-(4-cyano- 1H-pyrrolor2,3-blpyridin-2-vll-1 -methyl-I H-indole-5-carboxylic acid (2-hydroxy- 1LI-dimethyl-ethyl)-amide, A3-BI-C3 1, the product of the combination of group A3 in Table I and BI in Table 2 and C31I in Table 3:-

H

CN

O

N N N H CH 3 By proceeding in a manner similar to Example 14 above but using 3-(4-cyano-I H-pyrrolo[2,3b]pyridine-2-yl]-l -methyl- I H-indole-5-carboxylic acid [Example 15(r)] and 2-amino-2methylpropanol, there was prepared 3-(4-cvano- I H-pyrrolor2,3-blpy'ridin-2-vll- I1-methyl- I carboxyl ic acid (2-hydroxy- 1. 1-d imethyl-ethyl)-am ide as a solid. MS: 3 88(MH'). HPLC(Method C): RT =2.81 minutes.

WO 03/000688 PCT/GB02/02799 -151- (ap) 3-(4-cyano-l H-pyrrolof2,3-b1 ovridin-2-yll- 1-methyl-I H-indole-5-carboxvlic acid (2-hydroxy- 2-methyl-propyl)-am ide, A3-BJI-C97, the product of the combination of group A3 in Table I and B!I in Table 2 and C97 in Table 3:- HkJ

OH

N

N

By proceeding in a manner similar to Example 14 above but using 3-(4-cyano-I H-pyrrolo[2,3b~pyrid ine-2-ylj- I-methyl-I H-indole-5-carboxylic acid [Example 15(r)] and 3-amino-2-methyl-2propanol (prepared according to the literature procedure of Cabella et. al. Tetrahedron, 1995, 51 18-17-1 826), th ere was prepared 3-(4-cvano- IH-ovyrrolor2.3-blpyrid in-2-yll- i-methyl-I carboxylic acid (2-hydroxy-2-methyl-Rropyl)-amide as a yellow solid. LC-MS: METHOD D: RT 2.69 minutes, 388(MH+).

(aq) 2-f 5,6-dimethoxy-3-0 H-pyrrolo[2,3-b1pvridin-2-yfl-indol- I -yll- I -morpholin-4-yi-ethanone, A2-B 118-Cl, the product of the combination of group A2 in Table I and B 18 in Table 2 and C I in Table 3:- 0 0 By proceeding in a manner similar to Example 14(a) but using [5,6-dimethoxy-3-(1I-1-pyrrolo[2,3b]pyrid in-2-yl)-indol- I -yl]-acetic. acid [Example 13(g)) there was prepared 2-15,6-dimethoxy-34-(H pyrrolor2,3-blpyri din-2-yi)-indo -vl1- I-morpho Ii n-4-yl-ethan one as a pale yellow solid, m.p. 260'C (with decomposition). TLC: RF 0.37 (dichloromethane/methanol, MS: ESI; mlZ 421 MH+.

EXAMPLE r I -Methyl-3-( 1 H-pyrrolo[2.3-blpyridin-2-yl)- I H-indol-5-yloxy]-acetic acid, A2-B I -C6, the product of the combination of group A2 in Table I and B!I in Table 2 and C6 in Table 3:- WO 03/000688 PCT/GB02/02799 -152- 0/f0

OH

N NH A solution of 1 -methyl-3-[ I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-blpyridin-2-yl]- IH-indol-5-yloxy) acetic acid ethyl ester [500mg, Reference Example 15(b)] in methanol (25 mL) was treated with potassium hydroxide (5N, 3 ml) and then heated at reflux for 16 hours. The solvent was removed under reduced pressure and the residue was treated with water (10 mL). The pH of this mixture was adjusted to 7 by addition of acetic acid and the resulting colourless solid was collected by filtration then dried to give the title compound (1 70mg) as a colourless solid, m.p. >300 0 C. MS: 322(M1-i).

24 1 -methyl-3-( H-pvrrolor2.3-bpVyridin-2-yl)- 1 H-indol-5-yloxyl-propionic acid, A2-B I -C2, the product of the combination of group A2 in Table I and B I in Table 2 and C2 in Table 3:-

OH

Oy--n 0 N N

H

By proceeding in a manner similar to Example 15(a) above but using 2-41 -methyl-3-11 -(toluene-4sulfonyl)-lIH-pyrrolo[2,3-b] pyridin-2-yl)- IH-indol-5-yloxy} -propion ic acid ethyl ester [Reference Example there was prepared 2-Fl -methvl-3-( I 1-pyrrolor2,3-bl pyridin-2-yl)- propionic acid as a colourless solid, m~p. 177-178 0 C. MS; 336(M]-f').

I1-f1 -metbvl-3-( H-pyrrolo[23-blovridin-2-yD) H-indol-5-vloxvl-cyclobutane-1 -carboxyl ic aci A2-B 1-Gil1, the product of the combination of group A2 in Table I and B I in Table 2 and C II in Table 3:- WO 03/000688 WO 03/00688PCT/GB02/02799 -153o:: By proceeding in a manner similar to Example 15(a) above but using l-{1-methyl-3-[1-(toluene-4sulfonyl)- 1H-pyrrolot2,3-b]pyridin-2-yl]- IH-indol-5-yloxy) -cyclobutanecarboxyl ic acid ethyl ester [Reference Example there was prepared -methyl-3-( 1 H-pvrroloF2,3-b1 pyrid in-2-yl)- 1 Hindol-5-yloxyl-cyclobutane-1-carboxylic acid as a colourless solid, m.p. 168-169 0 C. MS: 362(MHj).

I -methyl-3-( H-pvrrolof2,3-bjpyridin-2-yl)- I H-indole-5-carboxyl ic acid, A2-B I -C28, the product of the combination of group A2 in Table 1 and B I in Table 2 and C28 in Table 3:- -0H By proceeding in a manner similar to Example 15(a) above but using 1-methyl-3-[l-(toluene-4sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indole-5-carboxylic acid, methyl ester [Reference Example there was prepared 1 -methyl-3-( IH-pyrrolor2,3-blpyridin-2-yl)- carboxylic acid as a yellow solid, m.p. >300 0 C. MS: 29](MH-1).

(e) 1 -methyl-3-( IH-Ryrrolo[2,3-blpyridin-2-yl)- I H-indol-5-ol, A2-B I1-Cl 10, the product of the combination of group A2 in Table I and B I in Table 2 and CI10 in Table 3:- By proceeding in a manner similar to Example 15(a) above but using I-methyl-3-[1-(toluene-4sulfonyl)- I H-pyrrolo[2,3-b]pyridi n-2-yl]- I H-indol-5-ol [Reference Example there was prepared 1 -methyl-3-( 1H-pyrrolo[2,3-blpyridin-2-yl)- IH-indol-5-ol as a yellow solid, m.p. I 99-200*C. MS: WO 03/000688 PCT/GB02/02799 -154- I f -(cyclobutanecarboxylic acid)-3-r]IH-1ovrrolor2,3-blpyridin-2-yll-I cyclobutanecarboxylic acid, A2-B1I2-C 11, the product of the combination of group A2 in Table I and B 12 in Table 2 and ClII in Table 3:- 0/

OH

0 0 ,OH By proceeding in a manner similar to Example 15(a) above but using ]-{l-(cyclobutanecarboxylic acid ethyl ester)-3-[ 1-(toluene-4--sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indol-5-yloxy) cyclobutanecarboxylic acid ethyl ester [Reference Example there was prepared I1-fl -(cyclobutanecarboxylic acid)-3-r I H-pyrrolor2,3-blovridin-2-yl1l- H-indol-5-yloxyl cyclobutanecarboxylic acid as a yellow solid, m.p. 240 *C (with decomposition). MS: 444(MH-).

I -methyl-3-( IH-pvrrolor2,3-bl pyridin-2-yl)- 1I--indole-6-carboxyl ic acid,' A2-B I 8-C2 8, the product of the combination of group A2 in Table 1 and B 18 in Table 2 and C28 in Table 3:- By proceeding in a manner similar to Example 15(a) above but using l-methyl-3-[]-(toluene-4sulfonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl]- I H-indole-6-carboxylic acid, methyl ester [Reference Example there was prepared I -methyl-3-(I H-pyrrolo[2,3-bjpYridin-2-yl)- IH-indole-6carboxylic acid as a yellow solid, m.p. 359-361 0 C. MS 292(NfH-1).

(h) 3-ri -methyl-3-( IH-pyrrolo[2.3-bloyridin-2-yl)- IH-indol-5-vfl-propionic acid. A2-B I-C21, the product of the combination of group A2 in Table I and B1I in Table 2 and C21 in Table 3:- WO 03/000688 PCT/GB02/02799 -155-

OH

0 N

I

H

By proceeding in a manner similar to Example 15(a) above but using 3-{I-methyl-3-[l-(toluene-4sulfonyl)-lI H-pyrrolo[2,3-b]pyridin-2-y)- I H-indol-5-yi}-propionic acid ethyl ester [Reference Example there was prepared 3-f1 -methvl-3-( IH-pyrrolor2,3-blpyridin-2-yl)- acid as a yellow solid, m.p. 268-270 0 C. MS 320 (MI-If).

1-methyl-3-(SH-pyrrolo[2,3-blpvrazin-6-yl)-1H-indole-5-carboxylic acid, Al -BI-C28, the product of the combination of group AlI in Table I and B I in Table 2 and C28 in Table 3:-

OH

0

CN

N

NN

By proceeding in a similar manner to Example 15(a) but using 1-methyl-3-(5H-pyrrolo[2,3-b]pyrazinacid, methyl ester [Reference Example 19(b)] there was prepared I -methyl-3-(5H-pvrrolor2,3-blipvrazin-6-vl)- IH-indole-5-carboxylic acid as a brown solid, m.p. 3 50 0

C.

IIPLC (METHOD RT 5.85 minutes.

f2-methoxy-5-(5H-pyrrolo[2.3-blpyrazin-6-yl)-phenoxylacetic acid, Al -B67, the product of the combination of group AlI in Table I and B67 in Table 2:- 0 0

H

By proceeding in a manner similar to Example 15 above but using [2-methoxy-5-(5H--pyrrolo[2,3b]pyrazin-6-yl)-phenoxy]-acetic acid ethyl ester [Example 27), there was prepared [2-methoxv-5-(5Hpyrrol o[2,3 N pyrazi n-6-yi)-phenoxyl acetic acid as a white solid, m.p. 330-332'C. MS: 300(MHW).

WO 03/000688PC/B0029 PCT/GB02/02799 -156- 3 4r2-d imethyl am i no-5-(5H4-prrolo[2.3-bl pyrazin-6-y I'l-phenyll prop ion i c acid, A32-B74, the product of the combination of group A32 in Table I and B74 in Table 2:- 0

OH

N

NN

H

By proceeding in a manner similar to Example 15 above but using ethyl 3-[2-dimethylamino-5-(5Hpyrrolo[2,3-b~pyrazin-6-yl)phenyl]propionate [Reference Example there was prepared 3 -[2-dimethylamino-5-(5H-pyrrolo[2,3 -bi Dvrazin-6-yi)-pheflyllpropionic acid as an orange solid, m.p.

269-271 MS: 311 (MH-l).

3-flI -methyl-3-(5H-pyrrolor2,3-blpyrazin-6-yl)- I H-indol-5-yllcarbonylaminopropionic acid, AlI-B I1-C5 8, the product of the combination of group AlI in Table I and B I in Table 2 and C58 in Table 3:- By proceeding in a manner similar to Example 15 above but using* I-methyl-3-(5H-pyrrolo[2,3bjpyrazin-6-yl)-1H-indole-5-carboxylic acid 2-carboethoxyethylamide [Example 14(y)] and sodium hydroxide there was prepared 3-rl -methyl-3-(5-pyorrolor2.3 -blpyrazin-6-yl)- yllcarbonylaminop ropionic acid as an orange solid (35mg). MS: 364(MH+). HPLC (Method RT 1 .24 minutes.

(in) 3 ,5-dimethyl-isoxazole-4-yl)- 1H-pyrrolo[2,3-b]pyridine-2-yl]- I-methyl-i carboxylic' acid, A83-BI-C28, the product of the combination of group A83 in Table I and B I in Table 2 and C28 in Table 3:- WO 03/000688 PCT/GB02/02799 -157- CK1 By proceeding in a manner similar to Example 15 above but using 3-[4-(3,5-dim'ethyl-isoxazole-4yl)-l -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine-2-yl]- 1-methyl-I H-indole-5-carboxyl ic acid, methyl ester [Reference Example there was prepared 3-[4-(3,5-dimethyl-isoxazole-4-yl)-I Hpyrrolof2.3-blpyridine-2-yl-1-methyl-I H-indole-5-carboxylic acid as a yellow solid, m.p. >305 0

C.

LC-MS (METHOD RT =2.57 minutes.

3- [4-(3,5-imethyl-isoxazole-4vl)- I H-pyrrolof2,3-blpyridine-2- yll-I H-indole-5-carboxv lic acid, A83-B2-C28, the product of the combination of group A83 in Table I and B32 in Table 2 and C28 in Table 3:t N 0 0

O.'

N N By proceeding in a manner similar to Example 15 above but using 3-[4-(3,5-diinethyl-isoxazole-4yl)-lI -(toluene-4-sulfonyl)- I H--pyrrolo[2,3-b]pyridine-2-yl]- I H-indole-5-carboxyl ic acid, methyl ester [Reference Example there was prepared .5-dimethyl-isoxazole-4-yl)- I H-ovrrolo[2,3acid as a yellow solid, m.p. >300'C. MS: 373(MH+).

4-(3,5-diinethyl-isoxazole-4-yi)-2-(5-nethoxy- 1 -methyl- I H-indol-3-yl)- I H-12yrrolor2,3blo yridine. A83-B I-CI1, the product of the combination of group A83 in Table I and B I in Table 2 and C1 in Table 3:- N-0

H

By proceeding in a manner similar to Example 15 above but using 4-(3,5-dimethyl-isoazol-4-yl)-2- I-methyl- I H--indol-3-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridime [Reference Example there was prepared 4-(3,5-dimethyl-isoxazole-4-yl)-2-(5-inethoxv- I-methyl-I H-indol- 3-yI)-IH-pvrrolor2.3-blpvyridine as a yellow solid, m.p. 254-255'C. MS: 373(MH+).

WO 03/000688 PCT/GB02/02799 -158r~l 4-(3 .5-dimethyl-isoxazole-4-yl)-2-(5-methoxy- I H-indol-3-vl)- I H-pyrrolor2,3-bl pyridine.

A83-B2-CI, the product of the combination of group A83 in Table I and B32 in Table 2 and ClI in Table 3:- N-0

NN

H

By proceeding in a manner similar to Example 15 above but using 4-(3,5-dimethyl-isoazol-4-yl)-2- IH-indol-3-yl)- I-(tol uene-4-su Ifonyl)- IH-pyrrolo[2,3-b]pyridime [Reference Example 4 there was prepared 4-(3 .5-dimethyl-isoxazole-4-yl)-2-(5-methoxy- I H-indol-3-yl)- 11pyrrolo[2,3-blpyridine as a yellow solid, m.p. 270-27]'C. TLC: RF =0.29 (ethyl acetate/heptane, 4:1).

34(4-methoxy- IH-pyrrolor2,3-blpyridine-2-yl)-i -methvl-I H-indole-5-carboxyl ic acid, AS-B 1-C28, the product of the combination of group A5 in Table 1 and BI in Table 2 and C28 in Table 3:- 0 o"

H

N

N

H

By proceeding in a manner similar to Example 15 above but using 3-[4-(methoxy-l-(toluene-4su Ifonyl)- 1H-pyrrolo[2,3-b]pyridine-2-yl]- 1-methyl-I H-indole-5-carboxylic acid, methyl ester [Reference Example there was prepared 3-(4-methoxy- I 1-pyrrolor2,3-blpyridine-2-yl)- Imethyl-I H-indole-5-carboxvylic acid as apink solid. LC-MS: METHOD D: RT 2.39 minutes, 322(MH+).

3-(4-cyano- IH-pvrrolof2,3-bl pyridine-2-yl)- 1-methyl- IH-indole-5-carboxylic acid, A3-B I-C28, the product of the combination of group A3 in Table I and B l in Table 2 and C28 in Table 3:- WO 03/000688 PCT/GB02/02799 -159- By proceeding in a manner similar to Example 15 above but using 3-(4-cyano-I H-pyffolo[2,3b~pyridine-2-yl)-1 -methyl-lI H-indole-5-carboxylic acid, methyl ester [Reference Example there was prepared 3-(4-cvano-1 H-pyrrolo[2.3-blpyridine-2-yl)-1 -methyl-I H-indole-5-carboxv lic acid as a pink solid. HPLC (Method RT 2.89 minutes. MS: 31 7(MH+).

CK1 3-0 H-pyrrolof2,3-blnyridine-2-yl)-I H-indole-5-carboxvlic acid,. A2-B2-C28, the product of the combination of group A2 in Table 1and B2 in Table 2 and C28 in Table 3:- 0 OH N

N\

By proceeding in a manner similar to Example 15 above but using I1-(toluene-4-sulfonyl)-3-[] (toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine-2-yl)- I H-indole-5-carboxyl ic acid, methyl ester [Reference Example 12 there was prepared 341IH-pyrrolof2.3-blpyridine-2-yl)-1H-indole-5carboxylic acid as a yellow solid, rn.p. >300-C. 'H NMR [(CD 3 2 S0]: 8 12.85-12.95 12.10- 12.00 (lH, 8.65 (IH, 8.31 dd); 8.28 (1H, 8.25 (IH, dd); 7.85 (IH, dd); 7.55 (IH, 7.30 (I H, in); 6.97 (1IH, d).

Wt 2-(5-methoxvl- IH-indol-3-yl)- IH-pyrrolo[2,3-blpvridine -4-carboxylic acid, A67-B2-C I, the product of the combination of group A67 in Table I and B2 in Table 2 and ClI in Table 3:- 4 u1T0 OH

NI

H

By proceeding in a manner similar to Example 15 above but using 2-(5-inethoxy-IH-indol-3-yl)-I- (toluene-4-su Ifonyl)- 1 H--pyrrolo[2,3-b]pyridine-4-carboxylic acid tert-butyl ester [Reference Example there was prepared 2-(5-methoxyl- IH-indol-3-yl)- IH-pyrrolo[2,3-bl pyridine -4-carboxyl ic acid as a dark solid. MS: 308(M4H+), TLC: RF =0.04 (ethyl acetate/heptane, 3: 1).

WO 03/000688 PCT/GB02/02799 -160- CK1 Potassium 2-(5-methoxvl- IH-indol-3-vli)- I 1-prrolor2.3-blpyridine-4-carboxylate, potassium salt of A2-B32-C28, the product of the combination of group A2 in Table I and B2 in Table 2 and C28 in Table 3:- 0 ox

NI

H

H

S 5 By proceeding in a manner similar to Example 15 above but using 1-methyl-3-[]-(toluene-4sulfonyl)- I H-pyrrololl2,3-b]pyrid in-2-yl] I H-indole-S-carboxylic acid, methyl ester [Reference Example 19 and evaporation of the reaction mixture followed by suspension in a minimal volume of water, collection of the solid and drying at 60'C under vacuum, there was prepared potassium I H-indol-3-yl)-I H-pyrrolo[2,3-b] pyridine-4-carboxylate. TLC: RIF 0.00 (ethyl acetate/pentane, 2:3).

1 H NMR [(CD 3 2 S0]: 588.57 (1 H, 8. 10, (1 H, dd); 7.90 in); 7.33 (1 H, 7.00 (1 H, dd); 6.75 (I H, d).

EXAMPLE 16 I-Methvyl-3-( 1H-pvrroloF2,3-bl pyridin-2-yl)- 1H-indol-5-yloxyl-ethanol. A2-B I-C3, the product of the combination of group A2 in Table 1 and B I in Table 2 and C3 in Table 0 N NHIN A solution of {I -methyl-3-[ I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b~pyridin-2-yl]- IH-indo1-5-yloxy} acetic acid ethyl ester [1 20mg, Reference Example 15(b)] in dry tetrahydrofuran (5 mL) was treated with lithium alumninium hydride (1 OM solution in tetrahydrofuran, 50.Il) at 0 0 C under a nitrogen atmosphere. The mixture was allowed to warm to ambient temperature, then stirred for 3 hours and then carefully poured into water (75 mL). The mixture was extracted three times with ethyl acetate mL). The combined organic extracts were washed with brine (75 mL), then dried over sodium sulfate and then evaporated to give the title compound (45mg) as a colourless solid, m.p. 209-2 10*C. MS: 3 08(MH+).

WO 03/000688 WO 03/00688PCT/GB02/02799 -161- 2-ri -methyl-3-( IH-pyrrolof2,3-blpyridin-2-vy )I H-indol-5-yloxyl-propan- I-ol, A2-B I -C7, the product of the combination of group A2 in Table I and B I in Table 2 and C! in Table 3:-

OH

0 N' N

N

H

By proceeding in a manner similar to Example 16(a) above but using 2-{1-methyl-3-[l-(toluene-4sulfonyl)- I H-pyrrolo[2,3-b]pyrid in-2-yl]-] H-indol-5-yloxy) -prop ionic acid ethyl ester [Reference Example there was prepared 2-lI -methyl-3-(] -12vrro lo[2.3-bjpvridin-2-yl)- I propan-l-ol as acolourless solid, m.p. 164-165TC. MS: 32O(MH+).

IIJIl-methyl-3-( H-pyrrolof 2.3 Npyrid in-2-yll- I H--indol-5-loxy-cvclobUtVU I-methanol, A2-B I-C1 2, the product of the combination of group A2 in Table I and BI in Table 2 and C12 in Table 3:-

OH

H

By proceeding in a manner similar to Example 16(a) above but using 1-{(I-methyl-3-[l -(toluene-4sulfonyl)-1 H-pyrrolo[2,3-b] pyrid in-2-yl]- IH-indol-5-yloxy}-cyclobutanecarboxyl ic acid ethyl ester [Reference Example there was prepared I 1-4 1-methyl-3-(IH-pyrroloF2.3-bl pyridin-2-yl)- IH- I-methanol as a colourless solid, m.p. 144-146-C. MS: 348(MH+). HPLC (METHOD RT 6.37 minutes.

2-(6-phenyl-5 H-pyrrolof2.3-blpyrazin-7-yl)-ethanol, A44-B 100, the product of the combination of group A44 in Table I and B 100 in Table 2:-

OH

N

N

H

WO 03/000688 PCT/GB02/02799 -162- By proceeding in a manner similar to Example 16(a) above but using (6-phenyl-5H-pyrrolo[2,3b]pyrazin-7-yl)-ac etic acid [Reference Example 35], there was prepared 2--henyl-5H-pyrrolor2.3blpyrazin-7-yi)-ethanol as a colourless solid, m.p. 201-202*C. MS: 348(MH--). HPLC (METHOD A): RT 6.37 minutes. [Elemental analysis:- C, 70.68; H, 5.77; N,17.44%. Calculated for C 13 HI 1

N

3 0:- C, 70.28; H, 5.48; N, 17.56%].

2-[2-methoxv-5-(5H-pyrrolo[2.3-bl avrazin-6-yl)-phenoxyl-ethanoI Al -B66, the product of the combination of group AlI in Table I and B66 in Table 2:j-OH

(N/

0

H

By proceeding in a manner similar to Example 16 above but using [2-methoxy-5-(5H-pyrrolo[2,3b]pyrazin-6-yl)-phenoxy]-acetic acid ethyl ester [Example 27], there was preparcd 2-r2-methoxvy-S- (5H-r2yrrolo[2.3-blrpyrazin-6-yl)-phenoxyl-ethanoI as a yellow solid, m.p. 203-205 0 C. MS: 286(MI-1).

3-r2-dimethylamino-5-(5 H-pyrrolor2,3-blavrazin-6-yl)-phenvl-propan- I -ol Al -B73, the product of the combination of group AlI in Table I and B73 in Table 2:-

OH

NI1

N/

N

N

H

By proceeding in a manner similar to Example 16 above but using ethyl 3-[2-dimethylamino-5-(5Hpyrrolo[2,3-b]pyrazin-6-yl)phenyl]propionate [Reference Example there was prepared 3-r2-dimethylamino-5-(5H-prrolof2.3-blavrazin-6-y)-phenl-ropan- 1-al as a yellow solid, m.p.

203-2 04'C. MS: 297(MH+).

WO 03/000688 PCT/GB02/02799 -163g) 31f6-r44 I -methyl)ethoxyphenyll-5H-pyrrolor2.3-blpvrazin-7-y I Prolanol, A30-B63, the product of the combination of group A30 in Table 1 and B63 in Table 2:-

OH

0

H

By proceeding in a manner similar to Example 16 above but using methyl)ethoxyphenyl]-5H-pyrrolo[2,3-b]pyrazin-7-yl }propionic acid [Example 25(b)] there was r~~l prepared 3-16-f 1-methyl')ethoxvbenyll-5H-pyrrolof2,3-blpyrazin-7-yl I ropanol as a yellow solid (7mg). MS: 3 l2(M1-i+). HPLC (Method RT =2.9 minutes.

EXAMPLE 17 2-(5-Methoxy- 1-methyl-I H-indol-3-yl)- IH-pyrrolof2,3-bl pyridine. A2-B 1-Cl, the product of the combination of group A2 in Table I and B I in Table 2 and C I in Table 3:- 0

K-N

N N

H

A solution of 2-(S-methoxy- 1-methyl-I H-indol-3-yl)- I-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridine 1.45g, Reference Example 13(b)] in methanol (100 mL) was treated with potassium hydroxide (5N, mL) then heated at reflux for 2 hours. The reaction mixture was cooled then evaporated. The residue was treated with water (150 mL) and the resulting solid was filtered then dried to give the title compound (0.75g) as a tan solid, ni.p. 226-227C. MS: 278(MH-l).

3-fl -methyl-3-( IH-pyrrolor2.3-blpyridin-2-yl)- II--indol-5-yloxvyl-propane- 1 2-diol, A2-B I-C9, the product of the combination of group A2 in Table 1 and B]I in Table 2 and C9 in Table 3:-

(_COH

OH

WO 03/000688 WO 03/00688PCT/G B02/02799 -164- By proceeding in a manner similar to Example 17(a) above but using 3-f I-methyl-3-[l-(toluene-4su lfonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl]- I H-indol-S-yloxy} -propane- 1,2-dial [Reference Example 16], there was prepared 3-Fl -methyl-3-( IH-pyrroloF2.3-blnvridin-2-yll- IH-indol-5-yloxvl-propane-1I 2-d ioI as a colourless solid, m.p. 202-203 0 C. MS: 338(MI-I).

3-Fl -methyl-3-( H-pyrrolor2,3-blpyridin-2-l)-1 H-indol-5-yloxcyl-propan- I -ol, A2-B I -C4, the product of the combination of group A2 in Table I and BlI in Table 2 and C4 in Table 3:-

HO

By proceeding in a manner similar to Example 17(a) above but using 3-f{1-methyl-3-[l -(toluene-4su Ifonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indol-5-yloxy} -propan- I-ol [Reference Example 17], there was prepared 3-Fl -methvl-3-( IH-pyrrolo[2.3-blpyridin-2-yl)- I H-indol-5-yloxyl-opan-lI-ol as a yellow solid, m.p. 192-193'C. MS: 322(NM).

3-rFl -methyl-3-( H-pyrrolof23-blpvridin-2-yl)- 1 H-indol-5-yloxyl-propan-2-ol, A2-B I -C5, the product of the combination of group A2 in Table I and B I in Table 2 and C5 in Table 3:-

OH

By proceed ing in a manner similar to Example 1 7(a) above but using 3-{j I -methyl-3-[ I-(toluene-4su Ifonyl)- 1 H-pyrrolo[2,3-b]pyrid in-2-yl]- I H-indol-5-yloxy} -propan-2-ol [Reference Example 17], there was prepared 34F1 -methyl-3-( H-pyrrolo[2,3-bjpvridin-2-yl)- I H-indol-5-vloxL~y-propan-2-ol as a yellow solid, m.p. 201-202'C. MS: 32(MH+).

2-Fl -methyl-5-(2H-tetrazol-5-vl)- 1H-indol-3-vll- I orrolor2,3-blpyridine, A2-B I-C3 6, the product of the combination of group A2 in Table I and B I in Table 2 and C36 in Table 3:- WO 03/000688 WO 03/00688PCTGB02IO2 799 -165- K

N

N

N

H

By proceeding in a manner similar to Example 17(a) above but using 2-[l -methyl-5-(1 trimethyistannanyl- IH-tetrazol-5-yl)- IH-indol-3-yl]- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 20], there was prepared 241 -methyl-5-(2H--tetrazol-5-yl)- IH-indol-3-vfl-1 Hpvrrolor2.3-blnvridine as a yellow solid, m.p. 303'C. MS: 316(MH+).

2-fl -methvl-5-(2-methyl-2H-tetrazol-5-vi 1-1H-indol-3-vll- IH-pyrrolo[2,3-bl pyridine, A2-BI-C35, the product of the combination of group A2 in Table I and B I in Table 2 and in Table 3:-

NN

N-

H

By proceeding in a manner similar to Example 17(a) above but using 2-[1-methyl-5-(2-methyl-2H- H-indol-3-yl]- 1-(toluene-4-sulfonyl)-I H-pyrrolo[2,3-b] pyridine [Reference Example 21], there was prepared 2-fl -methvl-5-(2-methl-2H--tetrazol-5-vl)- 1H-indol-3-yll- IH-pyrrolor2,3 bipyridine as a beige solid, m.p. 299-300'C (with decomposition). MS: 330(MHW).

2-fl -methvl-5-( 1-methyl-I H-tetrazol-5-yl)- 1H-indol-3-vll- I H-pyrrolo[2,3-blpyridine

'N

H

By proceeding in a manner similar to Example 17(a) above but using 2-[1-methyl-5-(I-methyl-]H- IH-indol-3-yl]- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 211, there was prepared 2-ri -methyl-S -(1-methyl-I H-tetrazol-5-vD I -I-indol-3-yll- IH-pyrrolof 2.3bIpyridine as a beige solid, m.p. 286-289 0 C (with decomposition). MS: 330(MH+).

WO 03/000688 WO 03/00688PCT/G B02/02 799 -166- 1 -r 1-methyl-3-(1 H-ovrrolor2.3-bloyridin-2-yl)- I1--indol-5-vll-ethanone, A2-B I -C20, the product of the combination of group A2 in Table I and B I in Table 2 and C20 in Table 3:- 0 N

N

H

By proceeding in a manner similar to Example 17(a) above but using l-[1-methyl-3-{(l-(toluene-4sulfonyl)- 1 H-pyrrolo[2,3-b~pyridin-2-yI I H-indol-5-yl]-ethanone [Reference Example 22], there was prepared I1-[1 -methyl-3-(I H-pyrrolo[2,3 -bl pyridin-2-yi)- IH-indol-5-vil-ethanone as a beige sol id, m.p.

210 0 *C (with decomposition). MS: 29O(MH+).

24(5,6-d imethoxy'- I1-methyl- I H-indol-3-yl)- I H--pyrrolof2,3-blpylidine. A2-B 17-Cl1, the product of the combination of group A2 in Table I and 1317 in Table 2 and ClI in Table 3:- 0 N

N

H

By proceed ing in a manner si m ilar to Examp le 17(a) above but using 2-(5,6-d imethoxy- I -methyl- I Hindol-3-yl)- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example there was prepar ed 2-(5,6-dimethoxy- I1-met hyl- I H-indol-3-yl)-1 H-nvrrolo[2.3-blpyridine as a beige solid, m.p.

283-285'C (with decomposition). MS: 3O8(MH+). I HNMR [(CD 3 2 S0]: 11.75 (1IH, 8. 10 (1 H, dd), 7.85 (1IH, dd), 7.77 (1IH, 7.41 (1IH, 7.13 (1 H, 7.00 (1 H, dd), 6.75 (1IH, 3.85 (3 H, s), 3.84 (3H, 3.80 (3H, s).

1-methyl-3-( IH-pyrrolor2,3-blpyrid in-2-yl)- IH-indol-5- yloxyl-r ropane- I 2-diol, A2-13I -C80, the product of the combination of group A2 in Table I and B I in Table 2 and in Table 3:- WO 03/000688 PCT/GB02/02799 -167- By proceeding in a manner similar to Example 17(a) above but using (R)-3-{I1-methyl-3-[lI-(toluene-4sulfonyl)- 1 H-pyrrolo[2,3 -bjpyridin-2-yl)-I H-indol-5-yloxy) -propane-I ,2-diol [Reference Example there was prepared -methyl-3-( H-pyrrolq[2,3-bl oyridin-2-yfl- I propane- 1,2-diol as a colourless solid, m.p. 182-185 0 C. MS: 338(MH+).

JI -methyl-3 -0 H-pyrrolo[2,3-bl pyridin-2-yl)- I H- indol-5 -Yloxvl-pro Pane- I1.2-d io.

A2-B1-C79, the product of the combination of group A2 in Table I and BI in Table 2 and C79 in Table 3:- 0

OH

N

NN

H

By proceeding in a manner similar to Example 17(a) above but using (S)-3-{1-methyl-3-[I-(toluene-4sul fonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl]- I H-indol-5-yloxy} -propane-I 1,2-d iol [Reference Example there was prepared I -methyl-3-( IH-pyrrolor2,3-blpyridin-2-yl)- propane- I .2-diol as a colourless solid, m.p. 153-i156 0 C. MS: 338(MH+).

2-[5-(2-methoxy- I -rnethyl-ethoxcy)- I1-methyl-i H-indol-3-yll- I H-pvrrolor2,3-bl pyridine.

A2-B I-C 17, the product of the combination of group A2 in Table I and B I in Table 2 and C 17 in Table 3:- 0

N

H

By proceeding in a manner similar to Example 17(a) above but using 2-[5-(2-methoxy- I-methylethoxy)-lI-methyl- IH-indol-3-yl]- 1-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridime [Reference Example 25], there was prepared 2-[5-(2-methoxvy-l1-methvl-ethoxv'- I-methyl-I H-indol-3 -yll- 1Hpyrro lo r2.3 -bl pyri dine as a yellow solid, m.p. 150-15 1 C. MS: 336(MH-I).

(in) 2-11 -methiyl-5-(5-methyl-r I 2,41oxadiazol-3-yll- IH-indol-3-vll IH-pyrrolof2,3-blpvridine, A2-BI-C68, the product of the combination of group A2 in Table 1 and BI in Table 2 and C68 in Table 3:- WO 03/000688 PCT/GB02/02799 -168- N

"NN

N N By proceeding in a manner similar to Example 17(a) above but using 2-[l [1 ,2,4]oxadiazol-3-yI)- IH-indol-3-yl]- I-(toluene-4-sulfonyl)-1 H-pyrrolo[2,3 -b]pyridine [Reference example 271, there was prepared I-methyl-5-(5-methyl-[ I 2,41oxadiazol-3-vl)- IH-indol-3-yll- IHpyrrolo[2.3-blpyridine as a cream solid, m.p. 290-294 0 C. MS: 330(MH+).

(R)-3-[6-methoxv-I -methyl-3-( IH-Dvrrolor2,3-blpyridin-2-yl)- IH-indol-5-vloxyl-propane- 1.2diol, A2-1I7-C80, the product of the combination of group A2 in Table I and B 17 in Table 2 and C80 in Table 3:-

OH

OH

0 W~e N N N

H

By proceeding in a manner similar to Example 17(a) above but using (R)-3-{6-methoxy-1 -methyl-3-[1- (tolI uene-4-sulfonyl)- I H-pyrrolo[2,3 pyrid in-2-yl]- I H-indol-5 -yloxy} -propane- I ,2-diol [Reference Example 24(c there was prepared (R)-3-[6-methoxv- I-methyl-3-( IH-nvrrolor2.3-blpvridin-2-vl')- I inidol-5-yloxyl-propane-I.2-dioI as a cream solid. MS: 368(MH+). HPLC (METHOD RT 5.81 minutes.

6-methoxy- I -methyl-34( H-pyrrolor2,3-blpyridin-2-vyl)-I H-indol-5-ol, A2-B 1 7-Cl 10, the product of the combination of group A2 in Table I and BI17 in Table 2 and C 10 in Table 3:- Ho

H

By proceeding in a manner similar to Example 17(a) above but using 2-(5-hydroxy-6-niethoxy-lmethyl- IH-indol-3-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine (Reference Example 28], there WO 03/000688 PCT/GB02/02799 -169was prepared 6-methoxcy-l1-methyl-3-( 1H-pyrrolo[2.3-blnvrid in-2-:yl)- Il--indol-5-ol as a brown solid.

MS: 294(MH-1). HPLC (METHOD RT =6.37 minutes.

2-(5-methoy- 1-methvl-I H-indol-3-vylI-4-phenyl- IH-pyrrolof 2.3-bi pyridine, A 13-B 1-Cl, the product of the combination of group Al3 in Table I and BI in Table 2 and CI in Table 3:- N /CH, N N NH 3

H

By proceeding in a similar manner to Example 17(a) but using 2-(5-methoxy-1 -methyl-I H-indol-3-yl)- 4-phenyl- I -(toluene-4-su lfonyl)-1 H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-(5-methoxy- I -methyl-; I H-indol-3-vI)-4-phenyl- I H-pyrrolof2,3-bl ovridine as a yellow solid.

'H NMIR [(CD3) 2 SO]; 5 11.98 (l H, 8.21 (1IH, d, J=3.5 Hz); 7.94 (1 H, 7.86 (2H, d, J=8.8 Hz); 7.59 (2H, t,3J88 Hz); 7.47 (2H, in); 7.39 (1IH, d, J= 1.9 Hz); 7.17(lIH, d, J=3.5 Hz); 6.93 (1IH, dd, J=8.8, 1.9 Hz); 6.82 (1IH, 3.84 (3 H, 3.82 (3 H, s).

I-methyl-5-(pyridin-4-yl)- IH-indol-3-yll-4- IH-pyrrolor2,3-blpyridine, A2-B I-C3 7, the product of the combination of group A2 in Table I and B I in Table 2 and C37 in Table 3:-

N

By proceeding in a similar manner to Example 17(a) but using 2-[5-(pyridin-4-yl)-1 -iethyl-1 H-indol- 3-yl]-l 7-(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine (Reference Example 60) there was prepared 24 1 -methyl-5-(Vyridin-4-yl)-1 H-indol-3-yll-4-l H-pyrrolof2,3-blpyridine as a yellow solid, m.p. 325- 330-C. IHNMR [(CD 3 2 S0]; 58.65 (2H, d, J7.2 Hz); 8.20 (IH, 8.15 (lH,mi); 8.04 (IH,s); 7.88 (3H, in); 7.72 (2H, in); 7.03 (1I-H, t, J=7.2 Hz); 6.96 (1lH, 3.93 (3H, s).

2-(5-metlioxy- I-methyl-I H-indol-3-yl)- IH-pyrrolof2,3 -bi nyrid ine-4-carbon itri le, A3-B I-Cl, the product of the combination of group A31 in Table I and B I in Table 2 and C I in Table 3:- WO 03/000688 PCT/GB02/02799 -170- ICH 3 0

N

N CH 2

H

By proceeding in a similar manner to Example 17(a) above but using 2-(5-methoxy-l-methyl-1 H-indol- 3 -yl)-I toluene-4-su Ifonyl)-! H-pyrrolo[2,3 -b]pyridine-4-carbonitri le [Reference Example 13(h)) there was prepared 2-(5-methoxy- 1-methyl- I H-indol-3-yI)- I H4-pyrrolof 2.3-b] cyrid ine-4-carbon itrile as an orange solid, m.p. 304-305 0 C. 'HNMR [(CD 3 2 S0]: 812.60 (1H, 8.24 (1H, 8.07 (lH, 7.50 (3 H, in); 6.96 (1IH, d, J=8.6 Hz); 6.8 8 (11-H, 3.91 (3 H, 3.86 (3 H, s).

4-chloro-2-(5-methoxcy-I -methyl-I H-indol-3-yi)-l H-pyrrolor2.3-blpyridine, A28-B I -Cl1, the product of the combination of group A28 in Table I and B I in Table 2 and C I in Table 3:-

,CH,

0 C1

N.N,

N N

CH,

H

By proceeding in a similar manner to Example 17(a) above but using 4-chloro-2-(5-methoxy- I -methyl- I H-indol-3-yl)- 1-(toluene-4-su Ifonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 13(i)] there was prepared 4-chloro-2-(5-methoxiy-lI-methyl- IH-indol-3-yl)- IH-pyrroloF2,3-blpvridine as a tan solid, m.p.

250-252'C. MS: 3I2(MNfW).

2-(5-methoy- 1-methyl-I H-indol-3-yl)-4-(pyridin-3-y)-1 H-nvrrolof2,3-blpyr idine, the product of the combination of group A15 in Table I and BI in Table 2 and Cl in Table 3:- /CH 3 N N CH 3

H

By proceeding in a similar manner to Example 17(a) above but using 2-(5-methoxy-l -methyl-1 H-indol- 3-yI)-4-(pyridin-3-yl)- I-(tol uene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-(5-methoxy- I-methyl- IH-indol-3-yl)-4-(pyridin-3-yI)-]IH-Ryrrolor2.3-bl nyridine as a yellow solid, in.p. 248-249'C. MS: 355(MIV).

WO 03/000688 PCT/GB02102799 -171- 2-(5-methoxy- I-methyl-I H-indol-2-yl)- IH-pyrrolor2,3-blpyridime A2-B20-C 1, the product of the combination of group A2 in Table I and B20 in Table 2 and C I in Table 3:- N N N H H 3

C

By proceeding in a similar manner to Example 17(a) above but using 2-(5-methoxy-1-methyl-IH-indol- S 2-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b)pyridine [Reference Example 2(p)3, and recrystall ising the reactioh' product from ethyl acetate then washing with diethyl ether, there was prepared H-indol-2-yO)-IH-pyrrolor2,3-blpyridine as a yellow crystalline solid, m.p.

234-235-C. I H-NMR {(CD 3 2 S0}: 8 12.15-12. 10 I1H); 8.275-8.225 (dd, I 8.00-7.975 (dd, I 7.475-7.45 I 7.125-7.075 (in, 2H); 6.925-6.90 I 6.875-6.825 (in, 3.95-3.90 (s, 3H); 3.80-3.775 3H).

2-(5-methoxv- 1-methyl-I H-indol-3-vl)-3-methyl- 1H-pvrrolof2,3-blpyridine. A84-B I-Cl, the product of the combination of group A84 in table I and B I in table 2 and ClI in table 3:-

O~

N

N

H

By proceeding in a manner similar to Example 17(a) above but using 2-(5-methoxy-1-methyl-IH-indol- 3-yl)-3-methyl- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-(5-methoxy-1-methyl-I H-indol-3-yl)-3-methvl-l H-p2yrrolor2,3-blpyridine as a beige solid, m.p. 237*C. [Elemental analysis:- C, 74.15; H, 6.10; N, 14.54%. Calculated for C 1 8

H

17

N

3

C,

74.2 1; H, 5.88; N, 14.42%].

2-(IH-px'rrol-2-yl)-IH-pyrrolo[2,3-blpyridine A2-BI 15, the product of the combination of group A2 in table I and BI 115 in table 2:-

N

HH

By proceeding in a manner similar to Example 17(a) above but using 2-(IH-pyrrol-2-yl)-1-(toluene-4sulfonyl)-IH-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-(]H-pyrrol-2yl):-I H-pyrrolo[2,3-bjpx'ridine as a yellow solid, m.p. 240'C (with decomposition). [Elemental WO 03/000688 PCT/GB02/02799 -172analysis:- C, 72.11;- H, 4.95; N, 22.94%. Calculated for C I IH 9

N

3 C, 72.33; H, 4.97; N, 21.85%]. MS: El (70eV); m/z =183 155 1-methyl-I H-pyrrol-2-vl)- IH-pyrrolof2.3 -bpridine. A2-B53, the product of the combination of group A2 in table 1 and B53 in table 2:-

/N

N

By proceeding in a manner similar to Example 17(a) but using 2-(1-methyl-1 H-pyrrol-2-yl)-] -(toluenle- 4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example there was prepared -methyl-I Hpyrrol-2-yl)- IH-pyrrolo2,3-blpyridifle as a white solid, m.p. 183'C. MS: El (70eV); m/z 197 M+- (100%).

4-chloro-2-(5-methoxy- 1 H-indol-3-vl)- I H-ovrrolor2,3-blpvridifle A28-B2-C 1, the product of the combination of group A28 in Table I and B2 in Table 2 and C I in Table 3:- N N N\ By proceeding in a manner similar to Example 17 above but using 4-chloro-2-(5-methoxy-1I H-indol- 3-yl)- I-(toluene-4-sulfonyl)- 1 H-pyrrolo{2,3-b~pyridifle [Reference Example there was prepared 4-hoo2(-ehUI-no--i-HDroo2 rdn as a solid. LC-MS: METHOD D: RT 2.76 minutes, 298(MH+).

5-methoxv-l1-methvl-3-( 1H-pyrrolo[2,3-blnvridin-2-vl)-1 H-indol-6-ol, A2-B 119-Cl, the product of the combination of group A2 in Table I and BI 119 in Table 2 and C I in Table 3:- By proceeding in a manner similar to Example 17(a) above but using 2-(6-hydroxy-5-methoxy-1methyl-I H-indol-3-yl)- I-(toluene-4-su Ifonyl)- 1H-pyrrolo[2,3-b]pyridine [Reference Example 83], there WO 03/000688 PCT/GB02/02799 -173was prepared 5-methoxy-l1-methyl-3-( IH-pyrrolo[2,3-bl pyrid in-2-vl)- 1H-indol-6-ol as an off-white solid, m.p. 250'C. MS: El (70eV); m/z= 293 (100%).

(aa) 2-(6-isopropoxy-5-methoxv- I -methyl- I H-indol-3-yl)- I H-ovrrolo[2.3-blop'ridine, A2-B 1 20-Cl1, the product of the combination of group A2 in Table I and B120 in Table 2 and C I in Table 3:- 0 By proceeding in a manner simi lar to Example 17(a) above but using 2-(6-isopropoxy-5-methoxy-1Imethyl-I H-indol-3-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 84], there was prepared 2-(6-isopropoxv-5-methoxy- 1-methyl-I H-indol-3-vlV I H-pyrrolo 2.3 -blpyridine as an off-white solid, m.p. 21 6'C. MS: El (70eV); m/z 335 M- 293 278 (ab) 2-[5,6-dimethoxy-lI-(2-morphol in-4-yl-ethyl)- IH-indol-3-vll- IH-pyrrolo[2,3-bl pyridine, A2- B 122-C 1, the product of the combination of group A2 in Table I and B 122 in Table 2 and C I in Table 3:- 0 0-1~ N

NN

0 By proceeding in a manner similar to Example 17(a) above but using 2-[5,6-dimethoxy-I1-(2morphol in-4-yl-ethyl)- IH-indol-3 I-(toluene-4-sulfonyl)- I 1-pyrrolo[2,3 -b]pyridine [Reference Example there was prepared 2-f 5,6-d imetloxy- 1-(2-mo~pholinA-yl-ethvl)- IH-indol-3-yll- IHpyrrolo[2,3-blpyridine as pale pink solid, m.p. 21 8'C. MS: ESI; mlz 407 MH+.

EXAMPLE 18 I -Methyl-3-0 H-pyrrolo[2.3 -bi pvridin-2-yl)- IH-indol-5-ylamine. A2-B I -C63, the product of the combination of group A2 in Table I and B I in Table 2 and C63 in Table 3:- WO 03/000688PC/B /079 PCT/GB02/02799 -174- 2 N

N

H

A stirred solution of [I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- 1 H-indol-5-yl]-carbamic acid, iertbutyl ester [0.2g, Reference Example 30] in dichioromethane was treated with trifluoroacetic acid (2 mL). After stirring at ambient temperature for 16 hours the reaction mixture was evaporated. The residue was suspended in saturated sodium bicarbonate solution (10 mL) and the resulting solid was filtered then dried to give the title comnound as a yellow solid, m.p. 247-248 0 C. MS: 263(MH+).

EXAMPLE 19 1-Methyl-3-( I H-pyrrolo[2,3-bl ovridin-2-yl)- I A2-B I-C62, the product of the combination of group A2 in Table 1 and B I in Table 2 and C62 in Table 3:-

HN-S-*

N

N

H

A solution of I -methyl-3-(l I pyrrolo[2,3-b]pyridin-2-yl)- 1 H-indol-5-ylamine [52.4mg, Example 18] in dichloromethane (5 mL) was treated with triethylamnine (30g~l) followed by methane sulfonyl chloride (1 741). After stirring at ambient temperature for 16 hours the reaction mixture was diluted with dichloromethane (10 mL), then washed with water (10 mL), then washed with brine (10 mL), then dried over magnesium sulfate and then evaporated. The residual solid was triturated with diethyl ether to give the title compound as a yellow solid, m.p. 223-224 0 C. MS: 341 I-methyl-3-( IH-pyrroloF2.3-bl pyrid in-2-vl)- IH-indol-5-yll-acetamide, A2-B I -C45, the product of the combination of group A2 in Table I and BI in Table 2 and C45 in Table WO 03/000688 PCT/GB02/02799 -175- N NH By proceeding in a manner similar to Example 19(a) above but using acetyl chloride, there was prepared N-Fl -methyl-3-( H-VyrroloF2.3-boVridin-2-yl)-l H-indol-5-vll-acetamide as a yellow solid, m.p. 220-221 MS: 305(MH+).

N-1I -methyl-3-( H-pyrrolor2,3-blovridin-2-yl)- I H-indol-5-yllmethyl thien-2-yl-sulfonamide.

A2-BI1-C69, the product of the combination of group A2 in Table I and B I in Table 2 and C69 in Table 3:so

NH

N NN- By proceeding in a manner similar to Example 19(a) above but using H-pyrrolo[2,3-b]pyridin-2yl)-I -methyl- IH-indol-5-yl]-methylamine [Example 52] and 2-thienyl sulfonyl chloride there was prepared N-f 1 I-methyl-3-( I I-pyrrolor2.3-bliovridin-2-vl)-1 H-indol-5-vll methyl Ithien-2-ylsu Ifonamide as a* pale orange solid, m.p. 226-227*C.

EXAMPLE f 14-5-(0 -Hydroxymethyl-cyclobutoxy)-3-( I H-pyrrolor2,3-blpyridin-2-vl)-indol- I -yllcyc lobutyl) -methanol, A2-B 13-C 12, the product of the combination of group A2 in Table I andBl13 in Table 2and C12 in Table 3:- WO 03/000688 PCT/CB02/02799 -176- CqOH

HH

A stirred solution of l-{1-(cyclobutanecarboxylic acid ethyl ester)-3-[l-(toluene-4-sulfonyl)-IHpyrrolo[2,3-blpyridin-2-yl]- IH-indol-5-yloxy} -cyclobutanecarboxyl ic acid ethyl ester [0.54g, Reference Example 23(d)] in tetrahydrofuran (50 mL) at 0 0 C under nitrogen was treated dropwise with a solution of lithium tetrahydridoaluminate in tetrahydrofuran (4.9 mL, 1.0M). After stirring for 2 hours at 0 0 C the reaction mixture was stood at ambient temperature for a further 18 hours then treated dropwise with water (20 mL) and then filtered through Hyflo Super Gel®, diatomaceous earth. The filter pad was washed with ethyl acetate (20 mL), the two-phase filtrate was separated and the aqueous layer was extracted twice with ethyl acetate (25 The combined organic phases were washed with brine (25 then dried over magnesium sulfate and then evaporated. The residue was triturated with diethyl ether and the insoluble material was subjected to flash column chromatography on silica eluting with a mixture of dichloromethane and methanol (19: 1, v/v) to give the title com~ound 19g) as a cream solid, m.p. 165-166*C. MS: 418(MH+').

f 14 I-methyl-3-(5H-pyrrolo[23-blpvrazin-6-y)-I H-indol-5-yloxyl-cyclobutyl )-methanol, A1-BI-C13, the product of the combination of group Al in Table I and BI in Table 2 and Cl 3 in Table 3:-

H

By proceeding in a similar manner to Example 20(a) above but using 1-[1 -methyl-3-(5H-pyrrolo[2,3 -b]pyrazin-6-yl)- IH-indol-5-yloxy]-cyclobutylcarboxyl ic acid ethyl ester [Reference Example 15(e)] there was prepared f 14F1 -methyl-3-(5H-pyrrolor2,3 -blpyrazin-6-yl)-lI H-indol-5-vloxvl-cyclobutyll -methanol as a brown solid, m.p. 267-271 0 C. MS: 349(MH--).

WO 03/000688 PCT/GB02/02799 -177- EXAMPLE 21 2-(5-Methoxy-1 -methyl- I H-indol-3-yl)- I H-pyrrolof2,3-blpyridine methanesulfonate 0 /0

H

Methane sulfonic acid (7O0.d) was added to a solution of 2-(5-methoxy-l-methyl-1H-indol-3-yl)-IHpyrrolo[2,3-b]pyridine [300mg, Example 17(a)] in tetrahydrofuran (20 m-L) at ambient temperature.

The mixture was stirred for 45 minutes and the resultant precipitate isolated by filtration to give the title compound (390mg), as a yellow solid, m.p. 256-257C. [Elemental analysis:- C, 57.60; H, 4.77; N, 10.90%. Calculated for C 13 HI jN3O:- C, 57.90; H, 5.13; N, 11.25%).

6-(5-methoxy- 1-methyl-I H-indol-3 -yl)-5H-Rvrrolo[2.3-blpvrazine methanesulfonate ?Is- H= By proceeding in a manner similar to Example 21(a) above but using 6-(5-methoxy-1-methyl-1 indol-3-yl)-SH-pyrrolo[2,3-b~pyrazine [Example there was prepared 6-(5-methoxy- 1 -methyl- 1 Hindol-3-vll-5H-pvrrolo[2.3-blpvrazine methanesulfonate as a yellow solid, m.p. 245-250 0 C. MS: 279(M[44).

2-5-methoxy-341 H-pyrrolor2,3-blpyridin-2-yl)-indol-1I-vll- I-morphol in-4-yl-ethanone methanesulfonate 0 0

OR

N

NN

0 By proceeding in a manner similar to Example 2 1 above but using 2-[S-methoxy-3-(I H-pyrrolo[2,3b]pyrid in-2-yl)-indol- -morphol in-4-yl-ethanione [Example there was prepared WO 03/000688 PCT/GB02/02799 -178- 2-f 5-methoxv-3-(11 H-12rrolof 2,3-bi nvridin-2-yJ)-indol- I -vii- 1 -morphol in-4-yl-ethanone methanesulfonate as a yellow solid, m.p. 214-215*C. MS: 39l(MH+).

I -methyl-3-( IH-pyrrolo[2,3-blpyridin-2-yl)-1 H-indole-5-carboxylic acid (2-hydroxy-1 d imethyl-ethyfl-amide methanesulfonate 0 By proceeding in a manner similar to Example 21(a) above but using 1-methyl-3-(]H-pyrrolo[2,3b] pyrid in-2-yi)- IH-indole-5-carboxyl ic acid (2-hydroxy- 1,1-d imethyl-ethyl)-am ide [Example 14(m)], there was prepared I -methyl-3-( IH-ovrrolof2,3-bl pyridin-2-vl)- IH-indoie-5-carboxyl ic acid (2-hydroxy-1,1-dimethl-ethvl)-amide methanesulfonate as a yellow solid, m.p. 190-1921C. MS: 3 63(MH+).

6-F 5-(2-hydroxy- 1.1-dimethylethylcarbamoyl)- I-methyl-I H-indol-3-vll-5 H-pyrrolor2 23bipyrazine methanesulfonate

I

H

0 By proceeding in a similar manner to Example 2 1 but using I -methyl-3-(5H-pyrrolo[2,3-b]pyrazin- 6-yl)-1 H-indole-5-carboxyl ic acid (2-hydroxy- 1,1-dimethyl-ethyl)-amide [Example 14(s)] there was prepared 6-f 5-(2-hydroxy- 1.1-dimethylethylcarbamoyl)- 1-methyl-i H-indol-3-y1l-5H-pyrroio[2.3bipyrazine methanesulfonate as a brown solid, m.p. 240'C (with decomposition). 1H NMR

[(CD

3 2 S0]: 5 8.50 (1IH, 8.37 (1 H, d, J=3.0 Hz); 8.32 (IH4, d, J=3.0 Hz); 8.29 7.82 (1IH, d, J'=8.2 Hz); 7.77 (IH, 7.64 d, J=8.2 Hz); 7.20 (1H, 3.95 (3H, 3.59 (2H, 2.37 (3H, s); 1 .38 (6H, s).

2-r5-methoxy-3-(5H-pyrrolor2.3-blpyrazin-6-yl)-indol-l1-vii-l1-morphol in-4-yl-ethanone niethanesulfonate WO 03/000688 PCT/GB02/02799 -179-

ICH,

0 (N0 N N H

N

By proceeding in a similar manner to Example 2 1(a) but using 2-[5-methoxy-3-(5H-pyrrolo[2,3b]pyrazin-6-yI)-indol-1I-yl]-lI-morpholin-4-y-ethanone (Example 12) there was prepared 3-(5H-pyrrolor2,3-blpyrazin-6-yl)-indol- I -yii- I -morphol in-4-yl-ethanone methanesu Ifonate, m.p.

250-C. 'H NMR C(CD 3 2 S01: 8 8.32 (11-H, 8.22 (11-H, 8.11 911-H, 7.50 (1 H, 7.44 (1 H, d, 3=8.8 Hz); 7.04 (1 H, 6.93 91 H, d, J=8.8 Hz); 5.3 6 (2H, 3.90 (3 H, 3.61 (8H4, in); 2.3 1 (3 H, s).

2-(5,6-dimethoxy- 1-methyl-I H-indol-3-vI)-1 H-pvrrolor2,3-blpvridine methanesulfonate R 0 N N

N

H

By proceeding in a similar manner to Example 2 1(a) but using 2-(5,6-dimethoxy-l-methyl-IH-indol-3yl)-l H-pyrrolo[2,3-blpyridine [Example 1 there was prepared 2-(5.6-dimethoxy-1-methyl-I Hindol-3-yl)-lH-nvrolor2,3-blpwvidine methanesulfonate. IH NMIR[(CD 3 2 S0]: 88.25 (2H4,mi),7.90 (IH, 7.42 7.33 (IH, dd), 7.16 (IH, 7.04 (IH, 3.90 (3H, 3.85 (3H, 3.84 (3H, s), 2.36 (31H, s).

EXAMPLE 22 *-[6-(4-ert-Butlphenvl-5H-pyrrolor2,3-blpyrazin-7-yllethvl-2H-tetrazole, A3 5-B55, the product of the combination of group A35 in Table I and B55 in Table 2:-

N

CN

1 N

N

H

To a stirred solution of 3-[6-(4-lert-butyl phenyl-SH-pyrrolo[2,3-b]pyrazin-7-yl]-propionitri le [0.2g, Example 23] in toluene (25 mL), at room temperature under nitrogen, was added azidotributyltin (0.61 WO 03/000688 PCT/GB02/02799 -180mL). The reaction mixture was heated at 117 0 C. After 24 hours, an additional aliquot of azidotributyltin (0.21 mL) was added and the reaction mixture was heated for a further 24 hours. The reaction mixture was quenched with glacial acetic acid (44 mL) and stirred for 15 minutes before O partitioning between water and ethyl acetate. The two layers were separated and the organic fraction was washed with water, dried over magnesium sulfate and then evaporated. The residue was subjected C to flash column chromatography on silica eluting with ethyl acetate to give the title compound (0.06g) as an off-white solid. MS: 348(MH+).

SHPLC (Method RT=I.64 minutes.

EXAMPLE 23 3-r6-(4-tert-Butvlphenvl-5H-pyrrolor2.3-bpyrazin-7-yll-2H-propionitrile, A45-B55, the product of the combination of group A45 in Table I and B55 in Table 2:-

-N

N N

H

To a solution of 3-[ 6 4 -tert-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionamide g, Example 24] in tetrahydrofuran (15 mL) at room temperature was added triethylamine (1 mL) and phosphorus oxychloride (1 mL). The reaction mixture was heated at reflux for 30 minutes then poured into a solution of sodium hydrogen carbonate. The mixture was extracted with ethyl acetate and the combined organic extracts were washed with water, dried over magnesium sulfate and evaporated. The residue Swas subjected to flash column chiomatography on silica eluting with first a mixture of ethyl acetate and pentane v/v) then with ethyl acetate to give the title compound as a white solid, m.p. 215- 216 0 C. MS: 305(MH+).

EXAMPLE 24 3-r6-(4-tert-Butvlphenvl-5H-pyrrolor2,3-blvrazin-7-yll-propionamide. A32-B55, the product of the combination of group A32 in Table 1 and B55 in Table 2:- 0

NH

2

N

NNN4

H

To a solution of 3 6 4 -tert-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic acid [0.51 g, Example 25(a)] in dimethylformamide (15 mL) at room temperature under nitrogen was added WO 03/000688 PCT/GB02/02799 -181- O-benzotriazol-l-yl-N,N,N',N',-tetramethyluronium tetrafluoroborate (0.54g) and triethylamine (0.22 mL). Ammonia gas was bubbled through the solution for 5 minutes and the stoppered reaction mixture was allowed to stand at room temperature overnight. The solution was then poured into water and extracted with ethyl acetate. The organic extracts were washed with water and dried over sodium sulfate to afford the title compound as a white solid without further purification. MS: 323(MH+).

HPLC (Method RT 4.49 minutes.

EXAMPLE 3-[6-(4-tert-Butvlphenvl-5H-pvrrolor2.3-blpvrazin-7-vll-propionic acid, A31 -B55, the product of the combination of group A31 in Table 1 and B55 in Table 2:- 0

OH

N

N

H

To a solution of dimethyl 3-[6-(4-iert-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic-l, -diacid 1,1-dicarboxylate [0.4g, Reference Example 44(a)] in methanol (20 mL) was added IN sodium hydroxide solution (4 mL). The reaction mixture was heated at 50° C for 6 hours then allowed to stand at room temperature overnight. The solvent was removed by evaporation, 6N sulfuric acid solution mL) was added and the reaction mixture refluxed for 2 hours. After cooling, the solution was basified to pH 4 with IN sodium hydroxide solution and the resultant precipitate isolated by filtration and dried under vacuum to afford the title compound (0.26g) as an off-white solid without further purification, m.p. 274-275 0 C. MS: 324(MH+).

3-{6-F4-(-methyl)ethoxyphenyll-5H-pyrrolor2,3-bpvyrazin-7-yl}propionic acid, A31-B63, the product of the combination of group A31 in Table I and B63 in Table 2:-

H

0

H

By proceeding in a manner similar to Example 25(a) but using dimethyl methyl)ethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic 1,1-diacid 1,1-dicarboxylate [Reference Example there was prepared 3-{6-r4-(1-methyl)ethoxyphenvl]-5H-pyrrolo[2.3- WO 03/000688 PCT/GB02/02799 -182blpyrazin-7-vIlpropionic acid as a yellow solid. MS: 326(MH+). HPLC (Method RT =1.56 minutes.

3-F6-(4-fl uorophenyl)-5H-pyrrolo[2,3-blpyrazini-7-yll oropionic acid, A31I-B89, the product of the combination of group A31 in Table I and B89 in Table 2:-

H

Q I By proceeding in a manner similar to Example 25(a) but using dimethyl 3-[6-(4-fluorophenyl)-5Hpyrrol o[2,3 -b]pyrazi n-7-yl]-prop ionic 1,1-diacid 1,1-dicarboxylate (Reference Example there was prepared 3-[6-(4-fluorophenyl)-5H-pyrrolor2,3-blpyrazin-7-llpropjonic acid as an off-white solid.

I HNMR [(CD 3 2 S0]: 5 12.3 I H) 8.4 I1-H), 8.2 IH), 7.8 2H), 7.4 214),3.1 2H), 2.7 3-f 6-4-methoxyphenvl)-5H-pyrrolor2,3-bl nvrazin-7-vllnropion ic acid, A31I-B77, the product of the combination of group A31 in Table I and B77 in Table 2:- By proceeding in a manner similar to Example 25(a) above but using dimethyl methoxyphenyl)-5H-pyrrolo[2,3 -b]pyrazin-7-yl]-prop ionic 1,1 -diacid 1,1 -dicarboxylate [Reference Example there was prepared 3-r6-(4-methoxvohenyl)-5H-pvrrolo[2,3 -bi pyrazin-7-l nrooionic acid as an off-white solid. IH NMR [(CD 3 2 S0]: 8 12.0 I H) 8.3 I 8.2 IH), 7.7 2H), 7.1 2H), 3.8(s, 3.05 2H), 2.6 2H4). MS: 297(MH+).

EXAMPLE 26 3 -r 6 -(4-tert-Butvl-pheny1)-5H-pvyrrolor2.3-blpyrazin-7-vl12ropan- I -ol, A30-B55, the product of the combination of group A301 in Table I and B55 in Table 2:- WO 03/000688 PCT/GB02/02799 -183-

OH

N

N

H

To a mixture of 4N hydrochloric acid in dioxane and methanol (5 mL 1:1, v/v) was added 3-[6-(4-tertbutylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic acid [0.02g, Example 25(a)] and the reaction mixture was allowed to stir at room temperature overnight. After evaporation, the residue was suspended between sodium hydrogen carbonate solution and ethyl acetate. The phases were separated and the organic fraction was washed with water and dried over sodium sulfate. After evaporation, the residue was suspended in diethyl ether (50 mL). Lithium aluminium hydride (0.12mL of IM solution in diethyl ether) was added and the suspension heated to reflux for 2 hour. An additional aliquot of lithium aluminium hydride (0.12mL of 1M solution in diethyl ether) was added and the reaction mixture was heated for a further 1 hour. The reaction was quenched with a cold aqueous solution of potassium hydrogen sulfate added dropwise until hydrogen evolution ceased, diluted with water and extracted with ether. The combined organic fractions were washed with water, dried over sodium sulfate and subjected to flash column chromatography on silica eluting with ethyl acetate to give the title compound (0.035g) as an off-white solid, m.p. 187-189 0 C. MS: 310(MH+).

EXAMPLE 27 [2-Methoxv-5-(5H-pvrrolof2,3-blpyrazin-6-vl)-phenoxylacetic acid ethyl ester. Al -B68, the product of the combination of group Al in Table I and B68 in Table 2:- 0 OEt

(N

H

To a solution of 2-methoxy-5-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol [0.5g, Example 28] in dimethylformamide (10 mL) and cesium carbonate (0.67g) was added ethyl chloroacetate (0.025g).

The reaction mixture was heated at 50 0 C overnight. After cooling, the dimethylformamide was removed in vacuo and the residue partitioned between ethyl acetate and water. The organic fraction was dried over sodium sulfate, evaporated and subjected to flash column chromatography on silica eluting with 2.5% methanol in dichloromethane. This product was further triturated with a mixture of ethyl acetate and pentane to give the title compound as a white solid, m.p. 183-184°C. MS: 328(MH+).

WO 03/000688 PCT/GB02/02799 -184- EXAMPLE 28 2-Methoxy-5-(5H-pyrrolo[2,3-blpyrazin-6-yl)phenol, A -B70, the product of the combination of group Al in Table 1 and B70 in Table 2:-

OH

N N

H

To a solution of 6-(3-tert-butyldimethylsilyloxy-4-methoxy)phenyl-5H-pyrrolo[2,3-b]pyrazine [1.Og, Reference example 49] in tetrahydrofuran (50 mL) was added tetrabutylammonium fluoride (5.63 mL of a 1M solution in tetrahydrofuran). The reaction mixture was stirred at room temperature for 3 hours.

The tetrahydrofuran was removed under reduced pressure and the residue was suspended in water. The resultant solid was collected by filtration and dried under vacuum to afford the title compound as a white solid (0.56g) which was used without further purification. MS: 242(MIH). HPLC (Method B): RT 3.02 minutes.

EXAMPLE 29 3-Fluoro-2-(5-methoxv-l-methyl-lH-indol-3-vl)-l H-pvrrolor2.3-blpyridine. A62-B1-Cl, the product of the combination of group A62 in Table 1 and BI in Table 2 and Cl in Table 3:- N N

H

A solution of 2-(5-methoxy-l-methyl-lH-indol-3-yl)-lH-pyrrolo[2,3-b]pyridine [0.1g, Example 17(a)] in dry tetrahydrofuran (4 mL), at 0°C, was treated with methyl magnesium bromide (0.042 mL) and after stirring for a further 20 minutes at 0°C this mixture was treated with 1 -chloromethyl-4-fluoro-l,4diazoniabicyclo[2,2,2]octane bis(tetrafluoroborate) (0.13g). The reaction mixture was stirred at room temperature for 4 hours, then stood at room temperature overnight, then heated at 40 0 C for 4 hours, then heated at 80 0 C for 2 hours, then cooled to room temperature and then partitioned between ethyl acetate and water. The aqueous layer was extracted three times with ethyl acetate (25 mL). The combined extracts and ethyl acetate layer from the partitioning were washed with brine, then dried over magnesium sulfate and then evaporated. The residue was triturated with ethyl acetate to give the title compound (0.057g) as a white solid, m.p. 248-250 0 C. 1 H NMR [(CD3) 2 SO]: 5 12.20 (1H, 8.24 WO 03/000688 PCT/GB02/02799 0 -185- 0 C1 (lH, 7.81 (1H, 7.79 (1H, d, J=9.6 Hz); 7.46 (lH, d, J=9.6 Hz); 7.27 (1H, 7.18 (1H, dd, J=13.1, 6.0 Hz); 6.90 (1H, d, J=9.6 Hz); 3.88 (3H, 3.80 (3H, s).

EXAMPLE 3- {6-(4-Hvdroxvphenvl)-5H-pvrrolo[2.3-blpyrazin-7-yl}propionic acid, A31-B78, the product of the combination of group A31 in Table 1 and B78 in Table 2:- CO H

OOH

N N H

H

To a solution of dimethyl 3-[6-(4-(1-methyl)ethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic 1,1-diacid 1,1-dicarboxylate [0.77g, Reference Example 44(b)] in methanol (45 mL) was added IN sodium hydroxide solution (7.7 mL). The reaction mixture was heated at 50 0 C for 6 hours then allowed to stand at room temperature overnight. The solvent was removed by evaporation, 6N sulfuric acid solution (20 mL) was added and the reaction mixture refluxed for 12 hours. After cooling, the solution was basified to pH 4 with 4N sodium hydroxide solution and the resultant precipitate filtered and dried under vacuum to afford the title compound (0.42g) as a yellow solid which was used without further purification. MS: 284(MH+). HPLC (Method RT 2.3 minutes.

EXAMPLE 31 Ethyl 3-{6-(4-hvdroxvphenyl)-5H-pyrrolo[2.3-b]pvrazin-7-yl)propionate, A57-B78, the product of the S combination of group A57 in Table 1 and B78 in Table 2:- CO2Et

HOH

N

A solution of 3-{6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl}propionic acid (0.02g) [Example in ethanol (2 mL) was treated with a catalytic amount of para-toluenesulfonic acid. The mixture was refluxed for 4 hours, the solvent removed by evaporation and the precipitate filtered. The solid was then taken in ethyl acetate, the organic layer washed with water, brine, dried over magnesium sulfate and evaporated to give a yellow solid which was subjected to flash chromatography on silica, eluting with ethyl acetate) to give the title compound. MS: 298(MH+). HPLC (Method RT 2.58 minutes.

WO 03/000688 PCT/GB02/02799 -186- EXAMPLE 3 2 and -REFERENCE EXAMPLE 100 IH-indol-3-vl)- IH-pvrrolor2,3-blovridine-4-carbon itri Ic,.A3-B2-C 1, the product of the combination of group A3 in Table 1 and B2 in Table 2 and C I in Table 3:-

,CH

3

N

N N"H

H

By proceeding in a similar manner to Reference Example 12(a) but using 2-iodo- I-(toluene-4sulfonyl)- I H-pyrrolo[2,3-bjpyridine-4-carbonitrile [Reference Example 62(a)] there was prepared the IH-indol-3-vl)- IH-pyrrolor2,3-blpyridine-4-carbonitrile as a yellow solid, m.p. 303- 304*C, TLC RF 0.07 (ethyl acetate/heptane 1: 1) and 2-(5-methoxy-lH-indol-3-yl)-1-(toluene-4sulfonyl)-l H-pyrrolo[2.3-blpyridine-4-carbonitrile [Reference Example 100] as a brown oil. MS: 443(MH{). TLC: RF 0.38 (ethyl acetate/heptane 1: 1).

EXAMPLE 33 6-(4-Methylsulfinylphenyl)-5H-pvrrolor2,3-blpvrazine, A I-B93, the product of the combination of group AlI in Table I and B93 in Table 2:- /J N N 0

H

A stirred suspension of 6-(4-methylthiophenyl)-5H-pyrrolo[2,3-b]pyrazine [0.2362g, Example 1 in dichloromethane (20 mL) was treated with TBA oxone (2.545g). After 2 hours the resulting orange solution was evaporated. The residue was subjected to flash chromatography eluting with a mixture of methanol and dichloromethane 1, v/v) to give the title compound as a white solid. MS: 258(MH+).

I H NM4R [(CD 3 2 S0]: 8 12.66 (1IH, 8.41 (1 H, 8.24 (3H, in); 7.82 (2H, d, J=8.7 Hz); 7.33 (1IH, 2.81 (3 H, s).

EXAMPLE 34 6-(4-Methylsulfonylphenyl)-5 H-pyrrolo[2,3 -bi pyrazine, Al -B94, the product of the combination of group AlI in Table I and B94 in Table 2:- WO 03/000688 PCT/GB02/02799 -187-

CN,

N N 00

H

A stirred suspension of 6-(4-methylthiophenyl)-5--pyrrolo[2,3-b]pyrazine [0.1 25g, Example 1 in dichloromethane (15 mL) was treated with TBA oxone (1.35g). After 4 hours the reaction mixture was evaporated. The residue was subjected to flash chromatography eluting with a mixture of methanol and dichloromethane 1, v/v) to give the title compound as a white solid. MS: 274(MH+). IH NMR [(CD 3 2 S0]: S 12.78 8.44 (IH, 8.28 (3H,mi); 8.04 (2H, d, J=8.8 Hz); 7.40 (lH, s); 3.27 (3H, s).

EXAMPLE 3-(6-(4-Iert-Butvlphenl)-51-l-pyrrolor2.3-bl ovrazin-7-yl~propylamine A46-B5 5, the product of the combination of group A46 in Table I and B55 in Table 2:- N;2 N N

H

A solution of the 3-j[6-(4-tert-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl]-propionamide [0.2 g, Example 24] in dry tetrahydrofuran (20 mL) was treated with a solution of lithium aluminium hydride in diethyl ether (5 mL, I The solution was stirred at room temperature for 24 hours then treated with water (20 mL). This mixture was filtered through celite and the celite was washed twice with ethyl acetate (20 mL). The combined filtrate and washings were washed with water, then with brine, then dried over magnesium sulfate and then evaporated to give the title compound as a yellow solid 12 MS: 309(M1-1+). HPLC (Method RT 2.54 minutes.

EXAMPLE 36 N- 13-(6-(4-ter-t-Butvlpheniyl)-5 H-pyrrolor2,3-blpyrazin-7-flpropyl Iacetamide, A39-1355, the product of the combination of group A39 in Table I and B55 in Table 2:- WO 03/000688 PCT/GB02/02799 -188-

H

N

A solution of 3-(6-(4-tert-butylphenyl)-5 H-pyrrolo[2,3-blpyrazin-7-yI)propylamine (0.0324 mmol) [Example 351 in tetrahydrofuran (1.5 mL) was treated with acetyl chloride (0.0324 mmol) and triethylamine (0.0788 mmol). The solution was stirred at room temperature for 12 hours and then treated with water and ethyl acetate. The organic phase was dried over magnesium sulfate and then evaporated. The residue was subjected to column chromatography on silica eluting with ethyl acetate followed by a mixture of ethyl acetate and methanol 1, to give the title comound as a yellow solid. MS: 35 1(MI-l). HPLC (Method RT =3.05 minutes.

N- 13-(6-(4-tern-butylphenl)-5H-prrolo2,3-blpyrazin-7-l)hropy Icyclopropylcarboxyl ic acid amd A47-B55, the product of the combination of group A47 in Table I and B55 in Table 2:-

N

H

H

By proceeding in a manner similar to Example 36(a) above but using cyclopropylcarbonyl chloride, there was prepared N- f 3-(6-(4-ter-t-butwlphenvl)-5H-pvrrolor2,3-blpyrazin-7yl)nropyllcycloproovlcarboxvylic acid amide as a yellow gummy solid. MS: 377(MI-l). HPLC (Method RT 3.25 minutes.

N-f 3-(6-(4-lert-butvlvhenvl-5H-prrolor2,3-blpyrazin -7-l~propvllIbutvramide, A48-B55, the product of the combination of group A48 in Table I and B55 in Table 2:- WO 03/000688 PCT/GB02/02799 -189- 0

N

H

H

By proceeding in a manner similar to Example 36(a) above but using n-butyroyl chloride, there was prepared N-f 3-(6-(4-tert-butvlohenl)-5H-prrolof2,3-blpyrazin-7-yl~hropyl lbutyramide as a yellow gummy solid. MS: 379(MH+). HPLC (Method RT 3.28 minutes.

N-f 3-(6-(4-ter:-butvlphenvfl-SH-pyrrolor2.3-blovrazin-7-vflnropyl I methoxyacetamide, A49the product of the combination of group A49 in Table I and B55 in Table 2:-

N

H

H

By proceeding in a manner similar to Example 36(a) above but using methoxyacetyl chloride, there was prepared N- {346-(4-tert-but'vlphenyl)-5H-pvrrolo[2.3-blpvrazin-7-yl)propyl Imethox~yacetamide as a white solid.' MS: 381(M}1+). HPLC (Method RT= 3.15 minutes.

N-f3-(6-(4-tert-butvlphenyl)-5H-pyrrolor2,3-blpvrazin-7-vyl)propyvl thien-2ylcarboxyl ic acid amnide A50-B55, the product of the combination of group A50 in Table I and B55 in Table 2:-

SI

WO 03/0006,88 PCT/GB02/02799 -190- By proceeding in a manner similar to Example 36(a) above but using thien-2-ylcarbonyl chloride, there was prepared N-13-(6-(4-:ert-butylpthenylY5H-prrolof2,3-blpvrazin-7-vlmroply thien-2ylcarboxyl ic acid amide as a yellow solid. MS: 4l9(MH+). HPLC (Method RT 3.28 minutes.

EXAMPLE 37 N-13-(6-4-tert-Bu tvlohenyl)-5H-pyrrolor2.3-b] vrazin-7-yvlropyl n-propy urea, A51-B55, the product of the combination of group A51 in Table I and B55 in Table 2:- A solution of 3 -(6-(4-lert-butylphenyl)-SH-pyrrolo[2,3-b]pyrazin-7-yl)propylamine (0.0324 mmol) [Example 35] in tetrahydrofuran (2 mL) was treated with n-propyl-isocyanate (0.0324 mmol). The solution was stirred at room temperature for 12 hours and then treated with water (3 mL). The resulting precipitate was filtered, then washed with water and then dried under vacuum at 50*C to give the title compound as a beige solid. MS: 394(MI). HPLC (Method RT 3.25 minutes.

b) N-13-(6-(4-tert-butylphenyl)-5H-pvolo[2,3-blnazin-7-vlhropyl bN'-carboethoxymethyI urea, A52-B55, the product of the combination of group A52 in Table I and B55 in Table 2:- By proceeding in a manner similar to Example 37(a) above but using ethyl-isocyanatoacetate, there was prepared N- 1 -(6-(4-rert-butvlphenvl)-5H-pvrrolo[2,3-blpvrazin-7-vl)propyl carboethoxymethyl urea as a yellow solid. MS: 437(MH+). HPLC (Method RT 3.18 minutes.

WO 03/000688 PCT/GB02/02799 -191- C) N-f -methyl-3-( IH-pyrrolor2,3-blpyridin-2-yl)- 1H-indol-5-yllmethyl 1-N '-tetrahydropyran-2ylurea. A2-B1I-C74, the product of the combination of group A2 in Table 1 and B I in Table 2 and C74 in Table 3:- 0o By proceeding in a manner similar to Example 37(a) above but using H-pyrrolo[2,3-b]pyridin-2yl)-lI -methyl-I H-indol-5-yl]-methylamine [Example 52] and tetrahydropyran-2-yl isocyanate there was prepared N-f I -methyl-3-( H-pvyrrolor2.3-blnvridin-2-vfl- I H-indol-5-yll methyl) -N '-tetrahydropyran-2ylurea as a solid, m.p. 229-23 1 'C.

[0 EXAMPLE 38 N-13-(6-(4-tert-Butylohenl)-5H-prrolor23-blhvazin-7-yl~hropvl) -N'.N'-diethyI urea, A53-B55, the product of the combination of group A53 in Table I and B55 in Table 2:- A solution of 3-(6-(4-tert-butylphenyl)-5 H-pyrrolo[2,3-blpyrazin-7-yl)propylamine [0.0324 mmol, Example 35] in tetrahydrofuran (1.5 mL) was treated with diethylcarbamnyl chloride (0.0324 mmol) and triethylamine (0.0788 mmol). The solution was stirred at room temperature for 12 hours and water and ethyl acetate were added. The layers were separated and the organic solution was dried over magnesium sulfate. The drying agent was filtered and the solvent was evaporated. The residue was purified by column chromatography (silica gel, ethyl acetate followed by 10% methanol in ethyl acetate) to give the title comipound as a yellow solid. MS: 408(MH+F). HPLC (Method RT 3.4 minutes.

WO 03/000688 PCT/GB02/02799 -192- EXAMPLE 39 N-f 3-(6-(4-tert-Buvlphenv)-5H-prrolo[23-blhvrain-7-vlhronvl lmethanesulfonamide, A38-B55, the product of the combination of group A38 in Table I and B55 in Table 2:- 1 CN1 A solution of 3-(6-(4-ierz-butylphenyl)-5H-pyrrolo[2,3 -b]pyrazin-7-yl)propylamine [0.0324 mmol, Example 35] in tetrahydrofuran (1.5 mL) was treated with methanesulfonyl chloride (0.0324mmol) and triethylamine (0.0788 mmol). The solution was stirred at room temperature for 12 hours and water and ethyl acetate were added. The layers were separated and the organic solution was dried over magnesium sulfate. The drying agent was filtered and the solvent was evaporated. The residue was purified by column chromatography (silica gel, ethyl acetate followed by 10% methanol in ethyl acetate) to give the title compound as a yellow solid. MS: 387(MH±). HPLC (Method RT 3.23 minutes.

N-(3 -(6-(4-tert-Butvl~henl)-5H-Rrrolor23-bl]pvrazin-7-yl~hropl lth ien-2-vlsulfonamide, A50-B55, the product of the combination of group A50 in Table I and B55 in Table 2:- By proceeding in a manner similar to Example 39(a) above but using thien-2-ylsulfonyl chloride, there was prepared N-(3 -(6-(4-tert-Butvl ohenyl)-SH-pyrrolor2,3-blpyrazin-7-yl)propyl Ithien-2ylsulfonamide as a yellow solid. MS: 455(MH+). I-IPLC (Method RT 3.56 minutes.

N-(3 -(6-(4-ter-t-butylphenvl)-5H-pyrrolor2,3-blpvyrazin-7-yl)oroovl Idimethyl isoxazol-4ylsulfonamide. A54-1355, the product of the combination of group A54 in Table 1 and B55 in Table 2:- WO 03/000688 PCT/GB02/02799 -193- 0 0107 N N

H

By proceeding in a manner similar to Example 39(a) above but using 3,5-dimethylisoxazol-4-ylsulfony] chloride, there was prepared N- 246-(4-tet-buvlphenl)-5H-pyrrolo[2.3-blpyrazin-7vI~hropylldimethylisoxazol-4-ylsulfonamide as a gummy white solid. MS: 468(MH+). HPLC (Method RT =3.55 minutes.

N-f 3-(6-(4-tert-butvlphenyl)-5H-pyrrolo[2,3-blprazin-7-Yl~propylI 1-methyl imidazol-4vlsulfonamide, A56-B55, the product of the combination of group A56 in Table I and B55 in Table 2:- 0~

N

N

N

By proceeding in a manner similar to Example 39(a) above but using Il-methylimidazol-4-ylsulfonyl chloride, there was prepared N- f3-(6-(4-1erI-butvlphenyl)-5H-pyrrolor23-blhvrazin-7-Yl)prooyl I I methylimidazol-4-ylsulfonamide as a gummy white solid. MS: 453(MH+). H-PLC (Method RT 3.13 minutes.

EXAMPLE 2-(5-Methoxy- 1-methyl-i H-indol-3-yl)- 1H-pyrrolor2,3-blpyrid ine-4 carboyl ic acid (2hydroxy- 1.1-dimethyl-ethyl)-amide, A68-B I-Cl, the product of the combination of group A68 in Table I and B I in Table 2 and ClI in Table 3:- WO 031000688 PCT/GB02/02799 -194- HOCH 2 N 0

H

3 C CH 3 N N

N

He A solution of 2-(5-methoxy- 1-methyl-I H-indol-3-yl)- 1H-pyrrolo[2,3 -b]pyridine-4 carboxyl ic acid [32mg, Example 41(a)] in dry dimethylformamide (l0mL), under nitrogen, was treated with di isopropylethylamine (3 5ptL) followed by O-(7-azabenzotriazol-1 -yl)-I ,1,3,3 -tetramethyluron iurn hexafluorophosphate (38mg). After stirring at room temperature for I hour this mixture was treated with a solution of 2-amino-2-methyl- I-propanol (I 0.54L) in dry dimethylformamide (I mL) and stirring was then continued for a further 2 hours. The reaction mixture was evaporated and the residue was treated with saturated aqueous sodium bicarbonate solution (I 5mL). This mixture was stirred for I hour and the resulting yellow solid was filtered, then washed well with water and then dried at I 00 0

C

under vacuum to give the title compound (34mg) as a yellow solid, m.p. 210-2121C.

3-(4-chlora- IH-pyrroloF2.3-blpyridin-2yl)1 -methyl-I H-indole-5-carboxyl ic acid (2-hydroxy- 1, 1-dimethyl-ethfl)-amide. A28-B I-C3 1, the product of the combination of group A28 in Table I and B I in Table 2 and C3 I in Table 3:- 0 %CH 2

OK

C1~ H'C CH N N H me By proceeding in a manner similar to Example 40(a) above but using a mixture of 3-(4-chloro-] Hpyrrolo[2,3-b]pyridin-2-yl)-l -methyl-I H-indole-5-carboxylic acid and 3 -(4-chloro- I H-pyrrolo[2,3b]pyridin-2-yl)- 1-methyl- I H-indole-5-carboxyl ic acid, methyl ester [Example 41 and subjecting the crude reaction product to chromatography on silica, eluting initially with a mixture of ethyl acetate and heptane (85:15, v/v) then ramping up to ethyl acetate, there was prepared 3-(4-chloro- I H-pyrrobo[2.3bi pyridin-2-yl)- 1-methyl-I H-indole-5-carboxylic acid (2-hydroxy- 1. -dimethyl-ethyl)-amide as a reddish grey solid. MS: 397, 399(M+). RT =4.038 minutes.

r2-(5-methi-l I-methyl-I H-indol-3-yl)- IH-pyrrolor2,3-blpyridin-4-yl1-mopholmn-4-ymethaoe A 12-B I-CI1, the product of the combination of group A 12 in Table l and B]I in Table 2 and C I in Table 3: WO 03/000688 PTG0129 PCT/GB02/02799 -195- By proceeding in a manner similar to Example 40(a) above but using morpholine to replace the 2-amino-2-methyl- I -propanol there was prepared r2-(5-methoxy- -methyl-I H-indol-3-yi)- I Hpvrrolor2,3-blpyridin-4-yll-morpholin-4-yl-methanone as a solid, m.p. 259-260'C. MS: 39I(MH+).

3-f 6-(4-hydroxyphenyl)-5H-qyrrolor2,3-blpyrazin-7-yll-N-rnethylpropionamide. A33-B78, the product of the combination of group A33 in Table I and B78 in Table 2:- By proceeding in a manner similar to Example 40(a) above but using 3-[6-(4-hydroxyphenyl)-5Hpyrrolo[2,3-b]pyrazin-7-yl]-propionic acid (Example 30) and N-methylamine there was prepared 3-[6- H-pvrroloF2.3-blpyrazin-7-vll-N-methyloropionamide as a solid. MS: 297(MH+).

I -thyl-5-metihoxy- IH-indol-3-yll- I H-pyrrolor2,3 blpyridine-4-carboxyl ic acid (2-hydroxy- I.I-dimethvl-ethyl)-amide, A68-B3-C I, the product of the combination of group A68 in Table I and B3 in Table 2 and ClI in Table 3:-

H

By proceeding in a manner similar to Example 40 above but using 3y1)- IH-pyrrolo[2,3 ,-b]pyrid ine-4-carboxyl ic acid [Example 41 there was prepared 2-(I methoxy- 1 H-indol-3-yi)- I H-pyrrolo 2.3 blpyridine-4-carboxylic acid (2-hydroxv- 1. 1 -dimethyl-ethyl)amide as a green solid, m.p. 244-245'C. MS: 407(MH+).

WO 03/000688 PCT/GB02/02799 -196- 2-(5-methoxy- I -methyl- I H-indol-3-yI')- I H-ovrrolof2.3 blpyridine-4-carboxylic acid (2methoxy-ethyl) am ide, A69-B I-C 1, the product of the combination of group A69 in Table I and B]I in Table 2 and C I in Table Ome I N 5 By proceeding in a manner similar to Example 40 above but using 2-(5-methoxy- I-methyl- IHindol-3yl)- 1 H-pyrrolo[2,3,-b] pyridine-4-carboxylic acid [Example 41 and 2-methoxy-ethylamine there was prepared 2-(S-m ethoxv- I1-m ethyl- I H--indol-3 I H-pyrro lo[2.3 bl pyridine-4-carboxvlI ic acid (2-methoxv-ethvl) amide as a yellow solid, m.p. 248-249"C. MS: 379(MH+).

2-(5-methoxv- 1-methyl-i H-indol-3-yl)- IH-nvrrolor2.3.-blp~vridine-4-carboxyl ic acid (2-hydroxy-2-methvl-propvl) amide, A70-B 1-Cl, the product of the combination of group in Table I and BI in Table 2 and Cl in Table 3:- OMe By proceeding in a manner similar to Example 40 above but using 2-(5-methoxy-1-methyl-lHindol-3y1)- I H-pyrroJL[2,3,-bipyridine-4-carboxylic acid [Example 41 and 1 -amino-2-methylpropan-2-ol (prepared according to the literature procedure of Cabella et. al. Tetrahedron, 1995, 51 18-17-1 826), there was prepared 2-(5-methoxy-l -methyl-I H-indol-3-vl)- I H-twrrolo['23 ,-bpyridine-4carboxylic acid (2-hydroxy-2-methyl-propyl) amide as a solid. LC-MS: METHOD D: RT =2.54 .minutes, 393 .3 WO 03/000688 PCT/GB02/02799 -197- (11) 2-(5-methoxy- 1-methyl-i H-indol-3-yl)- IH-pvyrroloF2,3 blDvridine-4-carboxvl ic acid (2hydroxy-propyl) amide A85-B 1-Cl, the product of the combination of group A85 in Table I and BI in Table 2 and Cl in Table 3:- H 9m By proceeding in a manner similar to Example 40 above but using 2-{5-methoxy-l -methyl-I Hindol-3y1)- I H-pyrrolo[2,3 ,-bjpyridine-4-carboxylic acid [Example 41 and I -amino-propan-2-ol there was prepared 2-(5-methoxy- I1-methyl- I H-indol-3-yl)- I H-pyrroloU2,3 blrwridine-4-carboxylic acid (2-hydroxcy-propyl) amide as a solid. LC-MS: METHOD D: RT 2.74 minutes, 379(MH+).

2-(5-metho c-1-methyl-IH-indol-3-yi -1H-pyrrolor2,3 -blpridine-4-carboxylic acid (2-hydroxy)t-ih'l) amide A86-B I-C1I, the product of the combination of group A86 in Table I and BI in Table 2 and CI in Table 3:- By proceeding in a manner similar to Example 40 above but using 2-(5-methoxy- 1 -methyl- I Hindol-3yl)- I H-pyrrolo[2,3 ,-b]pyrid ine-4-carboxylic acid [Example 41 and 2-amino-ethanol there was prepared 2-(5-methoxy- 1-methyl-I H-indol-3 1I-pyrrolof23,-blpyridine-4-carboxylic acid (2-hydroxy-ethyl) amide as a solid. LC-MS: MIETHOD D: RT =2.22 minutes, 365(MH+).

WO 03/000688 PCT/GB02/02799 -198- 2-(5-methoxy -1 H-indol-3-yl)- I H-pyrrolof2.3.-blpvridine-4-carboxylic acid (2-methoxy-ethfl) amide A69-B2-C1, the product of the combination of group A69 in Table I and B2 in Table 2 and C I in Table 3:ome 0 NIH NIN N

HH

By proceeding in a manner similar to Example 40 above but using 2-(5-methoxy-IH-indol-3y1)-IHpyrrolo[2,3,-b]pyridine-4-carboxylic acid [Example and 2-methoxy-ethylamine there was prepared 2-(5-methoxy- I H-indol-3-yi)- 1 H-pyrrolo[2.3,-bl pyridine-4-carboxvl ic acid (2-methoxy-ethyl) amide as a solid. LC-MS (METHOD RT =3.65 minutes, 365(MH'D.

EXAMPLE 41 2-(5-Methoxv- 1-methyl-I H-indol-3-vl)- I H-pyrrolo[2,3-blpyridine-4 carboxylic acid, A67-B 1-Cl, the product of the combination of group A67 in Table I and BI in Table 2 and Cl in Table 3:ome HO 0 QC4U H Me A solution of 2-(5-methoxy- I-methyl-i H-indol-3-yI)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine- 4 carboxylic acid, terl-butyl ester [1 06mg, Reference Example in methanol (IlOmL) was treated with potassium hydroxide solution (IlmL, 5N) then heated at reflux temperature for I hour and then evaporated. The residue was treated with water (Il5mL) and the mixture washed with ethyl acetate (IlOmL). The pH of the aqueous solution was then adjusted to 4 by addition of hydrochloric acid and cooled in ice. The resulting yellow solid was filtered washed well with water and then dried at 80 0

C

under vacuum to give the title compound (33mg) as a yellow solid, m.p. >300 0 C. MS: 322(Ml-l).

3-(4-chloro- I H-pyrrolor2,3-bloyridin-2-yl)- 1 -methyl- I H--indole-5-carboxylic acid.

A28-B1I-C28, the product of the combination of group A28 in Table I and B I in Table 2 and C28 in Table 3; and 3-(4-chloro-I H-pyrrolor2,3-blpyridin-2-yl)-1-methyl- carboxvlic acid. methyl ester:- WO 03/000688 PCT/CB02/02799 -199- 0 2C and N Me H me By proceeding in a manner similar to Example 41 1(a) above but using 3 -(4-chloro-I-(toluene-4sulfonyl)- I-methyl-I H-pyrrolo[2,3-b~pyridin-2-yl)- IH-indole-S-carboxylic acid, methyl ester [Reference Example 19(d)] there was prepared a 60:40 mixture of 3-(4-chloro-1H-pyrro lo[2,3blpyridin-2-ylV 1-methyl-I H-indole-5-carboxylic acid and 3-(4-chloro- IH-pyrrolor2,3-blpyrid in-2-yl)- 1-methyl-l1--indole-5-carboxylic acid, methyl ester as an off-white solid. MS: 326 and 340(M+).

I-ethyl-5-methoxy- IH-indol-3yl)-I H-Dvrrolo[2.3 blpyridine-4-carbovl ic acid. A67-B3-C 1, the product of the combination of group A67 in Table I and B3 in Table 2 and C I in Table 3:- 0Me 0 OH >1N By proceeding in a manner similar to Example 41 above but using 2-(1 -ethyl- 5-meth oxy- IH-indol- 3y1)-l -(ioluene-4-sulfonyl)- IH-pyrrolo[2,3 ,-b]pyridine-4-carboxylic acid tert-butyl ester [Reference Example there was prepared 241 -ethyl-5-mnethoxy- I H-indol-3y')- I H-pyrrolo[2j3 -blpvridine-4carboxylic acid as a tan solid. MS: 336(MH+). TLC: RF =0.24 (ethyl acetate/heptane, 1: 1).

EXAMPLE 42 IH-indol-3-yl)- IH-pyrrolor2.3-blnyridine-4 carboxamide Al 0-B2-C I, the product of the combination of group AIO in Table 1 and B2 in Table 2 and Cl in Table 3:- Me 11,1 0 N N N

HH

A suspension of 2-(5-methoxy- IH-indol-3-yl)- I-(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b~pyridine-4 carbonitrile [0.25g, Reference Example 67(e)] in methanol (25mL) was treated with sodium hydroxide solution (1 .5g in 4mL water). The mixture was cooled in an ice-bath and then treated dropwise with hydrogen peroxide (0.35mL, After stirring at room temperature for I hour a further aliquot of hydrogen peroxide (0.3mL) was added to the reaction mixture and stirring was continued for a further 3 hours then the reaction was quenched by addition of sodium metabisulfite to remove excess hydrogen WO 03/000688 PCT/GB02/02799 -200- C1 peroxide. The reaction mixture was then diluted with water (75mL) and extracted twice with ethyl acetate (50mL). The combined extracts were washed twice with brine (3OmL), then dried over sodium sulfate and then evaporated. The residual yellow solid was subjected to chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane v/v) to give, after trituration with Smethanol and washing with diethyl ether, the title compound (50mg) as a yellow solid, m.p. >320*C.

MS: 307(MiH+).

EXAMPLE 43 3 46-(4-Morpholin4-yl phenvfll-H-pyrroloI23-bl~vrazin-7Vll-N-methylpropioflamide A33-1359, the product of the combination of group A33 in Table I and B59 in Table 2:- 0

NHCH,

H

A mixture of 3-[6-(4-trifluoromethanesuifonyloxyphelyl)-51-pyrTolo[2,3-b]pyrazil-7-y1]-Nmethylpropionamide [30mg, Reference Example acetonitrile (2mL) and morpholine was heated at 200'C in a microwave oven for 4 hours. The reaction mixture was then evaporated and the residue was triturated with ethyl acetate to give the title compound as a solid. MS: 429. l(M1.H+).

EXAMPLE 44 6-(4-Pvrrol idin-1I-yi phenyl)-5H-pyrrolor2,3-bl ovrazine. Al -B82, the product of the combination of group AlI in Table I and B82 in Table 2:-

N

H

A mixture of 6-(4-trifluoromethanesulfonyloxyphenyl)-5H-pyrrolo[2,3 -b]pyrazine [20mg, Reference Example dioxane (3mL) and pyrrolidine (0.2rnL) was heated at 200'C in a microwave oven for I hour. The reaction mixture was then evaporated and the residue was subjected to chromatography on silica eluting with a mixture of ethyl acetate and heptane v/v) to give, after trituration with a, mixture of ethyl acetate and methanol, the title compound (11mg) as a yellow solid. MS: 265.1(MI-l).

RT 2.92 minutes.

WO 03/000688 PCT/GB02/02799 1- EXAMPLE 6-(4-(Furan-2::yl)phenyY-5-Prolof2,3-blpyrazifle, AlI-B] 100, the product of the combination of group AlI in Table I and B 100 in Table 2:- N4 0

H

A mixture of 6-(4-trifluoromethanesulfonyloxyphenyl)-SH-pyrrolo[ 2 3 -b]pyrazine (20mg, Reference Example I dioxane (2.SmL), furan-2-boronic acid (9.8mg), sodium carbonate solution (0.O6mL, 2N), and tetrakis(triphenylphosphine)palladium[O] (4mg) was heated at I 80*C in a microwav'e oven for 40 minutes. The reaction mixture was then evaporated and the residue was subjected to chromatography on silica eluting with a mixture of ethyl acetate and pentane 1, v/v) to give, after trituration with a mixture of ethyl acetate and methanol, the title compound (7mg) as a yellow solid.

MS: 262.l1(MP+1). RT 3.05 minutes.

6-(-.,-iehlsxzl4V)hnl-Hproo23bprzn Al -B99, the product of the combination of group A] in Table I and B99 in Table 2:me H me By proceeding in a manner similar to Example 45 above but using 3,5-dimethyisoxazole-4-boronic acid, arnd subjecting the reaction product to chromatography on silica eluting with ethyl acetate, there was prepared 6-4(.-iehlsxzl4y~phnl-Bpoo23bprzn as beige solid. MS: 279(MI-l). RT =3.19 minutes.

EXAMPLE 46 2-[4-(5H-Pyrrolo[2.3.-blp~yrazifl-6-l~henyll-propa- 2 -ol. Al -B56, the product of the combination of group AlI in Table I and B56 in Table 2:- N CH3

H-H

A suspension of magnesium (2mg) in tetrahydrofuran (2mL) was treated with methyl iodide (0.O6mL) and when the all magnesium had reacted this solution was treated with a solution of I pyrrolof2,3-b]pyrazin-6-yl)phenyl] ethanone (I10mg, Example 47) in tetrahydrofuran. After stirring at WO 03/000688 PCT/GB02/02799 -202room temperature overnight the mixture was treated with methyl magnesium chloride (0.04ml of 2N solution in tetrahydrofuran) and after stirring for a further 2 hours TLC (ethyl acetate) indicated complete reaction. The reaction mixture was then poured into saturated ammonium chloride solution and this mixture was then extracted with ethyl acetate. The extract was evaporated and the residual solid (14mg) was subjected to thin layer chromatography on alumina eluting with a mixture of ethyl acetate and methanol (95:5, v/v) to give the title compound as a beige solid. MS: 254(MH 4 RT minutes.

EXAMPLE 47 1-r4-(5H-Pvrrolo[2.3-blpvrazin-6-vl)phenvyl ethanone, A1-B99, the product of the combination of group Al in Table 1 and B99 in Table 2:-

CCH

H

6 4 -trifluoromethanesulfonyloxyphenyl)-5H-pyrrolo[2,3-b]pyrazine [100mg, Reference Examnple 18(e)] was added to dry, degassed dimethylformamide (3mL), under nitrogen, followed by triethylamine (0.081mL), n-butylvinyl ether (0.49mL) 1,3-bis(diphenylphosphino)butane (34mg) and palladium acetate (17mg). The mixture was heated at 80 0 C for 12 hours, then cooled to room temperature, then treated with hydrochloric acid (7mL, IN), then stirred at room temperature for 1 houi, and then subjected to chromatography on silica eluting with a mixture of ethyl acetate and heptane v/v) to give the title compound (26mg) as a pale yellow solid. MS: 328.1(MH+). RT= 2.59 minutes.

EXAMPLE 48 6-[4-(4-{2-Morpholin-4-vlethvl I -piperazin- -vl)phenvll-5H-pvrrolo[23-blpvrazine. A1-B84, the product of the combination of group Al in Table I and B84 in Table 2:- N N 0 A mixture of 6-(4-piperazin-l-ylphenyl)-5H-pyrrolo[2,3-b]pyrazine (Example 49) and water (5mL) was treated with potassium hydroxide (71mg) and after complete solution this mixture was then treated with morpholinoethyl chloride (59mg) and the resulting slurry was stirred at room temperature overnight. The reaction mixture was treated with water (100mL). and then extracted three times with WO 03/000688 PCT/GB02/02799 -203- 0 Sethyl acetate (100mL). The combined extracts were washed with brine and then evaporated. The Sresidual orange solid was treated with ethyl acetate and methanol and this solution was then acidified ;by addition of hydrochloric acid (2N) in methanol and then concentrated on a steam bath to give after r treatment with ethyl acetate and dichloromethane the title compound (55mg) as an orange solid. LC- MS: Method A:RT 2.09 minutes, 393(MH+).

SEXAMPLE 49 S6-(4-Piperazin-l-vlphenvl)-5H-pyrrolo[2,3-blpyrazine, A1-B83, the product of the combination of group Al in Table 1 and B83 in Table 2:-

HN

A solution of 4-[4-(5H-pyrrolo[2,3,-b]pyrazin-6-yl)phenyl]piperazine-l-carboxylic acid, tert-butyl ester [100mg, Reference Example in anhydrous methanolic hydrogen chloride (15mL, 2N) was heated at 60 0 C for 18 hours then evaporated. The residue was suspended in dichloromethane (20mL) then treated with Argonaut Technologies MP carbonate resin, then stirred at room temperature for 4 hours.

After 1 hour the mixture was treated with methanol (2mL) to aid in solution of the hydrochloride salt.

The solid was washed twice with a mixture of dichloromethane and methanol (22mL, 10:1, The filtrate was evaporated and the residue was subjected to chromatography on silica gel eluting with a mixture of chloroform, methanol and ammonium hydroxide v/v/v) to give the title compound (25mg) as an off-white solid. LC-MS: Method A: RT 2.11 minutes, 280.1(MH+).

EXAMPLE 2-Methvl-4-[6-(4-tert-Butvl-phenvl)-5H-pyrrolor2.3-blpyrazin-7-vll-butan-2-ol, A59-B55, the product of the combination of group A59 in Table 1 and B55 in Table 2:-

OH

H

A solution of 4 6 -(4-tert-butyl-phenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-butan-2-one (10g, Example 51) in tetrahydrofuran (2.3mL), then diluted with ether (25mL), then cooled to 0°C and then treated with a solution of methyl magnesium bromide in diethyl ether (1 OmL, 3M). The mixture was allowed to warm to room temperature, then after 3 hours cooled to 0°C, then treated with a further aliquot of a WO 03/000688 PCT/GB02/02799 S-204- 0 solution of methyl magnesium bromide in diethyl ether (0.3mL, 3M), then allowed to warm to room Stemperature and then kept at room temperature overnight. The reaction mixture was then poured into hydrochloric acid (IN) and this mixture was made basic by addition of sodium hydroxide solution N (10N) and then extracted with ethyl acetate. The combined extracts were washed with water, then dried over sodium sulfate and then evaporated. The residue was subjected to chromatography on silica j eluting with ethyl acetate to give the title compound (0.5g) as an off white solid. MS: 338(MH+).

EXAMPLE 51 S4-r6-(4-tert-Butvl-phenyl)-5H-vrrolof2.3-blpvrazin-7-yl-butan-2-one, A58-B55, the product of the 0 10 combination of group A58 in Table I and B55 in Table 2:- K

H

A solution.pf.methyl acetoacetate (1.35mL) in N-methylpyrrolidone (15mL), cooled to 0oC, was treated portionwise with sodium hydride (0.33g, 60% dispersion in mineral oil) and after stirring at 0 C for 30 minutes this mixture was then treated with a solution of 6 -(4-tert-butylphenyl-5H-pyrrolo[2,3b]pyrazin-7-yl]methyltrimethylammonium iodide [2g, Reference Example 45(a)] in N-methylpyrrolidone (100mL). After stirring at room temperature overnight the reaction mixture was subjected to chromatography on silica eluting with a mixture of heptane and ethyl acetate. The resulting 2 -acetyl-[ 6 -(4-tert-butyl-phenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propionic acid, methyl ester C (1.2g) was dissolved in a mixture of sodium hydroxide (250mL, 2N), methanol (25mL) and tetrahydrofuran. This solution was then heated at 50 0 C for 1 hour, then evaporated, then acidified by addition of hydrochloric acid (25mL, 2N) and then extracted with ethyl acetate. The organic extract was dried over sodium sulfate and then evaporated to give the title compound MS: 322(MH+).

EXAMPLE 52 H-Pvrrolo[2.3-blpyridin-2-yl)-1-methyl-lH-indol-5-yll-methylamine, A2-B 1-C71, the product of the combination of group A2 in Table 1 and BI in Table 2 and C71 in Table 3:- WO 03/000688 PCT/GB02/02799 -205-

O

0 A solution of lithium aluminium hydride in tetrahydrofuran (14.04 mL, 1M) was treated with a solution g of 3-[1-(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridin-2-yl]-l-methyl-lH-indole-5-carbonitrile [2g, ,Reference Example 13(c)] in dry tetrahydrofuran (20 mL). The resulting suspension was stirred at room temperature for 5 hours then treated a further aliquot of lithium aluminium hydride in tetrahydrofuran (4.64 mL, IM) and stirring was continued for a further hour. The reaction mixture was cooled to 0°C, then treated with water (1.63 mL), and then filtered. The insoluble material was washed O with ethyl acetate and the combined filtrate and washings were evaporated to give the title compound as an orange solid (1.1 MS: 277(MH+).

EXAMPLE 53 C 2- r5-Methoxy-3-(lH-pyrrolo[2,3-blpyridin-2-vl)-indol--vl-1-(1-methylpiperazin)-4vl -ethanone, A2-B30-CI, the product of the combination of group A2 in Table I and B30 in Table 2 and Cl in Table 3:- MeO NMe A solution of [5-methoxy-3-(l H-pyrrolo[2,3-b]pyridin-2-yl)-indol- -yl]-acetic acid [9.6 mg, Example 13(a)] in dry dimethylformamide (0.31 mL) was combined with 2-(1H-benzotriazole-1-yl)1,1,3,3tetramethyluronium hexafluorophosphate (11.2 mg) in dry dimethylformamide (0.1 mL), then mixed for 1 hour at room temperature and then treated with a solution ofN-methylpiperazine (6mg) and diisopropylethylamine 5.24 pl in dry dimethylformamide (0.116 mL). The reaction mixture was agitated for 20 hours at room temperature. The crude mixture was then subjected to LC-MS triggered purification affording the title compound. LC-MS: METHOD C: RT 2.99 minutes, 404[M+H] By proceeding in a similar manner to Example 53, but replacing N-methylpiperazine with an appropriately substituted amine of formula HNY]y 2 there was prepared EXAMPLE 53(a) to EXAMPLE 53(cg) in Table 4.

TABLE 4 WO 03/000688 PCT/GB02/02799 -206- WO 03/000688 PCT/GB02/02799 -207- WO 03/000688 WO 03/00688PCTIGB02/02799 -208- EXAMPLE 53(q) H 2 N C251-23N502 426 2.6 2-15-Methoxy-3-(IBpyrrolo[2,3-b]pyridin- 2-yi)-indol- I H pyridin-4-yi-ethyl)acelamide EXAMPLE C25H28N402 417 3.57 N-Cyclopropylmethyl- 2-[5-methoxy-3-(J pyrrolo[2,3-b]pyridin- H N propyl-acetaniide EXAMPLE 5 3(s) 0C26H-30N402 431 3.64 N-(1-Cyclohexyl- \K ethyl)-2-[5-methoxy-3- (1 H-pyrrolo[2,3- H my b~pyridin-2-yi)-indoI- N H A y N I-yil-acetamide

H

EXAMPLE 53(t) 0 HC25H23N502 426 2.47 2-15-Methoxy-3-(I Hpyrrolo[2,3-b~pyridin- 2-yl)-indol- I -yl]-Nmethyl-N-pyridin-3- N ylmethyl-acetamide EXAMPLE 5 3(u) -0 C29H29N502 480 3.29 2-[5-Methoxy-3-(] Hpyrrolaj2,3-b)pyridin- 2-yI)-indol- Il-yI]- 1 yi)-ethanone EXAMPLE 53(v) C26H24N4O2S" 457 3.30 2-[5-Metboxy-3-(] H- 2-yi)-indol-1 -yfl-N-(2- H phenylsulfanyi-ethyl)acetarnide EXAMPLE ~\~oC28H27N503 482.2 2.67 2-[5-Methoxy-3-(IHpyrroio[2,3-blpyridinmorphoiin-4-yi- EXAMPLE 53(x) ____pheny])-acetamide WO 03/000688 PCTIGB02/02799 9- WO 03/000688 WO 03/00688PCT/GB02/02799 -210oC23H23N503 418 2.79 4-{2-[5-Methoxy-3- (]H-pyrrolo[2,3- N b~pyridin-2-y])-indol- 0 1-yi]-acet-yl}-l -methyl- H piperazin-2-one 0 EXAMPLE 53(ag) HoC22H22N402S 407 3.22 2-[S-Methoxy-3-(] Hs pyrrolo[2,3-b~pyridin- 2-yl)-indol- l-yl]-1 N lithiomorpholin-4-yi- C S elhanone EXAMPLE 53(ah) C6H4N03 441 3.13 N-(2-Hydroxy-2- C26N2phenyl-ethyl)-2-[5- OH methoxy-3-(1 Hcc N OH pyrrolo[2,3-b~pyridin- OH 2-y1)-indol- l-yl- EXAMPLE 53(ai) -0C24H26N403 419 3.19 ]-(2,6-Dimethy)f- morpholin-4-yl)-2-[5- '11 \,methoxy-3-(

IH-

r4 pyrrolo[2,3-b]pyridin- H IxN2-yi)-indol- I -yl]- YO ethanone EXAMPLE C29H31N502 482 2.88 N-(4- Diethylamninomethyl- N 3-(J H-pyrrolo[2,3- EXAMPLE 53(ak) b]pyridin-2-yi)-indol- -yll-?tcetamide rIrOH C26J-24N403 441 3.08 N.[2-(4-Hydroxy- QQ-~ methoxy-3-( I Hpyrrolo[2,3-b~pyridin- EXAMPLE 53(al) 2-y))-indo1-yi]acetamide C23H24N403 405 3.01 2-[5-Methoxy-3-(IH- HN pyrrolo[2,3-blpyridin- 2 2-y1)-indol-I -yi]-N- N.~(tetrahydro-furan-2ylmethyl)-acetamide EXAMPLE 53(am) C24H21N502 412 2.68 2-[5-Methoxy-3-(] H- I pyrrolo[2,3.b~pyridin- N 2-yI)-indol-1 -yl]-Npyridin-2-ylmethyl- N acetamide

H

EXAMPLE 53(an) WO 03/000688 WO 03/00688PCT/GB02/02799 -211oC23H26N402 391 3.36 N-(1,2-Dimethyl-

H

2 N IH-pyrrolo[2,3- N-I 1-yi]-acetamide EXAMPLE 53(ao) C30H-25N503 504 3.25 N-(3-Benzyloxypyridin-2-yi)-2-{5o 0 methoxy-3-(IH- N N .1Jpyrrolo[2,3-b]pyridin- H 2N No2-yl)-indol-1 -yl)- EXAMPLE 53(ap) C27H-21N502 448 3.05 2-15-Metboxy-3-(IH- H21w pyrrolo[2,3-b~pyridin- 2-yI)-indol- 1-yI]-N- CNH quinolin-3-yI- H acetamide EXAMPLE 027H21N502 448 3.49 2-[5-Methoxy-3-(] H- In pyrrolo[2,3-b]pyridin- 2 2-yi)-indol- I -yl]-Nacetamide

N

EXAMPLE oNN, C271-2]N502 448 2.76 N-Isoquinolin-5-y)-2- I [5-methoxy-3-(] Hi- IISN H 2 Npyrrolo[2,3-b~pyridin- 2-yl)-indol- I -yI)- N acetamide EXAMPLE 53(as C23H26N402 391 3.42 2-[5-Methoxy-3-(I H- 3 2 M pyrrolo[2,3-b]pyridin- N. 2-yl)-indol- 1 -yi3-N-(3- H methyl-butyl)acetamide EXAMPLE -0C27H21N502 448 2.97 N-Isoquinolin-1-yi-2- [5-rnethoxy-3-(1 H- H2 pyrrolo[2,3-blpyridin- H acetamide EXAMPLE 53(au) SC271H2IN502 448 3.29 2-[5-Methoxy-3-(] H- )L~iIpyrrolo[2,3-b]pyridin- N. H2N 2-yi)-indol-1I-yl]-N- H j~J7 quinolin-2-yl- H acetamide EXAMPLE C23H22N402 387 3.28 ]-(3,6-Dihydro-2Hl)773, pyridin-1-yl)-2-[5- [2M+HI+ metboxy-3-(1 H- P\ pyrrolo[2,3-b)pyridin- NH l 2-yI)-indol- I-yi]- (~jJ ethanane EXAMPLE 53(aw) WO 03/000688 PCT/GB02/02799 -212- WO 03/000688 WO 03/00688PCT/GBO2/02799 -213olHN C30H3]N502 494 2.94 2-[5-Methoxy-3-(] Hpyrrolo[2,3-b]pyridin- 2-yl)-indol- 1-y)I--4- N 0 (1 -phenyl-ethyl)piperaz in. I -y 6 ethanone EXAMPLE 53(bf) FNC28H34N603 503 2.61 2-15-Methoxy-3-(1-- N pyrrolo[2,3-b]pyridin- I 0 2-yi)-indoI- I -yl]-l -14- H (2-morpholin-4-yJethyl)-piperazin-1 -yI]- 00 ethanone EXAMPLE 53(bg) o 0r C29H29N503 496 3.16 1-14-(4-Methoxyphenyl)-piperazin- I1a yI]-2-[5-methoxy-3- W, (IH-pytrok$12,3b]pyridin-2-yl)-indol- )a oI 1-yi]-ethanone EXAMPLE 53(bh) 2N C25H27N503 446 3.26 2-[5-Methoxy-3-(] H-.

pyrrol o[2,3 -b]pyri din- ~2-yi)-indol- I 1. N 0~f (2-oxo-pyrrolidin- 1- NH N yl)-propyl)-acetamide EXAMPLE 53(bi) oC23H24N402 389 3.26 2-15-Methoxy-3-(l Hpyrrolo[2,3-blpyridin- 11"o2-yl)-indol- I-yI]-ipiperidin- 1-yI- H ethanone EXAMPLE 53(bj) C25H29N502 432 2.71 2-[5-Methoxy-3-(1 Ipyrrolo[2,3-b]pyridin- I. ''2-yi)-indol- I -y]N-2 H '3J&.~f')piperidin- I -yl-ethyl)- '3 acetamide EXAMPLE pC241-27N502 418 2.66 2-15-Methoxy-3-(I H- 0 2-yi)-indol- I '3 N~J~ pyrrolidin- l-yI-ethyl)acetamide EXAMPLE C25H29N503 448 2.68 I-[4-(2-Methoxy- N~ ethyl)-piperazin- I -yIj- NN- V- 2-[5-methoxy-3-(] 'H pyrrolo[2,3-b]pyridin- 2-yi)-indol- i-yi]o _______ethanione WO 03/000688 PCT/GB02/02799 -214- WO 03/000688 WO 03/00688PCT/GB02/02799 -215- 0 1C26H3 1N504 478 2.65 1-(4-[2-(2--ydroxyel 0'eihoxy)-ethyl]- L N piperazin- I methoxy-3-(] H- H I 0pyrrolo[2,3-b]pyridinethanone EXAMPLE 53(bt) C24H28N403 421 3.19 N-(]-Hydroxymethyl- 2 -m ethyl -butyl)-2- [5 L methoxy-3-(] Hpyrrolo[2,3-b)pyridin- N 2 HY 2-yl)-indol-1 -yl]- OH OH acetamide EXAMPLE 53(bu) -0 C26H24N402 425 3.52 I I methoxy-3.{1 pyrrolo[2,3 pyri din- U 2-yl)-indol-1 -y1]-N- H r"1~Imethyl-acetamide EXAMPLE 53(bv) -0C22H24N403 393 3.05 N-(2-Methoxy-1-

H

2 N 0 Nmethyl-ethyl)-2-[5methoxy-3-(] Hpyrroloj2,3-b]pyridin- N 2-yl)-indol-1 -yI]- EXAMPLE 53(bw) acetamide 0 H 2 N O C211-22N403 379, 2.79 N-(3-1-iydroxy-propyl)- OH757, 2-[5-metboxy-3-(l Hpyrrolo[2,3-b]pyridin- 2-yl)-indol- l-yl]- CN H H 1 acetanmide EXAMPLE 53(bx C25H22N403 427 3.45 N-(3-Methoxypheny'l)-2-[S-methoxya~I~2$3-(1 H-pyrrolo[2,3- N I -yl]-acetamide EXAMPLE C35H33N502 556 3.25 1-(4-Benziiydryl- ~piperazin- I N methoxy-3-(] H_ H 'kA I pyrrolol2,3-b)pyridin- 2-yI)-indol-1-yIIethanone EXAMPLE WO 03/000688 PCT/GB02/02799 -216- WO 03/000688 PCT/GB02/02799 -2 17no C28H28N403S 501 3.40 N-(2-Benzylsulfanyl- I- H' hydroxymethyl -ethyl)- BO 2-[5-methoxy-3-(l H- S pyrrolo[2,3-b~pyridin- I 2-yl)-indol- 1-yllacetamide EXAMPLE 53(cg) EXAMPLE 54 f2-(l H-Pyvrrolo[2,3-blhyridin-2-])-pyroJ-1 -vl-acetic acid. A2-BI 116, the product of the combination of group A2 in Table I and BI 116 in Table 2:-

HO

NN

H

A suspension of I-(toluene-4-sulfoniyl)-1I--pyrrolo[2,3-bjpyridin-2-yl)-pyrrol- 1-yl]-acetic acid, tertbutyl ester [400 mng, Reference Example 76] in methanolic potassium hydroxide solution (15.4 mL, 100 mgfmL) was agitated for 19 hours at room temperature then treated with dichloromethane (15 mL).

This mixture was titrated with aqueous hydrochloric acid (IN to adjsut the pH- to 2, then decanted.

The organic phase was separated and the aqueous phase was extracted with dichloromethane (10 mL).

The combined organic phases were washed with water (15 mL) and then evaporated yielding the title compound (137 mg). LC-MS: METHOD C: RT 2.20 minutes, 242.1 [M+Hj+ and 198.1 (decarboxylated fragment).

EXAMPLE 2-4 F2-( IH-Pyrroiof2,3-blpyridin-2-yl)- pyrrol-1 -yii- 1-cyclopropylamin&1 -ethanone.

P

HN

0

N

(I N>

H

A mixture of IH-pyrrolo[2,3-b]pyridil-2-y)-pyITol-l -yI]-acetic acid [10 mg, Example 54] and 1 H-benzotriazole- I -yl) 1, 1,3 ,3-tetramethyluronium hexafluorophosphate (15.7 mg) in dry WO 03/000688 PCT/GB02/02799 -218dimethylformamide (0.2 mL) was agitated for 1 hour then treated with cyclopropylamine (5.68 pL) and diisopropylethylamine (7.16 uL) in dry dimethylformamide (0.226 mL). After agitating for a further hours the crude mixture was subjected to LC-MS triggered purification affording the title compound. LC-MS: METHOD C: RT 2.44 minutes, 281 [M+H] and 224(fragment corresponding to the breaking of the amide bond).

By proceeding in a similar manner to Example CCR4, but replacing cyclopropylamine with an appropriately substituted amine of formula HNY 1 y 2 there was prepared EXAMPLE 55(a) to EXAMPLE 55(q) in Table 5. In the LC-MS of EXAMPLE 55(a) to EXAMPLE 55(q) the major ion was 224(fragment corresponding to the breaking of the amide bond).

Table WO 03/000688

F.XAMPL,

PCT/GB02/02799 -219- WO 03/000688 PCT/GB02/02799 -220- 0C2 )I 28N60 381 2.1 8 N-[3-(4-Methylpiperazin- l-yl)propyl]-2-[2-(] H- QQ-O pyrrolo[2,3-b]pyrid H 2-yl)-pyrrol- ]-yl- EXAMPLE 55(m) acetamide 0C22H30N60 395 2.12 N Dirnethylamino- H propyl)-piperazin-J yIV-242-( 1 H- EXAMLE 5(n)pyrrolo[2,3-bjpyrid EXAMLE 5(n)2-yl)-pyrro]l-ylJ- ______ethanone 0 C18H21N50 324 2.15 1-(4-Methyl-pipera: N- I -yI)- 2 2 H4pyrrolol2,3-b]pyrid 2-y1)Tpyrrol-) -y1]- N ethanone EXAMPLE 0 OH C24H23C1N402 435 3.19 I-[4-(4-Chlorophenyl)-4-hydroxypiperidin- I -yl]-2-[2 C2(I J--pyrrolof2,3- N H ci bjpyridlin-2-yl)-pyri EXAMPLE 55(p) I -yl]-elhanone 0u OHO C23H423N502 402 2.74 l-[4-(3-Hydroxyphenyl)-piperazin- I

H-

H pyrrolo[2,3-blpyrid EXAMPLE2-yl).-pyrroi- I -yIlethanone EXAMPLE 56 3-[5-Methoxv-2-( H-pvrrolo[2,3-blrpvridin-2-yi)-]I-(toluene-4-sulfonyl)-indoi-I -yil-oropionic acid.

ON

A mixture of 3-f5-methoxy-2-( IH-pyrroio[2,3-bjpyridin-2-yJ1)- I-(toluene-4-suifonyl)-indol- l-yl]propionic acid, methyl ester [1100 mg Reference example 77] and potassium hydroxide 13 52 mg] in methanol (3.5 mL) was agitated at room temperature for 21.5 hours. The reaction mixture was then evaporated and the residue was-resuspended in dichloromethane (10 mL) to which water (5 mL) was added. This mixture was titrated until pH=2 with IN aqueous hydrochloric acid. The resulting precipitate was filtered yielding the title compound (46 mg) as a cream solid. LC-MS: METHOD C: WO 03/000688 PCT/GB02/02799 -22 1- RT 2.76 minutes, 336.14 and 224 (fragment of major intensity corresponding to the breaking of the amide bond.

EXAMPLE 57 3-f 5-Methoxcy-2-( IH-pyrrolor2.3-bl pyrid in-2-yl)-indoj- I-vll- I-mornholin-4-vl-propai-1-one 0 0 A mixture of 3-[5-methoxy-2-( I H-pyrrolo[2,3-b]pyrid in-2-yl)- I -(toluene-4-sulfonyl)-indol-I -yl]propionic acid [10 m g, Example 563 and I1--benzotriazole-1 -yl)l ,1,3 ,3-tetramethyluronium hexafluorophosphate (1 1.2 mg) in dry dimethylformamide (0.41 mL) was agitated for 45 minutes then treated with a solution of morpholine (5.23 VL) and diisopropylethylamine (5.24 p1L) in dry dimethylformamide (0.126 mL). The reaction mixture was agitated for a further 15 hours then subjected to LC-MS triggered purification affording the title compound. LC-MS: METHOD C: RT 2.78 minutes, 405 .2iM4+H]+.

By proceeding in a similar manner to Example 57, but replacing morpholine with an appropriately substituted amine of formula H-NY 1 y 2 there was prepared EXAMPLE 57(a) to EXAMPLE 57(f) in Table 6.

Table 6 STRUCTURE

LC-MS:

and H~l2 Molecular METHOD C Nmnltr Example number Formula [M+HiI+ RT -Nmnltr (minutes) 6 2052N02 412 31 3-[5-Methoxy-2-(1 K Q ,.~.421-2N0 112 31 pyrrolo[2,3-blpyrid in- H (~.jI2-yl)-indol-1I-yl]-N- 0 phenyl-propionamide EXAMPLE 57(a) 0' 1110* C23H24N402S 421.2 3.07 3-[5-Methoxy-2-(I H- N pyrrolof2,3-b~pyridin- H 2-yi)-indol-1-yll-1 thiomorpholin-4-yl- 0 ~propan- I1-one EXAMPLE 57(b) WO 03/000688 WO 03100688PCT/GB02/02799 -222- H C241-27N502 418.2 2.42 3-15-Methoxy-2-(]-- N 2-yl)-indol- I 1 m ethyl-p iperazin- I -yl)- 0 propan- I1-one EXAMPLE 57(c) N NH 2 C24H26N403 419 3.13 3-[5-Methoxy-2-(I H- N N pyrrolo[2,3-b]pyridin- 0 2-yl)-indol- 1-yI]-N- 0 (tetrahydro-furan-2- 0 N9ylmethyl)- H propionamide EXAMPLE 57(d) 0 1 HN-\ C27H426N403 455 3.13 N-(2-Hydroxy-2- H HO methoxy-2-(] Hpyrrolo[2,3-b]pyridin- 0 2-yI)-indol--Ij- IiJN~Jpropionamide

HO

EXAMPLE 57(e) 0-on C21H22N403 379 2.67 N-(2-Hydraxy-ethyl)-3- KN~ H2 N Jr757 [5-methaxy-2-(1H- SH 2 pyrrolo[2,3-b]pyridin-2yl)-indol-1 -yI]- N jOH propionamide

H

EXAMPLE 57(f) EXAMPLE 58 I -f 4-(4-Chloro-Rheny))-4-hydroxy-piperidin-1I-yll-2- 15-methoxv-2-( 11--pyrrolor2,3-blovyridin-2-vI)indol-1I-yil-ethanone A solution of 3-15-methoxy-2-( I I-pyrrolo[2,3-b~pyridin-2-yl)-1 -(toluene-4-sulfonyl)-indol- I-yl]-acetic acid, tert-butyl ester [22.6 mg, Reference Example 78) in methanolic, potassium hydroxide solution (742 pL, 100 mg/mL was agitated for 15 hours at room temperature and then evaporated. The residue was suspended in dichloromethane (I mL) and treated with water followed by aqueous hydrochloric acid (IN) until the pH of the solution was 1. The Organic phase was decanted, then dried over magnesium sulfate and then evaporated. The residue was suspended in dry dimethylformamide (1.27 mL) and this mixture was treated with 2-(1l-l-benzotriazole-l -yl)I,I,3,3-tetramethyIUronium hexafluorophosphate (32 mg). After agitating for I hour the mixture was treated with 4-(4-chorophenyl)-4-hydroxypiperidine (35.6 mg) and diisopropylethylamn e (14.7 pL), then agitated WO 03/000688 PCT/GB02/02799 -223for a further 15 hours and then evaporated using a centrifuge evaporator. The residue was suspended in dimethylsulfoxide (3 mL) and subjected to LC-MS triggered purification in 6 injections affording the title compound (1.5 mg). LC-MS: METHOD C: R T 3.28 minutes, 515.1[M+H] and 304.1 (fragment of major intensity corresponding to the breaking of the amide bond).

EXAMPLE 59 -methyl-I H-indol-3-yl)-4-morpholin-4-vl-1 H-pvrrolof2.3-bpyridine, A20-B -C l, the product of the combination of group A20 in Table 1 and BI in Table 2 and Cl in Table 3:- S Me

H

Into a tube containing cesium carbonate (153 mg) was added a solution of 4-chloro-2-(5-methoxy-lmethyl-I H-indol-3-yl)-l-(toluene-4-sulfonyl)-I H-pyrrolo[2,3-b]pyridine [50 mg, Reference Example 13(i)] in 1,2-dimethoxyethane (1 mL), (ii) tris-(dibenzylideneacetone)-dipalladium(0) (15 mg) in 1,2dimethoxyethane (0.5 mL), (iii) 2-dicyclohexylphosphino-2'-(NN-dimethylamino)-biphenyl (42 mg) in 1,2-dimethoxyethane (0.5 mL) and (iv) morpholine (30 mg). This mixture was heated under agitation at 80 0 C for 15 hours and then filtered on a silica plug that was then washed with dichloromethane and methanol (1 mL each). The combined filtrate plus washings were evaporated using a centrifuge evaporator. The residue was dissolved in dimethylsulfoxyde (1 mL) and then subjected to LC-MS triggered purification (injections corresponding to 20 mg crude compound) affording 4-(morpholine- 4yl)-2-(5-methoxy- -methyl-l H-indol-3-yl)- -(toluene-4-su fonyl)-I H-pyrrolo[2,3-b]pyridine which was resuspended in methanol (2 mL) and magnesium turnings (89 mg, 15 equivalents from the mass measured after evaporation of the chromatographic solvent) were added. The suspension was then agitated for 15 hours at room temperature and then filtered on Celite. The filtrate was evaporated and the residue was solubilized in dimethylsulfoxide and subjected to LC-MS triggered purification according affording the title compound. LC-MS: METHOD C: RT 3.27 minutes, 363.3[M+H] By proceeding in a similar manner to Example 59, but replacing morpholine with an appropriately substituted amine of formula HNY 1

Y

2 there was prepared EXAMPLE 59(a) to EXAMPLE 5 9 in Table 7.

Table 7 STRUCTURE IHNYly2 Molecular LC-M S Nomenclature WO 03/000688 PCT/GB02/02799 -224- WO 03/000688 PCT/GB02/02799 -225- WO 03/000688 WO 03/00688PCT/GB02/02799 -226- C21H22N40 347 3.55 Cyclopropylmethyl-[2- 0 (5-methoxy- 1-methyl- HN HNY IH-indol-3-yl)-1-- HN H2 'pyrrolo[2,3 -bipyrid in- I 4-yl]-amine N N N EXAMPLE 59(n) 0C23H20N40 369.2 3.38 [-5meth -dl-3y) I ~~[-5meth -noxy--y O ,NH H-pyrrolo[2,3b]pyridin-4-yl)-phenyi- K" amine EXAMPLE_59(o) C21H24N40 349.2 3.43 Butyl-[2-(S-methoxy- 0 I-methyl-I H-indol-3yi)-l H-pyrrolo[2,3-

HNH

2 N? blpyridin-4-yl]-amine NIN

N

EXAMPLE 59(p) EXAMPLE IH-indol-3-yi)- 1H-pyrrolor2,3 blpvridine-4-carboxyl ic acid methylamide. A9-B32-G 1, the product of the combination of group A9 in Table I and B2 in Table 2 and ClI in Table 3:- A solution of 2-{5-methoxy- I H-indol-3-yl)- I H-pyrrolo[2,3-b~pyridine-4-carboxylic acid 11 g, Example 15(t)] in dimethyl formamide (5 mL) at room temperature was treated with triethylarmne (0.048 mL), methylamine (0.1 9m.L) and IH-benzotriazole- I-yl)-1 ,1I,3,3-tetramethyluronium tetrafluoroborate. The reaction mixture was allowed to stir at room temperature over-night, then poured into water (20 mL) and then extracted twice with ethyl acetate (20 mL). The combine extracts were washed with water (5 mL), then dried over sodium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica gel eluting with a mixture of methanol and ethyl acetate (49: 1, v/v) to afford the title compound as a yellow solid. MS: 321(MI-P). I H

NMVR[CD)

2 S0]: d 12.0 1 H, 1 1.4(I H, 8.4 (1 H, 8.2 (1IH, 8.0 (1IH, 7.54 (1IH, 7.40 (I H, 7.35 (1 H, 7. 10 (1 H, 6.85 (1IH, 3.80 2.90 (3H, d).

WO 03/000688 PCT/GB02/02799 -227- EXAMPLE 61 and REFERENCE EXAMfPLE 101.

IH-indol-3-yl)IH-pyrrolof2.3-blpridine-4-carboXilic acid, tert-butyl ester and miethoxy- IH-indol-3 -yl)-l -1(toluene-4-su Ifonyl)- I1--pyrrolo[2,3,-b]pyridine-4-carboxylic acid tertbutyl ester By proceeding in a similar manner to Reference Example 67(a) but using methoxy- I H-indole-3 -boron ic acid [Reference Example 74(b)] and 2-jodo- 1 -(toluene-4-sulfonyl)- I pyrrolo[2,3-b]pyridine-4 carboxylic acid, tert-butyl ester[Reference Example 62(e)] and subjecting the crude mixture to chromatography oni silica gel-eluting with a mixture of ethyl acetate and heptane (3:7 v:v) there wvas prepared 2-(5-methoxv- IH-indol-3 -vF)-1 1-1-yrrolof 2,3 -blpyridine-4-carbovl ic acid tert-butyl ester as a tan solid MS: 364(MH+) and 2-(5-rnethoxy-lH-indo1-3-yl)-I-(toluele-4-sulfoflyl)- IH-pyrrolo[2,3,-blpyridine-4-carboxylic acid tert-butyl ester (Reference Example 101) as a yellow/green oil. MS: 51 8(MH+).

EXAM4PLE 62 to EXAMPLE 126 The following compounds of Formula I in Table 8 are provided by the methods described in this Application: TABLE 8 STRUCTURE MP Molecular Formula METHOD D Microand RF analysis Example number

[M+H]

4 RT Found I (minutes) C17H15N302 294 2.35

H

NN

EXAMPLE WO 03/0010688 PCT/GB02/02799 (Ni -228- WO 03/000688 PCT/GB02/02799 -229- WO 03/000688 PCT/GB02/02799 -230- WO 03/000688 PCT/GB02/02799 -23 1- WO 031000688 PCT/GB02O2 799 -232- WO 03/000688 PCT/G B02/02799 -233- WO 03/000688 PCT/GB02/02799 -234- WO 03/000688 WO 03/00688PCTGB02IO2 799 -235- CK1 8.8 Hz); 7.42 (11-H, d J =2.4 Hz);.

7.01 (1 H, dd, J 7.8, 4.8 Hz); c-i 6.87 (1 H, dd, J 8.8, 2.4 Hz), 6.7 8 (1IH, d, J 2.4 Hz); 4.99 (I H, quint, J 8.0 Hz); 3.86 (3H, c-K1 2.58 2.53 (2H, in,1.93 1.88 (2H, in).

259-260 C22H22N403 391 N

N,

EXAMPLE 108 /208-209 Cl1HIN20 235

NN

EXAMPLE 109 C17H15N30 EXAMPLE 110 1 HNMR [(GD 3 2 S0]: 8 8.13 (I H, dd); 7.85 (1 H, dd); 7.83 (I1H, 7.5 7 (1IH, dd); 7.0 8 (1IH, 1Vt); 7.00 (1IH, dd); 6.78 (1 H, d); 6.73 (1 H, 4.08 (3H, 3.93 1(3 H, s).

WO 03/000688 PCT/GB02/02799 -236- WO 03/000688 PCT/GB02102799 -237- 0C 17H-116N40 293 1.39 EXAMPLE 122 C2lH24N6 348 2.47 N N

\N

EXAMPLE 123 7C20H20N402 0.If C: 65.72 (N H:5.51 N 15.67 0 EXAMPLE_124 0 C231-124N40 373.5 5.96 HN Method A CN N

/P

N_

EXAMPLE 125___ NBy C13HIOBrN3O 303.9 2.37 EXAMvPLE 126 a ethyl acetate b methanol dichloromethane 1:9 v:v C methanol ethyl acetate 1:9 v:v d penane ethyl acetate 1:2 v:v e methanol ethyl acetate 1:4 v:v f pentane ethyl acetate 1L1 v: v EXAMPLE 127 The following compounds of Formula I in Table 9 may be prepared by the methods described in this Application: WO 03/0010688 PCT/GB02/02799 -238- TABLE 9 WO 03/000688 PCT/G B02IJ2 799 -239- WO 03/000688 PCT/G B02102 799 -240- WO 03/000688 PCT/GB02/02799 -241- WO 03/000688 PCT/GB02/02799 -242- 4C~] WO 03/000688 PCT/GB02/02799 -243- C REFERENCE EXAMPLE 1 5-Methoxy- -methyl-I H-indole-3-carbonitrile 5-Methoxy-l-methyl-IH-indole-3-carboxaldehyde [76g, Reference Example and hydroxylamine 0 hydrochloride (55.9g) were stirred together in dimethylformamide (900 mL) under reflux for 1 hour.

The mixture was allowed to cool, then poured into water and then extracted with ethyl acetate. The combined extracts were washed with water then evaporated to give the title compound (53g) as a pale brown solid, m.p. 100-104 0 C. IHNMR [(CD 3 2 SO]: 8 8.17 (1H, 7.54 (1H, d, J=9.0 Hz); 7.09 S (1H, d, J=2.4 Hz); 6.97 (1H, dd, J=9.0 and 2.4 Hz); 3.82 and 3.84 (6H, s).

By proceeding in a manner similar to Reference Example 1 above but using phenylpyrazole-3-carbaldehyde [Reference Example 53(b)] there was prepared 1-methvl-3-cvano-5phenylpyrazole.

REFERENCE EXAMPLE 2 5-Methoxv-1 -methyl- 1 H-indole-3-carboxaldehyde A solution of 5-methoxyindole-3-carboxaldehyde (80g) in dimethylformamide (IL) under nitrogen was treated portion-wise with sodium hydride (20.1g, 60% dispersion in mineral oil) over 15 minutes. After stirring at ambient temperature for 30 minutes the mixture was treated dropwise with methyl iodide (31.3 mL) over 10 minutes and stirring was then continued for a further 2 hours. The reaction mixture was poured cautiously into water then extracted with ethyl acetate. The organic phase was washed with water, then dried over sodium sulfate and then evaporated. The residue was triturated with pentane to give the title compound (76g) as a pale brown solid, m.p. 133-134 0 C. 1H NMR [(CD 3 2 SO]: 8 9.86 (1IH, 8.20 (1H, 7.60 (1H, d, J=2.6 Hz); 7.50 (1H, d, J=8.9 Hz); 6.96 (1H, dd, J=8.9 and 2.6 Hz); 3.86 and 3.80 (6H, s).

By proceeding in a manner similar to Reference Example 2(a) above but using indole-3carbonitrile, there was prepared 1-methyl-IH-indole-3-carbonitrile, as a colourless crystalline solid, m.p. 61-63 0

C.

By proceeding in a manner similar to Reference Example 2(a) above but using carbonitrile, there was prepared I-methyl-I H-indole-5-carbonitrile. as a colourless crystalline solid, m.p. 77-79 0

C.

By proceeding in a manner similar to Reference Example 2(a) above but using indole-3carbonitrile and (3-bromopropoxy)-tert-butyldimethylsilane, there was prepared I-r3-(tert-butyl- WO 03/000688 PCT/GB02/02799 -244dirnethyI-silanyloxy)-propyl-IH-indole-3-carbonitrile as a clear colourless oil. TLC: RE 0.6 (dichioromethane). I NMR (CDCI 3 6 7.70 (1 H, d, J=8 7.56 (1 H, 7.39 (1 H, d, J=8 Hz); 7.27 (I H, t, J=8 Hz); 7.22 (1IH, t, J=8 Hz); 4.25 (2H, t, J=6 Hz); 3.49 (2H, t, J=6 Hz); 1.95 (2H, quintet, J=6 Hz); 0.87 (9H, 0.00 (6H, s).

By proceeding in a manner similar to Reference Example 2(a) above but using 5-methoxy-l Hindole-3-carbonitrile [Reference Example I1(a)] and (3-bromopropoxy)-tert-butyldimethiylsilane, there was prepared 1 -[3-(terti-butvl-dimethyl-silanloxyl-propyl1-5-methoxv- IH-inidole-3-carbon itrile, as a clear colourless oil. IH NMR [(CD 3 2 S0]: 58.18 (1H, 7.55 (IH, d, J9 Hz); 7.09 (IH,d, J2 Hz); 6.95 (1lH, dd, J--9 and 2 Hz); 4.27 (2H, t, J=6 Hz); 3.82 3.53 (2H, t, J=6 Hz); 1.95 (2H, quintet, J=6 Hz); 0.87 0.00 (6H, s).

By proceeding in a manner similar to Reference Example 2(a) above but using indole-3carbonitrile and (2-bromoethoxy)-ter-t-butyldimethylsilane, there was prepared l-r2-(tert-butyld imethyl-sil]any] oxy)-ethyll- IH-indole-3 -carbon itri le, as a clear colourless oil. TLC: RF =0.65 (dichloromethane).

By proceeding in a manner similar to Reference Example 2(a) above but using indole-3-carbonitrile [Reference Example I1(a)) and benzyl bromide, there was prepared I methoxy-I H-indole-3-carbonitrile as a brown solid, MS: 263.22(MH+). TLC: RF 0.8 (dichloromethane/methanol 19/1).

By proceeding in a manner similar to Reference Example 2(a) above but using 5-methoxy- IHindole-3 -carbonitrile [Reference Example 1 and 2-bromoethoxy-dimethyl-tertiarybuty si lane, there was prepared 1 -f 2-tertiarybutyl-d imethyl-si lanyloxy)-ethyll-5 -methoxcy- 1 H-indole-3 -carbon itri le. as a pale yellow solid, MS: 331 .23(MH-i). TLC: RF 0.6 (pentane/ethyl acetate: 812).

By proceeding in a manner similar to Reference Example 2(a) above but using' IH-pyrrole-3carbonitrile (prepared as described in Tetrahedron Letters, 1972, 52, 5337-5340), there was prepared 1 -methyl- IH-pyrrol e-3 -carbon itri Ie. as a brown oil, MS: l07(M1-l+). 1 H NMR [CDCI 3 8 7.09 (11-, in); 6.60 (11-H, in); 6.40 (1 H, in); 3.68 s).

WO 03/000688 PCT/GB02/02799 -245- ()By proceeding in a manner similar to Reference Example 2(a) above but using I H-pyrrole-2carbonitrile, there was prepared 1-methyl- IH-pyrrole-2-carbonitrile as a colourless liquid. MS:' 106(MH+). I HNMR [CDCI 3 8 6.80 (IH, in); 6.67*(IH, mn); 6.15 (1IH, in); 3.79 (3H, s).

By proceeding in a manner similar to Reference Example 2(a) above but using 2-phenyl- IHpyrrole-4-carbonitrile (prepared as described in Synthetic Communications, 25, (1995) 6, 795-802), there was prepared 1-methvl-2-phenyl-l H-pyrrole-4-carbonitrile as a cream solid, in.p. 50-5 1 0 C. MS: I 83(MH-U).

By proceeding in a similar manner to Reference Example 2(a) but using 4-methoxy-2-(5methoxy- I H-indol1-3 I -(toluene-4-sulIfonyl)- 1 H-pyrrolo[2,3-b] pyri dine (Reference Example 39) there was prepared 4-methoxy-2-(5-inethox'v- I-methyl-I H-indol-3-vl)- I-(toluene-4-sulfonvl)- IHpyrrolor2.3-blpvridine as a dark oilI. HPLC (METHOD RT 9.49 minutes. TLC: RF 0.50 (pentane/ ethyl acetate: 1 (in) By proceeding in a similar manner to Reference Example 2(a) but using 2-(5-methoxy- I Hindol-3-yl)-4-phenyl- i-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b] pyridine (Reference Example. 12(g)) there was prepared 2-(5-methoxy- I-methyl-I H-indol-3 -vl)-4-ohenyl- I-(tol uene-4-su Ifonyl)- IHpyrrolo[2,3-blovridine as a tan solid. 'H4 NMR [(CD 3 2 S0]; 5 8.39 (1IH, d, J=4.4 Hz); 7.71 (2H, d, J=7.2 Hz); 7.63 (3H, in); 7.52 (2H, t, 3=8.5 Hz); 7.44 (3 H, in); 7.29 (21-I, d, 1=7.2 Hz); 6.94 (1 H, s); 6.86 (1 H, d, J=8.5 Hz); 6.82 3.86 (3H, 3.71 (3H, 2.29 (3H, s).

By proceeding in a similar manner to Reference Example 2(a) but using 2-(S-methoxy-1 Hindol-3-yl)- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-bjpyridine-4 carboxylic acid, iert-butyl ester [Reference Example 67(b)] and methyl iodide there was prepared 2-(5-methoxv- I-methyl- IH-indol-3 yl)- I -(tol uene-4-sulfonyl)- I H-pyrroloF2,3-blpyridine-4 carboxylic acid. tert-butyl ester as a dark oilI which was used directly without further purification.

By proceeding in a similar manner to Reference Example 2(a) but using indol-3 -yl)-4-(pyridin-3-yl)-1 -(toluene-4-su Ifonyl)- IH-pyrrolo [2,3-bipyridine [Reference Example 67(d)] and methyl iodide there was prepared 2-(5-methoxv- -methvl-I H-indol-3-yl)-4-(pyridin-3-vl')- I (toluene-4-sulfonyl)- I H-pyrrolor2,3-blpyridine as a tan coloured oil which was used directly without fu~rther purification.

By proceeding in a similar manner to Reference Example 2(a) but using 2-(S-methoxy-1 Hindol-2-yI)- 1-(tol uene-4-sulfonyl)- I H-pyrro lo[2,3 -bipyridine [Reference Example 70] and methyl WO 03/000688 PCT/GB02/02799 -246iodide there was prepared 2-(5-methoxv- I -methyl- I H-indol-2-vlV I -(toluene-4-sulfonyl)- I Hpyrrolor2,3-blpyridine.

By proceeding in a manner similar to Reference Example 2 above but using 3-[4-methoxyl- 1 -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine-2-yI]- 1H -indole-5-carboxylic acid, methyl ester [Reference Example there was prepared 3-r4-methoxvl- I-(toluene-4-sulfonyl)-lIH-pyrrolof 2,3-.

blpyridine-2-yll-l -methvl-I H-indole-5-carboxcylic acid, methyl ester as an ivory solid. LC-MS: METHOD D: RT 3.26 minutes, 490(MH+).

By proceeding in a manner similar to Reference Example 2 above but using 3-[4-chloro-1I- (toluene-4-sulfonyl)- I H-pyrrol o[2,3-b]pyridine-2-yl)- I H-indole-5-carboxyl ic acid, methyl ester [Reference Example there was prepared 3-f4-chloro- 1 -(toluene-4-sulfonyl)- 1 H-pyrrolor2.3blpyrid ine-2-yil- I1-methyl- I H-ind ole-5-carboxylic acid, methyl ester as a white solid. MS: 494(MH+).

I-PLC(Method RT =4.88 minutes.

By proceeding in a manner similar to Reference Example 2 above but using indole-3carbonitrile and (2-bromomethoxyl-ethyl)-trimethyl-silane there was prepared ]-(2-triimethylsilanylethoxyvmethyl)-l H-indole-3 -carbon itri le. 1 H NNIR [(CD3) 2 S0]: 6 8.45 (1 H, 7.73 (JH, dd), 7.66 (I H, dd); 7.38 (1H, in); 7.30 (1IH, in); 5.64 (2H, 3.47 (2H, 0.9-0.8 (4H, in); -0.10 (9H, s).

REFERENCE EXAMPLE 3 6-fl -[3-(tert-Butvl-dimethyl-silanyloxv'l-prooyll- 1 H-indol-3-yll -5H-pvrrolo[2,3-blpyrazine By proceeding in a manner similar to Example 1 herein but using 1 -[3-(tert-butyl-dimethylsilanyloxy)-propyl]-1 H-indo le-3 -carbon itri le [Reference Example there was prepared the title compound as a solid. IH NMR [(CD 3 2 S0]: 8 12.1-12.2 (IH, broad 8.27 d, J=2.7 Hz); 8.14 8.10, 7.59 (each I1H, d, J "7.8 Hz); 8.09 (1IH, d, J=2.7 Hz); 7.29, 7.23 (each I H, td, J=7.1 and 1.1 Hz); 6.96 (1lH, 4.33 (2H, t, J=7.1 Hz); 3.62 (2H, t, J=6.0 Hz); 2.03 (2H, quintet, J=6.2 Hz); 0.89 (9H, 0.00 (6H, MS: 407(MTI-I).

By proceeding in a manner similar to Example 1 herein but using 1-[3-(tert-butyi-dimethyl- IH-indole-3 -carbonitri le [Reference Example there was prepared 6-f I -[3-(tei-i-buty-dimethyl-silanyloxy)-propyl1-5-methoxv.. IH-indol-3-yl I-5H-pyrrolof2.3-blpyrazine as a solid, TLC: RF =0.4 (ethyl acetate/pentane:I1/1). IH NMR [(CD 3 2 S0]: 8 8.27 (1H, d, 4 Hz); 8.08 (2H, mn); 7.50 (2H, mn); 6.96 (1 H, 6.91 (1H, dd, 6, 2 Hz); 4.29 (2H, t, 6 Hz); 3.89 3.61 (2H, t, 6 Hz); 2.00 (2H, in); 0.89 0.03 (6H, s).

WO 03/000688 PCT/GB02/02799 -247- By proceeding in a manner similar to Example I1(a) herein but using I -[2-QIert-butyl-dimethylsilanyloxy)-ethyl]- IH-indole-3-carbonitri le [Reference Example there was prepared 6-11I43 -(zertbutvl-dimethyl-silanyloxy)-ethvll-I H-indol-3-yll-5H-pyrrolor2.3-blpyrazine as a solid, TLC: RF 0.3 (ethyl acetate/pentane: MS: 393(M1I+).

By proceeding in a manner similar to Example 1(a) herein but using 1-[2-(teri-butyl-dimethyl- 1H-indole-3-carbonitrile [Reference Example there was prepared 6-f 1-F2-(terl-butvl-dimethyl-si lanyloxv)-ethvll-5-methoxv- IH-indol-3-vl I-SH-pvrroloL2.3-blpvrazi ne as a brown solid, TLC: RF 0.4 (dichloromethane/methanol 19/1). MS: 423(MH+).

*By proceeding in a manner similar to Example 1 herein but using 4-( 4 -cyanophenyl)piperazine-lI-carboxylic acid, tert-butyl ester [Reference Example 75], and subjecting the reaction product to chromatography on silica using gradient elution conditions [from a mixture of ethyl acetate and heptane 1, v/v) to ethyl acetate], there was prepared 4-r4-(5Hpyoo23-lyai--lpeylieaie croyi acid. tert-butyl ester as a an off-white solid.

LC-MS: Method A: RT 3.42 minutes, 380(M4H+).

By proceeding in a manner similar to Example 1(a) herein but using ]-(2-trimethylsilanylethoxymethyl)-lIH-indole-3-carbonitrile [Reference Example there was prepared 6-f l-(2trimethylsianyl-ethoxvymethyl)- 1 H-indol-3-vll-5H-pyrrolof2,3-blpyrazine as a pale yellow solid. TLC RIF 0.20 (ethyl acetate/pentane, 1: 1).

REFERENCE EXAMPLE 4 3-f3-(5H-Pyrrolor2,3-blpvrazin-6-yl)-indol- I -yll-propylbromide To a solution of 3 -[3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I -yl]-propan- 1 -ol I g, Example and carbon tetrabromide (1 .59g) in dichloromethane (40 mL) at ambient temperature was added a solution of triphenylphosphine Ilg) in dich loromethane (10 mL) over 2 minutes. The reaction mixture was stirred at ambient temperature for 3 hour, then stood for 18 hours and then evaporated to give the title compound which was used without further purification.

REFERENCE EXAMPLE Lndol izi ne-lI -carbon itri le A mixture of 2-pyridylacetontrile and chloroacetaldehyde (4.42g of 50% wt. solution in water) was heated at reflux in 1,4-dioxane (25 mL) for 5.5 hours. The reaction mixture was allowed to cool to WO 03/000688 PCT/GB02/02799 -248- 0 C, ambient temperature then evaporated. The residue was partitioned between ethyl acetate (100 mL) and hydrochloric acid (100 mL, 1M). The aqueous layer was extracted twice with ethyl acetate (100 mL).

The combined organic phases were washed with brine (50 mL), then dried over magnesium sulfate and O then evaporated. The residue was subjected to flash column chromatography on silica eluting with dichloromethane to give the title compound (1.83g) as a colourless solid, m.p. 53-54°C. MS: (S 143(MH+).

REFERENCE EXAMPLE 6 3-Methyl-indolizine- -carbonitrile A solution of propionaldehyde (36 mL) in diethyl ether (200 mL) and 1,4-dioxane (1.7 mL) at 5 0

C

under nitrogen was treated dropwise with bromine (24.7 mL) over 2 hours whilst maintaining the temperature at 5°C. After the addition was complete, the reaction mixture was stirred for a further minutes and then washed carefully with saturated sodium bicarbonate solution (100 mL). The organic phase was dried over sodium sulfate then concentrated in vacuo at 10 0 C and then added immediately to a solution of 2-pyridylacetonitrile (8.36 mL) in acetone (50 mL). The resultant mixture was heated at reflux under nitrogen for 6 hours, then allowed to stand at ambient temperature overnight and then evaporated. The residue was partitioned between ethyl acetate (500 mL) and hydrochloric acid (100 mL, IM). The organic layer was washed with brine (100 mL) and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) and then triturated with diethyl ether to give the title compound (4.0g) as a white solid, m.p.

98-100 0 C. MS: 157(MH+).

SREFERENCE EXAMPLE 7 Sodium-1 -formvl-piperidine-2-carboxylate To a solution of piperidine-2-carboxylic acid (30g) in formic acid (230 mL) was added acetic anhydride (147 mL) dropwise. The resultant exotherm was controlled by cooling the reaction mixture in an ice/water bath. After stirring at ambient temperature for 24 hours the reaction mixture was diluted with water (20 mL) and then concentrated in vacuo. The resultant oil was dissolved in a mixture of methanol (50 mL) and acetonitrile (500 mL). Sodium hydroxide solution (10M, 23 mL) was added and the reaction mixture stirred for 8 hours. The resultant precipitate was filtered, washed with acetonitrile, and ethyl acetate and dried in a vacuum oven to afford the title compound as a white solid which was used immediately without further purification.

REFERENCE EXAMPLE 8 5.6,7.8-Tetrahydro-indolizine-I -carbonitrile WO 03/000688 PCT/GB02/02799 -249-

O

C To a solution of sodium-l-formyl-piperidine-2-carboxylate (2.0g) (Reference Example 7) in dichloromethane (50 mL) at ambient temperature under nitrogen was added para-toluenesulfonyl chloride (2.31 After stirring for 10 minutes the mixture was treated dropwise with acrylonitrile S(0.88 mL) and triethylamine (1.5 mL) and stirring was continued for a further 1 hour when a second portion oftriethylamine (1.0 mL) was added. The reaction mixture was stirred for 18 hours and the dichloromethane removed in vacuo. The residue was taken up in water (50 mL) and extracted with 0ethyl acetate (200 mL). The combined organic extracts were evaporated in vacuo and the residue was Ssubjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (1.38g) as an orange oil, MS: 147(MH+). 1H NMR(CDCI 3 6.48 (1H, d, J=3.1 Hz); 6.36 (1H, d, J=3.1 Hz); 3.91 (2H, t, J=6.0 Hz); 2.89 (2H, t, J=6.0 Hz); 1.98 (2H, 1.88 (2H, m).

REFERENCE EXAMPLE 9 1-(Toluene-4-sulfonyl)- H-pyrrolo 2,3-blpyridine To a solution of 7-azaindole (25g), para-toluenesulfonyl chloride (44.5g) and a catalytic amount of tetrabutylammoniun sulfate in dry toluene (300 mL) was added sodium hydroxide (160g in 500 mL of water). The biphasic solution was stirred at ambient temperature for 3 hours then extracted twice with toluene (100 mL). The combined extracts were dried over magnesium sulfate then concentrated under vacuo. The resultant solid was triturated with diethyl ether then dried at 60 0 C under vacuo to yield the title compound (39.74g) as a pale yellow solid, m.p. 136-138 0

C.

By proceeding in a similar manner to Reference Example 9(a) but using 4-nitro-1 Huw pyrrolo[2,3-b]pyridine (prepared according to the procedure described by A. Ippolito et al., J. Med.

Chem. (1982), 25(10), 1258-61) there was prepared 4-nitro-l-(1-toluene-4-sulfonyl)- H-pyrrolof2,3blpvridine as an orange solid, m.p. 145-146 0 C. HPLC (METHOD Rr 10.80 minutes.

By proceeding in a similar manner to Reference Example 9(a) but using 4-chloro- Hpyrrolo[2,3-b]pyridine (Reference Example 64) there was prepared 4-chloro-l-(toluene-4-sulfonvl)-1 Hpvrrolor2.3-bpyridine as a white solid. MS: 307(M-f). 1 H NMR (CDCI 3 6 8.3 IH), 8.05 (d, 2H), 7.8 7.3 2H), 7.2 1H), 6.7 1H), 2.4 3H).

By proceeding in a similar manner to Reference Example 9(a) but using 5-bromo-1 Hpyrrolo[2,3-b]pyridine there was prepared 5-bromo- 1-(toluene-4-sulfonyl)- 1H-pvrrolo[2.3-blpyridine as a white solid, m.p. 138-140 0

C.

WO 03/000688 PCTICB02/02799 -250- By proceeding in a similar manner to Reference Example 9(a) but using pyrrolo[2,3-blpyrazine (Reference Example 42) there was prepared 6-Rhenyl-5-(toluene-4-sulfony)- 5H-pyrrolo[2.3-blpyrazine as a white solid. 1H NMR [(CDA)S0]: 5 8.44 (1 H, d, J=4.5Hz); 8.04 (2H, d, J=8.2Hz); 7.98 (1IH, d, J=4.5Hz); 7.69 (2H, d, J6.8Hz); 7.57 (tt, J=6.2, 1.8Hz); 7.51 (1IH, tt, J=6.8, 1.8Hz); 7.44 d, J=8.2Hz); 7.42 (1IH, d, J=4.5Hz); 6.92 (1 H, d, J=4.5Hz) which was without further purification.

By pitoceeding in a similar manner to Reference Example 9(a) but using I H-pyrrolo[2,3b]pyridine-4 carboxylic acid, tert-butyl ester [Reference Example 68] there was prepared N-toluene-4sulfonyl)-lH-pyrrolor2,3-blpyridine-4 carboxylic acid. tert-butyl ester as a yellow solid. MS: 373 By proceeding in a similar manner to Reference Example 9(a) but using 4-(pyridin-3-yl)-1 Hpyrrolo[2,3-b]pyridine [Reference Example 67(c)] there was prepared 4-(pyridin-3-yl)-1I-(toluene-4sulfonyl)-lH-pyrrolor2,3-blpyridine as a white solid, m.p. 175-176 0 C. MS: 350(M1-1).

By proceeding in a manner similar to Reference Example 9(a) above but using 3-methyl-I Hpyrrolo[2,3-b]pyridine [prepared according to the procedure described by D. Hands et al, Synthesis (1996), 877-882], there was prepared 3-methyl-I -(toluene-4-sulfonyl)- I 1-prrolol2.3-blhyridine as an orange solid. MS: El (70eV); mlz 286 M+ 221 131 104 (3 91 By proceeding in a manner similar to Reference Example 9 above but using 4-(3,5dimethyl-isoxazole-4-y I H-pyrrolo[2,3-b]pyridine [Reference Example 80], there was prepared 4-(3 .5-d imethyl-isoxazole-4-:yl)- I-(toluene-4-sulfonyl)IH-pyrrolof2,3-blpyridime as a white solid.

TLC: RIF =0.60 (ethyl acetate/heptane, MS: 368 By proceeding in a manner similar to Reference Example 9 above but using I carboxylic acid methyl ester, there was prepared I -(toluene-4-sulfonyl')-IH-indole-5-carboxylic acid methyl ester as a yellow solid. m.p. 139-140*C.

REFERENCE EXAMPLE 2-lodo- I -(toluene-4-sulfonyl)- 1 H-pVyrolof2,3-bl pyridime A solution of I -Qtoluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [54.4g, Reference Example in dry tetrabydrofuran (1200 mL) cooled to -78'C, was treated with a solution of butyllithium in hexanes (2.5M, 92 mL) over a 20 minute period. The solution was maintained at -78'C for 30 minutes, then a WO 03/000688 PCT/GB02/02799 -251- 0 C' solution of iodine (101 g) in tetrahydrofuran (600 mL) was added until the iodine colour persisted (ca.300 mL). The mixture was allowed to warm slowly to ambient temperature and the solvent removed under vacuo. The residue was partitioned between ethyl acetate (1000 mL) and water (500 0 mL) and the aqueous layer was extracted twice with ethyl acetate (500 mL). The combined organics were combined, dried over sodium sulfate and removed under reduced pressure to give a yellow solid which was triturated with diethyl ether to give the title compound (79.6g) as a pale yellow solid, m.p.

S105-107 0 C. MS: 399(MH+).

0REFERENCE EXAMPLE 11 0 10 3-Bromo-5-methoxy-indole-l-carboxvlic acid, tert-butyl ester A solution of 5-methoxyindole (10g) in dry dimethylformamide (150 mL) at ambient temperature was treated with bromine (4 mL) dropwise ensuring the temperature did not rise above 30 0 C. The mixture was treated immediately with triethylamine (28 mL) and 4-dimethylaminopyridine (0.5g) followed by a solution ofdi-tert-butyldicarbonate (18g) in dry dimethylformamide (80 mL) and stirring was continued for a further 4 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate (250 mL) and water (200 mL). The aqueous layer was extracted with ethyl acetate (100 mL). The combined organic phases were washed with water (100 mL), then with brine (100 mL), then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of pentane and ethyl acetate (19/1, v/v) to give the title compound (23.4g) as a colourless solid, m.p. 111-112 0

C.

By proceeding in a manner similar to Reference Example 11 above but using indole, there was prepared 3-bromo-5-cvano-indole-l-carboxylic acid, tert-butvl ester as a grey solid, m.p. 172-174C. MS: 322(MH+).

By proceeding in a manner similar to Reference Example 1 l(a) above but using 5,6-dimethoxy-indole, there was prepared 3-bromo-5,6-dimethoxy-indole-l-carboxvlic acid, tert-butvl ester as a lilac solid. TLC: RF 0.6 (pentane/ethyl acetate 19/1).

By proceeding in a manner similar to Reference Example 1 above but using 5-benzyloxy-6methoxy-indole [prepared according to the method described by Benigni, J. D. and Minnis, J.

Heterocycl. Chem., 387, 2, 1965 there was prepared 5-benzvloxv-3-bromo-6-methoxy-indole-1carboxylic acid, tert-butvl ester as a colourless solid. MS: 433(MH+). HPLC (METHOD RT 13.99 minutes.

WO 03/000688 PCT/GB02/02799 0-252-

O

C, By proceeding in a manner similar to Reference Example 1 l(a) above but using indole and an excess of di-tert-butyldicarbonate there was prepared butoxvcarbonvlamino-indole-1-carboxvlic acid, fert-butvl ester as an orahge oil. MS: 412(MH+).

TLC: RF 0.8 (pentane/ethyl acetate: 9/1).

By proceeding in a manner similar to Reference Example 11(a) above but using 1H-indole-6- Scarboxylic acid, methyl ester [Reference Example 31] there was prepared 3-bromo-indole-1.6- Sdicarboxvlic acid, 1-tert-butyl ester 6-methyl ester as a pale violet solid, m.p. 117-119 0 C. MS: 355(MH+).

By proceeding in a manner similar to Reference Example 11 above but using carboxylic acid methyl ester, there was prepared 3-bromo-indole-1,5-dicarboxvlic acid. 1-tert-butyl ester 5-methyl ester as a solid. MS: 320 HPLC (Method RT 4.54 minutes REFERENCE EXAMPLE 12 2-(5-Methoxv- H-indol-3-vl)-l-(toluene-4-sulfonyl)-I H-pyrrolo[2,3-blpvridine A stirred solution of 3-bromo-5-methoxy-indole-l-carboxylic acid, tert-butyl ester [50g, Reference Example 1 in tetrahydrofuran (800 mL), under nitrogen, was treated with tributylborate (49.5 mL) then cooled to -100 0 C and then treated with a solution of n-butyllithium in hexanes (94 mL, whilst keeping the temperature below -90 0 C. Once the addition was complete the mixture was allowed to warm slowly to room temperature over 1 hour and quenched by the addition of ice (lOg). The organics were removed under reduced pressure and the residue was partitioned between ethyl acetate (500 mL) and water (400 mL). The organic layer was dried over magnesium sulfate and then evaporated. The resulting boronic acid, a cream coloured solid (28g), was dissolved in dimethylformamide (600 mL) and the solution was treated with 2-iodo-l-(toluene-4-sulfonyl)-1 Hpyrrolo[2,3-b]pyridine [38.3g, Reference Example 10], then with saturated aqueous sodium bicarbonate (200 mL) and then with tetrakis(triphenylphosphine)palladium[0] The mixture was heated at reflux for 4 hours then allowed to cool to ambient temperature then concentrated to remove the dimethylformamide. The residue was partitioned between water (400 mL) and ethyl acetate (500 mL) and the aqueous was extracted twice with ethyl acetate (300 mL). The combined organics were dried over sodium sulfate then evaporated. The residual brown gum was triturated with ethyl acetate to give the title compound (27g) as a pale green solid. MS: 418.43(MH+).

By proceeding in a manner similar to Reference Example 12(a) above but using cyano-indole-1 -carboxylic acid, tert-butyl ester [Reference Example there was prepared WO 03/000688 PCT/GB02/02799 -253- 34r 1-(toluene-4-sulfonyl)-1 I -pyrrolol2.3-blpyridin-2-yll- IH-indole-5-carbonitri le as a colourless solid, m.p. 209-214*C. MS: 4l3(MH-').

(c By proceeding in a manner similar to Reference Example 12(a) above but using 3-bromo-5,6dimethoxy-indole-1-carboxylic acid, tert-butyl ester [Reference Example 11I(c)], there was prepared 2-(5.6-dimethoXy- I H-indol-3-yl)- I -(toluene-4-sulfonyl)- I H-pyrroloF2,3-blpyridime as a brown solid, By proceeding in a manner similar to Reference Example 12(a) above but using 5-benzyioxy-3bromo-6-methoxy-indole-1I-carboxyl ic acid, tert-butyl ester [Reference Example 11I(d)], there was prepared 2-(5-be -nzvloxy-6-methoxv- IH-indol-3-vJ)- I 4tol uene-4-sulfonyl)- 1 H-pvrrolof2.3-blpyridine as a colourless solid. MS: 524(MH4+). HPLC (METHOD A):RT 10.09 minutes.

By proceeding in a manner similar to Reference Example 12(a) above but using :ert-butoxycarbonylamino-indole-1-carboxylic acid, tert-butyl ester [Reference Example I11(e)], there was prepared 13- I -(toluene-4-sulfonyl)l- 1H-pyrrolo[2.3-b1 Dvridifl-2-yI1- IH-indol-5-vl -carbamic acid, tert-butyl ester as a tan solid. MS: 503(MH+). TLC: RF 0.62 (pentane/ethyl acetate 1/1).

By proceeding in a manner similar to Reference Example 12(a) above but using 3-bromoindole-I,6-dicarboxylic acid, 1-tert-butyl ester 6-methyl ester [Reference Example I1I(f)], there was prepared 34F1 -(toluene-4-sulfonvi)- I H-pyrrolor2.3-blnvridin-2-yll- I H-indole-6-carboxylic acid, methyl ester as a pale yellow solid, m.p. 214-216 0 C. MS: 446(MH-I).

By proceeding in a similar manner to Reference Example 12(a) but using 2-iodo-4-phenyl-I (toluene-4-sulfonyl)- IH-pyrrolo[2,3-bjpyridine [Reference Example 62(d)] there was prepared I H-indol-3-vl)-4-phenyl- I -(toluene-4-sulfonl)- I H-pyrrolor2,3-blpyridine as a white solid. HPLC (METHOD Rj- 11.63 minutes. MS: 494(MW).

By proceeding in a similar manner to Reference Example 12(a) but using 4-chloro-2-iodo-1- (toluene-4-sulfonyl)-1IH-pyrrolo[2,3-b]pyridine [Reference Example 62(b)] there was prepared 4-ch loro-2-(5-methoxy- 1H-indol-3-yl)- I-(toluene-4-sulfonyl)- IH-,pyrrolo[2.3- bI pyridine as a white solid. MS: 452 'H NMR (CDCI 3 6 8.4 I 7.6 7.5 I 7.3 5 I Hf), 7.2 (d, 2H), 6.9 (in, 2H), 6.7 I 3.8 3H), 2.3 3H).

WO 03/000688 PCT/GB02/02799 -254- By proceeding in a similar manner to Reference Example -12(a) but using 2-iodo-5-phenyl-1I- (toluene-4-su Ifonyl)- 1H-pyrrolo[2,3-b]pyridine [Reference Example 62(c)] there was prepared IH-indol-3-vl')- I-(toluene-4-sulfonl)-5-phenvl-1 H-pvrrolof2,3-b1 pyridine. MS: 494(MHf).

By proceeding in a similar manner to Reference Example 12(a) but using 4-chloro-2-iodo-l- (para-toluenesulfonyl)- IH-pyrrolo[2,3-b] pyridine [Reference Example 62(b)]and 4-terlbutylphenyl boronic acid there was prepared 4-chloro-2-(4-tert-butvlphenl)-1 -(para-toluenesulfonl)- IHpyrrolor2.3-blnyridine as a white solid. MS: 439(MW). TLC: RF 0.78 (ethyl acetate/heptane, 1: 1).

By proceeding in a manner similar to Reference Example 12(a) above but using 2-iodo-3methyl- I -(toluene-4-su Ifonyl)- 1 H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-(5-methoxv- I H-indol-3-yi)-3-methyl- I -4toluene-4-sulfonyl)-1 H-pyrrolo[2,3-bl nyridine as a yel low sol id. TLC: RF 0.51 (ethyl acetate/cyclohexane 1: MS: El (70eV); mlz =431 2 76 244 (3 By proceeding in a manner similar to Reference Example 12 above but using 4-(3,5dimethyl-isoxazol-4-yl)-2-iodo-l1-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridine [Reference Example 62(h)] and 3-bromo-indole-1,5-dicarboxylic acid, I-tert-butyl ester 5-methyl ester [Reference Example 11I(g)], there was prepared 3-r4-(3,5-dimethvl-isoxazole4-l)-1 -(toluene4-sulfonl~- 1H-pyrrolor2.3blpyridine-2-yll-1H-indole-5-carboxylic acid, methyl ester as a yellow solid, m.p. 155-156'C. TLC: RF 0.32 (ethyl acetate/heptane, 1: 1).

(in) By proceeding in a manner similar to Reference Example 12 above but using 4-(3,5dimethyl-isoxazol-4-yl)-2-iodo- 1 -{toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 62(h)] and 3-bromo-5-methoxy-indole-lI-carboxylic acid,.tert-butyl ester [Reference Example I11(a)], there was prepared 4-(3 .5-dimethvl-isoxazole-4-vl '-2-(5-methoxv- IH-indol-3-yl)-lI-(toluene-4sulfonyl)- I H-pyrrolo[2,3-blpyridine as a yellow sol id. TLC: RF =0.26 (ethyl acetate/heptane 1: 1).

MS: 513 By proceeding in a manner similar to Reference Example 12 above but using 4-(methoxy)- 2-iodo- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 62(i)] and 3-bromoacid, 1-tert-butyl ester 5-methyl ester [Reference Example I11(g)], there was prepared 3-[4-methoxy-lI-(tol uene-4-sulfonfl)- IH-pvyrrolor2.3-blnvridine-2-yll- acid, methyl ester as a white solid, MS: 476(MI-V'. HPLC (Method RT 4.72 minutes.

WO 03/000688 PCT/GB02/02799 -255- By proceeding in a manner similar to Reference Example 12 above but using 4-(chloro)-2iodo- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3- b]pyridine [Reference Example 62(b)] and 3-bromo-indole- I,S-dicarboxylic acid, I1-tert-butyl ester 5-methyl ester [Reference Example I1I(g)], there was prepared 3 -r4-ch loro-lI-(toluene-4-su lfonyl)- I H-ovrrolo[2.3-bl nyridine-2-yll-I 1 H-indole-5-carboxyl ic acid.

methyl ester as an off-white solid. MS: 480(MH+). HPLC(Method RT 4.77 minutes.

By proceeding in a manner similar to Reference Example 12 above but using trifluoromethanesulfonic acid- I -(toluene-4-sulfonyl)-l 1 indol-2-yl ester [Reference Example 71] and 1 -(toluene-4-su Ifonyl)- 1 H-indole-5-carboxylic acid, methyl ester, 3-boron ic acid [Reference Example starting from the addition of the boronic acid there was prepared 1-(toluene-4-sulfonyl)34-- (toluene-4-sulfonyl)- 1H-pyrroloF2,3-bl ovrid ine-2-yll- I l--indole-5-carboxyl ic acid, methyl ester as a colourless oil. TLC: RF 0.27 (ethyl acetate/pentane, 1:1).

By proceeding in a manner similar to Reference Example 12(a) but using 6-benzyloxy-3-iodo- 5-methoxy-indole-1 -carboxyl ic acid tert-butyl ester [Reference Example 821, there was prepared 2-o(6-benzyloxv-5-mnethoxy- IH-indol-3-vl')- I-(toluene-4-sulfonyl)-1 H-pvrrolo[2,3-blpyridine as a pale yellow solid, m.p. 222*C. TLC: RIF =0.33 (cyclohexane/ethyl acetate, 1/1).

REFERENCE EXAMPLE 13 5-Methoxv-3 -rI -(tot uene-4-su Ifonyl)- 1 H-pyrro lof2,3-bl pyrid in-2-yll-indol- I -yvI -acetic acid ethyl ester A solution of 2-(5-methoxy-1 H-indol-3-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [6.6g, Reference Example 12(a)] in dimethylformamide (100 mL), under a nitrogen atmosphere, was treated with sodium hydride (700mg, 60% dispersion in oil). After stirring at ambient temperature for minutes the mixture was treated dropwise with ethyl chloroacetate (2.0 mL, 23.75mmol) and stirring was continued for an additional 4 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, then dried over sodium sulfate and then evaporated to give the title compound (5.77g) as a yellow solid, MS: 504(M1-I). HPLC (METHOD RT =11.88 minutes.

By proceeding in a manner similar to Reference Example 13(a) above but using methyl iodide, there was prepared 2-(5-methoxy- 1-methyl-I H-indol-3-yl)- 1-(toluene-4-sulfonyl)- IH-pyrrolor2,3bipyridine. as a yellow solid, mn.p. 103-105'C. MS: 432(MH+).

WO 03/000688 PCT/GB02/02799 -256- By proceeding in a manner similar to Reference Example 13(a) above but using 3-[l-(toluene.

4-sulfonyl)- 1l--pyrrolo[2,3-b]pyridin-2-yl]- IH-indole-5-carbonitri le [Reference Example 12(b)] and methyl iodide, there was prepared 34F 1-(toluene-4-sulfonyl)- 1H-pyrrolof 2.3-bi pyridin-2-yfl- i-methylas a colourless solid, m.p. 189-191'C. MS: 427(MH+).

By proceeding in a manner similar to Reference Example 13(a) above but using 2-(5,6-dimethoxy- 1H-indol-3-yl)- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 12(c)] and methyl iodide, there was prepared 2-(5,6-dimethoxy- I-methyl-I H-indol-3-yfl-I (toluene-4-sulfonyfl-IH-pyrrolof2.3-blpvridine, as a brown solid, MS: 462(MH+). IH NMvR [(CD3) 2 SO]: 8 11.22 (1IH, 8.32 (1 H, dd), 7.92 dd), 7.55 7.45 (1IH, 7.28 (1IH, dd), 7.22 (2H, 7.00 (1H, 6.92 (IH, 6.75 (1H, 3.82 (3H, 3.72 (3H, 2.25 s).

By proceeding in a manner similar to Reference Example 13(a) above but using 2-(5-benzyloxy-6-methoxy- I H-indol-3-yl)- 1-(tol uene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 12(d)] and methyl iodide, there was prepared 2-(5-benzylox-v-6-methoxy- Imethyl-I H-indol-3-yfl- I-(toluene-4-sulfonyl)- IH-2yrrolo[2,3-blpyridine as a colourless solid. MS: 538(MHi+). HPLC (METHOD RT =1 1.57minutes.

By proceeding in a manner similar to Reference Example 13(a) above but using {3-[1-(toluene- 4-sulfonyl)- 11H-pyrrolo[2,3-b]pyridin-2-yl]- I H-indol-5-yl} -carbamic acid, tert-butyl ester [Reference Example 12(e)] and methyl iodide, there was prepared f3-rl -(toluene-4-sulfonyl)- IH-pvrrolol2,3blpyridin-2-vll-1 -methyl-I H-indol-5-:yl 1-carbamic acid, tert-butyl ester as a tan solid. MS: 51 7(MH+).

TLC: RF =0.7 (pentane ethyl acetate By proceeding in a manner similar to Reference Example 13(a) above but using 3-[1-(toluene- 4-sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indole-6-carboxyl ic acid, methyl ester [Reference Example 12(f)] and methyl iodide, there was prepared 3-Fl -(toluene-4-sqlfonyl)- I H-pyrrolor2,3blpyridin-2-yll- I-methyl-1 H-indole.6-carboxylic acid, methyl ester as a tan solid. MS: 460(MH+).

TLC: RIF 0.6 (pentane ethyl acetate By proceeding in a similar manner to Reference Example 13(a) above but using 2-(S-methoxy- I Hindol-3-yl> I -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine-4-carbonitrile (Reference Example 100) there was prepared 2-(S-methoxy- 1-methyl-I H-indol-3-vl)- I-(toluene-4-su Ifonyl)- IH-pyrrolor2,3- WO 03/000688 PCT/GB02/02799 -257blpyridine-4-carbonitrile as a yellow oil. TLC: RF 0.40 (ethyl acetate:heptane, 1: MS: 457(MH+).

By proceeding in a similar manner to Reference Example 13(a) above but using 4-chloro-2-(5methoxy- IH-indol-3-yI)-1 -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b] pyridine [Reference Example 12(h)] and methyl iodide, there was prepared 4-chloro-2-(5-methoxy-I -methyl-I H-indol-3-yl)-l -(toluene-4sulfonylb-1H-pyrrolor2,3-blovridine as a off-white solid. MS: 466(MHF*} IHNMR (CDC] 3 ):8~8.35 ~~K1 7.56 2H), 7.39 iR); 7.16-7.3 (in,2H), 7.05 2H), 6.95-7.0 (in, 21-)6.6 IH) 3.9 (s,3H) 3.8 3H) 2.3 3H).

4 C~ By proceeding in a similar manner to Reference Example 13(a) above but using I H-indol-3-yl)-5-phenyl- I -(toluene-4-sulfonyl)- 1 H-pyrrolo[2,3-b] pyridine [Reference Example 12(i)] and methyl iodide, there was prepared 2-(5-methoxy- I1-methyl- I H-indol-3-vyl)-5-phenyl- I -(toluene-4sulfonvyl)-l H-pyrrolo[2.3-blpyridine as a yellow solid, mn.p. 181-1 83*C. MS: 5O8(MI-l+).

By proceeding in a manner similar to Reference Example 13(a) above but using I J--indol-3-yl)-3-methyl- I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 12(k)] and methyl iodide, there was prepared 2-(5-methoxv- -methyl-I H-indol-3-vl)-3-methyl-1 -(toluene-4sulfonyl)-IH-pvrrolo[2,3-blpvridine as a yellow solid. TLC: RF= 0.31 (ethyl acetate/cyclohexane, MS: El (70eV); m/z =445 290 258 By proceeding in a manner similar to Reference Example 13(a) above but using 2-(1 H-pyrrol- 2-yl)- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 67(g)] and methyl iod ide, there was prepared 1-methyl-I H4-pyrrol-2-yl)- I-(toluene-4-sulfonyl)-I H-pyrrolor2,3-bl pvridine as a rust solid.-TLC. RF 0.28 (dichloromethane). MS: El (70eW); mn/z =351 196 (100%).

(in) By proceeding in a manner similar to Reference Example 13 above but using diinethyl-isoxazole-4-yl)- 1-(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine-2-yl]- I carboxylic acid, methyl ester (Reference Example [126)] and methyl iodide, there was prepared 2-[4- (3 .5-dimethyl-isoxazole-4-vl)- I-(toiuene-4-sulfonyfl)-1H-pyrrolor2.3 -blpyridine -2-yl1- 1-methyl-I Hacid, methyl ester which was used directly in the preparation of Example 1 By proceeding in a manner similar to Reference Example 13 above but using 4-(3,Sdimethyl-isoxazole-4-yl)-2-(5-methoxy- I H-indol-3-yl)- I-(toluene-4-sulfonly)- IH-pyrrolo[2,3b]pyridine [Reference Example 12(k)] and methyl iodide, there was prepared 4-(3,5-dimethyl-isoxazol- WO 03/000688 WO 03100688PCT/GB02/02799 -258- 4-yl)-2-(5-methoxy- I-methyl-I H-indol-3-vl)- I-(toluene-4-sufonvl)- 1H-pvrrolo[2.3-blpyridine as a yellow oil which was used immediately without further purification. MS: 527(MH 4 TLC RF 0.35 (ethyl acetate/heptane 1: 1).

By proceeding in a manner similar to Reference Example 13 above but using I H-indol-3 I-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3,-blpyridine-4-carboxylic acid, tert-butyl ester [Reference Example 101] and ethyl iodide, there was prepared 2-(1-ethyl-5-methoxy-IH-indol-3y1)-l- (toluene-4-sulfonyl)- IH-pyrrolo[2,3,-blpyridine4-carboxylic acid tert-butyl ester as a brown oil which was used directly in the preparation of Example 41 TLC: RF 0.60 (ethyl acetate/heptane, 1: 1).

By proceeding in a manner similar to Reference Example 13(a) but using 2-(6-benzyloxy-5methoxy- 1 H-indol-3-yl)- I uene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 12(q)] and methyl iodide, there was prepared 2-(6-benzvloxv-5-methoxv- 1-methyl-I H-indol-3-vl)- 1 -(toluene- 4-sulfonyl)- IH-pyrrolor2.3-blpvridine as an off-white solid. TLC: RF =0.41 (dichloromethane/ethyl acetate, 37/3). MS: El (70eV); m/z =537 446 291 By proceeding in a manner similar to Reference Example 13(a) but using 2-(5,6-dimethoxy- I H-indol-3-yI)- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b~pyridine (Reference Example 12(c)] and tertbutyl bromoacetate, there was prepared 1 5,6-dimethoxv-3-r 1 -(toluene-4-sulfonylI- H-pyrrolo[2.3blpvridin-2-Ylj-indol-1-vI -acetic acid tert-butyl ester as a pale green solid. TLC: RF 0.62 (dichloromethane/methanol, 19/1). MS: Cl (NH 3 xmz= 562 MH-I.

By proceeding in a manner similar to Reference Example 13(a) but using 2-(5,6-dimethoxy-I Hindol-3-yI)- 1-(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 12(c)], 4-(2-chloroethyl)morpholine hydrochloride and an excess of sodium hydride, there was prepared 2-rS.6-dirrnethoxy-l I -2-morpholin-4-yl-ethyl)- I H-indol-3-yll- 1 -(toluene-4-sulfonyl)-l H-pyrrolor2j3b~pyridine as a purple foam. TLC: RF 0.62 (dichloromethane/methanol, MS: El (70eV); m/z= 560 M+ 292 100 (100%).

REFERENCE EXAMPLE 14 3-4I -(Toluene-4-sulfonfl)- I H-pyrrolor2,3-bjpyridin-2-yj-I 1-methyl-I To a solution of 2-(5-methoxy- 1-methyl-I H-indol-3-yl)-] -(toluene-4-sulfonyl)- I H-pyrrolo[2,3 b]pyridine 2 4.5g, Reference Example 13(b)] in dichloromethane (500 mL), at 0O'C under an atmosphere of nitrogen, was added a solution of boron tribromide in dichloromethane (60 mL, I OM) and the mixture was stirred at 0"C for 1 hour. The reaction mixture was allowed to warm slowly to WO 03/000688 PCT/GB02/02799 -259- ~K1 ambient temperature and stirring continued for 12 hours. A solution of sodium carbonate (I M, 250 mL) was added to the mixture and stirring was continued vigorously for 3 hours. The precipitated solid was collected by filtration, washed with dichloromethane (100 mL) and dried to give the title compound (I 8.75g) as a colourless solid, m.p. 256-257C. MS: 41 8(MH+).

By proceeding in a manner similar to Reference Example 14(a) above but using I H-indol-3 -yl)-l -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyrid ine [Reference example there was prepared 3-[1-(toluene-4-sulfonyl)-IH-pyrrolo[2,3-blpyridin-2-yll-IH-indol-5-oI as a beige solid, m.p.

By proceeding in a manner similar to Reference Example 14(a) above but using 4-chloro-2-(5methoxy- 1-methyl-i H-indol-3-yl)- I-(toluene-4-su Ifonyl)- IH-pyrrolo[2,3-b]pyrid ine [Reference Example and subjecting the reaction product to chromatography on silica eluting with a mixture of dichloromethane and methanol (91:2, vlv) there was prepared 3-[4-chloro- I-(toluene4-sulfonl)- 1 H-Vyrrolo[2.3-b1Vyridin-2-ylJ- 1-methyl-I H-indol-5-ol as an off white solid LC-MS: Method A: RT= 3.01 minutes, 452. REFERENCE EXAMPLE 2-(5-AI lyloxy- 1-methyl-I H-indol-3-vf)l -(tol uene-4-sulfonyt)- I H-pyrrolor2,3-blpyridine A solution of I -methyl-3-[ I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH-indol-5-ol [2.1g, Reference Example 14(a)] in dry dimethylformamide (50 mL) was treated with potassium tert-butoxide (620mg) at 0 0 C under nitrogen. After stirring for 10 minutes the mixture was treated with ally] bromide (480pgl) and then allowed to warm slowly to ambient temperature. Stirring was continued for a further 6 hours after which time the mixture was poured carefully into water and the aqueous phase extracted exhaustively with ethyl acetate. The combined organic extracts were washed twice with brine (100 mL), then dried over sodium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane 1, v/v) to give the title compound (1.2g) as a yellow foam, m.p. 257-259'C. MVS: 458(MI-I+).

By proceeding in a manner similar to Reference Example 15(a) above but using ethyl-2chloroacetate there was prepared fI -methyl-3-F I-(toluene-4-su lfonyl)-1H-pvrrolor2,3-blpyridin-2-yll- I H-indol-5-yloxv) -acetic acid ethyl ester as a yellow solid. TLC: RF 0.45 (ethyl acetate/pentane MS: 504(MH+).

WO 03/000688 PCT/GB02/02799 -260- By proceeding in a manner similar to Reference Example 15(a) above but using ethyl 2bromoproprionate there wvas prepared 2-f 1 -methvl-3 I -(toluene-4-sulfonyl)- IH-nvrrolor2,3-blpyrid in- 2-vll- I H4-indol1-5-yloxvlI -prop ionic acid ethyl ester as a yellow sol id. TLC: RF =0.47 (ethyl By proceeding in a manner similar to Reference Example 15(a) above but using ethyl- Ibromocyclobutanecarboxylate there was prepared 1-f 1 -methyl-3-flI-(toluene-4-sulfonyl)-1Ipyrrolor2,3-blpyridin-2-yll-1 H-indol-5-yloxyl-cvclobutanecarboxvlic acid ethyl ester as acolourless solid, m.p. 189-190 0 C. MS: 544(MH+).

By proceeding in a similar manner to Reference Example 15(a) above but using I -methyl-3- (5H-pyrrolo[2,3-b] pyrazin-6-yl)- I 1-indol-5-oI (Example 7) and ethyl I -bromocyclobutane carboxylate there was prepared f11 -methyl-3-(5 H-pvrrolof2,3-blpyrazin-6-yl)- I cyclobutylcarboxylic acid ethyl esteras a tan solid. TLC: RF 0.23 (dichloromethane/methanol, 19: 1).

HPLC (METHOD RT 7.71 minutes.

REFERENCE EXAMPLE 16 3-fl -Methyl-3-r I-(toluene-4-sulfonyl)- 1 H-pyrrolof2,3-bi pyridin-2-vll- IH-indol-5-ylovl -propane- 1,2diol A solution of 2-(5-al lyloxy- 1-methyl-I H-indol-3-yl)- 1-(toluene-4-sulfonyl)- 1I--pyrrolo[2,3-b]pyridine [45.7mg, Reference Example 15 in acetone (10 mL) was treated with a solution of 4methylmorpholine-N-oxide (6mg) in water (I mL). This mixture was then treated with osmium tetroxide (2.S%/wt in tert-butanol, 6 drops) and the mixture stirred at room temperature for 12 hours.

The reaction mixture was diluted with water (75 mL), and extracted exhaustively with ethyl acetate, The combined organ ics were washed twice with brine (75 mL), then dried over magnesium sulfate and then evaporated. The residue wvas subjected to flash column chromatography on silica eluting with ethyl acetate to give the title compound (33mg) as a colourless solid. TLC: RF 0.25 (ethyl acetate).

REFERENCE EXAMPLE 17 3-fl -Methyl-3-f I-(tol uene-4-sulfonyl)- 1H-pvrrolo[2.3-blpyridin-2-yll- 1H-indol-5-vloxyl -propan- I-ol and 3-fl -Methvl-3-rlI-(toluene-4-sulfonvl)- IH-pyrrolof2,3-blpyridin-2-yl-1H-indol-5-yloxy)-propan- 2-ol A solution of 2-(5-aI lyloxy- 1-methyl-I H-indol-3-yl)- I-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridine [91 mg, Reference Example 15(a)] in dry tetrahydrofuran (5 rnLL) was treated with a solution of borane- WO 03/000688 PCT/GB02/02799 -261tetrahydrofuran complex in tetrahydrofuran(1 200gl, I OM). After stirring at ambient temperature for 7 hours the reaction mixture was treated with ethanol (9 drops), 5N potassium hydroxide (4drops) and hydrogen peroxide (6 drops) and stirring was continued for 12 hours during which time a white solid was precipitated. The reaction mixture was diluted with water (50 mL) and the pH- of this mixture was adjusted to 10 by addition of potassium hydroxide solution (I M) before exhaustively extracting with ethyl acetate. The combined organic extracts were dried over sodium sulfate then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane to give 3- 11I-mnethyl-3-[ I-(toluene.4-sulfonyl)- IH-nvrrolo[2,3-blovridin-2-vll- (50mg) as acolourless solid [TLC: RF=0.15 (ethyl acetate). MS: 476(MHjI] and 3- 11I-methyl-3-f I-(toluene-4-sulfonl)-1 H-pyrrolo[2,3-blpyridin-2-yll- yloxvyj-propan-2-ol (8mg) as a colourless solid. [TLC: RF =0.3 (ethyl acetate); MS: 476(MH 4 REFERENCE EXAMPLE 18 Trifluoro-methanesul fonic acid I -methyl-3-r 1-(toluene-4-sulfonyl)- 1H-Ryrrolo[2,3-bl pvridin-2yll-]H-indol-5-yl ester A suspension of I -methyl-3-[ I -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-2-yl]- I [398mg, Reference Example 14(a)] in dichioromethane (10 mL), cooled to -78 0 C-under a nitrogen atmosphere, was treated with triethylamine (0.15S mL) followed by N-phenyltrifluorometbanesulfonimide The resultant mixture was allowed to warm slowly to ambient temperature, stirring was continued for a fuirther 12 hours then saturated sodium bicarbonate mL) was added. The organic phase was separated and the aqueous phase was extracted twice with dichloromethane (20 rnL. The combined organics were dried over sodium sulfate then evaporated.

The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (380mg) as a colourless solid. MS: 492(MI-1). 1-PLC (METHOD RT =2.O2minutes.

By proceeding in a similar manner to Reference Example 18(a) but using 1 pyrrolo[2,3-b]pyrazin-6-yl)- 1H-indol-5-ol (Example 7) there was prepared trifluoro-methanesulfonic acid I -methyl-3-15H-pyrrolo[2.3-b] pvrazin-6-yll- IH-indol-5-vl ester as a purple solid. HIPLC (METHOD RT =8.12 minutes. 'H NMvR [(CD 3 2 S0]: 5 12.30 (1 H, s); 8.3 2 (1IH, 8.27 (1 H, d, J=3.5 8.23 (1 H, 7.97 (1IH, 7.76 (11-H, d, J=8.6 Hz); 7.08 (1IH, s); 3.96 (3H. s).

WO 03/000688 PCT/GB02/02799 -262- By proceeding in a similar manner to Reference Example 18(a) but using 4-hydroxy- IHpyrrolo[2,3-b]pyridime there was prepared trifluoro-methanesulfonic acid I H-pyrrolof2,3-blnvridin-4yl ester as a white solid. MS: 267(M-H+).

By proceeding in a similar manner to Reference Example 18(a) but using 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yI]-N-methylpropionamide [Example 40(d)] there was prepared 3-r6-44-trifluoromethanesulfonloxyphenl-5H-pyrrolo[2.3-bl ovrazin-7-yll-Nmethylpropionainide as a white solid. MS: 429.1(MI-i).

By proceeding in a similar manner to Reference Example 18(a) but using 6-(4-hydroxyphenyl)- 5H-pyrrolo[2,3-b]pyrazine [Example 1 there was prepared 6-(4-trifluoromethanesulfonyloxcyphenl)-5H-pyrrolo 2,3-b] pyrazine as a cream solid. MS: 344(Mf1+).

By proceeding in a similar manner to Reference Example 18(a) but using 3-[4-chloro-]-- (toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl-1 -methyl-I H-indol-5-ol [Reference Example 14(c)] there was prepared trifluoro-methanesulfonic acid 3-[4-chloro- I -toluene-4-sulfonyl)- 11pyrrolo[2.3-bIovridin-2-yll- I-methyl- IH-indol-5-yl ester as a white foam. LC-MS: Method A: RT 4.20 minutes, 584.1(M+).

By proceeding in a similar manner to Reference Example 18(a) but using I H-pyrrolo[2,3b]pyridine-4-ol [Reference Example 86] with a mixture of dichloromethane and dimethylformamide (10:4, v/v) as solvent and subjecting the crude product to flash column chromatography eluting with a mixture of ethyl acetate and heptane v:v) there was prepared trifluoro-methanesulfonic acid-I Hpvrrolor2.3-bJovridin-4-vl ester as a white solid. MS: 267(MI+), TLC: RF 0.46 (ethyl acetate/heptane, 1:1).

REFERENCE EXAMPLE 19 1 -Methyi-3-[ I-(toluene-4-sulfonyl)- I 1-pyrrolof 2,3-blpvridin-2-vlil- IH-indole-5-carboxyl ic acid. methyl ester A solution of trifluoro-methanesulfonic acid I -methyl-3-[ I -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3b]pyridin-2-y]-1I--indol-5-yl ester [3 00mg, Reference Example 18(a)] in a mixture of dry dimethylformamide (10 mL), methanol (6 mL) and triethylamine (2 mL) was treated with palladium acetate (24mg) and 1,3 bis(diphenylphosphino)propane and the mixture stirred at ambient temperature for 30 minutes. Carbon monoxide was introduced via a septum to the reaction vessel at a steady rate and the mixture heated at 90*G until no starting material was present as indicated by TLC (ethyl WO 03/000688 WO 03/00688PCT/GB02/02799 -263acetate/ pentane The mixture was then concentrated in vacuo and the residue partitioned between dichioromethane and water. The organic phase was washed with a saturated solution of lithium chloride, then dried over sodium sulfate and then evaporated. The residue was subjected to flash column chromatography on silIica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (200mg) as a colourless solid. MS: 460(Mi-I). HPLC (METHOD RT 10.23 minutes.

By proceeding in a similar manner to Reference Example 19(a) but using trifluoromethanesulfonic acid I -methyl-3-[51-I-pyrrolo[2,3-b]pyrazin-6-yl]- I H--indol-5-yl ester [Reference Example 18(b)] there was prepared 1 -methvl-3-(5H-pyrrolo[2.3-blpyrazin-6-vl)- carboxylic acid. methyl ester as a brown solid. MS: 307(MH+). 1-PLC (METHOD RT =6.64 minutes.

By proceeding in a similar marnner to Reference Example 19(a) but using trifluoromethanesulfonic acid I H-pyrrolo[2,3-b]pyridin-4-yl ester [Reference Example 18(c)] there was prepared I l-prrolof2.3-blnvridine-4 carboxylic acid. methyl ester as a yellow solid. MS: I 77(MI-l).

TLC: RF 0.4 ethyl acetate heptane, 1: 1, vfv).

By proceeding in a similar manner to Reference Example 19(a) but using trifluoromethanesulfonic acid 3-[4-chloro-lI-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridin-2-yl]- I-methyl-i Hester [Reference Example 18(f)] there was prepared 3-(4-chloro-l-(toluene-4-sulfonyl)-IHpyrrolo[2,3-blpyridin-2-vl~- -methyl-i H-indole-5-carboxvl ic acid, methyl ester as awhite foam. LC- MS: Method A: RT 3.95 minutes, 494(ME-U).

REFERENCE EXAMPLE I -Methyl-5-( -trimethyistannanyi-] H-tetrazol-5-yi)- I H-indol-3-yll- I -(toluene-4-sulfonyl)- 1 H- Ryrrolo[2.3-blpyridine *A solution of 1 -methyl-3-[ I-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]-lIH-indole-5carbonitrile [100mg, Reference Example 13(c)] in toluene (10 mL) was treated with trimethyltin azide (56mg, 0.28mmol) then heated under reflux for 14 hours. The white precipitate was collected by filtration washed with toluene (10 mL) and then dried to give the title compound (I125mg) as a colourless solid, m.p. 240-243'C *(with decomposition). MS: 633(MH-1).

REFERENCE EXAMPLE 21 WO 03/000688 WO 03/00688PCT/GB02/02799 -264- 2-ri -Methyl-5-(l -methyl- I H-tetrazol-5-yl)- 1 H-indol-3-yll- 1 -(toluene-4-sulfonyl)- I H-pyrrolo[2,3bipyridine and 241 -Methyl-5-(2-methyl-2H-tetrazol-5-vl)- IH-indol-3-yll-l1-(toluene-4-sulfonyl)- IHpyrrolof2,3-blpvridine Methyl iodide (2.5 rnL) was added to a solution of 2-[1-methyl-5-(l-trimethylstannanyl-IH-tetrazol-5yl)-1 H-indol-3-yI]- I-(toluene-4-sulfonyl)- I 1-pyrrolo[2,3-b~pyrid ine [620 mg, Reference Example at ambient temperature. The mixture was then allowed to stir at ambient temperature for 4 hours then was poured into water and then extracted with ethyl acetate. The combined extract was washed with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether 1, v/v) to give o 2-flI -methyl-5-(] -methyl- I H-tetrazol-5-yl)- I I--indol-3-yll- I -(toluene-4-sulfonyl)- I H-pvrrolo[2,3-.

*blpyridine (191 mg) as a colourless solid, [MS 506(MvNa+). I H NIVIR [(CD 3 2 S0]: 5 8.39 (dd, I H, J=4.8 and 1.6 Hz); 7.97 (in, I 7.96 I H, J=4.0 Hz); 7.90 IlH); 7.80 (dd, I1H, J=8.7 and 0.6 Hz); 7.70 (dd, I H, J=8.7 and 1.8 Hz); 7.56 (in, 2H); 7.30 (dd, I H, J=~7.7 and 4.8 Hz); 7.22 (in, 2H); 6.82 (s, IH); 4.19 3H); 4.0 3H); 2.23 3H)] and 2-[1-Methyl-5-(2-methvl-2H-tetrazol-5-yl)-IH-indol-3yfl-l -(toluene-4-sulfonyl)-1 H-pyrrolof2.3-blpvridine (77mg) as a colourless solid, m.p. 215-21 8*C [MS :506(MTNa+)].

REFERENCE EXAMPLE 22 11 -Methyl-3-[ I-(toluene-4-sulfonvl)-I H--Vyrrolo2.-blovridin-2-yl1- I H-indol-5-vl 1-ethanone o To dry, degassed'dimethylformamide (110 mL) under nitrogen at ambient temperature, was added trifluoro-methanesulfonic acid I -methyl-3-[ I-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridin-2-yl)- 1Hester [2.2g, Reference Example 18), triethylamine 15 mL), n-butylvinylether (2.87 mL), I ,3-bis(diphenylphosph inopropane) (413mg) and palladium acetate (232mg) sequentially. The mixture was heated at reflux for 2 hours then cooled to ambient temperature and then added to hydrochloric acid (90 mL, I This mixture was extracted with dichloromethane (200 mL). The organic extract was washed with saturated aqueous sodium bicarbonate, then with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane vfv) to give the title compound (I.lIg) as a yellow solid, m.p.

177-1781C. MS: 444(MH+).

REFERENCE EXAMPLE 23 f SI -(+)-2,2-Dimethvl-r I 31dioxolan-4-vlmethloxv)-I -methyl-I H-indol-3-yJI- I -(toluene-4sulfonvl)- 1 H-pyrrolor2,3-blpyridine A solution of I -methyl-3-[ I -(toluene-4-sulfonyl)- 1 H-pyrrolo[2,3-b~pyridin-2-yl]- I H-indol-5-ol [I.1I7g, Reference Example 14(a)] in dry dimethylformamide (50 mL) was treated with caesium carbonate (1.1 g) and tetrabutylammonium hydrogen sulfate (40mg). After stirr ing at ambient temperature for WO 03/000688PC/B /079 PCT/GB02/02799 -265minutes the mixture was treated with 2-dimethyl-1, 3-dioxolane-4-ylmethylparatoluenesulfonate (0.96g) then heated at 120*C overnight. The reaction mixture was concentrated in vacuo and the residue partitioned twice between dichloromethane (100 mnL) and water (50 mL) and the aqueous layers were extracted with dichloromethane (100 The combined organic phases were washed twice with brine (150 mL), then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichioromethane and methanol (199: 1, v/v) to give the title compound (1 .04g) as a yellow oil, MS: 532(MH+). I HNMR c-i [(CD 3 2 S0]: 8 1.30 (3H, 1.37 (3H, 2.29 (3H, 3.76 (1iH, dd, J=8.3 and 6.5 Hz); 3.90 (3H, s); 3.94-3.98 in); 4. 10 (1iH, dd, J=8.20 and 6.5 Hz); 4.41 (1 H, mn); 6.74 (1IH, 6.91 (1IH, dd, J=8.8 and 2.3 Hz); 6.98 (1iH, d, 1=2.4 Hz); 7.25 (2H, d, J=7.9 Hz); 7.29 (1 H, dd, J=7.8 and 4.9 Hz); 7.44 (1iH, d, J=8.8 Hz); 7.56 (1iH, d, J=8.3 Hz); 7.63 (1IH, 7.81 (2H, d, J=8.0 Hz); 7.92 (1 H, dd, J=7.7 and 1.6 Hz); 8.33. (1IH, dd, J=4.9 and 1.7 Hz).

By proceeding in a manner similar to Reference Example 23(a) above but using 2diinethyl- 1, 3-dioxolane-4-ylmethyl-paratoluenesulfonate there was prepared 2-r5-( dimethvl-f I.31dioxolan-4-ylmethoxvy)- 1-methyl-I H-indol-3-yll- 1 4toluene-4-sulfonyl)- 1H-o~vrrolof2,3blpyridine as a yellow oil, MS: 532(MH+). I HNMIR [(CD 3 2 S0]: 8 1.33 (3H1, 1.37 (3H, 2.29 (3H, 3.77 (1 H, dd, J=83 and 6.5 Hz); 3.88 (3H, 3.97-3.99 (2H, in); 4.11 (1iH, dd, J=8.3 and 6.6 Hz); 4.41 (1IH, mn); 6.74 (1 H, 6.94 (1IH, dd, J=8.8 and 2.3 Hz); 6.97 (1IH, d, 1=2.3 Hz); 7.25 (2H, d, J=8.1 Hz); 7.29 (1lH, dd, J=7.8 and 4.9 Hz); 7.44 (IH. d. 1=8.8 Hz); 7.57 (2H, d, J=8.4 Hz); 7.63 (1IH, 7.95 (1 H, dd, J~=7.81 and 1.7 Hz); 8.33 (1LH, dd, 1=4.88 and 1.7 Hz).

W By proceeding in a manner similar to Reference Example 23(a) above but using 6-methoxy- 1-methyl-i H-indol-3-yl)- 1-(toluene-4-suifonyl)-l1H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-[5-(USl-(+'1-2,2-diinethyl-[ 1 .3dioxolan-4-ylmethoxv)-6 methoxy-1-methyl-i H-indol-3-yll-l1-(toluene-4-sulfonyl)- IH-ovrrolo[2,3-b1 pyridine as a cream solid.

MS: 548(M1-i+). HPLC (METHOD RT 11.60 minutes.

By proceeding in a manner similar to Reference Example 23(a) above but using 3-[1 -(toluene- 4-sulfonyl)- I H-pyrrolo[2,3-b]pyridin-2-yl]-1 I--indol-5-ol [Reference Example 14(b)] and ethyl I1broinocyclobutane carboxylate, there was prepared 1-f 1-(cyclobutanecarboxylic acid ethyl ester)-3-l (toluene-4-sulfonyl)- I H-ovrrolor2.3-bl pyridin-2-yll- IH-indol-5-yloxcyl-cyclobutanecarboyl ic acid ethyl ester as a cream solid. MS: 657(MH+'). 1 H NMR [(CD 3 2 S0]: 8 8.35 (IH, dd, J =4.8 and 1.6 Hz); 7.9 (2H, in); 7.48 in); 7.28 (1 H, dd, J=7.7 and 4.8 Hz); 7.24 (21-1, d, J=8.4 Hz); 6.71 (1IH, dd, 1=8.9 and 2.4 Hz); 6.68 (1IH, 6.64 (1 H, d, J=2.4 Hz); 5.12 (lH, dd, J=8.8 and 8.8 Hz); 4.13-4.03 WO 03/000688 PTGO/29 PCT/GB02/02799 -266ri (41-1, in); 3.66 (1IH, dd, J=9.4 and 9.4 Hz); 2.64-1.82 (13 H, in); 1. 15 (3 H, t, J=7.1 Hz); 0.94 (31-H, t, J=7.1 Hz).

1 -11I-methyl-3-r I-(toluene-4-sulfonyl)- IH-pyrrolo[2.3-blpyridin-2-yll- pronan-2-one By proceeding in a manner similar to Reference Example 23 above but using I -methyl-3-[1 (toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridin-2-ylj]H-indol-5-ol [Reference Example 14(a)] and chioroacetone, there was prepared 1- (1-methvl-3-FI -(toluene-4-sulfonfl)- I l-nyrrolo[2,3-blpyridin-2yll-IH-indol-5-yloxvyl-propan-2-one as a pale yellow foam. IHNMR [(CD 3 2 S0]: 8 8.35 (IH, dd); 7.93 (IR, dd); 7.62 (1H, 7.55 (2H, 7.48 (IH, 7.28 (3H,mi); 6.92 (2H,mi); 6.72 (1H, 4.70 (2H, 3.90 (3H, 2.28 (3H, 2.15 (3H, s).

REFERENCE EXAMPLE 24 I -Methyl-3 -r I-(toluene-4-sulfonyl)- IH-pyrrolo(2,3-blpyridin-2-yilIH-indol-5-yloxyl propane- 1,2-diol A solution of iiethyl-[1 ,3]dioxolan-4-ylmethoxy)- 1-methyl-I H-indol-3-yl]- 1- (toluene-4-sulfonyl)-IH-pyrrolo[2,3-b]pyridine [1.04g, Reference Example 23(b)] in methanol (20 mL) was treated with hydrochloric acid (20 mL, I M) then heated under reflux for 3 hours. The reaction mixture was concentrated in vacuo and the residue subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane 1, v/v) to give the title compound (3 80mg) as a clear oil.

TLC: RIF =0.2 (pentane/ethyl acetate: MS: 492(MH+).

By proceeding in a manner similar to Example 24(a) but using 2-[5-({S}-(+)-2,2-diinethyl- [1 ,3]dioxolan-4-ylmethoxy)- 1-methyl-I H-indol-3-yl]- 1-(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 23(a)] there was prepared (S)-3-11I-methvl-3-r I-(tol uene-4-sulfonvl)- IHpyrrolor2,3-blbvridin-2-ll- I H-indol-5-yloxyl -propane- 1,2-diol as a clear oil.

MS: 492(MH 4 IH NMR [(CD 3 2 S0]: 5 8.33 (IH, dd, 4.9,1J1.7 Hz); 7.92 dd, 1=7.8 and 1.7 Hz); 7.62 7.56 d, J=8.8 Hz); 7.45 d, J=8.8 Hz); 7.29 dd, 3=7.8 and 4.8 Hz); 7.25 d, J=8.1 Hz); 6.96 (1IH, d, J=2.3 Hz); 6.92 (1IH, dd, J'=8.8 and 2.3 Hz); 6.75 (1 H, s); 4.93 (1IH, 4.66 (11-H, 5.13 (1lH, d, J=5.13 Hz); 3.88 (3 H, 3.80 (2H, d, J=5.9 Hz); 3.46 s); 2.23 (3H, s).

By proceeding in a manner similar to Example 24(a) above but using dimietbyl-[ 1,3]dioxolan-4-ylmethoxy)-6-inethoxy- 1-methyl-I H-indol-3 1-(toluene-4-su Ifonyl)- IHpyrrolo[2,3-b~pyridine [Reference Example 23(c there was prepared 6-methoxy-I -methyl-3- WO 03/000688 WO 03/00688PCT/GB02/02799 -267r I -(toluene-4-sulfonyh)- I H-pyrrolo[2.3-blpyridin-2-yll- I H- indo I-5-y Ioxyl -propane-1 .2-diol as a cream solid. MS: 522(N4H+). HPLC (METHOD RT 8.15 minutes.

REFERENCE EXAMPLE 2-f 5-(2-Methoxy- I-methyl-ethoxy)- 1-methiyl-I H-indol-3-yll-1 -(toluene-4-sulfonyl)- 1H-pyrrolo[2,3bipyridine A solution of triphenylphosphine (470mg) and diisopropyldiazodicarboxylate 3 50pi) in dry toluene mL) was treated with I -methyl-3-[l-(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-2-yl]-I H-indol- (I150mg, Reference Example 14(a)] followed by Il-methoxy-2-propanol (I 50pI). The resulting mixture was heated under reflux. for 5 hours then cooled and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixtureof ethyl acetate and pentane 1, v/v) to give the title compound (50mg) as a clear oil. TLC: RF 0.65 (pentane/ethyl acetate MIS: 480(MH+).

REFERENCE EXAMPLE 26 N-Hvdroxv- I-methyl-3-[ I-(toluene-4-su Ifonyl')- IH-pyrrolo[2,3-bl pyridin-2-yll- carboxamidine A solution of I -methyl-3-[ I-(toluene-4-sulfonyl)- 1H-pyrrolo[2,3-b]pyridin-2-yl]-I1H-indole-5carbon itrile [2.11 g, Reference Example 1 in ethanol (150 mL) at ambient temperature was treated with hydroxylamine hydrochloride (I1.72g) and potassium carbonate (3.43g). The reaction mixture was heated at reflux under nitrogen for 15 hours then filtered. The filtrate was evaporated to give the title compound (2.8g) as a dark green solid. MS: 460(MH+). l-PLC (METHOD RT =6.19 minutes.

REFERENCE EXAMPLE 27 2-fl -Methyl-5-(5-methyl-[1 .2,41oxadiazol-3-yl)- I H-indol-3-vl]- I- toluene-4-sulfonyl)l H-pyrrolor2.3bloyridine To a suspension of N-hydroxy- I-methyl-3-[ 1-(tol uene-4-su Ifonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]- IH- [0.7g, Reference Example 26] in toluene (30 mL) at ambient temperature under nitrogen was added acetic anhydride (0.467g). The reaction mixture was heated at reflux for hours then filtered. Thle filtrate was evaporated to give the title compound (0.32g) as a dark red oil which was used immediately without further purification.

REFERENCE EXAMPLE 28 2-(5-Hydroxy-6-methoxy- 1-methyl-I H-indol-3-yl)-I -(toluene-4-sulfonyl)- I H-pyrrolor2,3-blpyridine WO 03/000688 PCT/GB02/02799 -268- A solution of 2-(5-benzyloxy-6-methoxy-l-methyl-lH-indol-3-yl)-l-(toluene-4-sulfonyl)-lHpyrrolo[2,3-b]pyridine [6.26g, Reference Example 13(e)] in acetonitrile (500 mL) was treated with Ci sodium iodide (4.38g) followed by trimethylsilyl chloride (3.17 mL). The mixture stirred at 40 0 C for 3 hours then treated with further portions of sodium iodide (4.38g) and trimethylsilyl chloride (3.17 mL).

After stirring at 40 0 C for a further 12 hours the reaction mixture was evaporated. The residue was C treated with water (200 mL) and the mixture was extracted three times with ethyl acetate (200 mL).

The combined extracts were dried over magnesium sulfate then evaporated. The residual brown foam was triturated with ethyl acetate and diisopropyl ether to give the title compound (3.04g) as a light brown solid, m.p. 211-214 0 C. HPLC (METHOD RT 9.30 minutes.

0 c(N REFERENCE EXAMPLE 29 I-{6-Methoxv- Il-methyl-3-[1-(toluene-4-sulfonyl)-lH-pyrrolo[2,3-bJpyridin-2-vl-l cyclobutanecarboxylic acid ethyl ester Sodium hydride (43mg, 60% dispersion in mineral oil) was added to a stirred solution of 6-methoxy-l-methyl-lH-indol-3-yl)-l-(toluene-4-sulfonyl)-lH-pyrrolo[2,3-b]pyridine [400mg, Reference Example 28(a)] in dry dimethylformamide (20 mL) under a nitrogen atmosphere at ambient temperature. The mixture was allowed to stir for 1 hour then treated with ethyl-lbromocyclobutanecarboxylate (2161l) and stirring was continued overnight. Additional portions of sodium hydride (43mg, 60% dispersion in mineral oil) and ethyl 1-bromocyclobutanecarboxylate (216pl) were then added, then the mixture was heated at 50 0 C for 5 hours. The cooled reaction mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water, then with brine, then dried over magnesium sulfate and then evaporated.

w I The yellow residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (266mg) as a yellow oil. MS: 576(MH+).

HPLC (METHOD RT 11.07 minutes.

REFERENCE EXAMPLE rl-Methvl-3-(lH-pyrrolo[2.3-b]pyridin-2-yl)-lH-indol-5-yll-carbamic acid. tert-butyl ester A solution of {1-methyl-3-[ -(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridin-2-yl]- carbamic acid, tert-butyl ester [0.3g, Reference Example 13(f)] in methanol (15 mL) was treated with potassium hydroxide solution (5N, 2 mL) then heated at reflux for 4 hours. The reaction mixture was evaporated and the residue triturated with water to give the title compound (0.2g) as a tan solid. MS: 263(MH+). TLC: RF 0.3 (ethyl acetate).

WO 03/000688 PCT/GB02/02799 -269-

O

REFERENCE EXAMPLE 31 SH-Indole-6-carboxylic acid methyl ester A solution of H-indole-6-carboxylic acid (10g) in methanol (300 mL) was treated with concentrated sulfuric acid (0.5 mL) then heated on a steam bath for 10 hours. The solvent was removed under reduced pressure and the residue partitioned between saturated sodium bicarbonate solution (150 mL) and dichloromethane (150 mL). The aqueous layer was further extracted twice with dichloromethane (150 mL). The combined organics were dried over sodium sulfate then evaporated. The residue was Ssubjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (7:3, v/v) to give the title compound (7.4g) as a white solid, m.p. 79-81 C. MS: 176(MH+).

REFERENCE EXAMPLE 32 Dimethvl-(6-phenvl-5H-pvrrolo[2.3-bpyrazin-7-ylmethyl)-amine A solution of dimethylamine in tetrahydrofuran (0.5 mL, 2.0M) at 0°C was treated with glacial acetic acid 15l) then with formaldehyde 75 1p, 40% solution). After stirring at 0°C for 10 minutes this mixture was treated with 6-phenyl-5H-pyrrolo[2,3-b]pyrazine [0.195g, Example and then with tetrahydrofuran (3 mL) to ensure complete dissolution. The reaction mixture was allowed to warm to ambient temperature, then stirred overnight, then diluted with ethyl acetate (5 mL) and then extracted three times with hydrochloric acid (5 mL, IN). The combined acid extracts were adjusted to pH 6-7 by addition of potassium hydroxide solution The resulting pale yellow solid was filtered, then washed with water and then dried to give the title compound (0.16g) as a pale yellow solid, m.p. 191 192 0

C.

IW REFERENCE EXAMPLE 33 Trimethvl-(6-phenvl-5H-pyrrolor2.3-blpvrazin-7-ylmethyl)-ammonium iodide A solution of dimethyl-(6-phenyl-5H-pyrrolo[2,3-b]pyrazin-7-ylmethyl)-amine [5.1g, Reference Example 32] in ethyl acetate (100 mL) at 0°C was treated with a solution of iodomethane (40 mL) in ethanol (150 mL). The resulting mixture was stirred at 0°C for 2 hours. The precipitated solid was filtered then washed with ethyl acetate (10 mL) and then with diethyl ether (20 mL) to give the title compound as a yellow solid m.p. 224-225 0

C.

REFERENCE EXAMPLE 34 (6-Phenyl-5H-pyrrolor2,3-b]pyrazin-7-vl)-acetonitrile A solution of potassium cyanide (0.84g) in water (20 mL) was added rapidly to a stirred solution of trimethyl-(6-phenyl-5H-pyrrolo[2,3-b]pyrazin-7-ylmethyl)-anmonium iodide [1.lg, Reference Example 33] in dimethylformamide (20 mL) and the mixture heated at 75 0 C for 6 hours. The cooled WO 03/000688 PCT/GB02/02799 -270-

O

CN solution was diluted with water (100 mL) and the precipitated solid filtered to give the title compound as a yellow solid, m.p. 247-248 0

C.

REFERENCE EXAMPLE (6-Pienyl-5H-pyrrolo[2,3-blpvrazin-7-yl)-acetic acid S A solution of (6-phenyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-acetonitrile [70mg, Reference Example 34] in potassium hydroxide (10M, 5 mL) was heated at 100 0 C for 1.5 hours. The reaction mixture was allowed to cooled, then diluted with water (25 mL) and then acidified to pH 1 by addition of concentrated hydrochloric acid. The resulting pale yellow solid was filtered, then washed with water and then dried to give the title compound (40mg) as a yellow solid, m.p. 276-277 0

C.

REFERENCE EXAMPLE 36 l-Methvl-3-r -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-bjpyridin-2-vl]-l To a solution of I-methyl-3-[l-(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridin-2-yl]-IH-indole-5carbonitrile [500mg, Reference Example 13(c)] in tetrahydrofuran (20 mL) at 0°C was added diisobutylaluminium hydride (12 mL, 1M in tetrahydrofuran) under an atmosphere of nitrogen. The resultant solution was then allowed to warm to ambient temperature and stirred at this temperature for 2 hours. The reaction mixture was then poured into a solution of cold IN aqueous hydrochloric acid mL). After 1 hour, the mixture was made alkaline with saturated aqueous sodium hydroxide and extracted with ethyl acetate (40 mL). The organic layer was separated and the aqueous further extracted with ethyl acetate (2x20 mL). The organic extracts were combined, dried over magnesium sulfate and concentrated in vacuo to give the title compound (221mg) as a white solid, m.p. 188-189 0

C.

S MS: 430(MH+).

REFERENCE EXAMPLE 37 3-.1-Methyl-3-[ -(toluene-4-sulfonvl)-1H-pvrrolo[2.3-bpvridin-2-vll- H-indol-5-vl}-acrylic acid ethyl ester Triethylphosphonoacetate (60 mL) was added at 0°C to a suspension of sodium hydride (22.4mg, dispersion in mineral oil) in dimethoxyethane (3 mL). The resultant suspension was stirred at ambient temperature for 1 hour. I-Methyl-3-[-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridin-2-yl]-lH-indole- [120 mg, Reference Example 36] in dimethoxyethane (2 mL) was added and stirring was continued for 3 hours. The reaction mixture was then poured into water and extracted twice with ethyl acetate (30 mL). The combined organics were then washed with brine before drying over magnesium sulfate and then concentrated in vacuo to give the title compound (126mg) as a yellow solid, m.p. 159-162 0 C. MS: 500(MH+).

WO 03/000688 WO 03/00688PCT/GB02/02799 -271- CI REFERENCE EXAMPLE 38 3-f 1 Methyl -3-f I-(toluene-4-sulfonyl)-1 H-pyrrolo[2.3-blpvridin-2-vll-I I--indol-5-yll propionic acid ethyl este Palladium (15.7mg, 10% on activated carbon) was added to a suspension of 3-{1-methyl-3-[1 -(toluene- 4-sulfonyl)- 1H-pyrrolo[2,3-bjpyrid in-2-yl)I1H-indol-5-yl} -acrylic acid ethyl ester [100mg, Reference Example 37] in industrial methylated spirit (25 mL). The resultant suspension was then stirred under an atmosphere of hydrogen for 16 hours. The reaction mixture was then filtered through a pad of celite and the filtrate evaporated in vacuo. The resultant solid was triturated with water, filtered and dried to give the title compound (92mg) as a white solid, im~p. 280-282'C. MS: 5O2(MHW-).

C) [0 By proceeding in a manner similar to Example 38 above but using ethyl 3-[2-dimethylamino-5-(5 H-pyrrolo[2,3-b~pyrazin-6-yl)phenyl]prop.2-enonate (Reference Example 47), there was prepared ethyl 3 imethy [am ino-5 45 H-pyrro lo [2.3 -bl ovrazin-6-yl)phe ny 11prop ionate as an orange gum which was used directly in the next reaction. 'H NMR [(CD3) 2 S0]; 5 8.33 (1 H, 8.17 (I H, 7.94 (1lH, 7.82. (1 H, d, J=8.4 Hz); 7.20 (1IH, d, J=8.4 Hz); 7.03 (1 H, 4.07 (2H, q, J=7.6 Hz); 3.3 8 (2H, t, J=7.1 Hz); 3.00 (2H, t, J=7.1 Hz); 2.70 (6H, 1. 19 (3H, t, J=7.1 Hz).

REFERENCE EXAMPLE 39 4-Methoxy-2-(5-methoxv- 1H-indol-3-yl)- I -(toluene-4-sulfonl)- 1H-cvrrolor2.3-bl ,wridine By proceeding in a similar manner to Example 18 but using 2.{1-N-zert-butyloxycarbonyl-5-methoxy- 1 H-indo 1-3 -yi)-4-methoxy- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine (Reference Example there was prepared the title compound as a tan solid. HPLC (METHOD Rr 8.49 minutes. MS: 448(MH 4 REFERENCE EXAMPLE 24( -ten--B utvloxycarbonyl-5-methoxy- I H-indol-3-yl)-4-methoxy- I -(tol uene-4-sulfonyl)- I Hpyrrolor2,3-bloyridine A stirred solution of diisopropylamine (0.21 mnL) in tetrahydrofuran (5 mL), at -70'C and under nitrogen, was treated with a solution of n-butyllithiurn in hexanes (0.6 mL, I.SM) over 5 minutes, whilst maintaining the temperature below -65'C. After stirring for I hour the mixture was added, at 30*C, to a solution of 4-methoxy- I -toluene-4-sulfonyl)-1 H-pyrrolo[2,.3-b)pyridine (Reference Example 41, 280mg) in tetrahydrofiuran (10 mL), whilst maintaining the temperature below After allowing to warm to -1 5'C over I hour a solution of zinc chloride in tetrahydrofuran (2.8 mL, was added, maintaining the temperature below -10 0 After 30 minutes the reaction mixture was treated with tetrakis(triphenylphosph ine)palladium (54mg) and 3-bromo-5-methoxy-indole- Icarboxylic acid teri-butyl ester (Reference Example I1I(a), 152mg) and stirred at 60'C for 16 hours, then treated with water (30 mL). The mixture was extracted with ethyl acetate (3 x 25 mL). The WO 03/000688 PCT/GB02/02799 -272-

O

NC combined organics were washed with brine (2 x 15 mL), dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (45mg) as a white foam. TLC RF 0.34 0 (ethyl acetate/pentane: HPLC (METHOD RT 9.72 minutes.

REFERENCE EXAMPLE 41 S4-Methoxy-l-(l-toluene-4-sulfonvl)- H-pyrrolo[2,3-blpyridine SMethod A: A mixture of 4-nitro-l-(1-toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridine [Reference Example 0.77g] and dry dimethylformamide (25 mL) was treated with sodium methoxide (0.17g) and stirred at 50°C for 16 hours. A further portion of sodium methoxide (0.085g) was then added and stirring continued for 8 hours, then the dimethylformamide was removed in vacuo. The residue was dissolved in ethyl acetate (100 mL) and washed with a water/brine mixture 60 mL). The organics were dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give the title compound as a cream solid. HPLC: RT= 9.73 minutes. IHNMR[(CD 3 2 SO]: 8 8.22 (1H, d,J=8.2Hz); 7.96(2H, d, J=9.4Hz); 7.71 (IH, d, J=3.5 Hz); 7.39 (2H, d, J--9.4 Hz); 6.89 (1H, d, J=8.2 Hz); 6.72 (1H, d, J=3.5 Hz); 3.93 (3H, 2.30 (3H, s).

Method B: To 4-chloro-lH-pyrrolo[2,3-b]pyridine [2.3g, Reference Example 64] in a stainless steel pressure vessel was added sodium hydroxide and methanol (40 mL). The pressure vessel was sealed and heated at 170 0 C for 4 hours. After cooling, water (100 mL) was added and the mixture was neutralised by addition of excess solid carbon dioxide pellets (30g). After concentration to a slurry and l filtration, the residue was washed twice with water (5 mL) to afford 4-methoxy-I H-pyrrolo[2,3b]pyridine as a solid. To a mixture of 4-methoxy-lH-pyrrolo[2,3-b]pyridine (5.85g) in toluene (150 mL) and water (150 mL) was added potassium hydroxide pellets 4-methylbenzene sulfonyl chloride (7.53g) and tetra-n-butyl ammonium hydrogen sulfate (0.02g). This mixture was stirred at room temperature for 20 hours then extracted four times with ethyl acetate (100 mL). The combined organic extracts were concentrated and then subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and heptane (35:65, v/v) to afford the title compound as a white solid.

REFERENCE EXAMPLE 42 4-Phenvl- H-pyrrolo[2,3-blpyridine A suspension of 1-(2,6-dimethyl-l,4-dihydropyridin-4-one)-lH-pyrrolo[2,3-b]pyridinium tetrafluoroborate (Reference Example 43, 1.Og) in tetrahydrofuran (100 mL) was treated with a solution of phenylmagnesium bromide in tetrahydrofuran (9.6 mL, I M) and stirred at room temperature WO 03/000688 PCT/GB02/02799 -273for 72 hours before adding water ((100 mL) and the tetrahydrofuran removed in vacuo. The residue was extracted with chloroform (3 x 100 mL), and the combined organics dried over sodium sulfate and evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (99:1 v/v) to give the title compound (83mg) as a white solid. MS: 195(MI-). 'H NMR [(CD 3 2 SO]: 5 8.27 (1H, d, J=4.1 Hz); 7.78 (2H, d, J=8.2 Hz); 7.57 (3H, 7.48 (1H, t, J=8.2 Hz); 7.19 (1H, d, J=3.5 Hz); 6.60 (1H, s).

REFERENCE EXAMPLE 43 l-(2,6-Dimethyl-1.4-dihydropyridin-4-one)-l H-pyrrolo[2,3-blpyridinium tetrafluoroborate A mixture of ethyl O-2,4,6-trimethylsulfonylacetohydroxamate (28.5g) in perchloric acid (160 mL, was stirred at room temperature for 2 hours, then dichloromethane (30 mL) was added. The mixture was poured onto ice/water (1 litre) and rapidly extracted three times with dichloromethane (100 mL). The combined organics were washed twice with brine (100 mL) and dried over sodium sulfate. The organics were then added slowly to a solution of 1H-pyrrolo[2,3-b]pyridine (11.8g) in diclloromethane (100 mL). Filtration gave 1-amino-lH-pyrrolo[2,3-b]pyridinium 2,4,6trimethylphenylsulfonate, which was used directly in the next step.

A mixture of I-amino-I H-pyrrolo[2,3-b]pyridinium 2,4,6-trimethylphenylsulfonate 6.6g) and 3acetyl-6-methyl-2H-pyran-2,4(3H)-dione (8.8g) in concentrated hydrochloric acid (40 mL) was stirred at reflux for 4 hours, then cooled and concentrated in vacuo. The residue was dissolved in ethanol mL) and diluted with a solution oftetrafluoroboric acid in diethyl ether (54% v/v, 30 mL) and stirred for 1 hour at room temperature. Filtration gave the title compound (15.0g) as a white solid, m.p. 247- 248 0 C. 'H NMR [(CD 3 2 SO]: 8 9.24 (1H, d, J=7.5 Hz); 9.13 (1H, d, J=7.5 Hz); 8.08 (1H, d, J=4.2 Hz); 7.93 (1H, t, 1=7.5 Hz); 7.22 (1H, d, J=4.2 Hz); 6.83 (2H, 1.96 (6H, s).

REFERENCE EXAMPLE 44 Dimethyl 3-r6-(4-tert-butvlphenyl-5H-pyrrolo[2.3-blpyrazin-7-yll-propionicl,1-diacid 11dicarboxylate To a solution of dimethyl malonate (1.3g) dissolved in N-methylpyrrolidinone (30 mL) at o0C under nitrogen was added sodium hydride (0.39g) After 10 minutes, a solution of [6-(4-tert-butylphenyl-5Hpyrrolo[2,3-b]pyrazin-7-yl]methyltrimethylammonium iodide [1.12g, Reference Example 45(a)] was added and the reaction mixture was warmed to room temperature and allowed to stir for 3 hours. The reaction mixture was poured into water (200 mL) and extracted three times with ethyl acetate (100 mL). The combined organic fractions were dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound (0.5g) as a white solid. 'H NMR(CDCI 3 8 9.48 WO 03/000688 PCT/GB02/02799 -274rl (I H, 8.42 (IH, 8.16 7.64 (2H, d, J-=9.0 Hz); 7.58 d, 3=9.0 Hz); 4.45 (IH, t, J=8.2 Hz); 3.63 (2H, d, J=8.2 Hz); 3.58 (6H, 1.40 (9H, s).

By proceeding in a manner similar to Reference Example 44(a) above but using methyl)ethoxy)phenyl-5 H-pyrrolo[2,3-b]pyrazin-7-yl]methyltrimethyl ammonium iodide [Reference Example there was prepared di methyl 1-methyl)ethoxvphenyl)-5H-pyrrolo[ 2.3bIpvrazin-7-yll-propionic 1.1-diacid 1, 1-dicarboxylate as a beige solid. MS: 398(MH+). 'H

NMR[CDCI

3 8 10.1 (broad s, INH); 8.41 I H, 3=2.3 Hz); 8.16(d, I H, J=2.3 Hz); 7.62(d, 2H-, J18.21 Hz); 7.03(d, 2H, J=8.20 Hz); 4.64(m, I 4.45(t, I 3.78(d, I 3.60(s, 6H); 1.4 1(d, 6H, J=4.41 Hz).

By proceeding in a manner similar to Reference Example 44(a) above but using fluorophenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl] methyltrimethylammonium iodide [Reference Example there was prepared d imethyl 3-r6-(4-fluorophenyl)-5H-pyrolo[2,3 -blpyrazin-7-yll-propionic 1,1-diacid 1,1-dicarboxylate as an off-white solid. NMR DMSO 12.2 IN), 8.4 1H), 8.2 i14), 7.8 2H), 7.4 2H), 4.4 INH) 3.7 6H), 3.6 2H). MS: 3 57(MI-t).

By proceeding in a manner similar to Reference 44(a) above but using [6-(4-methoxyphenyl)- 5H-pyrrolo[2,3-b]pyrazin-7-yl]methiyltrimethylammonium iodide [Reference Example 45 there PO was prepared d irethyl 3-r6-(4-methoxyphenl)-5 H-pyrrolo[2,3.b1pyrazin-7-vI1-oropionic 1.1 -diacid 1.1-dicarboxylate as an off-white solid. MS: 369(MW).

REFERENCE EXAMPLE r6-(4-er-Butvlohenyl-5H-pvrrolor23-blpyrazin-7-vllmethyltrimethylammon ium iodide To a solution of [6-(4-tert-butylphenyl-5H-pyrrolo[2,3-b]pyrazin-7-yI]rnethyld imethylamine [0.8g.

Reference Example 46(a)] in tetrahydrofuran (50 mL) under nitrogen at 40*C was added methyl iodide mL). The reaction mixture was stirred for 4 hours and the solvent was evaporated. The residue was chased with toluene (30 mL) and dried under vacuum to afford the title compound as a yellow solid which was used immediately without further purification in the next reaction.

By proceeding in a manner similar to Reference Example 45(a) above but using methyl)ethoxy)phenyl-5H-pyrrolo[2,3-b~pyrazin-7-yl]methyldimethylamine [Reference Example there was prepared I-methvl~etlioxv~phenyl-5H-pyrrolof2,3-blpvrazin-7yllmethyltrimethvlammonium iodide as a beige solid, which was used immediately without further purification.

WO 03/000688 PCT/GB02/02799 -275- By proceeding in a manner similar to Reference Example 45 above but using ct fiuoroplienyl-5H-pyrrolo[2,3-b] pyrazin-7-yl)methyldimethylamine [Reference Example 46 there was prepared 6-(4-fluoroohlenyl)-5H-pyrrolof2,3-blkvrazin-7-yllmethltrimethlammonium iodide as a yellow solid. I HNMR [(CD 3 2 S0]: 8 13.0 I 8.5 I 8.4 I 7.7 2H), 7.6 2H), 3.1 2.9 9H). MS: 285 By proceeding in a manner similar to Reference Example 45 above but using CK1 ethoxyphenyl-5H-pyrrolo[2,3-b~pyrazin-7-yl]methyld imethylamime [Reference Example 46 there was prepared 6-(4-m ethoxyph enyl)-5H- pyrrolof 2.3-bl pyrazi n-7-yll methyl trimethylamm on iu i iodide as an off-white solid. MS: 297(MH+).

REFERENCE EXAMPLE 46 [6-(4-iert-Butvlpheii-5H-pyrrolo[2,3-b1 pyrazin-7-yllmethyldimethylamine To a solution of dimethylam ine (15 mL of a 2M solution in tetrahydrofuran) and acetic acid (0.45 mL) at 0 0 C was added formaldehyde (2.25 mL of a 40% aqueous solution). The reaction mixture was stirred for 10 minutes. A solution of 6-(4-iet-i-butylphenyl)-5H-pyrrolo[2,3-b]pyrazine [6.9g, Example 1 in tetrahydrofuran (400 mL) was added and the reaction mixture allowed to stir at room temperature overnight. The reaction mixture was washed with IN sodium hydroxide solution, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was subjected to flash column W0 chromatography on silica eluting with a mixture of tetrahydrofuran and methanol 1, v/v) to give the title compound 8g) as a yellow solid. MS: 309(MH+). HPLC (Method RT 1.93 minutes.

By proceeding in a manner similar to Reference Example 46(a) above but using 6-[44(1 methyl)ethoxyphenyl]-5H-pyrrolo[2,3-b]pyrazine [Example 1 there was prepared 6-44 1methvI)ethoxy)phenyI -5H-pyrrolo[ 2.3 -bl pyrazi n-7-yllmethyl-d imethy lam ie as a beige solid.

By proceeding in a manner similar to Reference Example 46 above hut using 6-(4-fluorophenyl)-SH-pyrrolo[2,3-b]pyrazine [Example I there was prepared uoroph enyl-5 H-pyrrolor12.3 -blpyrazi n-7-yllmethyId imethy lam m e as an off-white solid. lH NMR 2 S0]: 6 12.0 I 8.5 I 8.2 I 7.7 2H), 7.6 2H), 3.9 2H), 2.9 (s, 6H). MS: 27O(MH+).

By proceeding in a manner similar to Reference Example 46 above but using 6-(4-methoxyphenyl)-5H-pyrrolo [2,3-bjpyrazine [Example I there was prepared WO 03/000688 PCT/GB02/02799 -276- [C [6-(4-methoxvphenvl-5H-pyrrolo[2,3-blpyrazin-7-yllmethyldimethylamine as a off-white solid. MS: C¢ 282(MH+).

REFERENCE EXAMPLE 47 Ethyl 3-f2-dimethylamino-5-(5H-pyrrolo2,.3-blpvrazin-6-vl)phenyl prop-2-enonate To a solution of 6-(3-bromo-4-dimethylamino)phenyl-5H-pyrrolo[2,3-b]pyrazine [0.1g, Reference Example 48] in dry dimethylformamide (10 mL) in a schlenk tube was added ethyl acrylate (0.25 mL), S palladium (II) acetate (0.05g), tri-(2-methylphenyl)phosphine (0.07g) and tributylamine The tube was sealed and heated at 95 0 C for 24 hours then allowed to stand at room temperature for a further 24 hours. The reaction mixture was quenched with water (150 mL) and extracted into ethyl acetate (100 mL), washed with brine and dried over magnesium sulfate. After concentration in vacuo the resultant orange gum was triturated with toluene to afford the title compound as an orange solid (0.04g). TLC: RF 0.46 (ethyl acetate). 'H NMR [(CD 3 2 SO]: 8 12.40 (1H, 8.38 (1H, 8.34 (1H, 8.02 (1H, d, J=8.6 Hz); 7.89 (1H, d, J=16.5 Hz); 7.22 (1H, d, J=8.6 Hz); 7.19 (1H, 6.81 91H, d, .3=16.5 Hz); 4.23 (2H, q, J=7.1 Hz); 2.78 (6H, 1.30 (3H, t, J=7.1 Hz).

REFERENCE EXAMPLE 48 6-(3-Bromo-4-dimethylamino)phenyl-5 H-pvrrolo[2.3-b pyrazine To a stirred solution of 4-(dimethylamino)benzonitrile (2.19g) in chloroform (15 mL) was added pyridine (1.2 mL) and a solution of bromine (0.75 mL) in chloroform (15 mL) dropwise over minutes. Upon complete addition, the mixture was stirred for a further 30 minutes. The reaction mixture was diluted with dichloromethane and washed with water, brine and evaporated to afford a S yellow oil of3-bromo-4-dimethylaminobenzonitrile which was dissolved in tetrahydrofuran (25 mL).

Meanwhile, a stirred solution of diisopropylamine (2.7 mL) in tetrahydrofuran (50 mL), at -15°C and under nitrogen, was treated with a solution of n-butyllithium in hexanes (7.70 mL, 2.5M) over minutes, whilst maintaining the temperature below -10 0 C. After stirring for 30 minutes the mixture was treated with methylpyrazine (1.21g) over 15 minutes, then stirred for 1 hour. The solution of 3bromo-4-(dimethylamino)benzonitrile was added over 1 hour, keeping the temperature below -10 0

C.

The reaction mixture was allowed to warm to room temperature over 2 hours, then stood overnight, then treated with water (10 mL). The tetrahydrofuran was removed in vacuo and the resultant mixture was treated with a mixture of water and ethyl acetate (1:1 v/v) and the mixture stirred for 15 minutes.

The resultant precipitate was collected by filtration and washed thoroughly with water/ethyl acetate (1:1 v/v) to afford the title compound as a yellow solid TLC: RF 0.41 (ethyl acetate).

REFERENCE EXAMPLE 49 6-(3-tert-ButvldimethyIsilvloxv-4-methoxv)phenvl-5H-pyrrolo[2.3-blpyrazine WO 03/000688 PCT/GB02/02799 -277-

O

S A stirred solution of diisopropylamine (3.6 mL) in tetrahydrofuran (133 mL), at -15 0 C and under nitrogen, was treated with a solution of n-butyllithium in hexanes (11.21 mL, 2.5M) over 30 minutes, Ci whilst maintaining the temperature below -10 0 C. After stirring for 30 minutes the mixture was treated with methylpyrazine (2.04g) over 15 minutes, then stirred for hour and then treated with a solution of 3-tert-butyldimethylsilyloxy-4-methoxybenzonitrile (5.7g, Reference Example 50) in tetrahydrofuran C1 (20 mL) over Ihour, keeping the temperature below -10 0 C. The reaction mixture was allowed to warm to room temperature over 2 hours, then stood overnight, then treated with water (10 mL). The rC tetrahydrofuran was removed in vacuo and the resultant mixture was partitioned between ethyl acetate and water. The two layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organics were dried over sodium sulfate and evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (32:1, v/v) to give the title compound (1.62g) as a tan solid, which was used directly in the next step. 'H NMR

[(CD

3 2 SO]: 8 8.12 (1H, 7.96 (1H, 7.44 (1H, d, J=8.2 Hz); 7.33 (1H, 6.93 (1H, d, J=8.2 Hz); 6.84 (1H, 3.63 (3H, 0.82 (9H, 0.01 (6H, s).

REFERENCE EXAMPLE 3-ter-Butvldimethvlsilyloxv-4-methoxvbenzonitrile A solution of iso-vanillin (10.0g) in dimethylformamide (100 mL) was treated with hydroxylamine hydrochloride (9.14g) and heated under reflux for 1 hour. The dimethylformamide was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The aqueous fraction was exhaustively extracted with ethyl acetate and the combined organic fractions were dried over sodium sulfate and concentrated in vacuo to afford a brown solid, which was dissolved in tetrahydrofuran (200 W mL). After treatment with sodium hydride the reaction mixture was stirred at room temperature for 1 hour. A solution of tert-butyldimethylsilyl chloride (10.9g) in tetrahydrofuran (50 mL) was added and the mixture stirred under nitrogen overnight. The mixture was partitioned between water and diethyl ether. The organic extract was dried over sodium sulfate, concentrated in vacuo and subjected to flash column chromatography on silica eluting with a mixture of pentane and dichloromethane (1:3, v/v) to give the title compound (14.7g) as a colourless oil which was used immediately in the next reaction. 'H NMR [(CD 3 2 SO]: 8 7.30 (IH, d, J=8.0 Hz); 7.11 (IH, 7.01 (1H, 3.70 (3H, 0.81 (9H, 0.01 (6H, s).

REFERENCE EXAMPLE 51 4-1 -Methyl)ethoxvbenzonitrile A solution of 4-cyanobenzene (Ig) in hexamethylenetetramine (10 mL) was stirred at ambient temperature until dissolution. 25% aqueous sodium hydroxide (2.7 mL) was then added and the resulting solution stirred at ambient temperature for 30 minutes. 1-Methylethyl iodide (5.71g) was WO 03/000688 PCT/GB02/02799 6 -278- S added dropwise and the resulting solution stirred at ambient temperature for 5 hours then poured into water (30 mL). The mixture was extracted three times with ethyl acetate (30 mL) and the combined S organic extracts were washed with water, then with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and heptane v/v) to give the title compound (1.2g) as a white solid. MS: 162(MH+).

CN IH NMR(CD 3 2 SO: 8:7.58(d, 2H, J=8.12 Hz); 6.84(d, 2H, 1=8.12 Hz); 4.62(m, 1H); 1.38(d, 6H, 0 J=5.4 Hz).

SREFERENCE EXAMPLE 52 i C 10 1H-5-Cvano-l-methyl-2-(methvlthio)imidazole A solution of IH-l-methyl-2-(methylthio)imidazole-5-carboxaldehyde (0.76g) [Reference Example 53(a)] in dimethylformamide (15 mL) was treated with hydroxylamine hydrochloride (0.68g). The mixture was refluxed for 4 hours, cooled to ambient temperature and poured into water. Ethyl acetate was added and the organic layer washed with water, brine, dried over magnesium sulfate and evaporated to give the title compound (0.47g) as a beige solid which was used without further purification, m.p.l15 0 C. MS: 154(MH+).

REFERENCE EXAMPLE 53 I H-I -Methyl-2-(methvlthio) A stirred solution of 1H-l-methyl-2-(methylthio)imidazol-5ylmethanol (8.1g) [Reference Example 54] and manganese dioxide (28.97g) in dichloromethane (160 mL) was refluxed for 7 hours. The reaction mixture was cooled to ambient temperature and filtered through a pad of celite. The dichloromethane was evaporated to give the title compound (6.61g) as a yellow solid, which was used immediately in the next reaction.

By proceeding in a manner similar to Reference Example 53(a) above but using phenylpyrazol-3-ylmethanol [Reference Example 66], there was prepared 3-carbaldehvde, m.p. 106-108 0

C.

REFERENCE EXAMPLE 54 1H- To a stirring suspension of IH-l-methyl-2-(thio)imidazol-5ylmethanol (5g) [Reference example 55] in methanol (500 mL) is added dropwise IN sodium hydroxide solution (36 mL) at room temperature.

The suspension was stirred at ambient temperature for 10 minutes. lodomethane was added dropwise and stirring was continued for 12 hours. After evaporation of the methanol, the residue was dissolved in dichloromethane and water was added. The organic layer was washed with water, brine, dried over WO 03/000688 PCT/GB02/02799 -279rC magnesium sulfate and evaporated. The residue was crystallized from ether to give the title compound (4.3g) as a white solid, m.p. 51 C.

REFERENCE EXAMPLE 1H-1-Methyl-2-(thio)imidazol-5ylmethanol Ci A mixture of 12.8g of dihydroxyacetone dimer, 20.7g of potassium thiocyanate and 12.4g of methylamine was added to a solution of 16 mL of acetic acid and 100 mL of butanol. The resulting white mixture was stirred for 70h after which it was suspended in 50 mL of water and filtered The solid was washed with water (60 mL), then diethyl ether (60 mL) and dried in vacuo to give the title compound (16g) as a white solid, m.p 204 0

C.

REFERENCE EXAMPLE 56 3-Cvano-l-methyl-I H-indazole Sodium hydride (0.37g, 60% dispersion in mineral oil) was added to a solution of 3-cyano-1Hindazole (1.20g, Reference Example 57 in dry dimethylformamide (30 mL) under a nitrogen atmosphere at ambient temperature. The mixture was allowed to stir for I hour then treated with methyl iodide (0.85 mL) and stirring was continued for 1 hour. The reaction mixture was then poured into ice-water (15 mL). The precipitated solid was filtered then washed with water and then dried to give the title compound (0.80g) as a beige solid, m.p.73 0 C. IH NMR [(CD 3 2 SO]: 8 7.91 2H); 7.60 7.42 1H); 4.21 3H).

By proceeding in a manner similar to Reference Example 56(a) above but using 3-cyano-4-

I

w phenyl-1H-pyrrole [Reference Example 58], there was prepared 3-cvano-1 -methyl-4-phenyl- Hpyrrole.

By proceeding in a manner similar to Reference Example 56(a) above but using 2-phenyl-l Hpyrrole-3-carbonitrile [prepared according to the procedure described by I. A. Benages et al., J. Org.

Chem. (1978), 43(22), 4273-6], there was prepared 1-methyl-2-phenvl-lH-pyrrole-3-carbonitrile as a pink oil. TLC: RF= 0.86 (ethyl acetate/dichloromethane, 1:1).

By proceeding in a manner similar to Reference Example 56(a) above but using 5-methyl-1Hpyrrole-3-carbonitrile [prepared according to the procedure described by A. Padwa et al., J. Am. Chem.

Soc. (1986), 108(21), 6739-46], there was prepared 1,5-dimethvl-lH-pyrrole-3-carbonitrile as a yellow solid, m.p.54 0 C. TLC: RF- 0.50 (ethyl acetate/cyclohexane, 1:1).

WO 03/000688 PCT/GB02/02799 -280- By proceeding in a manner similar to Reference Example 56(a) but using 4-methyl-l H-pyrrole- 3-carbonitrile [prepared according to the procedure described by A. R. Katritzky et al, Heterocycles (1997), 44, 67-70], there was prepared 1,4-dimethvl-lH-pvrrole-3-carbonitrile as a yellow oil. TLC: RF 0.64 (ethyl acetate/cyclohexane, 1:1).

C REFERENCE EXAMPLE 57 3-Cvano- H-indazole C A solution of o-aminobenzyl cyanide (0.5g) in aqueous hydrochloric acid IN (9.6 mL), was treated with a solution of aqueous sodium nitrite IN (3.85 mL). After stirring at room temperature for minutes, the reaction mixture was filtered. The solid was recrystallised from ethanol to give the title compound (0.4g) as a yellow solid, m.p. 138-140 0 C. 'H NMR [(CD 3 2 SO]: 5 7.89 1H, J=7.7Hz); 7.76 1H, J=7.9Hz) 7.48 1H); 7.41 1H).

REFERENCE EXAMPLE 58 3-Cvano-4-phenvl-l H-pyrrole A solution of cinnamonitrile (16.53g) and (para-toluenesulfonyl)methylisocyanide (25g) in a mixture of ether and dimethyl sulfoxide (450 mL, 2:1) was added dropwise to a stirred suspension of sodium hydride (6.14g, 60% dispersion in mineral oil) in ether (50 mL). An exothermic reaction took place.

The reaction mixture was then stirred at room temperature for 2 hours, then diluted with water (500 mL) and this mixture was extracted three times with ether (250 mL). The combined extracts were washed with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to filter chromatography on a pad of silica eluting with a mixture of ethyl acetate and pentane (1 L, I 1:4, v/v) and then with a mixture of ethyl acetate and pentane (2 L, 2:3, Fractions containing the required material were evaporated and the residue was suspended in pentane (500 mL) with stirring, then filtered to give the title compound as a solid, m.p. 120-122 0 C. MS: 167(MH-).

REFERENCE EXAMPLE 59 4-Pyrazinyl-1-butene A solution of lithium diisopropylamine [prepared from a solution of butyl lithium in hexanes (100 mL, 2.5M) and diisopropylamine (25.3g) at -35 0 C] was treated with a solution of 2-methylpyrazine (23.5g) in dry tetrahydrofuran (300 mL) at -20 0 C. The mixture was stirred at -20 0 C for 1 hour then cooled to -78 0 C and treated with a solution of allyl bromide (30.8g) in dry tetrahydrofuran (300 mL). This mixture was warmed to room temperature and stirred at this temperature for 2 hours then left overnight and then treated with saturated ammonium chloride solution (50 mL) followed by water (200 mL).

The mixture was then extracted twice with ether (200 mL). The combined extracts were dried over WO 03/000688 PCT/GB02/02799 -281-

O

C'1 magnesium sulfate then evaporated. The residue was distilled to give the title compound (22g) as a colourless oil, b.p. 70 0 C/1 mm Hg.

REFERENCE EXAMPLE 2-[5-(pyridin-4-yl)- I-methyl-I H-indol-3-vll- -(toluene-4-sulfonvl)-1H-pyrrolo[2,3-blpvridine A mixture of benzyloxycarbonyl-l,2,5,6-tetrahydropyridin-4-yl)-l-methyl-IH-indol-3-yl]-l- (toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridine (1.7g, Reference Example 61) ethanol (53 mL) and palladium on carbon (0.35g) was stirred in the presence of hydrogen for 4 hours, then left standing at room temperature overnight. After a further day a further quantity of palladium on carbon (0.18g, 0 10 10%) was added and stirring was continued in the presence of hydrogen for a further 8 hours. After standing at room temperature for 4 days the reaction mixture was filtered through Hyflo and the filter pad was washed well with ethanol. The combined filtrate and washings was treated with palladium on carbon (0.35g) and the mixture was stirred in the presence of hydrogen. The mixture was filtered through Hyflo and the filter pad was washed well with ethanol. The combined filtrate and washings was evaporated and the residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give the title compound as a light brown solid, m.p. 82-85 0

C.

REFERENCE EXAMPLE 61 benzvloxycarbonyl- 1,2,56-tetrahvdropyridin-4-vl)-l-methyl-lH-indol-3-vll-l-(toluene-4sulfonv)- 1 H-pvrrolo[2.3-blpvridine A mixture of benzyl 1-[3,6-dihydro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl](2H)pyridinecarboxylate (2g, prepared according to the procedure described by P.Eastwood, CI Tetrahedron Letters, 2000, 41, pages 3705-3708), dichloro[l,l'-bis(diphenylphosphino)ferrocene]palladium[II] (0.25g,) and potassium carbonate (2.42g), under nitrogen, was treated with a solution of trifluoro-methanesulfonic acid I-methyl-3-[-(toluene-4-sulfonyl)- H-pyrrolo[2,3b]pyridin-2-yl]-1H-indol-5-yl ester [1.6g, Reference Example 18(a)] in dimethylformamide(76 mL).

The mixture was heated at 80 0 C for 4 hours (TLC indicated that starting material was still present), then treated with a further quantity oftrifluoro-methanesulfonic acid l-methyl-3-[1-(toluene-4sulfonyl)-lH-pyrrolo[2,3-b]pyridin-2-yl]- H-indol-5-yl ester (0.15g), then heated at reflux temperature for 4 hours and then left at room temperature overnight. A further quantity of trifluoromethanesulfonic acid I-methyl-3-[ -(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridin-2-yl]- ester [0.15g, Reference Example 18(a)] was added and the mixture was heated at reflux temperature for a further 4 hours then evaporated. The residue was partitioned between ethyl acetate and water, and the aqueous layer was extracted three times with ethyl acetate (50 mL). The combined organic phases were washed with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, WO 03/000688 PCT/GB02/02799 -282vlv) to give the title compound as a light brown viscous liquid which was used without further purification.

REFERENCE EXAMPLE 62 2-lodo- I-(toluene-4-sulfonyl)- IH-p2yrrolo[2.3-blpvrid ine-4-carbonitrile A stirred solution of diisopropylamine (0.38 ml) in tetrahydrofuran (7 mL), at -70'C and under nitrogen, was treated with a solution of n-butyllithium in hexanes (1.06 mL, 2.5M) over 5 minutes, whilst maintaining the temperature below 65'C. After stirring for 20 minutes the mixture was added, at -70'C, to a solution of I -(toluene-4-sulfonyl)-I H-pyrrolo[2,3-b]pyridine-4-carbonitrile (0.65g, Reference Example 63) in tetrahydrofuran (15 mL) and stirred at -70'C for 45 minutes. A solution of iodine (0.9g) in tetrahydrofuran (10 mL) was then added at -70'C. The reaction mixture was allowed to warm up to room temperature over I hour, and stirred for 18 hours, then treated with water (10 mL).

The reaction mixture was evaporated in vacuo and the residue partitioned between ethyl acetate mL) and water (50 mL). The insoluble material was filtered, washed with ether and dried in vacuo to give the title compound (0.45g) as a white solid. The filtrate was separated and the organics washed sequentially with saturated sodium thiosulfate solution (2 x 30 mL), water (30 mL) and brine (30 mL), dried over sodium sulfate and evaporated. The residue was triturated with diethyl ether to give a further quantity of the title compound (0.25g) as a cream solid. TLC RF 0.43 (ethyl acetate/heptane MS: 424 (MH~) By proceeding in a similar manner to Reference Example 62(a) but using 4-chloro- I-(toluene- 4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 4-chloro-2-iodo- I -(toluene-4-sulfonvi)-l H-pyrrolo[2,3-bjpvridine as an off white foam. MS: 432(MH{'} 'H NMR

(CDCI

3 858.25 I 8.05 2H), 7.3 2H), 7.15' I1-H), 7.1 I 2.4 (s,3H4) By proceeding in a similar manner to Reference Example 62(a) but using 5-phenyl-1 -(toluene- 4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example 671, there was prepared 2-iodo-5-phenvi- I1- (toluene-4-sulfonvl)-IH-pyrrolo[2.3-blpyridine as a light brown solid.

By proceeding in a similar manner to Reference Example 62(a) but using 4-phenyl-1 -(toluene- 4-sulfonyl)- I H-pyrrolo[2,3-bjpyridine [Reference Example there was prepared the 2-iodo-4phenyl- I (to] uene-4-sulfonyl)- IH-pyrrojor2,3-blpyridine as a white solid. 'H NMR [(CD 3 )2SO]; 8 8.43 (I H, d, J=4.5Hz); 8.04 (2H, d, J=8.2Hz); 7.98 (1IH, d, J=4.5Hz); 7.69 (2H, dd, J=7.2, 1.9Hz); 7.56 (2H, tt, J=7.2, 1.9Hz); 7.44 (2H, d, J=8.2Hz); 7.42 (1 H, d, J=5.OHz), 6.92 (1 d, J=4.OHz), which was used without further purification.

WO 03/000688 PCT/GB02/02799 -283- C1 By proceeding in a similar manner to Reference Example 62(a) but using l-(toluene-4sulfonyl)-lI--pyrrolo[2,3-b]pyridine-4 carboxylic acid, tert-butyl ester [Reference Example and subjecting the crude reaction product to chromatography on silica eluting with a mixture of ethyl acetate and heptane v/v) there was prepared 2-iodo-1-(toluene-4-sulfonvl)-IH-r'vrrolo[2,3bloyridine-4 carboxylic acid. tert-butyl ester as a dark oil. MS: 499(MH+).

By proceeding in a similar manner to Reference Example 62(a) but using 4-(pyridin-3-yl)- I -(toluene4-sulfonyl)- IH-pyrrolo[2,3-b]pyridifle [Reference Example there was prepared 2-iodo- 4-(oyridin-3-yl)-l-(tolueie-4-sulfonyl)- I H-pyrrolor2.3-blpvridine as a tan solid which was used without further purification.

By proceeding in a manner similar to Reference Example 62(a) above but using 3-methyl-I- (toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 2-iodo- 3 mtyI (oun4s fnl-IHRroIo-3-lyidn as a beige solid, m.p. 175'C. TLC: RIF 0.69 (ethyl acetate/cyclohexane, 1: 1).

By proceeding in a manner similar to Reference Example 62 above but using 4-(3,5dimethyl-isoxazole-4-yl)- 1 -(toluene-4-sulfonyl)- I H-pyrrolo[2,3-b]pyridine [Reference Example there was prepared 4-(3 .5-dimethyl-isoxazole-4-yl)-2-iodo-1 -(toluene-4-sulfonylV I H-pyrrolor2,3bloyridine as a white solid, m.p. 1 66-167'C. MS: 494(MH+).

By proceeding in a manner similar to Reference Example 62 above but using 4-methoxy-l- (toluene-4-su Ifonyl)- 1H-pyrrolo[2,3-bjpyridinte (Reference Example 411, there was prepared 2-iodo-4methoxy- I-(toluene-4-sulfonvl)- IH-ovrrolor2,3-blpyridine as a white solid. MS: 429(MH+).HPLC (Method C) RT 4.74 minutes.

REFERENCE EXAMPLE 63 1 -(Toluene-4-sulIfonyl)- I H-pyrrolof2,3 -blpyrid ine-4-carbonitrile A mixture of I-(2,6-dimetlhyl-1 ,4-dihiydropyridin-4-one)- IH-pyrrolo[2,3-b] pyridinium tetrafluoroborate (Reference Example 43, 5.0g) and water (80 mL) was treated with a saturated aqueous solution of potassium cyanide (25 mL) and stirred at room temperature for 48 hours. A solution of toluene-4-sulfonyl chloride (2.9g) in toluene (100 mL), a solution of sodium hydroxide in water (10 mL) and tetrabutylammonium hydrogen sulfate (0.05g) were added and stirred at room temperature 72 hours. The mixture was filtered through Celite and partitioned. The aqueous was WO 03/000688 PCT/GB02/02799 ,-284-

O

C extracted three times with ethyl acetate (50 mL) and the combined organics were washed with water mL), brine (50 mL), dried over magnesium sulfate and evaporated in vacuo. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and heptane (3/7, v/v) to give the title compound (1.1 g) as a white solid, TLC: RF 0.60 (ethyl acetate/heptane, 'H NMR [(CD 3 2 SO]: 5 8.54 (1H, d, J=4.7 Hz); 8.08 (2H, d, J=8.2 Hz); 7.95 (1H, d, J=3.6 Hz); 7.44 (1H, (N d, J=4.3 Hz); 7.31 (2H, d, J=8.2 Hz); 6.82 (1H, d, J=3.3 Hz); 2.39 (3H, and IH-pyrrolo[2,3- Sb]pyridine-4-carbonitrile (0.13g) as a white solid, TLC RF 0.24 (ethyl acetate/heptane 'H NMR r [(CD 3 2 SO]: 5 10.19 (1H, 8.44 (1H, d, J=4.6 Hz); 7.59 (1H, 7.40 (1H, d, J=4.6 Hz), 6.78 (1H, m).

N REFERENCE EXAMPLE 64 4-Chloro-lH-pyrrolo[2,3-blpyridine 1H-Pyrrolo[2,3-b]pyridine-N-oxide (10.0 g, Reference Example 65) in phosphorous oxychloride mL) was heated at reflux for 8 hours. The excess phosphorous oxychloride was evaporated and the residue was taken up in water and the solution was brought to a pH=8-9, the resultant precipitate was filtered and air-dried to give the title compound as an off-white solid (10.2 MS: 152(MH+). 1

H

NMR (CDC1 3 5 8.2 I 7.5 lH), 7.2 2H), 6.6 2H).

REFERENCE EXAMPLE 1H-Pyrrolof2.3-bpvyridine-N-oxide A solution of 3-chloroperbenzoic acid (224.3 g) in dichloromethane (1500 mL) was cooled to 00 C.

S To this a solution of 1 H-pyrrolo[2,3-b]pyridine (59.1 g) in dichloromethane (500 mL) was added dropwise over 30 minutes. The reaction mixture was stirred at room temperature for 1 hour. The solution was concentrated, diluted with methanol (1500 mL) and treated with 10% potassium carbonate in water (300 mL). The slurry was filtered and the filtrate was evaporated to dryness. The residue was chromatographed on neutral alumina with 20 methanol in dichloromethane to give the title compound as a tan solid (47.0 MS: 135( IHNMR (CDCI 3 8 13.1 1H), 8.2 (d,lH), 7.65 7.4 1H), 7.0 1H), 6.55 1H).

REFERENCE EXAMPLE 66 I-Methvl-5-phenylpvrazol-3-vlmethanol A stirred suspension of sodium borohydride (1.28g) in dry tetrahydrofuran (80 mL) was treated with calcium chloride (1.88g). The mixture was stirred for 1 hour then treated with a solution of ethyl 1-methyl-5-phenylpyrazol-3-ylcarboxylate (5.2g, prepared according to the procedure described by Martins et al., J. Heterocycl. Chem. (1999), 36(1), 217-220) in dry tetrahydrofuran (40 mL). After WO 03/000688 PCT/GB02/02799 -285- C, stirring at room temperature for 3 days and at reflux temperature for 8 hours the mixture was treated with sodium hydroxide solution (50 mL, IN). This mixture was stirred at room temperature for 1 hour, then evaporated to remove the organic solvents and then extracted three timeswith dichloromethane S (140 mL). The combined extracts were washed with water, then dried over magnesium sulfate and then evaporated to give the title compound as a white solid, m.p. 95-99 0

C.

0 REFERENCE EXAMPLE 67 5-Phenvl-I -(toluene-4-sulfonyl)- H-pyrrolo[2,3-blpyridine A mixture of phenyl boronic acid (1.74g), 5-bromo-l-(toluene-4-sulfonyl)-lH-pyrrolo[2,3-b]pyridine 0 10 [5g, Reference Example (tetrakis)triphenylphosphine palladium[0] (0.49g) and saturated aqueous sodium bicarbonate solution (133 mL) and dimethylformamide (266 mL), under nitrogen, was heated at reflux temperature overnight. The reaction mixture was filtered through Hyflo and then evaporated. The residue was partitioned between ethyl acetate (50 mL) and water (25 mL) and the aqueous layer was extracted with ethyl acetate (25 mL). The combined organic phases were washed with water (25 mL), then with brine (20 mL), then dried over magnesium sulfate and then evaporated.

The residue subjected to chromatography on silica eluting with a mixture of pentane and ether (1;1, v/v) to give the title compound as a white solid, mp. 151-152 0 C. MS: 335(MH+).

By proceeding in a similar manner to Reference Example 67(a) but using 1-tertbutyloxycarbonyl-5-methoxy-lH-indole-3-boronic acid [Reference Example 74(b)] and 2-iodo-l- (toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridine-4 carboxylic acid, tert-butyl ester [Reference Example 62(e)] and subjecting the crude product to chromatography on silica eluting with a mixture of ethyl rw acetate and heptane v/v) there was prepared 2-(5-methoxv-1 H-indol-3-vl)-l-(toluene-4-sulfonvl)- 1H-pyrrolor2,3-b1pyridine-4 carboxylic acid, tert-butvl ester as a yellow oil. MS: 518(MH+).

By proceeding in a similar manner to Reference Example 67(a) but using pyridine-3-boronic acid and trifluoro-methanesulfonic acid 1H-pyrrolo[2,3-b]pyridin-4-yl ester [Reference Example 18(c)] there was prepared 4-(pvridin-3-vl)- H-pyrrolo[2,3-blpvridine as a yellow solid, m.p. 162-163 0 C. MS: 196(MH+).

By proceeding in a similar manner to Reference Example 67(a) but using 1-tert- H-indole-3-boronic acid [Reference Example 74(b)] and 2-iodo-4- (pyridin-3-yl)- -(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [Reference Example 62(f)] and subjecting the crude product to chromatography on silica eluting with ethyl acetate there was prepared 2-(5-methoxv-I H-indol-3-vl)-4-(pvridin-3-vl)- -(toluene-4-sulfonvl)-1 H-pyrrolof2.3-b]pvridine as a yellow oil. MS: 495(MH+).

WO 03/000688 PCT/GB02/02799 -286- By proceeding in a similar manner to Reference Example 67(a) but using W-ert- I H-indole-3 -boronic acid [Reference Example 74(b)] and 2-iodo- I -(toluene-4-sulfonyl)- I H-pyrrolo[2,3 -b]pyridine-4-carbonitrile [Reference Example 62(a)] and subjecting the crude product to chromatography on silica eluting with ethyl acetate there was prepared IH-i ndol-3-yI)- I -(toluene-4-sulfonvl)- 1H-pyrrolo[2.3-blpvridine-4 carbon itrile as a green-brown solid. MS: 443(MH+).

By proceeding in a similar manner to Reference Example 67(a) but using a mixture of W-entbutyloxycarbonyl-5-metlioxy- I H-i ndole-3 -boron ic acid and 1 -tert-butyloxycarbonyl-5-rnethoxy- I Hindole-2-boronic acid [Reference Example 74(a)] and trifluoro-methanesulfonic acid I -(toluene-4sulfonyl)-IH-pyrrolo[2,3-bpyridin-2-yI ester [Reference Example 71] there was prepared a mixture of I-N-zerrf-butvloxvcarbonl-5-methoxV- 1H-indol-2-yl)- 1-(toluene-4-sulfonylI~-H-pyrrolof2.3bipyridime and I-N-tert-butvloxycarbonvl-5-methoxy- IH-indol-3-vl)- 1-(toluene-4-sulfonyl)- IHpvrrolo[2.3-blpyridine.

By proceeding in a manner similar to Reference Example 67(a) but using 2-iodo-l-(toluene-4sulfonyl)- 1H-pyrrolo[2,3 -blpyridime [Reference Example 10(a)] and I -tert-butyloxycarbonyl-]IHpyrrole-2-boronic acid, there was prepared 1H-ovrrol-2-yl)-1 -(tol uene-4-sulfonyl)- IH-pvyrrolof 2.3bipyridine as a brown solid. TLC: RF= 0.25 (dichloromethane). MS: El (70eV); mlz =337 M+- 182 155 REFERENCE EXAMPLE 68 1 1-p-yrrolo r2,3-blpyrid ine-4 carboxylic acid. tert-buty) ester A stirred suspension of I J--pyrrolo[2,3-b]pyridine-4 carboxylic acid (0.2g, reference Example 69) in dry dimethylformam ide (SmL), under nitrogen, was treated with 1,1 '-carbonyldiimidazole (0.2g).

After stirring at room temperature for I hour the resulting tan coloured solution was treated with ternbutanol (260liL) and DBU (203ltL). This mixture was stirred at 401C overnight then evaporated. The residue was partitioned between water (3OmL) and ethyl acetate (3OnmL) and the aqueous layer was then extracted twice with ethyl acetate (I OmL). The combined organics were washed twice with brine (IlOmL), then dried over sodium sulfate and then evaporated to give the title compound (0.21 g) as a yellow solid.

REFERENCE EXAMPLE 69 I H-gyrrolor2,3-blovrid ine-4 carboxylic acid WO 03/000688 PCT/GB02/02799 -287- A solution of 1H-pyrrolo[2,3-b]pyridine-4 carboxylic acid, methyl ester [1.8g, Reference Example 19(c)] in methanol (60mL) was treated with sodium hydroxide solution (25mL, 2N) and the mixture was stirred at room temperature for 2 hours then evaporated. The residue was treated with water and the pH of the mixture was adjusted to 3-4 by addition of hydrochloric acid. The resulting yellow solid was filtered, then washed well with water and then dried to give the title compound (1.1 g) as a yellow solid.

REFERENCE EXAMPLE H-indol-2-vl)-l-(toluene-4-sulfonvl)-lH-pvrrolor2.3-b]pyridine A stirred solution of -N-tert-butyloxycarbonyl-5-methoxy-lH-indol-3-yl)-l-(toluene-4-sulfonyl)- 1 H-pyrrolo[2,3-b]pyridine [2.2g, Reference Example 67(f)] in dichloromethane (150mL) was treated with trifluoroacetic acid (20mL). After stirring at room temperature for 3 hours the reaction mixture was poured into water (300mL) and this mixture was neutralised by addition of sodium bicarbonate.

The aqueous phase was separated and extracted with dichloromethane (1OOmL). The combined organic phase and extract were washed with brine (100mL), then dried over magnesium sulfate and then evaporated. The residue was triturated with pentane to give a tan solid (1.7g) which was warmed with ethyl acetate (50mL). The insoluble material was washed well with ethyl acetate to give the title compound m.p. 226-227 0

C.

REFERENCE EXAMPLE 71 Trifluoro-methanesulfonic acid I-(toluene-4-sulfonyl)-l H-pyrrolor2,3-blpvridin-2-vl ester A solution of 2,3-dihydro- -(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridin-2-one (11.7g, Reference Example 72) and diisopropylethylamine (8.5mL) in dichloromethane (500 mL), cooled to 0°C and under a nitrogen atmosphere, was treated dropwise with trifluoromethanesulfonit anhydride (6.4mL).

The resultant mixture was stirred at 0°C for 2 hours then treated with water (300mL). The aqueous phase was neutralised by addition of sodium bicarbonate then extracted twice with dichloromethane (200mL). The combined extracts and organic phase from the reaction were dried over magnesium sulfate then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and pentane v/v) to give after trituration with pentane and petroleum ether the title compound (9.08g) as a white solid.

REFERENCE EXAMPLE 72 2,3-dihvdro- -(toluene-4-sulfonyl)-lH-pyrrolor2,3-blpyridin-2-one A solution of 1-(toluene-4-sulfonyl)- lH-pyrrolo[2,3-b]pyridine-2-carbaldehyde (24.3g, Reference Example 73) in dichloromethane (700mL), under nitrogen and at 5 0 C, was treated with 3-chloroperbenzoic acid (26.7g, After stirring at 5°C for 16 hours a further aliquot of WO 03/000688 PCT/GB02/02799 -288-

C

1 3-chloroperbenzoic acid (15g, 70%) was added and stirring was continued for a further 6 hours at 5 0

C.

S The reaction mixture was then treated with sodium sulfite solution (1L, the organic phase was ,1 separated and the aqueous phase was extracted twice with dichloromethane (200mL). The combined Sorganic phase and extracts were washed with water (400mL), dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting initially with ,1 a mixture of ethyl acetate and pentane v/v) and then with a mixture of dichloromethane and methanol (95:5, v/v) to give the title compound (11.7g) as an orange solid.

REFERENCE EXAMPLE 73 1-(toluene-4-sulfonvl)- H-pyrrolo[2.3-blpvridine-2-carbaldehvde A solution of lithium diisopropylamine {prepared by treating a solution of diisopropylamine (33.6mL) in tetrahydrofuran (250mL) with butyl lithium in hexanes (70.4mL, 2.5M) at -35 0 C, at -75 0 C, was treated dropwise with a solution of 1-(toluene-4-sulfonyl)- IH-pyrrolo[2,3-b]pyridine [40g, Reference Example in dry tetrahydrofuran (250mL) at -75 0 C whilst maintaining the reaction temperature below -60 0 C. After stirring at -75 0 C for 3 hours the reaction mixture was allowed to warm to 5°C over 2 hours then recooled to -75°C and then treated with dimethylformamide(62mL). The reaction mixture was left to warm to room temperature over 1 hour then poured into hydrochloric acid (800mL, and then evaporated to remove the tetrahydrofuran. The resulting suspension was filtered and the solid was washed with water, then dried and then was subjected to flash column chromatography on silica eluting with dichloromethane to give the title compound (24.37g) as a white solid.

REFERENCE EXAMPLE 74 I-tert-butvloxvcarbonvl-5-methoxv-IH-indole-3-boronic acid and methoxy- H-indole-2-boronic acid A solution of 1-tert-butyloxycarbonyl-3-bromo-5-methoxy-lH-indole [6g, Reference Example 1 in dry tetrahydrofuran (100mL), cooled to -80 0 C and under nitrogen, was treated with a solution of tertbutyl lithium in pentane (22.6mL, 1.5M). After stirring at -80 0 C for 2 minutes this mixture was then treated with tributyl borate (5.9 mL) and stirring was continued at -80 0 C for 20 minutes. The reaction mixture was then allowed to warm to 0°C, then carefully treated with hydrochloric acid (50mL, IN), then extracted twice with ethyl acetate (75mL). The combined extracts were washed with brine then dried over magnesium sulfate and then evaporated to give the a mixture of 1-tert- H-indole-3-boronic acid and 1-tert-butvloxvcarbonvl-5-methoxv- 1Hindole-2-boronic acid (6.2g) as a brown oil. MS: 291(M+). This material was used directly without further purification.

WO 03/000688 PCT/GB02/02799 289-

O

C By proceeding in a similar manner to Reference Example 74(a) but carrying out the reaction at -100 0 C there was prepared -ter-butvloxvcarbonvl-5-methoxv-l H-indole-3-boronic acid as a brown oil. MS: 291(M+). This material was used directly without further purification.

REFERENCE EXAMPLE CK 4-(4-cyanophenyl)piperazine-l-carboxvlic acid, tert-butyl ester A mixture of 4-fluorobenzonitrile (3.6g) and N-tert-butyloxycarbonylpiperazine (5.58g) in acetonitrile 1 (60mL) was heated at 80 0 C for 72 hours. The reaction mixture was then cooled to room temperature and then treated with a mixture of sodium bicarbonate solution and ethyl acetate (300mL, 1:1, v/v).

The organic phase was separated and then evaporated. The residue was subjected to chromatography on silica gel eluting with a mixtures of heptane and ethyl acetate (from 3:7 to 1:1, v/v) to give the title compound (2g) as a white solid.

REFERENCE EXAMPLE 76 -(Toluene-4-sulfonyl)-I H-pvrrolo[2.3-blpyridin-2-vl)-pyrrol- -yl]-acetic acid tertio butyl ester N

N

0

N

N Y\ 0 A solution of 2-(1H-pyrrol-2-yl)- -(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridine [1.15g, Reference iW Example 67(g)] in dry tetrahydrofuran (40 mL), under an argon athmosphere and at room temperature, was treated with sodium hydride (163mg, 60% dispersion in oil) then dropwise with a solution of tertbutyl bromoacetate (1.33g) in dry tetrahydrofuran (4 mL). The mixture was agitated for 24 hours at room temperature then treated with saturated aqueous ammonium chloride solution (3 mL) and then extracted with ethyl acetate (10 mL). The organic phase was washed with water (15 mL), then dried over magnesium sulfate and then evaporated. The residue was triturated with ether and filtered yielding the title compound (1.19g) as a beige solid. LC-MS; Method C: RT 4.31 minutes, 452.18[M+H] REFERENCE EXAMPLE 77 3-15-Methoxv-2-(l H-pvrrolo[2.3-bpvridin-2-vl)- 1-(toluene-4-sulfonvl)-indol- -yvl-propionic acid methyl ester.

I

WO 03/000688 PCT/GB02/02799 -290- "N N 04 NZ 0 0 A solution of 2-(5-methoxy- H-indol-2-yl)- -(toluene-4-sulfonyl)-l H-pyrrolo[2,3-b]pyridine [582mg,

S

Reference Example 70] in dry dimethylformamide (40 mL) was treated with methyl-3bromopropionate (610 VL) and potassium carbonate (387 mg). The reaction mixture was heated under agitation at 92 0 C for 48 hours, then treated with further aliquots of methyl-3-bromopropionate (458 g L) and potassium carbonate (580 mg), then heated under agitation for an additional 24 hour period, then treated with further aliquots of methyl-3-bromopropionate (153 gtL) and potassium carbonate (193 mg) and then heated under agitation for an additional 3.5 hour period. The reaction mixture was cooled to room temperature and then evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was washed with aqueous hydrochloric acid thne with aqueous sodium hydroxide then dried over magnesium sulfate and then evaporated yielding a brown oil (700 mg) which was subjected to LC-MS triggered purification (in 34 injections) yielding the title compound (433 mg) as a yellow solid. LC-MS:Method C: RT 4.16 minutes, 504.07[M+H] REFERENCE EXAMPLE 78 3-[5-Methoxy-2-( H-pyrrolo[2,3-blpyridin-2-vl)-I -(toluene-4-sulfonvl)-indol- -vll-acetic acid tertbutyl ester.

A solution of 2-(5-methoxy-I H-indol-2-yl)- -(toluene-4-sulfonyl)-lH-pyrrolo[2,3-b]pyridine [20 mg, Reference Example 70] in dry tetrahydrofuran (1.5 mL), under argon, was treated with sodium hydride (3 mg, 60% dispersion in oil), then the mixture was agitated at room temperature for 15 minutes and then the mixture was treated with tert-butylbromoacetate (14 pL) and this mixture was agitated for 3 days at room temperature. The reaction mixture was treated with ethyl acetate (2 mL) and a few drops of a saturated aqueous ammonium chloride solution. The organic phase was then dried over magnesium sulfate and then evaporated yielding the title compound (22 mg) as a yellow solid. LC-MS: Method C: RT 4.44 minutes, 532.1 [M+H] WO 03/000688 PCT/GB02/02799 -291-

O

0

N,,

N

a REFERENCE EXAMPLE 79 S 1-{-Methyl-3-[l-toluene-4-sulfonyl-l H-pvrrolo[2,3-bppridin-2-yl]-lH-indol-5lox-prpan-2-ol Ho s--o 0

N

N H To a solution of 1-l{ -methyl-3-[-toluene-4-sulfonyl)-l H-pyrrolo[2,3-b]pyridin-2-yl- yloxy}-propan-2-one [0.2g, Reference Example 23 in dry tetrahydrofuran (5 mL) under nitrogen at -78°C was added diisopinocampheyl boron chloride The reaction mixture was stirred for minutes at -78Cain d then at -20C for a further 5 hours. The reaction mixture was poured' into wter mL), treated with solid sodium bicarbonate (1.0g) and stirred at room temperature for one hour before extraction with ethyl actetate (2 x 25 mL). The combined organic extracts were washed with water (30 mL), the with brine (25 mL), then dried over sodium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica gel eluting with ethyl acetate and pentane v:v) to afford the title compound as a yellow oil. TLC: Rp 0.22 (ethyl acetate/pentane 1:1).

Cc REFERENCE EXAMPLE 4-(3.5-Dimethyl-isoxazole-4-yl)-l 1H-pyrrolo[2,3-bpyridine -0 To a solution oftrifluoro-methanesulfonic acid-lH-pyrrolo[2,3-b]pyridin-4-yl ester [4.05g, Reference Example 18(g)] and 3,5-dimethylisoxazole-4-boronic acid (2.31g) in dimethylformamide (100 mL) was added tetrakis(triphenylphosphine)palladium[0] and saturated sodium bicarbonate solution mL). The resulting mixture was stirred at 1100C for 5 hours. The reaction mixture was cooled and filtered through celite. The filtrate was evaporated to dryness and the residue partitioned between ethyl acetate (100 mL) and water (50 mL). The aqueous phase was extracted with ethyl acetate and the combined organic fractions were washed twice with brine (30 mL), then dried over magnesium sulfate WO 03/000688 PCT/GB02/02799 -292and then evaporated to afford the title compound as an orange oil which was used immediately without further purification for the preparation of Reference Example 9(i).

REFERENCE EXAMPLE 81 3-(4-cvano-1H-pyrrolo[2,3-bpyridin-2-vl)- 1-methyl-IH-indole-5-carboxvlic acid, methyl ester

N

N No A mixture of 3-[4-chloro- -(toluene-4-sulfonyl)- H-pyrrolo[2,3-b]pyridine-2-yl]-l-methyl-IH-indoleacid, methyl ester [0.4g, Reference Example zinc powder (0.05g), Zinc cyanide (0.117g), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (II) complex with dichlroromethane (catalytic) and N,N-dimethylacetamide (8 mL) was heated at 130 150 oC for hours. The reaction mixture was cooled, filtered and the precipitated washed with dimethylformamide (2 mL). The filtrate was diluted with ethyl acetate (120mL) and the solution extracted with water (2 x mL). The combined organic layer was evaporated and the residue subjected to flash column chromatography on silica gel eluting with a mixture of heptane and ethyl acetate (7:3 v/v) moving to neat ethyl acetate to give the title compound (0.12g) as a bright yellow solid. MS: 331(MH+).

HPLC(Method RT= 4.01 minutes.

REFERENCE EXAMPLE 82 6-Benzyloxy-3-iodo-5-methoxy-indole- -carboxvlic acid tert-butvl ester A solution of 6-benzyioxy-5-methoxyindole (1.90g, prepared according to procedure described by Benigni, J. D. and Minnis, R. J. Heterocycl. Chem. 1965, 2, 387 and Sinhababu, A. K. and Borchardt, R. J. Org. Chem. 1983, 48, 3347) in dry dimethylformamide (37.5 mL) was treated with ground potassium hydroxide (1.24g) and a solution of iodine (1.96g) in dry dimethylformamide (37.5 mL) dropwise at room temperature. The reaction mixture was stirred at room temperature for 2 hours, then treated with 4-dimethylaminopyridine (69mg) followed by a solution ofdi-tert-butyldicarbonate (2.05g) in dry dimethylformamide and stirring was continued for a further 1 hour. The reaction mixture was poured into aqueous sodium sulfite solution The aqueous phase was extracted three times with ethyl acetate (100 mL). The combined organic phases were washed with water (100 mL), then with brine (100 mL), then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture ofcyclohexane and ethyl WO 03/000688 PCT/GB02/02799 -293acetate v/v) to give the title compound (3.35g) as a white solid. TLC: RF 0.58 (dichloromethane). MS: El (70eV); m/z= 479 M 423 332 REFERENCE EXAMPLE 83 2-(6-Hvdroxv-5-methoxv-l-methyl-I H-indol-3-vl)- -(toluene-4-sulfonyl)- H-pyrrolo[2.3-blpyridine C A solution of 2-(6-benzyloxy-5-methoxy-l-methyl-lH-indol-3-yl)-l-(toluene-4-sulfonyl)-lH-

O

O pyrrolo[2,3-b]pyridine [1.24g, Reference Example 13(p)] in acetonitrile (100 mL) was treated with

O

rC iodotrimethylsilane (820 1 The reaction mixture was stirred at 50 0 C for 2 hours and then 0concentrated in vacuo. The residue was treated with water (40 mL) and the mixture was extracted three 10 times with dichloromethane (100 mL). The combined organic phases were washed with brine (40 mL), then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of cyclohexane and ethyl acetate v/v) to give the title compound (686mg) as a white foam. TLC: RF 0.27 (cyclohexane/ethyl acetate MS: El m/z 447 M 292 (100%).

REFERENCE EXAMPLE 84 2-(6-Isopropoxy-5-methoxy-l-methyl- H-indol-3-vl)- -(toluene-4-sulfonvl)-lH-pyrrolof2.3-b]pyridine Potassium carbonate (70mg) was added to a solution of 2-(6-hydroxy-5-methoxy- I-methyl-I H-indol-3yl)-l-(toluene-4-sulfonyl)-lH-pyrrolo[2,3-b]pyridine [112mg, Reference Example 83] in dry dimethylformamide (5 mL) under an argon atmosphere at ambient temperature. The mixture was allowed to stir for 10 minutes then treated with 2-bromopropane (661l) and heated at 70 0 C for 3 hours.

Additional portions of potassium carbonate (70mg) and 2-bromopropane (66.l) were then added and the mixture was stirred and heated at 70 0 C for 4 hours. The cooled reaction mixture was poured in water (20 mL) and extracted three times with ethyl acetate (40 mL). The combined organic phases were washed with brine (20 mL), then dried over magnesium sulfate and then evaporated. The brown residue was subjected to flash column chromatography on silica eluting with a mixture of cyclohexane and ethyl acetate v/v) to give the title compound (56mg) as an off-white foam. TLC: RF 0.47 (cyclohexane/ethyl acetate, MS: CI (NH 3 m/z= 490 MH+.

REFERENCE EXAMPLE Methyl 1-(toluene-4-sulfonvll-1H-indole-5-carboxvlate 3-boronic acid To a solution of mercuric acetate (0.72g) in glacial acetic acid (25 mL) at room temperature was added 1-(toluene-4-sulfonyl)-1H-indole-5-carboxylic acid methyl ester [0.75g, Reference Example 9 and the reaction mixture was stirred at room temperature for 6 hours and allowed to stand over night. The reaction mixture was diluted with water (50 mL) and stirred for a further three hours. The resultant WO 03/000688 PCT/GB02/02799 -294white solid was collected by filtration, washed with water (2 x 10 mL) and dried to afford methyl-3acetomercurio-l-(toluene-4-sulfonyl)-l H-indole-5-carboxylate (1.1 To a solution of the meruric acetate derivative (1.1 g) in dry tetrahydrofuran (25 mL) under a nitrogen atmosphere was added borane tetrahydrofuran complex (15 mL of a ].OM solution in tetrahydrofuran). The mixture was stirred at room temperature for 2.5 hours before careful addition of water (5 mL) while cooling with a C water bath. The reaction mixture was filtered and the filtrate concentrated to 25 mL before dilution in ethyl acetate (75 mL). The organic fraction was washed with water (30 mL) and brine 30 mL), dried over magnesium sulfate and evaporated to 10 mL. The product was precipitated by addition of a small amount of pentane. The resultant solid was isolate by filtration and washed with pentane to afford the title compound as a white solid (0.5 MP: 188-190 0

C.

4 C'1 REFERENCE EXAMPLE 86 IH-pvrrolor2.3-blpyridine-4-ol 4-Chloro-lH-pyrrolo-[2,3-b]pyridine [80 g, Reference Example 64] was treated with 10% aqueous sodium hydroxide solution (330 g) and heated to 180 0 C for 8 hours in a parr bomb with magnetic stirring. The reaction mixture was cooled to room temperature and excess sodium hydroxide was neutralized with a large excess of solid carbon dioxide pellets. Undissolved starting material was removed by filtration and the filtrate was concentrated in vacuo. The residue was extracted with hot methanol (3 x 1000 mL). The combined methanol extracts were concentrated and the residue purified 0 by flash column chromatography on silica gel eluting with a mixture ofdichloromethane and methanol (9:1 v:v to 4:1 v:v) to afford the title compound as a solid (63 TLC: RF 0.32 (dichloromethane methanol 4/1).

WO 03/000688 PCT/GB02/02799 -295- IN VITRO TEST PROCEDURES A. IN VITRO TEST PROCEDURES FOR SYK 1. Inhibitory effects of compounds on Syk kinase Inhibitory effects of compounds on Syk kinase were determined using a time-resolved fluorescent assay.

The catalytic domain of Syk kinase (residues A340-N635 was expressed as a fusion protein in yeast cells and purified to homogeneity. Kinase activity was determined in 50mM Tris-HCI buffer pH containing 50mM NaCI, 5mM MgCI 2 5mM MnCl 2 I tM adenosine triphosphate and 1 OiM synthetic peptide Biotin-( p-Alanine) 3 -DEEDYE1PP-NH 2 Enzyme reactions were terminated by the addition of buffer containing 0.4M KF, 133mM EDTA, pH 7.0, containing a streptavidin-XL665 conjugate and a monoclonal phosphospecfic antibody conjugated to a europium cryptate Features of the two fluorophores, XL-665 and Eu-K are given in G.Mathis et al., Anticancer Research, 1997, 17, pages 3011-3014. The specific long time signal of XL-665, produced only when the synthetic peptide is phosphorylated by Syk, was measured on a Packard Discovery Microplate analyzer or on an LJL Biosystems Analyst AD microplate reader. Inhibition of syk activity with compounds of the invention was expressed as percentage inhibition of control activity exhibited in the absence of test compounds.

Particular compounds of the invention inhibit syk activity with IC 50 s in the range 100 micromolar to 3 nanomolar. Preferred compounds of the invention inhibit syk activity with IC 50 s in the range 100 nanomolar to 3 nanomolar. Especially preferred compounds of the invention inhibit syk activity with

IC

50 s in the range 10 nanomolar to 3 nanomolar.

2. Antigen-induced degranulation of Rat Bosophilic leukemia (RBL) cells as measured by r 3 H1 5-hydoxvtryptamine (serotonin) release 2.1 Cell culture, labelling of RBL-2H3 cells and performance of assay.

Method A: For each 24-well culture plate to be set up, 6 x 106 cells RBL-2H3 cells were washed and resuspended in 15 mL DMEM-10 containing 251 of ImCi/ mL 3 H]-serotonin (0.5pCi/mL final concentration) and 1 itg/ mL (15 mL) of anti-DNP IgE. 0.5 mL of cell suspension was added into each well of a 24-well plate. Cells were incubated for 2 days at 37 0 C, until they have reached confluence.

The medium was gently aspirated from each well and the cells were then washed with assay buffer. A final volume of 200 mL of assay buffer or the test compounds at the appropriate concentrations) WO 03/000688 PCT/GB02/02799 -296was then added to each of three replicate wells. lOOng/ mL of DNP (antigen) was then added to all 4 wells (excluding negative control wells i.e. to measure spontaneous 3 H]-serotonin release in the CK absence of receptor cross-linking). The cells were incubated for 30 minutes at 37 0 C and the reaction was stopped by transferring 100l of the supernatant from each sample into a liquid scintillation microtitre plate kept on ice. 200p.l of scintillant-40 was then added to each well of the microtitre plate and the plate was read on a Topcount Liquid Scintillation Counter.

C Method B: RBL-2H3 cells are maintained in T75 flasks at 37 0 C and 5%CO 2 and passaged every 3-4 Sdays. To harvest cells, 5 ml trypsin-EDTA is used to rinse the flask once, then 5 ml trypsin is added to 10 each flask, and incubated at room temperature for 2 minutes. Cells are transferred to a tube with 14ml medium, spun down at 1100 rpm RT for 5 minutes andresuspended at 2x10 5 /ml. Cells are sensitized by adding Il l of DNP-specific IgE to every 10 ml of cells. 200pl of cells are added to each well of a flat-bottom 96 well plate (40,000 cells/well), and the plate incubated overnight at 37 0 C and 5%CO 2 The next day compounds are prepared in 100% DMSO at 10mM. Each compound is then diluted 1:100 in assay buffer and then diluted further in 1% DMSO-assay buffer to obtain final concentrationsof 0.03-30uM. 80pl assay buffer is added to each well, followed by 101l of diluted compound.

Incubation follows for 5 minutes. 10pl of DNP-HSA (100ng/ml) is added to each well and incubated at 37 0 C (no CO2) for 30 minutes. As one control, 1% DMSO alone (no compound) is added to a set of wells to determine total release. As another control, add buffer instead of DNP-HSA to another set of wells to determine the assay background. After the 30 minutes incubation, the supernatants are transferred to a new 96-well plate. Add 50pl supernatant to each well of an assay plate. Add 100 l of Iv substrate solution to each well and incubate at 37 0 C for 90 minutes. Add 50pl of 0.4 M glycine solution to stop the reaction and the plate is read at 405 nm on a Molecular Devices SpectraMax 250 plate reader.

2.2 Calculation of results Method A The mean s.e.m. of each set of triplicate wells was calculated.

(ii) Maximum response was the positive control wells containing antigen (10ng/mL) but no compound.

(iii) Minimum response was the control wells containing no antigen and no compound.

(iv) Using these values as the maximum (100%) and minimum values respectively, the data was normalised to give a percentage of the maximum response.

A dose response curve was plotted and the IC 50 of the compound was calculated.

WO 03/000688 PCT/GB02/02799 S -297- I Method B The mean SD of each set of triplicate wells was calculated.

S(ii) Maximum response was the positive control wells containing antigen (100ng/mL) but no compound.

(iii) Minimum response was the control wells containing buffer (no antigen) and no compound.

C, (iv) Using these values as the maximum (100%) and minimum values respectively, the Sexperimental data was calculated to yield a percentage of the maximum response (designated control).

A dose response curve was plotted and the IC 50 of the compound was calculated using Prism GraphPad software and nonlinear least squares regression analysis.

Compounds of the invention inhibit antigen-induced degranulation of Rat Bosophilic leukemia (RBL) cells with EC 50 s in the range 100 micromolar to 0.01 micromolar.

B. IN VITRO TEST PROCEDURES FOR KDR 1. Inhibitory effects of compounds on KDR Inhibitory effects of compounds on KDR-substrate phosphorylation assay were determined using a flashplate 96-multiwell plates, New England Nuclear) assay.

The cytroplasmic domain of human enzyme has been cloned as glutathione S-transferase (GST) fusion into the pFastBac-GST tagged (reading frame) B baculovirus expression vector. The protein has been expressed in SF21 cells and purified to about 60% homogeneity.

Kinase activity was determined in 20mM 4-morpholinepropanesulfonic acid sodium salt, MgCI 2 10mM MnCI 2 ImM Dithiothreitol, 2.5mM ethyleneglycol-bis (beta-aminoethylether)- N,N'tetraacetic acid, 10mM p-glycerophosphate, pH 7.2 containing 10 mM MgC12, 100 JM Na 3

VO

4 ImM NaF. 10 pl of compound were added to 70p1l of kinase buffer containing 100ng of Kinase Domain Receptor (KDR) enzyme at 4 0 C. Reaction was started by addition of 20pul of solution containing 2pg of substrate (SH2-SH3 fragment of PLCy expressed as GST fusion protein 2iCi y 33 P[ATP] and 2 1 M cold ATP. After Ih incubation at 37 0 C, reaction was stopped by addition of 1 volume (100l) of 200mM EDTA. The assay buffer was then discarded and the wells washed three fold with 300 l of phosphate buffered saline. Radioactivity was measured in each well using a Packard Model Top Count NXT instrument.

WO 03/000688 PCT/GB02/02799 -298- S Background signal was deduced from the measurement of radioactivity in quadruplate wells containing radioactive ATP and substrate alone in kinase buffer.

1 Control activity was deduced from the measurement of radioactivity of quadruplate wells containing the complete assay cocktail (y 33 P-[ATP], KDR and PLCg substrate) in the absence of test compound.

Inhibition of KDR activity with compound of the invention was expressed as percentage inhibition of C"1 control activity exhibited in the absence of test compound.

0 SU5614 1pM (Calbiochem) was included in each plate in quadruplate as a control of inhibition.

C' ICso's were calculated for compounds of the invention by plotting a dose-response curve. IC 50 corresponded to the concentration of compound of the invention that induced a 50% inhibition of kinase activity.

Particular compounds of the invention inhibit KDR activity with IC 50 s in the range 100 micromolar to 0.3 micromolar.

2. Cellular activity on endothelial cell 2.1 Inhibition of Vascular endothelial growth factor (VEGF)-dependent human dermal microvascular endothelial cells (HDMEC) proliferation.

The anti-KDR activity of the molecules of the invention was evaluated by 4 C]-thymidine uptake on HDMEC (Human Dermal Microvascular Endothelial Cell) in response to VEGF.

HDMEC (Promocell, passage 5 to 7) were seeded in 100gl at 5,000 cells per well in Cytostar 96- C, multiwell plates (Amersham) precoated with Attachment factor (AF, Cascad Biologics) at 37 0 C,

CO

2 at day 1. On day 2, complete cell medium (Basal medium supplemented with 5% of Fetal calf serum (FCS) and cocktail of growth factors) was replaced by minimum medium (basal medium supplemented with 5% of FCS) and cells were incubated for another 24h. On day 3, medium was replaced by 200 pl of fresh minimum medium supplemented or not with 100 ng/ml VEGF (R&D System) and containing or not compounds of the invention and 0.1 Ci 1 4 C]-thymidine. Cells were incubated at 37 0 C, 5% CO 2 for 4 days. [1 4 C]-thymidine uptake was then quantified by counting the radioactivity. Assays were performed in three replicate wells. The final concentration of DMSO in the assay is The inhibition is calculated as [cpm(+vEGF) cpm (+VEGF+ cpd)/ cpm(+VEGF)- cpm 100.

2.2 Effect of molecules on VEGF-independent HDMEC growth: WO 03/000688 PCT/GB02/02799 -299-

O

S HDMEC (5,000 cells per well) are seeded in complete medium (CM) in Cytostar 96-multiwell plates (Amersham) precoated with Attachment factor (AF, Cascad Biologics) at 37 0 C, 5% CO2, at day 1.

S Complete medium is then removed and cells are incubated in 20 0 p1 of complete medium containing molecules of the invention and 4 C]-thymidine (0.1 ICi) The uptake of [1 4 C]-thymidine is quantified using Wallac betaplate after 3 days of incubation. The inhibition is calculated as [cpm(cM) cpm (CM CN +cpd)/ cpm(CM)]x 00.

C. IN VITRO TEST PROCEDURES FOR AURORA2 1. Inhibitory effects of compounds on Aurora2 kinase Inhibitory effects of compounds on Aurora2 kinase were determined using a nichel-chelate flashplate radioactive assay.

N-terminally His-tagged full length recombinant aurora2 was expressed in E.coli and purified to near homogeneity.

N-terminally His-tagged NuMA (Nuclear protein that associates with the Mitotic Apparatus) Cterminal fragment (Q1687-H2101) was expressed in E.coli, purified by nichel chelate chromatography and used as substrate in Aurora2 kinase assay. For kinase activity determination NuMAsubstrate was freshly equilibrated in kinase buffer (50 mM Tris-HCI, pH7.5, 50 mM NaCI, 10 mM MgCI 2 supplemented with 10% glycerol and 0.05% NP40 by chromatography on a Pharmacia PDIO column.

The kinase activity of Aurora2 was measured in a nichel chelate flashplate (New England Nuclear, model SMP107). Each well contained 100 pl of the following solution 0.02 gM Aurora2 0.5 pM NuMAsubstrate; 1 U.M ATP supplemented with 0.5 tCi[y ATP. The solutions were incubated for 30 minutes at 37 The assay buffer was then discarded and the wells rinsed twice with 300 pl of kinase buffer. Radioactivity was measured in each well using a Packard Model Top Count NXT instrument.

Background signal was deduced from the measurement of radioactivity in duplicate wells containing radioactive ATP alone in kinase buffer treated in the same manner as other samples.

Control activity was deduced from the measurement of radioactivity of duplicate wells containing the complete assay cocktail (ATP, Aurora2 and NuMA substrate) in the absence of test compound.

Inhibition of Aurora2 activity with compound of the invention was expressed as percentage inhibition of control activity exhibited in the absence of test compound. Staurosporin was included in each plate as a control of inhibition.

WO 03/000688 PCT/GB02/02799 -300-

O

SICo's were calculated for compounds of the invention by plotting a dose-response curve. corresponded to the concentration of compound of the invention that induced a 50% inhibition of S kinase activity.

Particular compounds of the invention inhibit Aurora2 activity with IC 5 0 s in the range 100 micromolar CK to 0.1 micromolar. Preferred compounds of the invention inhibit Aurora2 activity with IC 50 s in the range 100 nanomolar to 10 nanomolar.

0 D. IN VITRO TEST PROCEDURES FOR FAK A 1. Inhibitory effects of compounds on FAK Inhibitory effects of compounds on FAK kinase autophosphorylation assay were determined using a time-resolved fluorescent assay.

The full length cDNA of human enzyme has been cloned into the pFastBac HTc baculovirus expression vector. The protein has been expressed and purified to about 70% homogeneity.

Kinase activity was determined in 50 mM Hepes pH 7.2 containing 10 mM MgCl 2 100 U.M Na 3

VO

4 15 PM adenosine triphosphate. Enzyme reactions were terminated by the addition of Hepes buffer pH containing 0.4 M KF. 133 mM EDTA, BSA 0.1% containing an anti-6His antibody labelled with XL665 (FAK is His-tagged) and a monoclonal tyrosine phosphospecfic antibody conjugated to a europium cryptate Features of the two fluorophores, XL-665 and Eu-K are given in G.Mathis et al., Anticancer Research, 1997, 17, pages 3011-3014. The specific long time signal of XL-665, produced only when the FAK enzyme is autophosphorylated, was measured on a Packard Discovery Microplate analyzer. Inhibition of FAK activity with compounds of the invention was expressed as percentage inhibition of control activity exhibited in the absence of test compounds.

2. Proliferation/viability of human melanoma SK-Mel-28 cells as measured by 14 C] Thymidine uptake 2.1 Cell culture, labelling of SK-Mel-28 cells and performance of assay.

SK-Mel-28 were seeded at 5,000 cells per well in Cytostar 96-multiwell plates (Amersham) at 37 0

C,

5% CO2, at day 1. On day 2, cell medium was replaced by fresh Eagle's minimum essential medium (MEM) culture medium supplemented with 10 FCS, 1% non essential amino acids, I sodium WO 03/000688 PCT/GB02/02799 -301pyruvate and containing 0.1 pCi of 4 C]-Thymidine plus increasing concentrations of compounds in a 200 l final volume. Cells were incubated at 37 0 C, 5% CO 2 for 48 hours. 4 C]-Thymidine uptake was Squantified by counting the radioactivity 48 hours after initiation of treatment. Assays were performed in three replicate wells.

C1 2.2 Calculation of results The mean s.e.m. of each set of triplicate wells was calculated.

(ii) Maximum response was the positive control wells containing cells but no compound.

(iii) Minimum response was the control wells containing no cell and no compound.

(iv) Using these values as the maximum (100%) and minimum values respectively, the data were normalized to give a percentage of the maximum response.

A dose response curve was plotted and the IC 5 0 (the concentration of drug that induces a decrease in [14C]-thymidine uptake) of the compound was calculated.

3. Migration of human melanoma SK-Mel-28 cells on Fibronectin matrix 3.1 Cell culture and performance of assay.

SK-Mel-28 (250,000 cells were pretreated with increasing concentrations of compounds for 15 min at 37 0 C, 5 CO 2 They were then loaded in presence of the compound on the upper side of 12 jm 12multiwell chemotaxis Boyden chambers (Becton Dickinson) and allowed to migrate to the lower chamber containing fibronectin (10 gg/ml) as chemoattractant in basal RPMI culture medium for 24 hours at 37 0 C, 5 CO 2 Cells were then fixed and stained in Diff-Quick (Diff-Quick Fix, I and II solutions, Dade Behring) and cells from the upper side of the chamber were removed. Stain was solubilized from lower side adherent cells and cell migration was quantified by optic density measurement. Assays were performed in two replicate wells.

3.2 Calculation of results The mean s.e.m. of each set of duplicate wells was calculated.

(ii) Maximum response was positive control wells containing cells but no compound and allowed to migrate on fibronectin.

(iii) Minimum response was the control wells containing cells but no compound and allowed to migrate on basal culture medium w/o chemoattractant.

WO 03/000688 PCT/GB02/02799 -302- (iv) Using these values as the maximum (100%) and minimum values respectively, the data were normalized to give a percentage of the maximum response.

A dose response curve was plotted and the IC 50 (the concentration of drug that induces a decrease in cell migration) of the compound was calculated.

Particular compounds of the invention inhibit FAK activity with IC 50 s in the range 100 micromolar to 0.3 micromolar.

E. IN VITRO TEST PROCEDURES FOR IGFIR 1. Inhibitory effects of compounds on IGFIR Inhibitory effects of compounds on IGF IR- autophosphorylation activity were determined using a time-resolved fluorescent assay.

The cytoplasmic domain of human IGFIR has been cloned as glutathione S-transferase (GST) fusion into the pFastBac-GST tagged baculovirus expression vector. The protein has been expressed in SF21 cells and purified to about 80% homogeneity.

Kinase activity was determined in 50 mM Hepes pH 7.5 containing 5 mM MnCI 2 50 mM NaCI, 3% Glycerol, 0.025% Tween 20, 120 piM adenosine triphosphate. Enzyme reactions were terminated by the addition of 100 mM Hepes buffer pH 7.0, containing 0.4 M KF, 133 mM EDTA, BSA 0.1% containing an anti-GST antibody labelled with XL665 and an anti-phosphotyrosine antibody conjugated to a europium cryptate Features of the two fluorophores, XL.665 and Eu-K are given in G.Mathis et al., Anticancer Research, 1997, 17, pages 3011-3014. The specific long time signal of XL-665, produced only when the IGFIR enzyme is autophosphorylated, was measured on a Victor analyser (Perkin-elmer). Inhibition of IGF 1R kinase activity with compounds of the invention was expressed as percentage inhibition of control activity exhibited in the absence of test compounds.

2. Proliferation/viability of human breast carcinome MCF-7 cells as measured by 14 C] Thymidine uptake 2.1 Cell culture, labelling of MCF-7 cells and performance of assay.

The antiproliferative effect of the molecules on MCF-7 cells was evaluated by 14 C]-thymidine uptake 72 hours after IGF1-induced cell proliferation.

WO 03/000688 PCT/GB02/02799 -303- S MCF-7 cells were seeded at 25,000 cells per well in Cytostar 96-multiwell plates (Amersham) at 37 0

C,

S 5% CO 2 at day 1, left overnight in EMEM medium supplemented with 10% of FCS to allowed cell S attachment. At day 2, the medium culture was changed for EMEM/HamF 2, 50/50 in order to S deprivate the cells for 24 hours. On day 3, cell medium was replaced by fresh EMEM with 1% of sodium pyruvate, penicillin, streptamicin and 50ng/ml final concentration of IGFI. Then, 0.1 pCi of C 14 C]-Thymidine and 3 tl of compounds were added in 213 1 l final volume. Cells were incubated at 37 0 C, 5% CO 2 for 72 hours. 1 4 C]-Thymidine uptake was quantified by counting the radioactivity 72 hours after IGF I-induced proliferation (Microbeta trilux counter, Perkin-elmer). IC 50 determinations were performed in duplicate with I 10 increasing concentrations.

2.2 Calculation of results The mean s.e.m. of each set of duplicate wells was calculated.

(ii) Maximum response signal value was calculated from the positive control wells.containing cells stimulated by IGFI but no compound.

(iii) Minimum response signal value was calculated from the control wells containing cells unstimulated by IGFI and no compound.

(iv) Using these values as the maximum (100%) and minimum values respectively, the data were normalized to give a percentage of the maximum response.

A dose response curve of 10 points was plotted and the IC 50 (the concentration of drug that induces 4. a 50% decrease in specific signal) of the compound was calculated by non-linear regression analysis.

3. IGF1R autophosphorylation in MCF7 cell line after IGFI stimulation 3.1 Cell culture and performance of assay.

IGF1-induced IGFIR autophosphorylation in cells was evaluated by ELISA technique.

MCF-7 cells were seeded at 600 000 cells per well in 6-multiwell plates, left over night in 10% serum and then serum-starved for 24h. Compounds are added to medium 1 hour before IGFI stimulation.

After 10 minutes of IGFI stimulation, cells are lysed with Hepes 50mM pH7.6, Triton X100 1%, Orthovanadate 2mM, proteases inhibitors. Cell lysates are incubated on 96-multiwell plates pre-coated with anti-IGFI R antibody, followed by incubation with an anti-phosphotyrosine antibody coupled to peroxydase enzyme. Peroxidase activity level (measured by OD with a luminescent substrate) reflects receptor phosphorylation status.

WO 03/000688 PCT/GB02/02799 -304- S 3.2 Calculation of results The mean s.e.m. of each set of duplicate wells was calculated.

(ii) Maximum response signal value was calculated from positive control wells containing lysates of C, cells stimulated by IGFI but no compound.

(iii) Minimum response signal value was calculated from the control wells containing lysates of unstimulated cells and no compounds.

(iv) Using these values as the maximum (100%) and minimum values respectively, the data were normalized to give a percentage of the maximum response.

A dose response curve was plotted and the IC 50 (the concentration of drug that induces a decrease in OD measure) of the compound was calculated.

Particular compounds of the invention inhibit IGFIR activity with IC 5 0 s in the range 100 micromolar to 60 nanomolar. Preferred compounds of the invention inhibit IGFIR activity with IC 50 s in the range 100 nanomolar to 60 nanomolar. IN VIVO TEST PROCEDURES FOR SYK INHIBITORS 1. Inhibition of antipen induced airway inflammation single-and multiple-day oral dosing studies.

Compounds of the invention were assessed in the allergic Brown Norway rat. The models used in these in vivo studies mimic relevant pathological features of allergic airway disease. These studies !r demonstrated that compounds of the invention inhibit the accumulation of inflammatory cells in the airways allergic twenty-four hours after antigen inhalation. The endpoints measured included the appearance of inflammatory leukocytes in the bronchoalveolar lavage fluid (BALF), lung digest fluid, and in the tissue as quantified by histopathological analysis.

Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (100g, i.p) administered with aluminium hydroxide (100 mg, On day 30, the rats were exposed to a 1% aerosol of ovalbumin for a period of 30 minutes. The animals were then returned to housing.

Protocol for Dosing Test drug was administered orally 1 hour before the initiation of the allergen inhalation challenge.

Four hours after the end of the antigen inhalation challenge, a second dose of drug was given orally.

Doses of compound were administered at half log divisions between 3 and 100 mg/kg.

WO 03/000688 PCT/GB02/02799 -305- In separate studies drug was administered two times daily for 4 days before the inhalation of antigen.

The final dose of compound in these studies was also given at 4 hours after the antigen challenge.

Protocol for Bronchoalveolar lavage (BAL) recovery Twenty-four hours after the antigen inhalation challenge, cells were recovered from the airway lumen by bronchoalveolar lavage by euthanizing the animals, and washing the lungs with three 5-mi aliquots of RPMI/FCS. The washes were allowed to remain in the lungs for 30 seconds each before gentile removal. The three samples were pooled and total and differential white blood cell counts were measured on BAL samples. An ARGOS system was used to assess total cells and differential cell counts were made using light microscopy of Wright-Giemsa stained cytocentrifuge preparations.

Protocol for Histopathology of lungs Immediately after BAL, the lungs were insufflated with 10% neutral buffered formalin (NBF), at water pressure. The lungs were removed and placed in jars of 10% NBF. After fixation in 10% NBF for a minimum of 24 hours the lungs were processed through graded alcohol and into wax locks. The lungs were blocked longitudinally and one 2 pnm longitudinal section for each animal was cut at the level of the main bronchi. Sections were then stained with haematoxylin and eosin. Pathological assessment of sections was performed and a grading for the bronchiolar epithelium and sub-mucosa was assigned Protocol for lung digest In some studies the lung itself was digested, to recover the inflammatory cells localized within the tissue. In these studies the cells were obtained by perfusing the left lung with RPMI/FCS in order to remove the blood pool of cells immediately after BAL. In the se studies the he right hand side of the lung was insufflated and fixed with buffered formalin for histopathological analysis. The lung to undergo digestion was standardized across animals by taking a 300mg the section of the lung tissue and exposing it to collagenase digestion. This freed the cells within the lung tissue and allowed their recovery. Total and differential cell counts were performed on these recovered cells.

Results Following antigen inhalation there was a significant increase in the numbers of eosinophils and neutrophils in the non-drug treated groups. His was evidenced by the significant increase in BAL and tissue digest eosinophil and neutrophils numbers as well as the lung histopathology score.

(ii) No changes in BAL macrophage/monocyte cell numbers were observed with antigen challenge or with any drug treatment.

WO 03/000688 PCT/GB02/02799 -306- (iii) The compound as able to inhibit significantly the infiltration ofneutrophils and eosinophils 24 hours after antigenic challenge compared to the non-drug treated controls as assessed in all three methods noted above. The dose range for efficacy was between 3 and 100 mg/kg po.

(iv) In the multiple-day drug administration studies, there was quantitatively similar inhibition of the cellular influx as seen in the single day studies.

These results indicate that compounds of the invention demonstrate anti-inflammatory activity when given prophylacticlly ir a rat model of antigen induced leukocyte infiltration 2. Inhibition of antigen induced airway inflammation -single-day ip dosing studies Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (100g, i.p) administered with aluminium hydroxide (100 mg, On day 30, the rats were exposed to a 1% aerosol of ovalbumin for a period of 30 minutes. The animals were then returned to housing.

Protocol for Dosing Test drug was administered four times intraperitoneally rather than po. The dosing regimen was min pre-challenge and 2, 4 and 8 hours after allergen inhalation challenge.

Protocol for Bronchoalveolar lavage (BAL) recovery Twenty-four hours after the antigen inhalation challenge, cells were recovered from the airway lumen by bronchoalveolar lavage by euthanizing the animals, and washing the lungs with three 5-ml aliquots of RPMI/FCS. The washes were allowed to remain in the lungs for 30 seconds each before gentile removal. The three samples were pooled and total and differential white blood cell counts were measured on BAL samples. An ARGOS system was used to assess total cells and differential cell counts were made using light microscopy of Wright-Giemsa stained cytocentrifuge preparations.

Protocol for Histopathology of lungs Immediately after BAL, the lungs were insufflated with 10% neutral buffered formalin (NBF), at water pressure. The lungs were removed and placed in jars of 10% NBF. After fixation in 10% NBF for a minimum of 24 hours the lungs were processed through graded alcohol and into wax locks. The lungs were blocked longitudinally and one 2 pm longitudinal section for each animal was cut at the level of the main bronchi. Sections were then stained with haematoxylin and eosin. Pathological assessment of sections was performed and a grading for the bronchiolar epithelium and sub-mucosa was assigned.

WO 03/000688 PCT/GB02/02799 -307- Protocol for lung digest In some studies the lung itself was digested, to recover the inflammatory cells localized within the tissue. In these studies the cells were obtained by perfusing the left lung with RPMI/FCS in order to remove the blood pool of cells immediately after BAL. In the se studies the he right hand side of the lung was insufflated and fixed with buffered formalin for histopathological analysis. The lung to undergo digestion was standardized across animals by taking a 300mg the section of the lung tissue and exposing it to collagenase digestion. This freed the cells within the lung tissue and allowed their recovery. Total and differential cell counts were performed on these recovered cells.

Results Following antigen inhalation there was a significant increase in the numbers of eosinophils and neutrophils in the non-drug treated groups. This was evidenced by the significant increase in BAL and tissue digest eosinophil and neutrophil numbers as well as the lung histopathology score.

(ii) Compounds of the invention were able to inhibit significantly the infiltration of neutrophils and eosinophils 24 hours after antigenic challenge compared to the non-drug treated controls as assessed in all three methods noted above. The dose range for efficacy was between 3 and 100 mg/kg po.

These results indicate that compounds of the invention demonstrate anti-inflammatory activity when given prophylacticlly in a rat model of antigen induced leukocyte infiltration either orally or intraperitoneally.

3. Inhibition of acute antigen induced bronchoconstriction in the allergic rat Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (1004g, i.p) administered with aluminium hydroxide (100 mg, On the day of study the rats were surgically prepared for the measurement of pulmonary mechanics and mechanically ventilated. After a five-minute equilibration period, the animals received a bolus of ovalbumin (1 mg per rat). The animals were then followed for minutes and peak changes from base line resistance recorded as the response to antigen challenge.

Protocol for Dosing Test drug was given either p.o. or i.p. 24 and 2 hours before the iv bolus injection of ovalbumin. The range of compound delivered in these studies was 10-100 mg/kg po.

WO 03/000688 PCT/GB02/02799 S-308- Results Following antigen challenge in the non-drug treated and budesonide control-treated animals there was C a significant increase in the airway resistance over baseline. In contrast, compounds of the invention significantly inhibited the antigen-induced bronchoconstriction.

C These results indicate that compounds of the invention inhibit antigen-induced bronchoconstriction.

CK 4. Inhibition of Sephadex induced rat lung edema and cytokine gene expression in the allergic rat S 10 Protocol for Sephadex administration Male Sprague-Dawley rats (400 were dosed i.t. with vehicle (saline) or Sephadex (5mg/kg) in a dose volume of I ml/kg under halothane anesthesia in oxygen for 3 min).

Protocol for Dosing Drug was administered p.o. 1 hour before and 5 hours after Sephadex i.t in a dose volume of Iml/kg..

Protocol for Assessing edema as an endpoint Twenty-four hours after Sephadex administration the animals were sacrificed with Euthatal (lml/kg the heart and lungs removed en bloc. An increase in wet weight was used as an index of edema.

The wet weight determined and then corrected for 100g initial body weight.

Protocol for RT-PCR (measurement of cytokine gene expression) UF RNA was isolated from lung tissue by a guanidium thiocyanate-phenol-chloroform extraction technique. RNA was reverse transcribed to cDNA using AMV reverse transcriptase. cDNA for IL-4, eotaxin and GAPDH (control gene) were amplified by PCR using oligonucleotide sequences synthesized (Gibco) from published sequences.

The PCR reagents were overlaid with mineral oil and amplification was carried out through 25-35 cycles of denaturation at 95 0 C for 1 minute, annealing at 55-65°C for 1 minute and extending at 72 0

C

for 7 minutes. The PCR products, stained with ethidium bromide, were electrophoresed in 2% agarose gels to visualize cDNA bands.

Bands of each target fragment were visualized by ultraviolet transillumination and photographed.

Photographs were scanned on a densitometer and integrated optical densities (OD x mm) of each band were calculated by image analysis software (Imagemaster, Pharmacia). For each animal, the amount of each cytokine PCR product was normalized to the amount of GAPDH PCR product.

WO 03/000688 PCT/GB02/02799 O -309- S Results Sephadex instillation alone evoked a significant edema of 32% (ii) Compounds of the invention inhibited the edema in a dose dependant manner by at doses of 30 and 100mg/kg C (iii) Sephadex caused an increased expression of the Th-2 cytokines IL-4 and IL-5 together with the CC chemokine eotaxin in the lung 24 hours after challenge. There was a trend toward an increase in the CK expression of IL-5 and eotaxin mRNA.

(iv) L-4 mRNA expression was dose dependently inhibited by compounds of the invention.

Compounds of the invention inhibit Sephadex induced lung edema in the rat, which is associated with a reduction in Sephadex induction of IL-4.

Inhibition of antigen-induced histamine release in the allergic Brown-Norway rat Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (100Pg, i.p) administered with aluminium hydroxide (100 mg, On the day of study, the rats were surgically prepared for the infusion of antigen. After a five-minute equilibration period, the animals received a bolus of ovalbumin (1 mg per rat). Blood samples were taken 2 minutes after ovalbumin challenge and plasma histamine levels were measured using a histamine ELISA.

?1 Protocol for Dosing Test drug was given i.p. 30 min before ovalbumin challenge. Only a single 30 mg/kg i.p.

concentration was used in this study Results Following antigen challenge, preferred compounds of the invention for inhibition ofsyk activity significantly inhibited the antigen-induced histamine release in comparison to the vehicle treated group.

These results indicate that compounds of the invention inhibit antigen-induced histamine release.

6. Inhibition of ED-l+ alveolar macrophages in rat lung tissue WO 03/000688 PCT/GB02/02799 S-310- Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (100pg, i.p) administered S with aluminium hydroxide (100 mg, On day 30, the rats were exposed to a 1% aerosol of ovalbumin for a period of 30 minutes. The animals were then returned to housing.

S Protocol for Dosing Test drug was given either p.o. or i.p. 24 and 2 hours before the iv bolus injection of ovalbumin. The S range of compound delivered in these studies was 10-100 mg/kg po.

Protocol for EDI quantification I Alveolar macrophages were quantified following immunostaining with ED-I antibody in paraffinembedded lung tissue sections.

Results Ovalbumin challenge resulted in a 10-fold increase in the number of EDI+ macrophages in the alveolar bed.

(ii) Inhibition ofSyk Kinase significantly reduced the ovalbumin-induced increase in EDI alveolar macrophages in a dose-dependent manner.

Oral administration of compounds of the invention produced a dose-related reduction in ED-1+ alveolar macrophages following ovalbumin challenge.

7. Inhibition of antigen-induced airway neutrophilia in the Brown-Norway rat Protocol for sensitization and challenge Brown Norway rats were sensitized on days 0, 12 and 21 with ovalbumin (100pg, i.p) administered with aluminium hydroxide (100 mg, On day 30, the rats were exposed to a 1% aerosol of ovalbumin for a period of 30 minutes. The animals were then returned to housing.

Protocol for Drug dosing One hour before antigen challenge, rats were dosed orally. The range of compound delivered in these studies was 1-100 mg/kg po.

WO 03/000688 PCT/GB02/02799 -311- Protocol for cell analysis Four hours after challenge, cells were recovered from the airway lumen by bronchoalveolar lavage (RPMI/FCS as previously described). Immediately after lavage, lungs were perfused with RPMI/FCS to remove the blood pool of cells. 300 mg of tissue was chopped and cells were recovered by enzymatic (collagenase) disaggregation. Differential cell counts were made by light microscopy of C stained cytocentrifuge preparations stained with Wright-Giemsa stain.

Results Four hours after antigen challenge a significant increase in neutrophils was observed in both the 0 10 BAL and lung tissue.

S(ii) The ovalbumin-induced increase in neutrophils in the BAL, but not the lung tissue, was significantly suppressed by compounds of the invention.

8. Inhibitory effects on LPS-Induced TNFa Production/Release Protocol In vivo challenge of mice with bacterial lipopolysacchride (LPS) leads to production of proinflammatory cytokines, including TNFa and IL-11. At numerous time following dosing with compounds of the invention BALB/c mice (males, 25 gbw) were challenged with LPS (40 jig, E.

coli serotype 011 1:B4). Sera collected at 90 minutes following LPS challenge were analyzed by ELISA for levels of pro-inflammatory cytokines, including TNFa.

qI Results Oral dosing of mice with compounds of the invention (3-60mg/kg) produced a dose dependent inhibition of serum levels of TNFc without significantly affecting levels of IL-13. Duration of action studies demonstrated that oral dosing with compounds of the invention could produce significant inhibition of serum TNFa levels when compounds were administered up to 4 hours prior to LPSchallenge. LPS-induced increases in serum TNFa levels in vehicle-treated mice were compared to compound-treated mice using a one way ANOVA and Dunnett's test for multiple comparisons.

Significance was accepted at p 0.05 9. Inhibitory effects on Collagen-Induced Arthritis in Rats: Protocol Collagen-induced arthritis (CIA) can be elicited in susceptible strains of rats, mice and non-human primates. CIA was induced in female Lewis rats (140-150 gbw) by the intradermal injection of bovine WO 03/000688 PCT/GB02/02799 -312cll (400ug) suspended in incomplete Freund's adjuvant (IFA) on days 0 and 7. Oral dosing with compounds of the invention was initiated on day 6 and continued daily until study termination on day 21.

Results Ankle joint swelling was measured 3x/week with the aid of calipers. Data are presented as decrease in joint swelling compared to vehicle-treated rats. A significant inhibition in joint inflammation was observed in rats orally dosed with compounds,of the invention (30 mg/kg b.i.d).

Significance (p 0.05) is determined by a one-way Anova and Dunnett's test for multiple comparisons.

Inhibitory effects on MoAb-Induced Arthritis in Mice: Protocol Not only can CIA be induced by the injection of cII, but a passive form of disease can also be elicited by injection of mice with a cocktail of monoclonal antibodies (MoAb) raised against 4 crossreacting/disease epitopes derived from chick clI. Induction of arthritis is dependent on the formation of immune complexes, complement activation and neutrophil/macrophage migration into the joints. Due to the role played by Fcy receptors (FcyRI and FcyRIl) in the induction of arthritis, this model was also chosen to profile compounds of the invention. BALB/c mice (males, 6-8 weeks of age) were injected on day 0 with MoAb (2 mg, and day 2 with LPS (25 i.g, Dosing with compounds of the invention was initiated on the day of MoAb injection and continuing until study termination on day 14.

Mouse joints were macroscopically scored 3X/week for the development of arthritis incidence of disease) and disease severity (the number of mice having at least one affected paw divided by the total number of animals per group). Disease severity scores for each animal range from 0-4 paw (with a possible maximum score of 16 mouse) depending on clinical signs of disease which are assessed from 0 no visible signs of arthritis (negative) to 4 ankylosis or total loss ofjoint function.

Results Significant dose-dependnet inhibition in joint swelling was observed in mice orally dosed with compounds of the invention (10, 30 mg/kg Additionally, significant dosed-dependent inhibition of histological parameters, pannus, inflammation, cartilage ad bone erosion was also observed in mice orally dosed with either 10 or 30 mg/kg b.i.d.

11. Inhibition of Arthus Reaction in the Mouse Ear WO 03/000688 PCT/GB02/02799 -313- 0 CKl Protocol Ear thickness was measured at baseline in Balb/c mice. This was followed by oral administration of compound 15 minutes before the intradermal injection of IgG to ovalbumin in the right ear and saline Scontrol vehicle in the left ear performed under anesthesia. Immediately after administration ofIgG the animals were challenged with 1001l of ovalbumin mixed with Evans blue into the tail vein. At timepoints 15 minutes, 45 minutes, 2.15 hours, 4.5 hours, and 6 hours the thickness of the ears were remeasured and then removed for analysis of Evans blue content.

Results At all time points, both Evans blue extravasation and increased ear thickness were increased in the control treated animals and significantly inhibited compared to the controls in the compound treated animals. The left ears in all animals were not significantly changed from baseline. Therefore, compounds of the invention significantly suppressed the Arthus reaction.

12. Passive Cutaneous Anaphvlaxis in the Mouse Ear BALB/c mice were sensitized, in both ears, with an intradermal injection of 25 ug of monoclonal IgE anti DNP. After 16 to 20 hours, compounds of the invention were delivered intradermally to the right ear, and the left ear of the same mouse was injected with. The thickness of the ears were measured min after intradermal injections, and values were recorded as time zero. 15 min after the delivery of compound or the vehicle, the animal was injected iv (tail vein) with of 150 ug of DNP and ear swelling was recorded at 15, 30 and 60min. The net increase in each ear was calculated by subtracting the l values at time 0 from those at time 15, 30 and 60 min. The percent inhibition of ear swelling is I-Rt/Lt.

Results Compounds of the invention significantly inhibited ear swelling, at all time-points 13. Airway Reactivity and Eosinophilia in Allergic Antigen Challenged Mice Protocol Sensitization:.

Mice are sensitized with an intraperitoneal injection of 0.2 ml saline containing 1 mg of A1 2 0H 3 hydrogel suspension and 11 ug of ovalbumin (ova) on days 0 and 7.

Dosing and challenge: WO 03/000688 PCT/GB02/02799 -314- The sensitized mice were dosed orally with compounds of the invention twice daily at 30 mg/kg from the initiation of sensitization. The mice were challenged from day 14 for 4 days for 25 min exposure to an aerosolized solution of 6% ova. 18 hrs after the last ova challenge, the.airway hyperreactivity to aerosolized methacholine was measured wusing whole-body barometric S plethysmography. The next day the animals were sacrificed and bronchoalveolar lavage collected and the eosinophils quantified.

Results Treatment with compounds of the invention in the above protocol inhibited the induction of airway hyperreactivity that was measurable in control animals. The inhibition of the hyperreactivity was not statistically significant. In addition the eosinophilia found in the control treated animals was also not significantly inhibited though there was a small decrease in the magnitude of this response in the compound treated animals.

14. Skin Allergic Inflammation in Mice Protocol The mice were sensitized ip with OVA+Alum on day 0 and 7. On day 20 the animals were challenged subcutaneously with OVA. Compound was given orally 15 min before and 2 h after challenge with

OVA.

Results The compound of invention inhibited the resultant mast activation, Neutrophils influx, Th2 lymphocyte and Eosinophil infiltration.

Claims (56)

1. A pharmaceutical composition comprising a selective kinase inhibitory amount of a compound of general formula xl N N H wherein:- R I represents aryl or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl; heterocycloalkyl, nitro, R 4 -C(=O)-0R 5 Iy 2 -NYI 1 y 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -S0 2 -NY Iy 2 and R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl, -Z 2 R 4 -SO 2 Ny 3 y 4 -NY I y 2 or lower alkyl optionally substituted by a substituent selected from aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z 2 R 4 -C(=O)-Ny 1 y 2 -C0 2 R 8 -Ny 3 y 4 -N(R 6 -N(R 6 2 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 Y 4 -SO 2 NYly 2 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2 R 4 -CQ'0)-0R 5 or -C(=O)-Ny 3 y 4 R 4 represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO or a 6- or 7-membered cyclic acetal derivative thereof), -C(0)-NY 1 y 2 -C(=O)-0R 5 -NY 1 I y 2 -N(R 6 7 -N(R 6 3 Y 4 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -Z 3 R 7 and one or more groups selected from hydroxy, alkoxy and carboxy; R 5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R 6 represents hydrogen or lower alkyl; WO 03/000688 PCT/GB02/02799 -316- R7represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8represents hydrogen or lower alkyl; R represents aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cya no, CK1 halo, heteroaryl, heterocycloalkyl, -CHO or a 6- or 7-membered cyclic acetal derivative thereof)i I y 2 -C(0O)-0R 5 -NY I y 2 -N(R 6 )-C(0O)-R 7 -N(R 6 3 y 4 -N(R 6 S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -Z 3 R 7 and one or more groups selected from hydroxy, alkoxy and carboxy; X I represents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-hialo, C-CN, C-R 4 C-Ny 1 y 2 C-OH, C-Z 2 R, C-C(=O)-0R 5 C-C(=O)-NY 1 y 2 C-N(R 8 C-N(R 6 7 C-N(R 6 3 y 4 C-N(R 6 )-S0 2 -NY 3 y 4 C-N(R 6 )-S0 2 -R, C-S0 2 -Ny 3 y 4 C-NO 2 or C-alkenyl or C-alkynyl optionally substituted by one or more groups selected from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, Iy 2 -C(=O)-0R 5 -NY Ily 2 -N(R 6 )-C(=_OyZR 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -S0 2 -NYl y 2 and -Z 2 R 4 Y I and y 2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, heterocycloalcyl, hydroxy, -C(=O)-Ny 3 Y 4 5 -Ny 3 y 4 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 and -OR 7 or the group -NY I y 2 may form a cyclic amine; y 3 and y 4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -Ny 3 y 4 may form a cyclic amine; ZI represents 0 or S Z 2 represents 0 or S(O)n; Z 3 represents 0, S(O)n, NR 6 n is zero or an integer I or 2; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate; together with one or more pharmaceutically acceptable carriers or excipients.

2. A compound of formula WO 03/000688 WO 03/00688PCT/GB02/02799 6 -317- xl 3 IR H wherein:- RI represents aryl or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R 4 -C(=O)-Nyly 2 -NY 1 y 2 -N(R 6 7 -N(R 6 3 Y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -NY 3 y 4 -S0 2 -NY 1 Iy 2 and R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl, -Z 2 R 4 -SO 2 Ny 3 y 4 -Ny Iy 2 or lower alkyl optionally substituted by a substituent selected from aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z 2 R 4 -C(=O)-Ny 1 y 2 -CO-,R 8 -Ny 3 y 4 -N(R 6 -N(R 6 )-C(=O)-Nyly 2 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -SONy ly 2 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyaio, halo, heteroaryl, lower alkyl, -Z 2 R 4 -C(=O)-0R 5 or 3 y 4 R4represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO or a 6- or 7-membered cyclic acetal derivative thereof), -C(0)-NY Iy 2 -C(=O)-OR 5 -Ny 1 Y 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 )-S0-11 7 -N(R 6 )-S0 2 -Ny 3 y 4 -Z 3 R 7 and one or more groups selected from hydroxy, alkoxy and carboxy; R 5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R 6 represents hydrogen or lower alkyl; R 7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or hetierocycloalkylalkyl; R 8 represents hydrogen or lower alkyl; WO 03/000688 WO 03/00688PCT/GB02/02799 -318- R represents aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO or a 6- or 7-membered cyclic acetal derivative thereof), -C(=O).NY 1 Iy 2 -C(=O)-0R 5 -NY I y 2 -N(R 6 )-CQ'O)-R 7 -N(R 6 3 y 4 -N(R 6 )-S0 2 -R 7 -N(R 6 Y 3 y 4 -Z 3 R 7 and one or more groups selected from hydroxy, alkoxy and carboxy; X I represents N, CH, C-aryl, C-lieteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-11 4 C-NY I y 2 C-OH, C-Z 2 R, C-Ce=O)-0R 5 C-C(=O)-Ny Iy 2 C-N(R 8 C-N(R 6 7 C-N(R 6 3 y 4 C-N(R 6 )-S0 2 -Ny 3 y 4 C-N(R 6 )-S0 2 -R, C-S0 2 -Ny 3 y 4 C-NO 2 or C-alkenyl or C-alkynyl optionally substituted by aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, Iy 2 -CQO-)-0R 5 -Ny Iy 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -NY 3 y 4 -S0 2 -NY' Iy 2 and -Z 2 R 4 Y I and y 2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(=O)-Ny 3 y 4 -C(=O)-0R 5 -Ny 3 y 4 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 )-50 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 and -OR 7 or the group -NY Iy 2 may form a cyclic amine; y 3 and y 4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -Ny 3 y 4 may form a cyclic amine; Z I represents 0 or S Z 2 represents 0 or SO, Z 3 represents 0, S(O)n, NR 6 n is zero or an integer I or 2; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate; provided that such compound is other than 2-phenyl- I Hpyrrolo[2,3-b]pyridine, 2-(4-bromo-phenyl)-3- methyl-I H-pyrrolo[2,3 -b~pyridime, 4-(3-methyl- IH-pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid methyl ester, 2-(4-chloro-phenyl)- I H-pyrrolo[2,3-b~pyridine, 2-(4-methoxy-phenyl)- 1 H-pyrrolo[2,3- b]pyridime, 5-methyl-2-phenyl- IH-pyrrolo[2,3 -b]pyridine, 4-methyl-2-phenyl- IH-pyrrolo[2,3- b]pyridine, 2-pyridin-3 -yl- IH-pyrrolo[21,3-b]pyridime, 4-(3-methyl- IH-pyrrolo[2,3-b]pyridin-2-yl)- benzoic acid, 2-(4-methoxy-phenyl)-3-methyl- I H-pyrrolo[2,3-b]pyridine, 2-(4-methyl-phenyl)-3- methyl-I H-pyrrolo[2,3 -b]pyridine, 4-(3-methyl- I H-pyrrolo[2,3 -bipyrid in-2-yI)-benzoic acid isopropyl ester, 2-phenyl-3-methyl- I H-pyrrolo[2,3-b]pyridi ne, 5-bromo-2-phenyl-3-mdthyl- I H-pyrrololl2,3- WO 03/000688 PCT/GB02/02799 -319- b]pyridine, 6-chloro-2-phenyl- IH-pyrrolo[2,3-b]pyridine, 6-cbloro-4-methyl-2-phenyl- IH-pyrrolo[2,3- b~pyridine, 4-methyl-2-phenyl- I H-pyrrolo[2,3-b]pyridin-3-yl-carboxaldehyde, 2-phenyl- I H- pyrrolo[2,3 pyridin-3-yl-acetonitri le, 2-phenyl-3-prop- I-enyl- IH-pyrrolo[2,3 -b]pyridine, 4-methyl-2- phienyl- IH-pyrrolo[2,3-b~pyridin-3-yI-carboxaldehyde, dimethyl-(2-phenyl-1 H-pyrrolo[2,3-b~pyrid in-3 ylmethyl)-amine, 2,2'-diphenlyl- 1H, I'H-[3 ,3']bi[pyrrolo[2,3-blpyridiniyl], 2-(2-phenyl-I H-pyrrolo(2,3- b]pyridin-3-yi)-acetam ide, 3-allyl-2-phenyl- IH-pyrrolo[2,3-b]pyridine, (2-phenyl-]IH--pyrrolojj2,3- b]pyridin-3-yl)-aceton itri le, 2-phenyl- 1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde, 3-rnorphol in-4- ylmethyl-2-phenyl- I H-pyrro lo[2,3-b]pyridine, N-[2-(2-phenyl- I H-pyrrolo[2,3 -b]pyridin-3-yl)-ethyl]- acetam ide, 6-phenyl-5 H-pyrrolo[2,3 -b]pyrazine, 6-{4-methoxy-phenyl)-51H-pyrrolo[2,3-bjpyrazine, 6- (4-ch loro-pheinyl)-5 H-pyrrolo[2,3 -b]pyrazine, 6-(2-chloro-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 3- 4 methiyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine, or 2-methyl-6-phenyl-5H-pyrrolo[2,3-b~pyrazine and 7- methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine.

3. A compound according to claim 2 wherein R 1 is optionally substituted heteroaryl.

4. Acmon15odn ocam3weenR1i pinlysbtttdaaeeorl A compound according to claim 3 wherein R' is optionally substituted azahelteroay substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted imidazolyl, optionally substituted indazolyl, optionally substituted indol izinyl, optionally substituted tetrahydroindolizinyl or optionally substituted indazolinyl.

6. A compound according to claim 5 wherein R' is optionally substituted indolyl, optionally substituted indolizinyl or optionally substituted pyrrolyl.

7. A compound according to claim 6 wherein R' is optionally substituted indol-3-yl, indolizin-I yi, optionally substituted pyrrol-3-yl, optionally substituted indol-2-yi or optionally substituted pyrrol- 2-yl.

8. A compound according to any one of claims 3, 4, 5, 6 or 7 wherein the substituents; with which the heteroaryl groups of R' are optionally substituted are one or more groups selected from alkylenedioxy, alkenyl, alkcenyloxy, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, R 4 -C(=O)-0R 5 Iy 2 -Ny Iy 2 and -OR

9. A compound according to claim 2 wherein R' is optionally substituted aryl. WO 03/000688 PCT/GB02/02799 -320- O A compound according to claim 9 wherein R' is optionally substituted phenyl.

11. A compound according to claim 10 wherein R' is 4-substituted phenyl.

12. A compound according to claim 11 wherein R' is 4-tertiarybutylphenyl.

13. A compound according to claim 9 or 10 wherein the substituents with which the heteroaryl groups of R' are optionally substituted are one or more groups selected from from alkylenedioxy, halo, Sheteroaryl, hydroxy, R 4 -NY1Y 2 and -OR

14. A compound according to any one of claims 2 to 12 wherein R 2 is hydrogen.

15. A compound according to any one of claims 2 to 12 wherein R 2 is acyl.

16. A compound according to any one of claims 2 to 12 wherein R 2 is halo.

17. A compound according to any one of claims 2 to 12 wherein R 2 is lower alkyl optionally substituted by cyano, halo, hydroxy, heteroaryl,-C(=O)-NY 1 Y 2 tetrazolyl, -C0 2 R 8 -Ny 3 y 4 -N(R 6 -N(R 6 )-C(=O)-NYlY 2 -N(R 6 )-SO 2 -R 7 or -N(R 6 )-SO2-NY 3 y 4

18. A compound according to any one of claims 2 to 12 wherein R 2 is lower alkenyl.

19. A compound according to any one of claims 2 to 18 wherein R' is hydrogen. A compound according to any one of claims 2 to 18 wherein R 3 is -C(=O)-OR 5

21. A compound according to any one of claim 2 to 18 wherein R 3 is

22. A compound according to any one of claims 2 to 18 wherein R is lower alkyl.

23. A compound according to any one of claims 2 to 18 wherein R 3 is methyl.

24. A compound according to any one of claims 2 to 23 wherein X' is N. WO 03/000688 PCT/GB02/02799 -321- S 25. A compound according to any one of claims 2 to 23 wherein X' is CH. (NCi S 26. A compound according to any one of claims 2 to 23 wherein X' is C-halo.

27. A compound according to any one of claims 2 to 23 wherein X' is C-C1. 0i. S28. A compound according to any one of claims 2 to 23 wherein X' is C-CN. 0 29. A compound according to any one of claims 2 to 23 wherein X' is C-OH. A compound according to any one of claims 2 to 23 wherein X' is C-yl. A compound according to any one of claims 2 to 23 wherein X' is C-heayl.

32. A compound according to any one of claims 2 to 23 wherein X 1 is C-heteroaryl.

33. A compound according to any one of claims 2 to 23 wherein X' is C-azaheteroaryl.

34. A compound according to any one of claims 2 to 23 wherein X' is C-pyridyl. CH 3 A compound according to any one of claims 2 to 23 wherein X' is C CH 3

36. A compound according to any one of claims 2 to 23 wherein X' is C-Z 2 R.

37. A compound according to any one of claims 2 to 23 wherein X' is C-lower alkoxy. 38 A compound according to any one of claims 2 to 23 wherein X' is C-OCH 3

39. A compound according to any one of claims 2 to 23 wherein X' is C-C(=O)-OR 5 WO 03/000688 PCT/GB02/02799 -322- A compound according to any one of claims 2 to 23 wherein X 1 is C-C(=O)-OH.

41. A compound according to any one of claims 2 to 23 wherein X1 is C-C(0)-OtBu.

42. A compound according to any one of claims 2 to 23 wherein X' is C-C(=O)-NY 'y 2

43. A compound according to any one of claims 2 to 23 wherein X 1 is C-C(&O)-NH 2 N1--CH 3 C-C(=O)-NH-CH 2 -CH2)-CH 2 -CH 3 C-(O C-C(=O)-NH-CH 2 -CH2)OH, C-C(=O)-NH-CH 2 -CH(CH 3 )OH, C-C(=O)-NHl-CH 2 -C(CH 3 2 -OH, 0 C-C(--O)-NH-C(CH 3 2 -CH 2 OH, C-C(=O)-NH-CH 2 CH 2 OCH 3 C-C(=O)-NH-CHTO C-C(=O)-NH-CH 1 0 I C-C(=O)-N(CH 3 2 \0, HO CH 3 C-C(0O)-NO OH or C-C(=O)-Nc

44. A compound according to any one of claims 2 to 23 wherein X3 is C-C(=O)-Nil-C(CH 3 2 -CH 2 0H. A compound according to any one of claims 2 to 23 wherein X' is C-Ny'y 2

46. A compound according to any one of claims 2 to 23 wherein X 1 is CH 3 CH 3 0 CH 3 0 2 C CH 3 C-NH\/b C-NH\/IC-NRb/CNH\/ OCR 3 C-NIH d ,C-NII CH 3 C-Nil 0 OCH 3 WO 03/000688 PCT/GB02/02799 -323- C-NII-CH-' C-NH-CR,-C C-NH-CHi F, C-NH-CH 2 /OCH3, C-NH-CH2 a /NH-CO -0 or C-N 0. CH0 3 O

47. A compound according to any one of claims 2 to 23 wherein X1 is C-N- b

48. A compound according to any one of claims 2 to 23 wherein X1 is C-heterocycloalkenyl.

49. A compound according to any one of claims 2 to 23 wherein X' is C NO H orG C N-CO 2 tBu A compound according to claim 2 of formula (1a): 24 5 R 3 3 (la) wherein: R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl, -Z 2 R 4 -SO 2 Ny 3 y 4 -NY 1 y 2 or lower alkyl optionally substituted by a substituent selected from aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, WO 03/000688 PCT/GB02/02799 -324- CI -Z 2 'R 4 Iy 2 -C0 2 R 8 -Ny 3 y 4 -N(R 6 -N(R 6 C(=O)-NY 1 2 I n -N(R 6 7 -N(R1 6 )-S0 2 -R1 7 -N(R 6 )-SO 2 -Ny 3 y 4 -SO 2 NYly 2 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2 R 4 -C(=O)-0R 5 or -C(=O)-Ny 3 y 4 X I represents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R 4 c-Ny I y 2 COC-Z 2 R, C-C(=O)-0R 5 C-C(=0)-Nyly 2 CNR)C=)R C-N(R 6 7 C-N(R 6 3 y 4 C-N(R 6 )-S0 2 -N 3 4 C-( 6 -R, 4 C-S0 2 -Ny 3 y 4 C-NO 2 or C-alkenyl or C-alkynyl optionally substituted by one or more groups selected from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C(=O)-Nyly 2 OR 5 -NYI 1 y 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -S0 2 -NY Iy 2 and -Z 2 R 4 R 9 is hydrogen, alkenyl or R 4 RIO is alkenyloxy, carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, R 4 -C(=O)-Nyly 2 -OR1 4 -N(R 6 )-C(0O)-R 7 -N(R 6 )S0 2 -R 7 or -Ny Iy 2 p is zero, or an integer I or 2; and the residue R 3 is attached to position 2 N N H or 3 of the indole ring; or (.inwan N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate.

51. A compound according to claim 50 wherein RW is hydrogen.

52. A compound according to claim 50 or 51I whe rein R 3 is hydrogen.

53. A compound according to any one of claims 50 to 52 wherein X1 is N; CH; C-aryl; C-heteroaryl; C-halo; C-CN; C- Z 2 R; C-C&=O)-0R 5 C-C&=O)-NY'y 2 or C-Ny Iy 2

54. A compound according to any one of claims 50 to 52 wherein X' is phenyl.

55. A compound according to any one of claims 50 to 52 wherein X1 is C-azaheteroaryl. WO 03/000688 PCT/GB02/02799 -325- CK156. A compound according to any one of claims 50 to 52 wherein X1 is C-pyridyl or CH 3 -N CH 3

57. A compound according to any one of claims 50 to 52 wherein X1 is C-Cl. a"

58. A compound according to any one of claims 50 to 52 wherein X1 is C-lower alkoxy. 59 opudacrdn oayoeo cam 0t 2weri 1i ]C3 59 6. A compound according to any one of claims 50 to 52 wherein X' is C-Q=OCH 3 1 6. A compound according to any one of claims 50 to 52 wherein X' is C-C(=O)-OtE. C3 C-C(=O)-NH--CH 2 -CH 2 OH, C-C(=O)-NH-CH 2 -CH(CH 3 )OH, C-C(=O)-NH-CH 2 -C(CH 3 2 -OH, C-C(=O)-NH-C(CH 3 2 OH, or C-C(=O)-NH--CH 2 CH 2 OCH 3

62. A compound according to any one of claims 50 to 52 wherein X1 is C-C(=O)-NH-C(CH 3 2 -CH 2 OH. (W63. A compound according to any one of claims 50 to 52 wherein X1 is CHR 3 CH 3 0 CH 3 0 2 C CH 3 C-NH\ /C-NHb\ /CNH\b CNH\ OCH 3 C-N'H C-NH -0/CR 3 C-NH -O/OCR 3 C-N-CR-< C-NH-CR 2 0 C-NH-C--a~ F WO 03/000688 PCT/GB02/02799 -326- C-NH-CH C 3 NH-CO or C-N 0. CH 0 C\64. A compound according to any one of claims 50 to 52 wherein X1 is C-N- H A compound according to any one of claims 50 to 52 wherein X 1 is N, C-H, C-CN, CH 3 CH 3 O0 -N C I, C-NH or C-C(=O)-NH-C(CH 3 2 -CH 2 OH. CH 3

66. A compound according to any one of claims 50 to 65 wherein R1' 0 is carboxy (or an acid bioisostere); hydroxy; alkyl substituted by carboxy; alkyl substituted by -N(R 6 )-SO 2 -R 7 -N(R 6 )-CO-Ny 3 y 4 heteroaryl; -OR 4wherein R 4 is alkyl; -OR 4 wherein R 4 is alkyl or cycloalkylalkyl (OWsubstituted by one or more hydroxy groups; -ORW wherein W. is alkyl or cycloalkyl substituted by one or more carboxy groups; -OR 4 in which R 4 is cycloalkyl substituted by -C&0O)-NY IYI; -C(0O)-R wherein R is alkyl; Iy 2 or -N(R 6 7

67. A compound according to any one of claims 50 to 65 wherein B. is 68 A compound according to any one of claims 50 to 65 wherein R' 0 is -CH 2 CH 2 CO 2 H.

69. A compound according to any one of claims 50 to 65 wherein R1 0 is S -C 2NH S0 2 2\ 11 WO 03/000688 PCT/GB02/02799 -327- A compound according to any one of claims 50 to 65 wherein R' 0 is /0 -CH-2 IM-CO-M. N CH 3

71. A compound according to any one of claims 50 to 65 wherein R' 0 is NZCH 3 N/ I or pyridyl.

72. A compound according to any one of claims 50 to 65 wherein R'0 is -OCH 3

73. A compound according to any one of claims 50 to 65 wherein R 1 0 is -OCH 2 C 2 H C-CR 2 2 1 1 -OCH 2 CH 2 CH 2 OH, -OCH (CH 3 )CH 2 OH, -OCH 2 CR (OH)CHR 3 -O-C_-CH 2 or -OCR 2 CH (OH) CH 2 OH

74. A compound according to any one of claims 50 to 65 wherein is -OCR (CHR 3 CH 2 OCH 3 A compound according to any one of claims 50 to 65 wherein R1 0 is -OCR 2 CO CO H H C-CH 2 -OCR (CR 3 Co 2 H, -0-C-CR 3 or -O-C-CH 2 2og CO 2 H 2C-CR 2 21 1 2

76. A compound accord ing to any one of claims 50 to 65 wherein 111 0 is -0-C-CR 2 or CONH 2 -0-C-R 2 CONHCH 3 WO 03/000688 PCT/GB02/02799 -328-

77. A compound according to any one of claims 50 to 65 wherein R" 0 is -C(0)-CH 3

78. A compound according to any one of claims 50 to 65 wherein R1 0 is -CONH 2 1 -CONHCH 3 -CONHCH (CH 2 OH 2 -CONHCH 2 CH 2 OH, -CONHC (CH 3 2 CH 2 OR, I- 5 -C(=O)-NH-CH 2 -C(CH 3 2 -OH, -C(=O)-NH-CH 2 -CH 2 -CO 2 H, -CONHCH 2 CH 2 OCH 3 N

479. A compound according to any one of claims 50 to 65 wherein R1 0 is -NHC(=O)CH 3 80. A compound according to any one of claims 50 to 65 wherein R1 0 is carboxy, pyridyl, S0 -CH--NH-SO 2 0 2 I-jNH-CO-NH H 2C-CR Co2 H H 2C-CH2 2I I2 I2 21 I NH -OCR 3 '-0-C-CR 2 -0-C -CR 3 -0-C-CR, or 1I11 2 NkiN CH 2OH C 2 H CONH 2 -CONRC (CR 3 2 CH 2 oH, -C(=O)-NI--CH 2 -C(CH 3 2 -OH or -CONHCH2 CR2 OCR 81. A compound according to any one of claims 50 to 80 wherein p islIand R1 0 is attached at position 5, or position 6 of the indolyl ring. 82. A compound according to any one of claims 50 to 80 wherein p is 2 and W 10 is attached at position 5 or position 6 of the indolyl ring. 83. A compound according to 50 wherein R2 is hydrogen; R3 is hydrogen; X I is CH, C-aryl, C-heteroaryl, C-halo, C-CN, C-lower alkoxy, C-C&0O)-0R 5 C&=O)-NY I y 2 or C-Ny Iy 2 R 9 is hydrogen, C 1 4 alkyl, C]I 4 alkyl substituted by hydroxy, C 1 4 alkyl substituted by WO 03/000688 PCT/GB02/02799 -329- -N(R6)C(=0)-R7 C 1 4 alkyl substituted by y 2 or cycloalkylalkyl substituted by hydroxy; R 10 is carboxy or an acid bioisostere; hydroxy; alkyl substituted by carboxy; alkyl substituted by -N(R 6 )-SO 2 -R 7 alkyl substituted by -N(R 6 )-CO-NY 3 Y 4 heteroaryl; -OR 4 wherein R 4 is alkyl; -OF4 wherein R 4 is alkyl or cycloalkylalkyl substituted by one or more hydroxy groups;-OR 4 wherein R 4 is alkyl substituted by one or more alkoxy groups; -OR 4 wherein R4 is alkyl or cycloalkyl substituted by one or more carboxy groups; -OR 4 wherein R 4 is cycloalkyl substituted by ly 2 wherein R is alkyl; -C(=O)-NY 1 Y 2 or -N(R 6 7 and wherein the R10 group is attached to position 5, or position 6, of the indolyl ring when p is 1; and the R 10 groups are attached to positions 5 and 6 of the indolyl ring when p is 2; or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate. 84. A compound according to claim 83 wherein X' is C-phenyl.. CH 3 A compound according to claim 83 wherein X' is C-pyridyl or C I 0 CH3 86. A compound according to claim 83 wherein X' is C-Cl. 87. A compound according to claim 83 wherein X' is C-OCH 3 88. A compound according to claim 83 wherein X' is C-C(=O)-OtBu. 89. A compound according to claim 83 wherein X' is C-C(=O)-NH-CH 3 C-C(=O)-NH-CH 2 CH 2 0H, C-C(=O)-NH-CH 2 -CH(CH3)OH, C-C(=O)-NH-CH 2 -C(CH 3 2 -OH, C-C(=O)-NH-C(CH 3 2 CH 2 0H or C-C(=O)-NH-CH 2 CH 2 0CH 3 A compound according to claim 83 wherein X' is C-C(=O)-NH-C(CH 3 2 -CH 2 0H. WO 03/000688 PCT/GB02/02799 -330- CHO 3 N CHO 91. A compound according to claim 83 wherein X' is C-NH- S 92. A compound according to any one of claims 83 to 91 wherein R 9 is -CH 3 or-CH 2 CH 3 93. A compound according to any one of claims 83 to 91 wherein R 9 is -CH 2 OH, -CH 2 CH OH 0 or -CH 2 CH 2 CH 2 OH 94. A compound according to any one of claims 83 to 91 wherein R 9 is -CH 2 CH 2 CH2NHC(=O)CH 3 A compound according to any one of claims 83 to 91 wherein R 9 is -CH2-C -N O or -CH-CO-NH N 2 2 CH 3 H C-CH 2 96. A compound according to any one of claims 83 to 91 wherein R 9 is -C-CH NH 97. A compound according to any one of claims 83 to 96 wherein R i is N NN 98. A compound according to any one of claims 83 to 96 wherein R 10 is CH2H2CO2 99. A compound according to any one of claims 83 to 96 wherein R 0 i is S -CH-NH-SO 98 2 opudacrigt n n f lis8 o9 hri 1 s 2 2 2 WO 03/000688 PCT/GB02/02799 -331- 100. A compound according to any one of claims 83 to 96 wherein R1 0 is -CH 1\THCON~H CH 3 101. A compound according to any one of claims 83 to 96 wherein R'O is or ~.CH 3 or pyridyl. 102. A compound according to any one of claims 83 to 96 wherein R 1 0 is -OCH 3 103. A compound according to any one of claims 83 to 96 wherein R1 0 is -OCH 2 CH 2 OH, H1 1 -OCH 2 CH 2 CH 2 OH, -OCH (CH 3 )CH 2 OH, -OCH 2 CH (OH) CH 3 -O-C-CH 2 or CH 2 O -OCH 2 CH (OH) CH 2 OH kw 104. A compound according to any one of claims 83 to 96 wherein R 1 0 is -OCH (CH 3) CH 2 OCH 3 105. A compound according to any one of claims 83 to 96 wherein R1 0 is -OCH 2 C 2 H, H C-CH 2 21 1 2 -OCH (CH 3 CO 2 H or -O-C-CH 2 CO 2 H WO 03/000688 PCT/GB02102799 -332- H 2H C-CH 2 106. A compound according to any one of claims 83 to 96 wherein R1 0 is -o-C--CH 2 or CIONH 2 H C-CH 2 22 CONHCH3 107. A compound according to any one of claims 83 to 96 wherein R' 0 is -C -CH 3 108. A compound according to any one of claims 83 to 96 wherein R 1 0 is -CONH 2 -CONHCH 3 CONHCH (CH 2 OH 2 -CONHCHiCH 2 OH, -CONHC (CH 3 2 CH 2 0H, H-CH 2 -C(CH 3 -C(=O)-NH-CH2-CH 2 -CO 2 H, -CONHCH 2 CH 2 0CH, -CONHCH 2 CH 2 CONH 2 or CN N NH 109. A compound according to any one of claims 83 to 96 wherein 111 0 is -NHC CH 3 (W110. A compound accord ing to claim 50 wherein R 2 is hydrogen; R(3 is hydrogen; XI isN; R 9 is hydrogen; C 1 4 alkyl; C I -alkyl substituted by hydroxy; C 1 4 alkyl substituted by ;C 1 4 alkyI substituted by -C(=O)-NYI y 2 cycloalkylalkyl substituted by hydroxy; RIO is carboxy or an acid bioisostere; hydroxy; alkyl substituted by carboxy; alkyl substituted by -N(R 6 )-S0 2 -R 7 alkyl substituted by -N(R 6 )-CO-Ny 3 y 4 heteroaryl; -OR 4 wherein R 4 is alkyl, -OR 4 wherein R 4 is alkyl or cycloalkylalkyl substituted by one or more hydroxy groups; -OR1 4 wherein R 4 is alkyl substituted by one or more alkoxy groups; -OR1 4 in which R 4 is alkyl or cycloalkyl WO 03/000688 PCT/GB02/02799 -333- substituted by one or more carboxy groups; -OR 4 in which R 4 is cycloalkyl substituted by -C(=O)-NY 1 Y2 in which R is alkyl; Y 2 or -N(R 6 7 and wherein C the Rl0 group is attached to position 5, or position 6, of the indolyl ring when p is 1; and O the R 0 groups are attached to positions 5 and 6 of the indolyl ring when p is 2; or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide Sor prodrug of such salt or solvate. 111. A compound according to claim 110 wherein R 9 is -CH 3 or -CH 2 CH 3 '1l 10 112. A compound according claim 110 wherein R 9 is is -CH2OH, -CH2CH2OH or -CH 2 CH 2 CH 2 OH -CH 2 CH 2 CH 2 NHC(=O)CH 3 113. A compound according to claim 110 wherein R 9 is 114. A compound according to claim I10 wherein R 9 is -CH2-C -N O or 15 114. A compound according to claim 110 wherein R 9 is -CHrC -N 0 or H2C-CH 2 CH 2 OH 116. A compound according to any one of claims 110 to 115 wherein R 10 is N11 117. A compound according to any one of claims 110 to 115 wherein R 10 is -CH 2 CH 2 CO 2 H WO 03/000688 PCT/GB02/02799 -334- 118. A compound according to any one of claims 1 10 to 115 wherein R1 0 is S -CH 2 NH -S S 2 119. A compound according to any one of claims 1 10 to 115 wherein R1 0 is 0 -CH 2 NH-CO-NH_ CH3 120. A compound according to any one of claims 1 10 to 115 wherein R1 0 is 3 I or pyridyl. N -OCH3 121. A compound according to any one of claims 1 10 to 115 wherein R1 0 is 122. A compound according to any one of claims 1 10 to 115 wherein 111 0 is -OCH 2 CH 2 OH, H C C 21 1 2 -OCH 2 CH 2 CH 2 OH, -OCH (CH 3 CH 2 OH, -OCH 2 CH (OH) CH 3 -O-C-CH 2 or CH 2 OH -OCH 2 CH (OH) CH 2 OH 123. A compound according to any one of claims 1 10 to 11 5 wherein R' 0 is -OCH (CH 3 )CH 2 0CH 3 124. A compound according to any one of claims 1 10 to 115 wherein R1 0 is -OCH 2 CO 2 H H C-CH 2 -OCH (CH) CH or 21-C 1C 2 CO 2 H WO 03/000688 WO 03/00688PCT/GB2/02799 -335- H C-CH 2 21 1 125. A compound according to any one of claims 110 to 115 wherein R1 0 is -0-C--cH or CONH 2 H C-CH 2 22 CONHCH 3 126. A compound according to any one of claims 1 10 to 115 wherein Rio is -C -CH 3 127. A compound according to any one of claims 110 to 115 wherein R1 0 is -CONH 2 -CONHCH 3 ,-CONHCH(CH 2 OH 2 -CONHCH2 CH2 OH, -CONHC (CH 3 )2 CH 2 OH, -C(=O)-NH-CH 2 -C(CH 3 2 -OH, -C(=O)-NH-CH 2 CH 2 -CO 2 H, -CONHCH 2 CH 2 OCH 3 -CONHCH 2CH 2CONH 2or CN N--NH 128. A compound according to any one of claims 110 to 115 wherein R 10 is -NHC 3C' 129. A compound according to claim 2 of formula (lb) (lb) wherein R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl, -Z 2 R 4 -SO 2 NY 3 y 4 -N'V'y 2 or lower alkyl optionally substituted by a substituent selected from aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, WO 03/000688 PCT/GB02/02799 -336- Cl -Z 2 R 4 -C(=O)-Ny 1 Y 2 -C0 2 R 8 -NY 3 y 4 -N(R 6 -N(R 6 2 -N(R 6 )-C(0O)-0R 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -SO 2 NY Iy 2 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2 R 4 -CQ=O)-0R 5 or -C(=O)-Ny 3 y 4 X I represents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R 4 C-NY 2 C-OH, C-Z 2 R, C-C(=O)-0R 5 C-C(=O)-NYly 2 C-N(R 8 C-N(R 6 7 C-N(R 6 3 y 4 C-N(R 6 )-S0 2 -Ny 3 Y 4 C-N(R 6 )-S0 2 -R, C-S0 2 -N-y 3 y 4 C-NO 2 pr C-alkenyl or C-alkynyl optionally substituted by one or more groups selected from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, Iy 2 OR 5 -NY 1 Iy 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S02-Ny 3 y 4 -So0 2 -NY Iy 2 and -Z 2 R 4 R 9 is hydrogen, alkenyl or R 4 R 1 0 is alkenyloxy, carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, R 4 y 2 -OR 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 or -Ny Iy 2 p is zero, or an integer I or 2; or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate. 130. A compound according to claim 129 wherein R 2 is hydrogen. 131. A compound according to claim 129 or 130 wherein R 3 is hydrogen. 132. A compound according to any one of claims 129 to 131 wherein X1 is N, CH, C-aryl, C- heteroaryl, C-halo, C-CN, C- Z 2 R, C-C&=O)-0R 5 C-C(=O)-NY Iy 2 or C-Ny I y 2 133. A compound according to any one of claims 129 to 131 wherein X1 is C-phenyl. 134. A compound according to any one of claims 129 to 131 wherein X1 is C-azaheteroaryl. WO 03/000688 PCT/GB02/02 799 -337- CK1135. A compound according to any one of claims 129 to 131 wherein X1 is C-pyridyl or CH 3 C\ CH3 136. A compound according to any one of claims 129 to 131 wherein X1 is C-Cl. 137. A compound according to any one of claims 129 to 131 wherein X1 is C-OC- 3 13.Acmon codn o n n fcam 2 o11 hri 'i -]O-tu 139. A compound according to any one of claims 129 to 131 wherein X1 is C-C&=O)-NOt-Cu. C-C(=O)-NH-CI- 2 -CH 2 OH, C-C(=O)-NH-CH 2 -CH(CH 3 )OH, C-Cq=O)NH-CH 2 -C(CH 3 2 -OH, C-C(=O)-N'H-C(CH 3 2 -CH 2 OH, or C-C(0-)-NH-CH 2 CH 2 OCH 3 140. A compound according to any one of claims 129 to 131 wherein X' is C-C&(O)-NH-C(CH 3 2 CH 2 OH. CH 3 141. A compound according to any one of claims 129 to 131 wherein X 1 is C-Nil :b CH 3 0 CH 3 0 2 C CH 3 OCH 3 C-NH\b /C-NH\ ~C-NH\/ C-NH /CH 3 C-NH -0/OCH 3 C-NH-CH C-NH-CH 2 O ,C-NH-CH 2 O F, C-NH-CH 2 /OCH 3 C-NHCH NH-CO or C-N 0. WO 03/000688 PCT/GB02/02799 -338- O CO SCH 3 O 142. A compound according to any one of claims 129 to 131 wherein X' is C-NH- 143. A compound according to any one of claims 129 to 131 wherein X' is N, C-H, C-CN, CH 3 CH O C C-NH or C-C(=O)-NH-C(CH 3 )2-CH 2 0H. CH 3 144. A compound according to any one of claims 129 to 143 wherein R 9 is hydrogen. 145. A compound according to any one of claims 129 to 143 wherein R 9 is C 1 -4alkyl. 146. A compound according to any one of claims 129 to 143 wherein R 9 is -CH 3 147. A compound according to any one of claims 129 to 143 wherein p is zero. 148. A compound according to claim 129 wherein: SR 2 is hydrogen; R 3 is hydrogen; X' is CH, C-aryl, C-heteroaryl, C-halo, C-CN, C-lower alkoxy, C-C(=O)-OR 5 C-C(=O)-NY y 2 C-NY 1 y 2 R 9 is hydrogen or C l4alkyl; p is zero; or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate. 149. A compound according to claim 148 wherein X 1 is C-phenyl. WO 03/000688 PCT/CB02/02799 -339- CH -N 150. A compound according to claim 148 wherein X1 is C-pyridyl or CI CH 3 c-i 151. A compound according to claim 148 wherein X 1 is C-Cl. 152. A compound according to claim 148 wherein X1 is C-OCH 3 153. A compound according to claim 148 wherein X1 is C-C(=O)-0tBu. 154. A compound according to claim 148 wherein X' is C-C(=O)-NH-CH 3 C-C(=0)-NH-CH 2 CH 2 OI-, C-C(=O)-NH-CH2)-CH(CH 3 )OH, C-C(=0)-NH-CH 2 -C(CH 3 2 -OH, C-C(=0)-NH-C(CH 3 )2- CH 2 0H or H-CH 2 CH-,OCH 3 155. A compound according to claim 148 wherein X1 is C-C(=0)-NH-C(CH 3 2 -CH 2 OH. CH 3 0 156. A compound according to claim 148 wherein X1 is C-NH 157. A compound according to any one of claims 148 to 156 wherein R(9 is hydrogen. 158. A compound according to claim 129 wherein: R 2 is hydrogen; R 3 is hydrogen; X1 is N; l{9 is hydrogen or C I 4 al kyl; and p is zero. 159. A compound according to claim 158 wherein R 9 is -CH 3 160. A compound according to claim 2 of formula (1c): WO 03/000688 WO 03100688PCT/GB02/02799 6 -340- R 2R Cx H R 0 3(Rc) 'ClC optionally substituted by a substituent selected from aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z 2 R 4 Iy 2 -C0 2 R 8 -Ny 3 Y 4 -N(R 6 -N(R 6 1y 2 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -SO 2 NY 1 Iy 2 and one or more halogen atoms; R3represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2 R 4 -C(=O)-OR 5 or -C&=O)-Ny 3 y 4 X I represents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R 4 C-NY 1 y 2 C-OH, C-Z 2 R, C-C(=O)-0R 5 C-C(=O)-Ny 1 y 2 C-N(R 8 C-N(R 6 7 C-N(R 6 )-Ce=O)-Ny 3 y 4 C-N(R 6 )-S0 2 -Ny 3 y 4 C-N(R 6 )-S0 2 -R, C-S0 2 -Ny 3 y 4 C-NO 2 or C-alkenyl or C-alkynyl optionally substituted by one or more groups selected from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C(=O)-NYlY 2 OR 5 -NY I y 2 -N(R 6 7 -N(R 6 3 Y 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-SO 2 -Ny 3 y 4 -S0 2 -NY' Iy 2 and -Z 2 R 4 R 9 is hydrogen, alkenyl or R 4 RIO is alkenyloxy, carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, R 4 I y 2 -OR 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 or R 2 210 -NY I y 2 p is zero, or an integer I or 2; and the residue R 3 is attached to position 2 H or 3 of the pyrrole ring and the group -(RIO)p is attached to position 4 or 5 of the pyrrole ring; or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate. WO 03/000688 PCT/GB02/02799 -341- 161. A compound according to claim 160 wherein R 2 is hydrogen. 162. A compound according to claim 160 or 161 wherein R 3 is hydrogen. 163. A compound according to any one of claims 160 to 162 wherein X1 is N, CH, C-aryl, C-lieteroaryl, C-halo, C-CN, C-Z 2 R, C-C("'O)-0R 5 C-C(=O)-NYly 2 or C-Ny 1 Y 2 164. A compound according to any one of claims 160 to 162 wherein X' is C-phenyl. 165. A compound according to any one of claims 160 to 162 wherein X1 is C-azaheteroaryl. 166. A compound according to any one of claims 160 to 162 wherein X' is C-pyridyl or CHE 3 N C CH 3 167. A compound accordin g to any one of claims 160 to 162 wherein X' is C-Cl. 168. A compound according to any one of claims 160 to 162 wherein X' is C-OCH 3 169. A compound according to any one of claims 160 to 162 wherein X1 is C-C(=O)-OtBu. 170. A compound according to any one of claims 160 to 162 wherein X1 is C-C('0)-NH-CH 3 C-C(=O)-NH-CH 2 -CH 2 OH, C-C(=O)-NH-CH 2 -CH(CH 3 )OH, C-C(=-O)-NH-CH 2 -C(CH 3 2 -OH, C-C(=O)-NH-C(CH 3 2 -CH 2 OH, or C-C()NH-CH 2 CH 2 OCH 3 171. A compound according to any one of claims 160 to 162 wherein X' is C-C&=O)-NH4-C(CH 3 2 CH 2 OH. WO 03/000688 PCT/GB02/02799 -342- CH 3 172. A compound according to any one of claims 160 to 162 wherein X' is C-NH CH 30 CH 3 O 2 C CH 3 OCH 3 C1 C-NH\b /CNH\ b C-NHd ~C-NH\ C\C-NH CH 3 C-NH OCH 3 C-NH-CH 2 §J C-NH-CH 2 0 C-NH-CHl l F, C-NH-CH7& /OCH 3 1 C-NH--CH 2 /NH-CO C-N 0. CH 3 0 173. A compound according to any one of claims 160 to 162 wherein X1 is C-NH 174. A compound according to any one of claims 160 to 162 wherein X1 is N, C-H, C-CN, CH 3 CH 3 O0 C- C-NB- or C-C(=O)-NHi-C(CH 3 2 -CH 2 0H. CH 3 175. A compound according to any one of claims 160 to 174 wherein R 9 is C I alkyl. 176. A compound according to any one of claims 160 to 174 wherein R 9 is -CH 3 177. A compound according to any one of claims 160 to 176 wherein p is 1. 178. A compound according to any one of claims 160 to 177 wherein R' 0 is aryl. 179. A compound according to any one of claims 160 to 177 wherein R1 0 is phenyl. WO 031000688 PCT/GB02/02799 -343- 180. A compound according to claim 160 wherein: R 2 is hydrogen; R 3 is hydrogen; X' is CH, C-aryl, C-heteroaryl, C-halo, C-CN, C-lower alkoxy, or R 9 is C I 4 alkyl; p is 1; and R' 0 is aryl.

4181. A compound according to claimn 180 wherein X1 is C-pheny!. CH 3 182. A compound according to claim 180 wherein X1 is C-pyridyl or C 0 CH 3 183. A compound according to claim 180 wherein X1 is C-Cl. 184. A compound according to claim 180 wherein X1 is C-OCH 3 (Wv185. A compound according to claim 180 wherein X1 is C-C(=O)-OtBu. 186. A compound according to claim 180 wherein X' is especially C-C(0)-NH-CH 3 NH-CH 2 -CH 2 OH, C-C(=O)-NH-CH 2 -CH(CH 3 C-C(=O)-NH-CH 2 -C(CH 3 2 -OH, C-C(=O)-NI--C(CH4 3 2 -CH 2 OH or C-C(0)-NH-CH 2 CH 2 OCH 3 187. A compound according to claim 180 wherein X1 is C-C(0)-N-C(CH 3 2 -CH 2 OH. 188. A compound according to claim 180 wherein X 1 is C-NH b 189. A compound according to any one of claims 180 to 188 wherein R 9 is -CH 3 WO 03/000688 PCT/GB02/02799 -344- 190. A compound according to any one of claims 180 to 189 wherein R1 0 is phenyl. 191. A compound according to claim 160 wherein: R is hydrogen; R 3 is hydrogen; X1 is N; R 9 is CI- 4 alkyl; p is 1; and R'O is aryl. 192. A compound according to claim 191 wherein R 9 is -CH 3 193. A compound according to claim 191 or 192 wherein R1 0 is phenyl. 194. A compound according to claim 2 of formula (Id): R34 2 3 H (Id) wherein R2represents hydrogen, acyl, cyano, halo, lower alkenyl, -Z 2 R, 4 -SO 2 Ny 3 y 4 -NY I y 2 or lower alkyl optionally substituted by a substituent selected from ary], cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z 2 R 4 -C(=O)-Nyly 2 -C0 2 R 8 -Ny 3 y 4 -N(R 6 -N(R 6 2 -N(R 6 7 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y 4 -SO 2 NY 1 y 2 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -Z 2 R 4 -C&=O)-0R 5 or 3 y 4 X I represents N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R 4 C-NY I y 2 C-OH, C-Z 2 R, C-C(=O)-0R 5 C-C(=O)-Ny Iy 2 C-N(R 8 C-N(R 6 7 C-N(R 6 3 y 4 C-N(R 6 )-S0 2 -Ny 3 y 4 C-N(R 6 )-S0 2 -R, WO 03/000688 PCT/GB02/02799 -345- C-S0 2 -Ny 3 y 4 C-NO 2 or C-alkenyl or C-alkynyl optionally substituted by one or more groups selected from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, Iy 2 OR 5 -NY I y 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 )-C(0O)-0R 7 -N(R 6 ).S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 Y 4 -S0 2 -NY 1 Iy 2 and -Z 2 R 4 p is zero, or an integer I or 2; and R 1 0 is alkenyloxy, carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, R 4 I y 2 -OR 4 -N(R 6 7 -N(R 6 )-S0 2 -R 7 or -NY 1 Iy 2 or an N-oxide, prodrug, or pharmaceutically acceptable salt or solvate of such compound; or an N-oxide or prodrug of such salt or solvate. 195. A compound according to claim 194 wherein R 2 is hydrogen, lower alkyl, lower alkyl substituted by -CONY' y 2 lower alkyl substituted by carboxy, lower alkyl substituted by tetrazolyl; lower alkyl substituted by hydroxy, or lower alkyl substituted by -N(R 6 )-S0 2 -R 7 -N(R6)-C(0O)-R or 196. A compound accord ing to claim 195 wherein R 2 is methyl. 197. A compound according to claim 195 wherein R 2 is -CH 2 CH 2 CONE- 2 or -CH 2 CH 2 CONI-CH 3 198. A compound according to claim 195 wherein R 2 is -CH 2 CH 2 CO 2 H. 199.~ ANopudacrigt liH15weenR s-HC~/ 200. A compound according to claim 195 wherein R 2 .is -C--HCHOHo -C 2 CH- C(CH) 2 0H 201. A compound according to claim 195 wherein R? is CH 2 CH 2 CH 2 0HSorCH 202. A compound according to claim 195 wherein R 2 is CH 2 CH 2 CH 2 NHC(=O)-CH 3 203. A compound according to claim 195 wherein R2 is -CH 2 CH 2 C(0)CH- 3 WO 03/000688 PCT/GB02/02799 -346- 204. A compound according to any one of claims 195 to 203 wherein R is hydrogen. C'N 204. A compound according to any one of claims 195 to 203 wherein X' is hydrogen. 206. A compound according to any one of claims 195 to 205 wherein p is 1. 207. A compound according to any one of claims 195 to 206 wherein R' 0 is alkyl. 1 209. A compound according to any one of claims 195 to 208 wherein RI 0 is attached position 4. 210. A compound according to claim 194 wherein: R 2 is hydrogen, lower alkyl, lower alkyl substituted by -CONY 1Y 2 lower alkyl substituted by carboxy, lower alkyl substituted by tetrazolyl, lower alkyl substituted by hydroxy, lower alkyl substituted by -N(R 6 )-S0 2 -R 7 lower alkyl substituted by -N(R 6 R 3 is hydrogen; X' is N; pis 1; R 1 0 is alkyl; and (W RI 0 is attached at position 4. 211. A compound according to claim 210 wherein R 2 is methyl. 212. A compound according to claim 210 wherein R 2 is -CH 2 CH 2 CONH 2 or -CH 2 CH 2 CONHCH 3 213. A compound according to claim 210 wherein R 2 is -CH 2 CH 2 CO 2 H. N- NH 214. A compound according to claim 210 wherein R 2 is -CH CH N N WO 03/000688 PCT/GB02/02799 -347- 215. A compound according to claim 210 wherein R 2 is-CH 2 CH 2 CH 2 OH or -CH 2 CH 2 C(CH 3 2 0H. 216. A compound according to claim 210 wherein R 2 is CH 2 CH 2 CH 2 NHSO 2 CH 3 217. A compound according to claim 210 wherein R 2 is CH 2 CH 2 CH 2 NHC(=O)CH 3 218. A compound according to any one of claims 210 to 217 wherein R 10 is tertiary-butyl. 219.. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk comprising administering to said patient a pharmaceutically effective amount of a composition according to claim I. 220. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 221. A method of treating inflammatory disease in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1. 222. A method of treating inflammatory disease in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amout of a composition according to claim 2. 223. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of FAK comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. 224. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of FAK comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 225. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of KDR comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. WO 03/000688 PCT/GB02/02799 -348- 226. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of KDR comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 227. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Aurora2 comprising administering to said patient a pharmaceutically effective amount of a composition according to claim I. 228. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Aurora2 comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 229. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of IGFIR comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. 230. A method of treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of IGFIR comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 231. A method of treating cancer in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. 232. A method of treating cancer in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 233. A method according to claim 221 or 222 wherein the inflammatory disease is asthma, inflammatory dermatosis, allergic rhinitis, allergic conjunctivitis or joint inflammation. 234. A method according to claim 221 or 222 wherein the inflammatory disease is asthma, psoriasis, dermatitis herpetiformis, eczema, necrotizing vasculitis, cutaneous vasculitis, bullous disease, allergic rhinitis, allergic conjunctivitis, arthritis, rheumatoid arthritis, rubella arthritis, psoriatic arthritis or osteoarthritis. 235. A compound according to claim 2 of formula (I) WO 03/000688 PCT/GB02/02799 -349- cq R2 O x 3 1 N R N 0N H (I) wherein:- RI represents aryl or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, hydroxy, heteroaryl, heterocycloalkyl, y 2 -N(R 6 7 -N(R 6 3 y 4 -N(R 6 7 -N(R 6 )-SO 2 -R 7 -N(R 6 )-S0 2 -NY 3 Y 4 and -S0 2 -NY y 2 or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 236. A compound according to claim 160 wherein R 9 is CIA alkyl substituted by alkoxy or Ci 4 alkyl substituted by -NY'Y 2 and R I 0 is optionally substituted heteroaryl or optionally substituted aryl. 237. A method of treating Chronic Obstructive Pulmonary Disease, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. 238. A method of treating Chronic Obstructive Pulmonary Disease, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. 239. A method according to claim 231 or 232 wherein the cancer being treated is colorectal, prostate, breast, thyroid, skin, colon or lung cancer. 240. A method of inhibiting angiogenesis, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a composition according to claim 1. 241. A method of inhibiting angiogenesis, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 2. WO 03/000688 PTG0129 PCT/GB02/02799 -350- 242. A compound according to claim 2 which is 1-methyl-i H-i ndol-3-y1)-5H-pyrrolo[2,3-b]pyrazine; i-methyl-I H-indol-3-yI)-5H-pyrrolo[2,3-b]pyrazine; 6-(3-bromophenyl)-5H-pyrrolo[2,3-b]pyrazine; 7- iso-propyl-6-phenyl-5 H-pyrrolo[2,3-b]pyrazine; 6-(4-bromoplieny I)-SH-pyrrolo[2,3-b]pyrazine; 2-(4-bromophienyl)-l I pyrrolo[2,3-b]pyrazine; 6-(4-[1I,3]dioxan-2-yl-phenyl)-5 H-pyrrolo[2,3-b]pyrazine; ,3]dioxan-2-yl-phenyl)-5H-pyrrolo[2,3-b]pyrazine; 2-(5H-pyrrolo[2,3-b] pyrazin-6-yi)-,quinolime; 3-(5H-pyrrolo[2,3-bjpyrazin-6-yI)-isoquinioline; 1-methyl-i H-indol-5-yl]-5H-pyrrolo[2,3-b]pyrazine; 1 -methyl- I H-indol-3-yl)-2-methyl-5H-pyrrolo[2,3-b]pyrazine; 3-inethyl-6-( 1-methyl-I H-indol-3 -yI)-5H--pyrrolo[2,3-blpyrazine; 6-(lI -benzyl-5-methoxy- I H-indol-3-yI)-5H-pyrrolol2,3-b]pyrazine; 6-(lI-methyl-1 H-pyrrol-3-yI)-5H-pyrrolo[2,3-b]pyrazine; 6-(lI -methyl- I H-pyrrol-2-yl)-5H-pyrrolo[2,3-b]pyrazine; 6-indolizin- I -yI-5H-pyrrolo[2,3-b]pyrazine; 6-(3-methyl-indolizin- I -yl)-SH-pyrrolo[2,3-b]pyrazine; 6-(lI -methyl-2-phenyl- I H-pyi-roI-4-yI)-5H--pyrrolo[2,3-b]pyrazine; 6-(5,6,7,8-tetrahydro-indol izin- I -yI)-5H-pyrrolo[2,3-b]pyrazine; 6-furan-3-yl-5 H-pyrrolo[2,3-b] pyrazine; dimethyl-[4-(5H-pyrrolo[2,3-bjpyrazin-6-yl)-phenyl]-amine; 6-(5-methoxy- 1 -methyl- I I--indol-3-yI)-7-methyl-5H--pyrrolo[2,3-b]pyrazine; 6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-tert-butylphenyl)-7-methlyl-5H-pyrrolo[2,3-b]pyrazine; 6-(3 ,4-d imethoxyphenyl)-5H--pyrrolo[2,3-b]pyrazine; 6-(4-am inophenyl)-7-methyl-5H-pyrrolo[2,3-b] pyrazine; 6-[4-(lI -methyl)ethoxyphenyl]-5 H-pyrrolo[2,3-b]pyrazine; 6- (1 H- I -methyl-2-(methylthio)imidazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine; 6-(l1 -m-ethyl- I H-indazol-3-yl)-5 H-pyrrolo[2,3 -b]pyrazine; 6-(1I -methyl-4-phenyl- I H-pyrrol-3-yl)-5i--pyrrolo[2,3-b] pyrazirle; 6-(4-fluorophenyl)-5H-pyrrolo[2,3-b] pyrazi ne; 6-(4-methoxyphenyl)-5 H-pyrro lo [2,3-b]pyrazine; 6-[4-(tert-butyl)phenyl]-7-(prop- I -enyl)-5H-pyrrolo(2,3-b]pyrazine; WO 03/000688 PCT/GB02/02799 1- 6-(4-methylthiophenyl)-5 H-pyrrolo[2,3-b]pyrazine; 6-(3-methoxylphenyl)-5H--pyrrolo[2,3-bjpyrazine; 1-methiyl-i H-pyrazol-4-yI)-5 H-pyrrolo[2,3-b]pyrazine; I-methyl-5-phenyl- 1H-pyrazol-3-yl)-SH-pyrrolo[2,3 -b]pyrazine; 6-(pyridin-2-yI)-5H-pyrrolo[2,3-b]pyrazine; 6-(pyridin-4-yI)-5H-pyrrolo[2,3-b]pyrazine; 6-(3 ,4-d imethylphenyl)-5 H-pyrrolol2,3-b)pyrazine; 6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-trifluoromethoxyphenyl)-5 H-pyrrolo[2,3-b]pyrazine; 6-(4-aminopheiiyl)-5H-pyrrolo[2,3-blpyrazine; I-methy -2-phenyl- IH-pyrrol-3-yI)-51--pyrrolo[2,3-b]pyrazine; I,5-dimethyl- IH-pyrrol-3-yI)-5H-pyrrolo[2,3-blpyrazine; 1,4-d i-nethyl- II--pyrrol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; I -inethyl-4-phenyl- I H-pyrrol-3-yI)- I H-pyrrolo[2,3-b]pyridiiie; 3-[3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol-1 -yl]-propan- I -ol; 3-[5-methoxy-3-(5H-pyrrolc42,3-bjpyrazin-6-yI)-indol- I -yII-propan-]I-ol; 2-[3-(5H-pyrrolo[2,3-b]pyrazin-6-y)-indol- I -yJ]-ethanol; I H-indol-3-yI)-5H--pyrrolo[2,3-blpyrazine; 2-[5-methoxy-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I -yi]-ethanol; 3-{3-(5H-pyrrolo[2,3-b)pyrazini-6-yi)-indol-I -yl]-propylamine; 3-[S-methoxy-3-(5 H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I -yI]-propylamine; N- {3-13-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indol- I -yi]-propyl} -acetam ide; N-[4-(SH-pyrrolo[2,3-b]pyazin-6-yi)-plhenyll-acetamide; I-(3-morpholin-4-yl-propyl)- I H-indol-3-yI]-5H-pyrrolo[2,3-blpyrazine; 1-(3-piperidin- I -yi-propyl)- I H-indol-3-yIJ-51--pyrrolo[2,3-b]pyrazine; 6-f{ 1-[3 -(pyridin-3-yloxy)-propyl]- 1H-indol-3-yI }-5H-pyrrolo[2,3-b]pyrazine; I -methiyl-3-(5H-pyrro lo[2,3-b~pyrazin-6-yI)- 6-(2-ch loro-5-methoxy- 1-methyl-I H-indol-3-yI)-5H-pyrrolo[2,3-bjpyrazine; 3-(5H-pyrrolo[2,3-b~pyrazin-6-yI)-benzaldehyde; 4-(5H-pyrrolo[2,3-b]pyraziin-6-yl)-benzaldehyde; [3-(5H-pyrrolo[2,3 -b]pyrazin.-6-yI)-indol-1I-yl]-methanol; [3 -(5H-pyrrolo[2,3-b]pyrazi n-6-yI)-phenyl]-methianol; [4-(5H-pyrrolo[2,3-b]pyrazi n-6-yI)-phenyl]-methanol; H-iindol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; 2-[5-methoxy-3 H-pyrrolo[2,3-b]pyrazin-6-yI)-indol-I -morphol in-4-yi-ethanone; WO 03/000688 PCT/GB02/02799 -352- I -(2-morphiol in4-yl-2-oxo-ethyl)- I H-indol-3-yl]-1 H-pyrrolo[2,3-b]pyridine-4- carbonitrile; [5-methoxy-3-(IH-pyrrolo[2,3-b]pyridin-2-yI)-indol-1 -yI]-acetic acid; 4-methoxy-2-(5-methoxy- 1-methiyl-I H-indol-3-yI)- IH-pyrrolo [2,3-bjpyridine; 4-methoxy-2-(5-methoxy- IH-i ndol-3-yI)- IH-pyrrolo[2,3-b]pyridine; 4-ch Ioro-2-(4-ter--butylpheniyl)- I H-pyrrolo[2,3-b)pyridine; I -methyl- I H-indo l-3-yl)-5-phenyl- 1 H-pyrrolo[2,3-b]pyridine; 1 -methyl-3-(] H-pyrrolo[2,3-.b~pyridin-2-yI)- I H-indol-5-yloxy]-propan-2-oI; [5,6-dimethoxy-3-( I H-pyrrolor2,3-blpvridin-2-yl)-indol- I -yil-acetic acid; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yl]-l -morphol in-4-yi-ethanone; 1-11 -i-nethyl-3-( I H-pyrrolo[2,3-blpyrid in-2-yl)- I H-indol-5-yloxy]-cyclobutanecarboxyl ic acid amiide; 1 -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)- JH-indol-5-yloxy]-cyclobutanecarboxylic acid methylarnide; I -methyl-3-( IH-pyrrolo[2,3-bjpyridin-2-yl)- IH-indole-5-carboxylic acid methylamide; 1 -methy IH-pyrrolo[2,3-b]pyrid in-2-yI)- IH-indole-5-carboxylic acid (2-hydroxy-ethyl)-amide; I -methy H-pyi~rolo[2,3 -b]pyrid in-2-yl)- IH-indole-5-carboxyl ic acid (2-morpholin-4-yl-ethyl)- amide; I -methyl-3-( I 1-pyrrolo[2,3 -b~pyridin-2-yl)- IH-indole-5-carboxyl ic acid (2-carbainoyl-ethyl)-am ide; I -methyl-3-( IH-pyrrolo[2,3 -b]pyrid in-2-yl)- IH-indole-5-carboxyl ic acid b is-(2-hydroxy-ethyl)-am ide; 1 -methyl-3-( I H-pyrrolo[2,3-bjpyrid in-2-yl)- I H-indole-5-carboxyl ic acid amide; I -methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)- IH-indole-5-carboxylic acid (2-hydroxy- 1,1-bis- hydroxymethyl-ethyl)-amide; I -methyl-3-( IH-pyrrolo[2,3-bjpyridiri-2-yl)- IH-indole-5-carboxyl ic acid (2-hydroxy-lI-hydroxymethyl- I -methyl-ethyl)-aniide; I -methyl-3-( I H-pyrroio[2,3-b]pyrid in-2-yI)- I H-indole-5-carboxylic acid (2,3-dihydroxy-propyl)- arnide; I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)- IH-indole-5-carboxylic acid (2-hydroxy- 1,1-dimethyl- ethyl)-amide; I -methyl-3 H-pyrrolo[2,3-b]pyridin-2-yI)- 1H-indole-5-carboxylic acid (2-hydroxy- I-hydroxymethyl- ethyl)-amide; 1 -rethyl-3-( 1H-pyrrolo pyridin-2-yI)- IH-indole-6-carboxyl ic acid (2-carbamoy l-ethyl)-am ide; I -methyl-3-( IH-pyrrolo[2,3 -b]pyrid in-2-yl)- IH-indole-6-carboxyl ic acid (2-hydroxy-ethyl)-arnide;, I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indole-6-carboxyl ic acid (I H-[1I,2,4]triazol-3-yI)- amide; I -methyl-3-( IH-pyrrolo[2,3 -b]pyrid in-2-yI)- IH-indole-6-carboxyl ic acid (2-hiydroxy- I-hydroxymethyl- ethyl)-amide; WO 03/000688 PCT/GB02/02799 -353- I -methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yi)- IH-indole-S-carboxyl ic acid (2-hydroxy- 1,1 -dimethyl- ethyl)-amide; 3-[6-(4-tert-butylpheniyl)-5H-pyrrolo[2,3-b]pyrazin-7-ylJ-N-methylpropionamide; 3-[6-(4-ter-t-butylpheny[)-5 H-pyrrolo[2,3-blpyrazin-7-yl]-N,N-dimethylpropionanide; I -methyl-3 H-pyrrolo[2,3-b]pyrazin-6-yI)- IH-indole-5-carboxyl ic acid 2-methoxyethylamide; I -methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I I-indole-5-carboxyl ic acid 2-thien-2-ylethylarniide; I -methyl-3-.(5H-pyrrolo[2,3-b]pyrazin-6-yI)- IH-indole-5-carboxyl ic acid 2-fluoroethylam ide; I -methiyI-3-(5H--pyrroio[2,3-b]pyrazin-6-yi)- I H-indole-5-carboxyl ic acid 2-carboethoxyethylamide; I -methyl-3-(5 H-pyrroio[2,3-b]pyrazin-6-yi)- I H-indole-5-carboxylic acid (hydroxymethyl)- carbomethoxy-methylamide; 4 ~1 -methyl-3-(5 H-pyrroio[2,3-b]pyrazin-6-yi)- IH-indole-5-carboxyl ic acid 2-hydroxyethyiamide; I -methyl-3-(5H-pyrro 1012,3-b] pyrazin-6-yI)- I H-indole-5-carboxyl ic acid methylamnide; I -rnethyl-3-(5 H-pyrroio[2,3-b~pyrazin-6-yi)- IH-indole-5-carboxylic acid dimethylaniide; [I -methyi-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yl)- I H-indoi-5-yI] morphol in-4-yI ketone; 4-hydroxy-[ I -[1I -methyl-3-(5H-pyrrolo[2,3 -b]pyrazin-6-yI)- I 1 -methyl-3-(5H-pyrrolo[2,3 pyrazin-6-yI)- I FM ndol-5-y1] carbony Iam inoprop ionic acid niethylamide; I -methyl-3-(51--pyrrolo[2,3-b]pyrazin-6-yI)-I 1--indole-5-carboxylic acid 3 -hydroxypropy lam ide; 3- I-methylI)ethoxyph enyl]-S H-pyrrolo [2,3 pyrazin-7-yI }prop ionic acid metbylamide; ZO 3 -[6-(4-methoxyphenyl)-5 H-pyrro Io [2,3 pyrazi n-7-yl]prop ion ic acid methylamide; 3- -methyi)ethoxyphenyl]-5H-pyrrolo[2,3-b]pyrazin-7-y propionainide; 3- 6-(4-hydroxyphenyl)-5H-pyrrolc{2,3-b]pyrazin-7-yi propionamide; 3-[6-(4-fl uorophenyl)-5 H-pyrrolo [2,3 pyrazin-7-yI] prop ionic acid methylamide; imethyi-isoxazolyi-4-yi)- I H-pyrroio[2,3-b]pyrid in-2-yi]- -i-ethyl-I 1--indole-5-carboxyi ic acid (2-methoxy-ethyi)-amide; 3-[4-(3,5-dimnethyl-isoxazolyl-4-yi)- 1H-pyrrolo[2,3-b]pyridin-2-yI]- IH-indole-5-carboxylic acid (2- methoxy-ethyi)-am ide; 3-(4-cyano- IH-pyrrolo[2,3-bjpyridin-2-yI]-I -methyl- IH-indoie-5-carboxyl ic acid (2-hydroxy- ,1 dimethyl-ethyi)-amide; 3-(4-cyano- IH-pyrrolo[2,3-b] pyrid in-2-yI]-l1-methyilH-indole-5-carboxyl ic acid (2-hydroxy-2-methyl-.. propyl)-amide; 2-r5,6-dimethoxy-3-( 1H-pyrroior2,3-blrpyridin-2-yi)-indoi-1I-yii-lI-morpholin-4-yi-ethanone:, [I -methyi-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-I H-indoi-5-yloxy]-acetic acid; 1 -methyl-3-( I H-pyrrolo(2,3-b]pyridin-2-yi)- I H-indoi-5-yloxy]-propionic acid; I-[l -methiyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)- IH-indoi-5-yioxy]-cyciobutanecarboxylic acid; I -methyl-3-(I 1 H-pyrrolo[2,3-b]pyridin-2-yi). I H-indoie-5-carboxyl ic acid; WO 03/000688 WO 03100688PCTIGBO2/02 799 -354- CK1 1 -methyl-3-( I H-pyrrolo[2,3-bjpyridin-2-yl)- 1 1- {]I-(cyclobutanecarboxyl ic acid)-3- IH-pyrrolo[2,3-b]pyridin-2-yII- IH-indol-5-yloxy} cyclobutanecarboxylic acid; 1 -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)- IH-indole-6-carboxylic acid; 3-LI -methyl-3 I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yl]-propionic acid; I-methyl-3-(5H-pyrroloII2,3-b]pyrazin-6-y1)-1H-indole-5-carboxylic acid; [2-r-nethoxy-5-(51H-pyrrolo[2,3-b]pyrazin-6-yl)-phenoxy]acetic acid; 3 imethy lam ino-5-(5 H-pyrrolo[2,3 pyrazin-6-yi)-phenyl]propion ic acid; 3 [I -methy 1-3 H-pyrrolo [2,3 -b]pyrazin-6-y1)- 1 H-indol1-5-yl]carbonylIam inoprop ionic acid; C) 10 3-[4-(3,5-dimethyl-isoxazole-4-yl)- IH-pyrrolo[2,3-b]pyridine-2-yl]- 1-methiyl-I 4 (Ni acid; 3-[4-(3,S-imethyl-isoxazole-4-yl)- I H-pyrrolo[2,3-b]pyridine-2-yl]- I H-indole-5-carboxylic acid; 4-(3 ,5-dimethyl-isoxazole-4-yI)-2-(5-methoxy- I -methyl- I I--indol-3-yI)- I H-pyrrolo[2,3-b]pyridine; 4-(3 ,5-dimethyl-isoxazole-4-yl)-2-(5-methoxy- I H-indol-3-yl)- I H-pyrrolo[2,3-b)pyridine; 3-(4-methoxy- IH-pyrrolo[2,3 pyrid ine-2-yl)- I-methyl-i H-indole-5-carboxylic acid; 3-(4-cyarno- IH-pyrrolo[2,3-blpyridine-2-yI)-I -methyl-I H-indole-5-carboxylic acid; 3 H-pyrrolo72,3 -b]pyridine-2-yl)-l1H-indole-5-carboxylic acid; H-indol-3-yl)- IH-pyrroio[2,3-b]pyridine -4-carboxylic acid; potassium 2-(5-metlhoxy4- IH-indol-3-yl)- IH-pyrrolo[2,3-b]pyridine-4-ca rboxylate; I-methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- I-methyl-3-( IH-pyrrolo[2,3-b]pyrid in-2-yl)- IH-indol-5-yloxy]-propan- I-ol; I -methyl-3-( I H-pyrrolo[2,3-b)pyridin-2-yl)- I H-indol-5-yloxy]-cyclobutyl} -methanol; 2-(6-phenyl-5H-pyrrolo[2,3 -b]pyrazin-7-yl)-ethaniol; 341 -methy l-3-(5H-pyrrolo[2,3-blpyrazin-6-yl)- IH-indol-5-yl]carbonylaminopropioniic acid; 2-[2-methoxy-5-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenoxy]-ethanol; 3 imethiylamino-5-(5H-pyrrolo[2,3-b]pyrazin-6-yI)-phenyl)-propan-l1-ol; 3-1{6-1j4-(] -methyl)ethoxyphenyl]-5H-pyrrolo[2,3-b~pyrazin-7-yl }propanol; 1-methyl-I H-indol-3-yl)- IH-pyrrolo[2,3-b]pyridine; I-methyl-3-(l H-pyrrolo[2,3-b]pyridin-2-yI)- IH-indol-S-yloxy]-propane-l ,2-diol; 1-methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-l H-indol-5-yloxy)-propan- I-ol; 341 -methyl-3-( IH-pyrrolof2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-propan-2-ol; I-methyl-S-(2H-tetrazol-5-yl)- IH-indol-3-yi]- IH-pyrrolo[2,3-b]pyridine; I-methyl-5-(2-methyl-2H--tetrazol-5-yl)- IH-indol-3-yIj]IH-pyrrolo[2,3-b]pyridine; 1-methyl-I H-tetrazol-5-yI)- IH-indol-3-yl]- 1H-pyrrolo[2,3-b]pyridine; I-[I -methyl-3-(1 H-pyrrolo[2,3-b]pyridin-2-yl)- I 2-(5,6-dimethoxy- 1-methiyl-I 1--indol-3-yi)- II--pyrrolo[2,3-b]pyridine; I-methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yI)- 1H-indol-5-yloxy]-propane-I ,2-diol; WO 03/000688 PCT/GB02/02799 -355- -methyl-3.( I H-pyrrolo[2,3-b]pyrid in-2-yl)- I H-indol-5-yloxy]-propane- 1,2-dial; 2-[5-(2-methoxy- I -methyl-ethioxy)-l -methyl-i H-indol-3-yl]- 1 H-pyrrnlo[2,3-b]pyridine; I -methyl-5-(5-methyl-[1I,2,4]oxadiazol-3-yl)-1 H-indol-3-yl]-1 H-pyrrolo[2,3-blpyridine; (R)-3-[6-methoxy- I -methyl-3-(l 1 pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-propane- 1,2-dial; 6-methoxy- I -metlhyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I 2-(S-methoxy- 1-methyl-I H-indol-3-yI)-4-phenyl- I H-pyrrolo[2,3-b]pyridine; 2-[5-(pyridin-4-yl)- 1 -methyl- I H-indol-3-y]]- I H-pyrrolo[2,3-b]pyridine; I-methyl- I H-indol-3 -yl)-lI H-pyrrolo[2,3-b]pyridine-4-carbonitri le; 4-chloro-2-(5-mnethoxy- I -methyl-I H-indol-3-yI)- I H-pyrrolo[2,3-b]pyridine; 2-(5-methoxy- 1-methyl-i H-indol-3-yI)-4-(pyridin-3-yI)- IH-pyrrolo[2,3-b]pyridine; 1-methyl-I H-indol-2-yl)- I H-pyrrolo[2,3-blpyridime; -m-ethyl-i H-i ndol-3-yl)-3-methyl- 1 H-pyrrolo[2,3-b]pyridine; 1 H-pyrrol-2-yl)- I H-pyrrolo[2,3-b]pyridine; 1-methyl-i H-pyrrol-2-yi)- I H-pyrrolo[2,3-blpyridine; 4-chloro-2-(5-methoxy- I H-indol-3 -yI)-lI H-pyrrolo[2,3 -b]pyri dine; I -metliyl-3-( I H-pyrrolo[2,3-cb~pyridin-2-yI)- I H-indol-6-oI; 2-(6-isapropoxy-5-methoxy- I -methyl- I H-indol-3-yI)-l I pyrrolo[2,3-b]pyridine; 2-[5,6-dimethoxy- I -(2-morpholin-4-yl-ethyl)-1 H-indol-3-yl]- I H-pyrrolo[2,3-b]pyridine; I -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)- I I -methyl-3-(I H-pyrrolo[2,3-b~pyridin-2-yI)-1 I-methyl-3-( 1H-pyrrolo[2,3-b]pyrid N- {I -methyl-3-( IH-pyrrolo [2,3-b]pyrid in-2-yl)- IH-indol-5-yl]methyl }thien-2-yI-sulfonan ide;, I-hydroxym ethyl-cyclobutoxy)-3 H-pyrrolo[2,3-b]pyridini-2-yl)-indol-1I-yI]-cyclobutyl methanol; 1-[l1 -methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yi)- I H-indol-5-yloxy]-cyclobutyl -methanol; 5-[6-(4-iert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]ethyl-2H-tetrazole; 3-[6-(4-tert-butylphenyl)-5H-pyrrolo[2,3 -b]pyrazin-7-yl]-propionitri le; 3-[6-(4-terrt-butylphenyl-5 H-pyrrolo[2,3-b]pyrazin-7-yl]-propionamide; 3-[6-(4-tert-butylpheilyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl]-propionic acid; 3- 1-metbyl)ethoxyphenyl]-5H-pyrrolo[2,3-b]pyrazin-7-ylI propion ic acid; 3-[6-(4-fluorophenyl)-5H--pyrrolo[2,3-b~pyrazin-7-y]propionic acid; 3-[6-(4-methoxyphenyl)-5H-pyrro lo(2,3-bjpyrazin-7-yljpropionic acid; 3-[6-(4-terrt-butyl-phenyl)-5H-pyrrolo[2,3-b]pyrazin-7-y)-propan- 1-cl; [2-methoxy-5-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenoxy]acetic acid ethyl ester; 2-methoxy-5-(5H-pyrrolo[2,3 -b]pyrazin-6-yI)phenol; 3-fluoro-2-(5-methoxy- I-methiyl- I H-indol-3-yI)- I H-pyrrolo[2,3-b]pyridine; WO 03/000688 PCT/GB02/02799 -356- 3 6-(4-hyd roxyphenyl)-5 H-pyrro lo[2,3 pyrazin-7-yl1) prop ionic acid; ethyl 3- f6-(4-hydroxypheniyl)-5H-pyrrolo[2,3 -b]pyrazin-7-yI} propionate; IH-i ndol-3-yI)- IH-pyrrolo[2,3-blpyridine-4-carbonitrile; 6-(4-methylsulfinylphenyl)-5 H-pyrrolo[2,3-b]pyrazine; 6-(4-methylsu Ifonyl phenyl)-5H-pyrrolo[2,3-b]pyrazine; 3-(6-(4-terti-butylphenyl)-5 H-pyrrolall2,3-b]pyrazin-7-yI)propylamime; N- {3-(6-(4-terti-butylphenyl)-5H-pyrrolo[2Z3-b] pyrazin-7-yl)propyl }acetarnide; N- {3-(6-(4-iert-butylphenyl)-5 I--pyrrolo[2,3-b]pyrazin-7-yI)propyl }cyclopropylcarboxylic acid am ide; N- {3-(6-(4-tert-butylphenyl)-SH-pyrrolo2,3-b~pyrazin-7-yl)propyl }butyramide; N- {3-(6-(4-ter-t-butylphenyl)-51-I-pyrrolo[2,3-b] pyrazini-7-yl)propyl }methoxyacetam ide; {3-(6-(4-tet--butylpheniyl)-5H-pyrrolo[2,3-b]pyrazin-7-y)propyl }thien-2ylcarboxylic acid amide; N- {3 -(6-(4-tet--butylphenyl)-5H-pyrrolo [2,3 -b~pyrazin-7-yl)propyl }-N'-propyI urea; N-{3-(6-(4-tertf-buty lphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl)propyl)}-N '-carboethoxymethyl urea; N- I-methyl-3-( IH-pyrrolo[2,3-b]pyrid in-2-yl)- IH-indol-5-yl] methyl }-N'-tetrahydropyran-2-ylurea; N4-{3-(6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-b] pyrazin-7-yl)propyl)}-N' ,N '-diethyl urea; N- (-(6-(4-iert-butylphenyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl)propy }methanesulfonamide; N- {3-(6-(4-iert-butyl phenyl)-5H4-pyrrolo[2,3-b]pyrazin-7-yl)propyl }thien-2-ylsulfonamide N- {3-(6-(4-tert-butylphenyl)-51H-pyrrolo[2,3-b~pyrazin-7-yl)propyl }dimethylisoxazol-4-ysulfonam ide; N- {3-(6-(4-zert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl)propyl 1 -methylimidazol-4-ylsulfonamide; 2-(5-methoxy-I -methyl- I H-indol-3-yI)- IH-pyrrolo[2,3-b]pyridine-4 carboxylic acid (2-hydroxy- 1,- dimethyl-ethyl)-amide; 3-(4-chiloro- IH-pyrrolo[2,3-b]pyridin-2-yl)- I-methyl-I H-indole-5-carboxylic acid (2-hydroxy- 1,1 d imethyl-etbyl)-am ide; I-metlhyl- IH-indol-3-yl)- IH-pyrrolo[2,3-b]pyridin-4-yl]-morphol in-4-yl-methanone; 3-[6-(4-hydronyplienyl)-5H-pyrrolo[2,3-bjpyrazin-7-yl]-N-methylpropionamide; I -ethyl-5-methoxy-1 H-indol-3-yl)-l H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy- 1 I dimethyl-ethyl)-amide; 2-(S-methoxy- I -methyl- I I--i ndol-3-yi)- I H-pyrrolo[2,3 ,-bjpyridine-4-carboxyI ic acid (2-methoxy-ethyl) amide; 2-(5-methoxy- I -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3,-b]pyridine-4-carboxyl ic acid (2-hydroxy-2- methyl-propyl) amide; H-indo I-3-yl)-l H-pyrrolo[2,3 ,-b]pyridine-4-carboxylic acid (2-hydroxy- propyl) amide; I-miethyl- I H-indol-3-yl)- I H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy-ethyl) amide;I I H-mnd o-3 -yl)-l 1 H-pyrrolo[2,3 ,-b]pyridine-4-carboxyl ic acid (2-methoxy-ethyl) am ide; 1-methyl-I H-indol-3-yl)- I H-pyrrolo[2,3-bjpyridine-4 carboxylic acid; WO 03/000688 WO 03/00688PCT/GB02/02799 -357- 3-(4-chloro- IH-pyrrolof2,3-b]pyridin-2-yl)-l -methyl-I H-indole-5-carboxyl ic acid; I-ethyl-5 -methoxy- IH-i ndol-3y1)- IH-pyrrolo[2,3 ,-b]pyridine-4-carboxyl ic acid; IH-indol-3-yI)- IH-pyrrolo[2,3-b]pyridine-4 carboxamide; 3-[6-(4-morphol in4-yI phenyl)-SH-pyrrolo[2,3-b~pyrazin-7-yI]-N-methylpropionamide; 6-(4-pyrrol idin- I-yi phenyl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-(furan-2-yl)phenyl)-5 H-pyrro lo[2,3-b] pyrazine; ,5-d irnethyl isoxazol-4-yl)phenyl)-5H-pyrrolo[2,3-b]pyrazine; 2-[4-(5H-pyrrolo[2,3 ,-b]pyrazin-6-yl)phenyl]-propan-2-ol; I I--pyrrolo[2,3-b)pyrazin-6-yl)phenyl] ethanone; {2-morphol in-4-yl ethyl) -p iperazi n- I -yl)phenyl]-5H-pyrrolo [2,3 pyrazine; 6-(4-piperazin- I-ylphenyi)-5 H-pyrrolo[2,3 -b]pyrazine; 2-mnethy I-4-[6-(4-tert-butyl-phenyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl]-butan-2-ol; IH-pyrrolo[2,3-blpyridin-2-yI)- I-methyl-I 2- {[5-methoxy-3-( IH-pyrrolo[2,3 pyridin-2-yl)-indol- l-yi]-l-(1 -methylpiperazin)-4y1) -ethanone; N-cyclobutyl-2-[5-methoxy-3 IH-pyrrolo[2,3 -b)pyridin-2-yl)-indol- I-yI]-acetamide; N-(3-imidazol-I -yI-propyl)-2-[5-methoxy-3-( I I-pyrrolo[2,3-b]pyridin-2-yI)-indol-1I-yl]-acetamiide; I ihydro-pyrrol-1I-yI)-2-[5-rnethoxy-3-( IH-pyrrolo [2,3-b]pyrid in-2-yl)-indol- I-yl)-ethanone; N-cyclohexyl-2-[5-methoxy-3-( IH-pyrrolo[2,3 -b]pyridin-2-yl)-iridol-1I-yI]-acetamide; N-cyclopentyl-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yI]-acetam ide; N-(3-dimethyl-am ino-propyl)-2-[5-methoxy-3-( IH-pyrrolol2,3 -bipyrid in-2-yl)-indol- 1-yI]-acetam ide; 6- {2-[5-methoxy-3-( 1H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yI]-acetylam ino} -hexanoic acid methyl ester; 1-El ,4']bipiperidinyl-lI'-yI-2-[S-methoxy-3-(I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-1 -yl]-ethanone; N-(3 ,3 -dimethyl-butyl)-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yl]-acetamide; N-(3-ethoxy-propy I)-2-[5-methoxy-3 H-pyrrolo[2,3-b~pyridin-2-yI)-indol-1I-yI]-acetamide; 1 ,3-d imethyl-piperid in- 1-yi)-2-[S-methoxy-3-( IH-pyrrolo[2,3-blpyridin-2-yi)-indol- I-yl]-ethanone; 2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyrid in-2-yi)-indol-1I-yi]-N-(3-oxo-isoxazol id in-4-yl)-acetam ide; I -[4-(4-chloro-phenyl)-piperazin-1I-yl]-2-[5-methoxy-3-(I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-ylJ- ethanone; I -(4-hydroxy-piperid in-I -yl)-2-(5-i-nethoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol-1I-yl]-ethanone; 2-[5-methoxy-3-( 1H-pyrrolo[2,3 -b]pyridin-2-yl)-indol- I-yl]-I -thiazolidin-3-yI-ethanone; 2-[5-methoxy-3-(1I-pyri-oio[2,3-blpyridin-2-yI)-indol- I-yI]-I -[4-(3-phenyl-allyl)-piperazin- I-yl]- ethanone; N-furan-2-ylmethyl-2-[5-metlioxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol- I-yI)-acetamide; 2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyrid in-2-yI)-indol-1I-yI]-N-(2-pyridin-4-yI-ethyl)-acetamide; N-cyclopropylmethyl-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)-indol- 1-yI]-N-propyl-acetamide; WO 03/000688 PCT/GB02/02799 -358- -cyclohexyl-ethyl)-2-15 -methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-acetamide; 2-[S-methoxy-3-( I H-pyrrolo[2,3 -b~pyridin-2-yI)-indol- I -yI]-N-methyl-N-pyridini-3-ylmethyl-acetamide; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1 l-I -(4-m-tolyl-piperazin- I -yi)-etbanone; 2-[5-methoxy-3-( I H-pyrrolo[2,3-blpyridin-2-yI)-indol- I -yl]-N-(2-phenylsul fanyl-ethyl)-acetam ide; 2-[5-rniethoxy-3-( I H-pyrrolo[2,3-b)pyridin-2-yI)-indol- I -yI]-N-(4-morpholin-4-yI-phenyl)-acetain ide; N-cyclopropyl-2-[5-methoxy-3 H-pyrrolo[2,3-b)pyridiri-2-yI)-indol- I -yi]-acetamide; 2-[5-methoxy-34( H-pyrrolo[2,3-b~pyridin-2-yI)-indol- I -yI]-1 -(3-methyl-piperazin- I -yI)-ethanone; N-(4-cyclohexyl-phely)-2-15-.methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-acetamide; 2-[5-methoxy-3 H-pyrrolo[2,3 -b]pyridin-2-yI)-indol- I -yI]-N-(2-methyi-cyclohexyl)-acetamide;, N-cyclohexylmethyl-2-[5-metlhoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indoi- I -yi]-acetamide; 2-[5-methoxy-3-(] I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-lI -pyrrolidin-I -yi-ethanone; 4- (2-[5-methoxy-3-(l I pyrro io(2,3-b]pyridin-2-yI)-indol- I -yi]-acetyl -piperazin-2-one; 4- {2-[5-methoxy-3-( I H-pyrrolo[2,3 -b]pyridin-2-yI)-indol- 1 -yi]-acetyl I -3,3-dimethyl-piperazin-2-one; 4- {2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-acetyl -1 -methyl-piperazin-2-one; 2-[5-methoxy-3-( I H-pyrro Io[2,3-b]pyridin-2-yI)-indol- I -thiornorpholin-4-yi-ethanone;- N-(2-hydroxy-2-phenyl-ethyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yi)-inidol-l -yi]-acetam ide; I imethyl-morpholin-4-yI)-2-[5-methoxy-3-( I H-pyrrolo[2,3 -b]pyridin-2-yl)-indol- I -yi]-ethanone; N-(4-dietliylam inomethyl-phenyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b~pyrid in-2-yI)-indol- 1 -ylI- acetam ide; N-[2-(4-hydroxy-phenyl)-ethyl]-2-[5-methoxy-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)-indol- I -yi]-acetamide; 2-[5-methoxy-3-( I H-pyrro Io[2,3-b]pyridin-2-yI)-indol- I -yI]-N-(tetrahydro-furan-2-ylmethyl)- acevarnide; 2-[S-methoxy-3-( I H-pyrro Io[2,3-b]pyridin-2-yI)-indol- I -yI)-N-pyridin-2-ylmethyl-acetainide; N-(1I,2-d imethyl-propyl)-2-[5-methoxy-3-(I H-pyrrolo[2,3-b] pyridin-2-yI)-indol- I -yi]-acetamide; N-(3-benzyloxy-pyrid in-2-yl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-acetam ide; 2-[5-methoxy-3-(1 H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-N-quinol in-3-yi-acetamide; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I .yI]-N-quinol in-8-yi-acetamide; N-isoqu inol in-5-yI-2-[5-rnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-acetamide; 2-[5-inethoxy-3-( I H-pyrr-olo[2,3 -b]pyridin-2-yI)-indol- I -yI]-N-(3-methyl-butyl)-acetamide; N-isoquinol in- I -yI-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-I -yi]-acetamide; 2-[5-methoxy-3-(I H-pyrrolo[2,3-b~pyridin-2-yI)-indo -1I -yIJ-N-quinolin-2-yl-acetamide; 1 -(3,6-dihydro-2H-pyrid in- I -yI)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-ethanone; 2-[5-methoxy-3-( I H-pyrrol o[2,3-b]pyridin-2-yI)-indol- I -yl]-N-[3-(4-methyl-piperazin- I -yi)-propyl]- acetarnide; N-(2-cyclohex- I -enyl-ethyl)-2-[5-rnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indo I-I -yi]-acetam ide; I H-indol-3-yI)-ethyl]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol-] -yi]-acetamide; WO 03/000688 WO 03/00688PCT/GB02/02799 -359- 2-[5-irnethoxy-3-( I H-pyrrolo[2,3-blpyridin-2-yi)-indol- I I -[4-(tetrahydro-furan-2-carbonyl)- piperazin- I -yi]-ethanone; N-adamantan- I -yl-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yIl-acetamide; N-(2-dimethylamino-ethyl)-2-[5-methoxy-3 H-pyrrolo[2,3-b]pyridin-2-yi)-indol- I -yI]-N-rethyl- acetamide; I -(4-benzo[ I ,3]d joxoI-5 -ylm ethyl -p iperazi n- I -yI)-2-[5-methoxy-3-( I H--pyrrolo[2,3-b]pyrid in-2-yI)- indol- I -yI}-ethanone; I loro-benzyl)-p iperazini- I -yI]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yi)-indol- Il-yi]- ethanone; 2-15-iethoxy-3-(I I--pyrrolo[2,3-b]pyridin-2-yl)-indol- l-yi]-I -phenyl-ethyl)-piperazin- I yl]- ethanone; -methoxy-3-(] H-pyrrolo[2,3 -b~pyridin-2-yl)-indol- I-yI]-lI -[4-(2-morphol in-4-yl-ethyl)-piperazin- I yl]-ethanone; I -14-(4-metoxy-phenyl)-piperazi n- I -yI]-2-{5-methoxy-3-( I H--pyrrolo[2,3-b] pyridin-2-yl)-indol I -yIP- ethanone; 2-[5.methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol-1I-yi]-N-[3-(2-oxo-pyrrol idin-1I-yI)-propyl]- acetam ide; 2-[5-rnethoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yJ)-indol- I-yI]- I -piperidin- I -yI-ethanone; 2-[5-methoxy-3-( I H-pyrro Io[2,3-b]pyridin-2-yI)-indol-1I-yi]-N-(2-piperidin- I -yI-ethyl)-acetamide; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yI)-indol- I -yl]-N-(2-pyrrol idin- I -yI-ethyl)-acetamide; I -[4-(2-methloxy-ethy!)-piperazin- I -yI]-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yi)-indol- I -yI]- ethanone; I- [4-(2-di methy lam i no-ethyl)-pi perazin- 1 -ylI-2-[5-methoxy-3-( I H-pyrrolo[2,3 -b]pyridin-2-yI)-indol- I yI]-ethanone; N-isobutyl-2-[5-methoxy-3 H-pyrrolo[2,3-b]pyrid in-2-yI)-indol- I -yI]-acetamide; I -[4-(4-tert-butyl-benzy 1)-pi perazin- I -yi]-2-[5-methoxy-3-( IH-pyrrolo[2,3 -b]pyridin-2-yI)-indol- I -yI]- ethanone; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyrid in-2-yI)-indol-1I-yI]-N-( 1-methyl-3-pheriyl-propyl)-acetarnide; N-(4-diethylamino- I -methiyl-butyI)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yl]- acetamide; N-benzyl-N-(2-hydroxy-ethyl)-2-[5-methoxy-3 H-pyrrolo[2,3-b~pyrid in-2-yI)-indol-1I-yI]-acetam ide; 1- {4-[2-(2-hydroxy-ethoxy)-ethyl]-piperazin- I-yI }-2-[5-methoxy-3-(I H-pyrrolo[2,3 -b)pyrid in-2-yI)- indol-1I-yi]-ethanone; I -hydroxymethyl-2-rnethyl-butyl)-2-[5-r-nethoxy-3-(] H-pyrrolo[2,3-b]pyrid in-2-yI)-indol- I-yI]- acetam ide; N-benzy 1-2-[5-methoxy-3 H-pyrrolo(2,3 pyrid in-2-yI)-i ndo I- I -yi]-N-methyl-acetam ide; WO 03/000688 WO 03/00688PCT/GB02/02799 -360- N-(2-methoxy- I -methyl-ethyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yi]-acetamide; N-(.3-hydroxy-propyl)-2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- 1-yl]-acetam ide; N-(3-methoxy-phenyl)-2-[S-inethoxy-3 H-pyrrolo[2,3-b]pyridin-2-yi)-indol-1I-yl)-acetamide; I -(4-benzhydryi-piperazin- I -yI)-2-[5-i-nethoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol- 1-yIJ-ethanone; 1 -(4-benzyl-piperazin-1I-yI)-2-[5-methoxy-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-indol- I -yI]-ethanone; 2-[5-methoxy-3-( IH-pyrrolo [2,3 -b~pyridin-2-y1)-indol-1I-yi]-N-(3-pyrrol idin-1I-yI-propyl)-acetamide; N-(1 -benzyl-piperid in-4-yI)-2-[5-methoxy-3-(1 H--pyrrolo[2,3-b]pyridin-2-yI)-indol-1 -yl]-acetamide; I -[4-(4-chloro-phenyl)-4-hydroxy-piperidin- I -yI)-2-[5-methoxy-3 H-pyrrolo[2,3-b]pyrid in-2-yl)- indol-1 -yl]-ethanone; 2-{f2-[5-methoxy-3 I H-pyrro Io [2,3 -b)pyrid in-2-yI)-indo I- I -yl] -acety lam ino} -3 -methyl-pentanoic acid methyl ester; 2-[5-methoxy-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)-indol- I-yi]-N-(2-methyl-quinol in-4-yl)-acetam ide; N-(2-benzylsulfanyl- I-hydroxymethyl-ethiyl)-2-[5-methoxy-3-( IH-pyrrolo[2,3 -b]pyridin-2-yl)-indol- 1- yl]-acetarnide; IH-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I-yl]-acetic acid; H-pyrrolo[2,3 -b]pyridin-2-yI)-pyrrol- l-yI]; I -cyclopropylamino} -ethanone; N-(3-ethoxy-propyI)-2-[2-( 1 H-pyrrolo[2,3-b~pyridin-2-yl)-pyrrol- 1-yl]-acetamide; 1-pyrrol idin- H-pyrrolo[2,3-b]pyridin-2-yl)-pyrrol-1I-yl]-ethanone; I -(3,6-dihydro-2H-pyrid in- H-pyrrolo[2,3-b]pyridin-2-yl)-pyrro1-1I-yl]-ethanone; 1 -rnethyl-4- I H-pyrro lo[2,3-b]pyridirn-2-yl)-pyrrol-1I-yl]-acetyl)}-piperazin-2-one; I H-pyrrolo[2,3-b]pyridin-2-yl)-pyrrol- I -yl]-N-(tetrahydro-furan-2-ylmethyl)-acetamide; I -(2,6-dimethyl-morphol I H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I -yI]-ethanone; H-pyrrolo[2,3 -b]pyridin-2-y )-pyrrol- Il-yI]- I -thiomorphol in-4-yi-ethanone; I -(4-hydroxy-piperidin- Il-yI)-2-12-(I H-pyrrolo[2,3-b]pyridin-2-yl)-pyrrol- I -yI]-ethanone; 1 ,3-dimethyl-piperid in-I H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I -yI]-ethanone; 4- H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I -yi]-acetyl )-piperazin-2-one; I-methyl-butyl)-2-[2-( I H-pyrroloj2,3 -b]pyridin-2-yl)-pyrrol- I -yi]-acetamide; N-bicyclojj2.2. I ]hept-2-yI-2-[2-( I H-pyrrolo[2,3-b]pyridin-2-yl)-pyrro I-I -yf]-acetamide; N-[3-(4-methyl-piperazin- I -yI)-propylj-2-[2-( I H-pyrrolo[2,3 -b]pyridin-2-yi)-pyrrol- I -yi]-acetamide; I -[4-(3-dimethylamino-propyl)-piperazin- H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol-I -yI]- ethanone; 1 -(4-methyl-piperazin-I -yI)- 2 2 H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- I -yi]-ethanone; I Ioro-phenyl)-4-hydroxy-piperid in-I H-pyrrolo[2,3-b]pyridin-2-yI)-pyrrol- Il-yl]- ethanone; 1 -[4-(3-hydroxy-phenyi)-piperazin- I H-pyrrolo[2,3-b]pyridin-2-yl)-pyrrol- I-yl]-ethanone; 3 -methoxy-2-( I H-pyrro lo [2,3 pyrid in-2-yI)- indolI- I -y I]-prop ionic acid; WO 03/000688 WO 03/00688PCT/GB02/02799 -361- 3-[5-rnethoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- Il-yI]- I -morpholin-4-yI-propan- I -one; -methoxy-2-( I H-pyrrolo[2,3 -b]pyridin-2-yl)-indol- I -yI]-N-phenyl-propionarnide; 3-[5-methoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol- 1-yI]- I -thiomorphol in-4-yl-propan- 1 -one; 3 -[5-methoxy-2-( I H-pyrrolo[2,3-b]pyridin-2-yl)-indol-I -yl-lI -(4-methyl-piperazin- I -yi)-propan- 1-one; 3-[5-methoxy-2-( I H-pyrrolo[2,3-bjpyridin)-2-yl)-in do)- I -yI]-N-(tetrahydro-furan-2-ylmethyl)- propionamide; N-(2-hydroxy-2-phenyl-ethyl)-3-[5-methoxy-2-( 1 H-pyrrolo[2,3-b]pyrid in-2-yi)-indol- Il-yl]- prop ion am ide; N-(2-hydroxy-ethyl)-3 -r5-mlethoxy-2-( I H-pyrrolor2,3-blpyrid in-2-yl)-indol- I -yil-propionam ide: 1 -[4-(4-chloro-phienyl)-4-hydroxy-piperid in- I -yl]-2-[5-methoxy-2-( I H-pyrrolo[2,3-b~pyridin-2-yl)- indol- I -yll-ethanone; I -methyl- I H-indol-3-yJ)-4-morphol in-4-yl-] IH-pyrrolo[2,3-bjpyrid mne; I -methyl- I H-indol-3-yl)-4-piperidin- Il-yI-I H-pyrrolo[2,3-b~pyridine; I -methyl-I H--indol-3-yI)- 1 I--pyrrolo[2,3-b]pyridin-4-yl]-(2-methoxy-phenyl)-amine. [2-(5-methoxy- I -methyl- I I--indol-3-yl)- I H-pyrrolo[2,3 -b]pyridin-4-yI]-o-tolyl-amine; I1-methyl- I H-indol-3-yI)- I I--pyrrolo[2,3-b]pyridin-4-yl]-(3 -,tiethoxy-phenyl)-amine; 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3 -b]pyrid in-4-yI]-m-tolyl-amine; (4-fluoro-plhenyl)-[2-(5-methoxy- 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridin-4-yI]-amine; 1 -methyl- I H-indol-3-yl)- 1 H-pyrrolo[2,3-bjpyridin-4-yl]-(4-methox-y-phenyl)-amine; [2-(5-methoxy- 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridin-4-yl]-p-tolyl-aniine, 1 -methyl-I H-indol-3-yl)- I H-pyrrolo[2,3 -b]pyridin-4-yl]-amine; (4-fluoro-benzyl)-[2-(5-methoxy- 1 -methyl- I H-indol-3-yl)- I H--pyrrolo[2,3-b]pyridin-4-yI)-amine; (4-methoxy-benzyl)-[2-(5-methoxy- 1 -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridin-4-yl]-amine; (2-methoxy-ethyl)-j2-(5-methoxy- I -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3 -bipyrid in-4-yl)-amine; 3-[2-(5-methoxy- I -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridin-4-ylamino]-benzoic acid methyl ester; 1 -methyl-I H-indol-3 I I--pyrrolo[2,3-b]pyridin-4-yl]-am ine; I -methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyrid in-4-yl]-phenyl-amine; I -methyl- I H-indol-3-yl)-I H-pyrrolo[2,3-b]pyridin-4-yl]-amine; 2-(5-methoxy- I I--indol-3 I H-pyrrolo[2,3 pyridine-4-carboxylic acid methylam ide; or I H-indol-3 I H-pyrrolo[2,3 ,-bjpyridine-4-carboxylic acid, tert-butyl ester; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 243. A compound according to claim 2 which is 1 -methyl- I H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; WO 03/000688 WO 03/00688PCT/GB02/02799 -362- 6-(l -inethyl-lI H-indol-3-yI)-5H-pyrrolo[2,3-bjpyrazine; 3-[3-(5H-pyrrolo[2,3-b]pyrazinl-6-yl)-indol- I -yl]-propan- I -ol; 3-[5-methoxy-3-(SH-pyrrolo[2,3 -b]pyrazin-6-yJ)-indol- I -yl]-propan- I -ol; 2-[5-methoxy-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yi)-indol- I -yI]-ethanol; 6-(l1 H-indol-3-yI)-5H-pyrrolo[2,3-b]pyrazine; N-{3-[3-(5H-pyrrolo[2,3-b~pyraziin-6-yI)-indol- I -yI]-propyl} -acetamide; I -methyI-3-(5H-pyrrolo[2,3-blpyrazin-6-yl)- I [3-(5H-pyrrolo[2,3-b]pyrazin-6-yI)-iindol- I -yl]-methanol; I H-indol-3-yl)-5 H-pyrrololj2,3-b]pyrazine; 2-['-methoxy-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-indoI- I -yI]-I -morphol in-4-yi-ethanone; 1 -(2-morphol in-4-yl-2-oxo-ethyl)- I H-indol-3-yI]- I H-pyrrolo[2,3-b]pyridine-4- carbonitrile; 4-niethoxy-2-(5-methoxy- I1-methyl-I H-indol-3-yI)- I H-pyrrolo[2,3-b]pyridine; 4-inethoxy-2-(5-methoxy-]I H-indo l-3-yI)- I H-pyrrolo[2,3 -bipyridinie; 1I-[lI -methiyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I 1--indol-5-yloxy]-propan-2-ol; I -[II -methyl-3-( I H-pyrr6oci[2,3-b]pyridin-2-yl)-I H-indol-5-yloxy]-cyclobutanecarboxylic acid amide; I -[1I -inethyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H-indol-5-yloxy]-cyclobutanecarboxylic acid methylamide; I -methyl-3-( IH-pyrrolo [2,3-bjpyridiii-2-yl)- IH-indole-5-carboxyl ic acid (2-hydroxy-ethyl)-arniide; I-methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)- I H-indole-5-carboxylic acid (2-carbamoyl-ethyl)-am ide; I -methyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yI)-I H-indole-5-carboxylic acid amide; I-methyl-3-(I H-pyrrolo[2,3-b]pyridin-2-yl)- 1H-indole-5-carbox-ylic acid (2-hydroxy-I I-dimethyl- ethyl)-amide; I -methyl-3-( IH-pyrro io[2,3-b] pyridin-2-yl)- IH-indole-5-carboxyl ic acid (2-hydroxy- I-hydroxymethyl- ethyl)-amide; I -methyl-3 H-pyrrolo[2,3-b~pyrid in-2-yI)- IH-indole-6-carboxyl ic acid (2-carbamoyl-ethyl)-amide; I-methyl-3-( IH-pyrrolo[2,3-b]pyridini-2-yl)- IH-indole-6-carboxylic acid (I 1,2,4]triazol-3-yl)- amide; I -methyl-3 -(5H-pyrrolo[2,3-b]pyrazin-6-yl)- IH-indole-5-carboxyl ic acid 2-methoxyethylamide; 1 -methyl-3-(5H-pyrrolo[2,3 -bjpyrazin-6-yl)- I H-indole-5-carboxyl ic acid 2-hydroxyethylamide; I -methyl-3-(5 H-pyrrolo[2,3-b] pyrazi n-6-yI)- IH-iiidole-5-carboxyl ic acid methylamide; ,5-dimethyl-isoxazolyl-4-yl)- IH-pyrrolo[2,3-bjpyridin-2-yIJ- I-methyl-I H-indole-5-carboxyl ic acid (2-methoxy-ethyl)-amide; 3-[4-(3,5-dimethyl-isoxazolyl-4-yI)- IH-pyrrolo[2,3-b]pyridin-2-yI]- IH-indole-S-carboxylic acid (2- methoxy-ethyl)-amide; WO 03/000688 WO 03/00688PCT/GB02/02799 -363- 3-(4-cyano- IH-pyrrolo[2,3-b~pyridin-2-yl]-lI-methiyl-I H-indole-5-carboxylic acid (2-hydraxy- 1,1- dimethyl-ethyl)-amide; 3 -(4-cyano- 11--pyrrolo[2,3-bjpyridin-2-yl]- I-methyl-I H-indole-5-carboxylic acid (2-hydroxy-2-methyl- propyl)-amide; [1 -methyl-3-( 1 H-pyrro lo[2,3 pyrid in-2-yl)- I H-i ndol-5 -y loxy] -acetic acid; 2-fl1 -methyl-3-( I H-pyrrolof2,3-b~pyridin-2-yl)- I I--indol-5-ylaxy]-prapionic acid; 141 -methiyl-3-( IH-pyrrolo[2,3-b]pyridin-2-yl)- IH-indal-5-yloxy]-cyclobutane-lI-carboxylic acid; I -methyl-3-( IH-pyrrola[2,3-b]pyridin-2-yl)- I -methyl*3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- 1 H-indole-6-carbaxylic acid; 3-fl -methyl-3-( I H-pyrro lo[2,3 pyrid in-2-yl)- IH- indol-5 -yl]-prop ionic acid; I -methyl-3-(5H-pyrrolo[2,3-blpyrazin-6-yl)- I H-indale-5-carboxylic acid; ,5-d imethyl-isoxazole-4-yl)- I H-pyrrolo[2,3-b]pyridine-2-yl]- I-methyl- I H-indole-5-carboxyl ic acid; 3-f4-(3 ,5-imethyl-isoxaza le-4-yl)- 1H-pyrrolo[2,3-b~pyridine-2-yl]- IH-indole-5-carboxylic acid; 4-(3 ,5-d imethyl-isoxazole-4-yl)-2-(5-methaxy- 1-methyl-I H-indol-3-yl)- IH-pyrrolo[2,3-b]pyridime; -4-(3,5-dimethiyl-isoxazole-4-yl)-2-(5-methaxy- 1H-indol-3-yl)- IH-pyrrolof2,3-b]pyridine; 3-(4-methoxy- IH-pyrrolof2,3 -bipyrid ine-2-yl)- I-methyl-I H-indale-5-carboxyl ic acid; IH-pyrrolof2,3-b]pyridine-2-yl)- IH-indole-5-carboxylic acid; 2-fl -methyl-3 I H-pyrro lo[2,3 pyrid in-2-yl)- I H-i ndal-5-ylax%.y] -ethanol; 2-fl -methyl-3-( IH-pyrrolo[2,3-b]pyrid in-2-yl)- IH-indal-5-yloxy]-prapan- I-ol; (I-141 -methyl-3 H-pyrrolo[2,3 -b]pyrid in-2-yl)- I H-indol-5-yloxy]-cyclobutyl) -methanol; 2-(5-methaxy-l1-methiyl- IH-indol-3-yl)- IH-pyrrolo[2,3-b]pyridine; 3-fl -methyl-3-( IH-pyrrolo[2,3-b]pyrid in-2-yl)- IH-inda l-5-yloxy]-propane- 1,2-dial; 3-f 1-methyl-3-( IH-pyrralo[2,3-b] pyrid in-2-yl)- IH-indal-5-yloxy]-propan- I-al; I-methyl-3-( IH-pyrrolof2,3-b] pyrid in-2-yI)- 1H-indal-5-yloxy]-propan-2-ol; 2-fl -methyl-5-(2H-tetrazal-5-yl)-] H-iindol-3-yl]- IH-pyrrolo[2,3-b]pyridime; I -methiyl-5-(2-methyl-2H-tetrazal-5-yl)- IH-indol-3-yl]- IH-pyrralo[2,3-b~pyridime; I I-methyl-3-{I H-pyrrala[2,3-b]pyridin-2-yl)- 2-(5,6-dimethoxy- I-methy]l H-indol-3-yl)- IH-pyrralo[2,3-b]pyridine; I-rnethyl-3-( IH-pyrrolo[2,3 -b]pyridin-2-yI)- IH-indal-5-yloxy]-propanie- 1,2-d ial; 1-methyl-3-( 1H-pyrrolo[2,3-b]pyridin-2-yl)- IH-indol-5-yloxy]-propane- 1,2-dial; 2-[5-(2-rnethoxy- I-methyl-ethoxy)- I-methyl-I H-inldol-3-yl]- IH-pyrrolo[2,3-b]pyridime; 2-fl -methiyl-5-(5-methyl-[1I,2,4]oxadiazol-3-yl)- 1H-indal-3-yl]- IH-pyrralof2,3-b]pyridine; (R)-3-[6-methoxy- I-rnethyl-3-( IH-pyrralof2,3-b]pyridin-2-yl)- IH-indol-S-yloxyj-propane-1I,2-diol; 6-methoxy- I-methyl-3-( IH-pyrrolof2,3-b~pyridin-2-yi)- 1-methyl-I H-indol-3-yl)-4-phenyl- 1H-pyrrolo[2,3-b]pyridine; WO 03/000688 WO 03/00688PCT/GB02/02799 -364- I1-methyl- I H-indol-3-yl)- I H-pyrrolo[2,3-b]pyridine-4-carbonitri le; 4-chloro-2-(5-methoxy- 1-methlyl-i H-indol-3-yI)- IH-pyrrolo[2,3-b]pyridine; I-methyl-I H--indol-3-yI)-4-(pyridin-3-y)-I H-pyrrolo[2,3-b]pyridine;, 4-chloro-2-(5-methoxy- I H-indol-3-yl)- I H-pyrrolo[2,3-b] pyridine; -methyl-3 H-pyrrolo[2,3-bjpyridin-2-yl)- I I -hydroxyr-nethyl-cyclobutoxy)-3-( I H-pyrrolo[2,3-b]pyridin-2-yI)- indol- I -yi]-cyclobutyl methanol; I -methyl-3 H-pyrrolo[2,3-b] pyrazin-6-yl)- I H-indol-5-yloxy]-cyclobutyl) -methanol; 2-(5-methoxy-Il-indol-3-yl)- I H-pyrrolo[2,3-b]pyridine-4-carbonitrile; 2-(5-methoxy-I -methyl-I H-indol-3-yl)- IH-pyrrolo[2,3-b~pyridine-4 carboxylic acid (2-Iiydroxy-1,1I d imethyl-ethyl)-am ide; 3-(4-ch loro- IH-pyrrolo[2,3 -b]pyridin-2-yI)- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy- 1,- d imethyl-ethyl)-am ide; I -ethyl-5-methoxy- I H-i ndol-3-yl)- I H-pyrrolo[2,3 ,-b]pyridine-4-carboxyl ic acid (2-hydroxy- 1, 1 dimethyl-ethyl)-amide; 2-(5-methoxy--1 -methyl- I H-i ndol-3 I H-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy-2- methyl-propyl) amide; 1-methyl-I H-indol-3 -yI)-I H-pyrrolo(2,3 ,-b]pyridine-4-carboxylic acid (2-hydroxy- propyl) am ide; 2-(5-methoxy- 1-methyl-I H-indol-3-yI)- IH-pyrrolo[2,3,-b]pyridine-4-carboxylic acid (2-hydroxy-ethyl) amide; IH-indol-3-yI)- IH-pyrrolo[2,3 ,-b]pyridine-4-carboxyl ic acid (2-methoxy-ethyl) am ide; I H-indol-3-yI)- I H--pyrrolo[2,3,-b]pyridine-4-carboxylic acid methylamide; or IH-indol-3-yl)- 1H-pyrrolo[2,3 ,-b]pyridine-4-carboxylic acid, tert-butyl ester; or an N-oxide, prodrug, acid biolsostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 244. A compound according to claim to which is 6-(S-methoxy- I-methyl-I H-indol-3-yl)-5 H-pyrrolo[2,3-b]pyrazine; 1 I-methyl-3-( IH-pyrrolo[2,3-b~pyridin-2-yl)-I H-indol-5-yloxy]-cyclobutanecarboxylic acid am ide; ,5-dimethyl-isoxazolyl-4-yl)- 1H-pyrrolo[2,3-b]pyrid in-2-yI]- 1-methyl-I H-indole-5-carboxyl ic acid (2-methoxy-ethyl)-amide; 3-(4-cyano- IH-pyrrolo[2,3-bl pyrid in-2-yI3- 1-methyl-I H-indole-5-carboxyl ic acid (2-hydroxy-2-methyl- propy 1)-am ide; 3-[4-(3,5-dimethyl-isoxazole-4-yl)- IH-pyrrolo[2,3-b]pyridine-2-yl]- I-methyl-I acid; WO 03/000688 PCT/GB02/02799 -365- ,5-imethyi-isoxazole-4-yl)- IH-pyrrolo[2,3-b~pyrid ine-2-yI]- I H-indole-5-carboxyl ic acid; 4-(3,5-d imethyl-isoxazole-4-yl)-2-(5-methoxy- 1-methyl- I H-indol-3-yI). I H-pyrrolo[2,3-b]pyridine;- I -methyl-5-(2H-tetrazol-5-yI)- I H-indol-3-yl]- I H-pyrrolo[2,3-b]pyridine;- I -methyl- I H-indol-3 I H-pyrrolo[2,3-b)pyridine-4-carbonitrilIe; I I -methyl-3 -(5H--pyrrolo[2,3-bjpyrazin-6-yl)- I H-indol-5-yloxy]-cyclobutyl I -methanol; 1-methyl-i H-indol-3-y.)- 1H-pyrrolo[2,3-b]pyridine-4 carboxylic acid (2-hydroxy- 1,1- dirnethyl-ethyl)-aniide; or I-ethyl-5-methoxy- IH-indol-3-yI)- IH-pyrrolo[2,3 ,-b]pyrid ine-4-carboxyl ic acid (2-hydroxy- 1,1 dirnethyl-ethyl)-amide; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 245. A compound according to claim 2 which is 6-ind olizin-1-yI-5H-pyrrolo[2,3-b]pyrazine; or 6-(3-methyl-indol izin-1I-yl)-5H-pyrrolo[2,3-b]pyrazine; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 246. A compound according to claim 2 which is 6-(lI -methyl-4-phenyl- I H-pyrro l-3-yI)-5H-pyrrolo[2,3-b]pyrazine or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodr-ug, or acid bioisostere of such salt or solvate. 247. A compound according to claim 2 which is 6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-bjpyrazine; 6-(4-tert-butylphenyl)-7-rniethyl-5H-pyrrolo[2,3-b]pyrazine; 3-[6-(4-tertf-butylphienyl-5H-pyrrolo[2,3 -b]pyrazin-7-ylI-N-methylpropionamide; 5-[6-(4-tert-butylphenyl-5H-pyrrolo[2,3-b)pyrazin-7-yI]ethyl-2H-tetrazole; 3-[6-(4-Iert-butylphenyl-5 H-pyrrolo[2,3-b] pyrazin-7-yl]-propionainide; 3- [6-(4-tert-butylpheny 1-5 H--pyrro lo[2,3 -blpymazin-7-yiI-pro pion ic acid; 3-[6-(4-tert-butyl-phenyl)-5H-pyrrolol2,3-b]pyrazin-7-yl]-propan- I-ol; N- {3-(6-(4-ter-butylplhenyl)-5H--pyrrolo[2,3 -b]pyrazin-7-yl)propyl) acetam ide; N- {3-(6-(4-tert-butylphenyl)-5H-pyrrolof 2,3-blpyrazin-7-yl)propyl }methanesu ifonamide; 2-methyl-4-[6-(4-zert-butyl-phenyl)-SH-pyrrolo[2,3-b]pyrazin-7-ylj-butan-2-ol; or 4-[6-(4-tert-butyl-pheniyl)-5 H-pyrrolo[2,3-b]pyrazin-7-yl]-butan-2-one; WO 03/000688 WO 03/00688PCT/G B02/02 799 -366- or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate, of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 248. A compound according to claim 2 which is 1 -methyl-3-( I H-pyrrolo[2,3-b]pyridin-2-yl)- I H--indole-6-carboxylic acid; I -methyl-5-(pyrid in-4-yI)- I H-indol-3-yI]-4- I H-pyrrolo[2,3-b]pyridine; I -methyl-3-( I H-pyrrolo[2,3-b]pyrid in-2-yi)- I H-indol-S-yI] methyl~th ien-2-yl-sulfonam ide; N- {I -methyl-3-( I H-pyrrolof2,3 pyrid in-2-yi)- I H-indol-5-yl]methy) -tetrahiydropyran-2-ylurea; 2-[5-methoxy-3-( IH-pyn-olo[2,3-bjpyrid in-2-yI)-indol-1I-yl]-N-(2-methyl-quinol in-4-yI)-acetam ide; or [2-(5-methoxy- I1-methyl- I H-indol-3-yI)- I H-pyrrolo[2,3 -b]pyridin-4-yl]-{2-methoxy-phenyl)-amine; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate, of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate. 249. A compound according to.claim 2 which is 1-methyl-I H-pyrrol-2-yI)-5 H-pyrrolo[2,3-b]pyrazine; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bloisostere of such salt or solvate. 250. A compound according to claim 160 wherein R 9 represents optionally substituted C 1 4 alkyl. 251. A compound according to claim 160 wherein R1 0 represents optionally substituted aryl or optionally substituted heteroaryl. 252. A compound according to claim 160 wherein R 9 is C 1 .4 alkyl substituted by alkoxy or C 1 4alkyl substituted by -NYIy 2 and R1 0 is optionally substituted heteroaryl or optionally substituted aryl.